



(86) Date de dépôt PCT/PCT Filing Date: 2009/04/02
(87) Date publication PCT/PCT Publication Date: 2009/10/08
(85) Entrée phase nationale/National Entry: 2010/10/04
(86) N° demande PCT/PCT Application No.: US 2009/039272
(87) N° publication PCT/PCT Publication No.: 2009/124176
(30) Priorité/Priority: 2008/04/02 (US61/041,631)

(51) Cl.Int./Int.Cl. *A61K 31/122* (2006.01),
A61P 9/00 (2006.01)

(71) Demandeur/Applicant:
METAPROTEOMICS, LLC., US

(72) Inventeurs/Inventors:
KONDA, VEERA, US;
DESAI, ANU, US;
TRIPP, MATTHEW L., US;
DARLAND, GARY, US;
LAMB, JOSEPH, US;
BLAND, JEFFREY S., US;
EMMA, DENNIS A., US

(74) Agent: OGILVY RENAULT LLP/S.E.N.C.R.L.,S.R.L.

(54) Titre : INFLAMMATION ENDOTHELIALE ATTENUÉE PAR LA 1,3-CYCLOPENTADIONE SUBSTITUÉE ET
INTERACTIONS ENDOTHELIUM-MONOCYTE
(54) Title: SUBSTITUTED 1,3-CYCLOPENTADIONE ATTENUATED ENDOTHELIAL INFLAMMATION AND
ENDOTHELIAL-MONOCYTE INTERACTIONS

(57) Abrégé/Abstract:

Compositions and methods for reducing cardiovascular risk utilizing substituted 1,3- cyclopentadione compounds are described.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 October 2009 (08.10.2009)

PCT

(10) International Publication Number
WO 2009/124176 A1

- (51) **International Patent Classification:**
C07C 49/00 (2006.01)
- (21) **International Application Number:**
PCT/US2009/039272
- (22) **International Filing Date:**
2 April 2009 (02.04.2009)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/041,631 2 April 2008 (02.04.2008) US
- (71) **Applicant (for all designated States except US):**
METAPROTEMICS, LLC [US/US]; 100 Avenida La Pata, San Clemente, CA 92673 (US).
- (71) **Applicant and**
(72) **Inventor (for all designated States except US):** LAMB, Joseph [US/US]; 3016 37th Street, N.W., Gig Harbor, WA 98335 (US).
- (72) **Inventors; and**
(75) **Inventors/Applicants (for US only):** KONDA, Veera [US/US]; 5325 64th Avenue, N.W., Gig Harbor, WA 98335 (US). DESAI, Anu [US/US]; 5325 64th Ave., N.W., Gig Harbor, WA 98335 (US). TRIPP, Matthew, L. [US/US]; 4202 71st Avenue, N.W., Gig Harbor, WA 98335 (US). DARLAND, Gary [US/US]; 4102 Sutherland Ct., Gig Harbor, WA 98332 (US). BLAND, Jeffrey, S. [US/US]; 957 11th Lane, Fox Island, WA 98333 (US). EMMA, Dennis, A. [US/US]; 4822-133rd Street, N.W., Gig Harbor, WA 98332 (US).
- (74) **Agents:** ROY AEE, Atabak, R. et al.; McDermott Will & Emery LLP, 28 State Street, Boston, MA 02109 (US).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- with international search report (Art. 21(3))
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))



WO 2009/124176 A1

(54) **Title:** SUBSTITUTED 1,3-CYCLOPENTADIONE ATTENUATED ENDOTHELIAL INFLAMMATION AND ENDOTHELIAL-MONOCYTE INTERACTIONS

(57) **Abstract:** Compositions and methods for reducing cardiovascular risk utilizing substituted 1,3- cyclopentadione compounds are described.

**SUBSTITUTED 1,3-CYCLOPENTADIONE ATTENUATED ENDOTHELIAL
INFLAMMATION AND ENDOTHELIAL - MONOCYTE INTERACTIONS**

CROSS-REFERENCE TO RELATED APPLICATIONS

[001] This patent application claims priority to U.S. provisional application Ser. No. 61/041,631 filed on April 2, 2008, the contents of which are incorporated herein in its entirety by reference.

BACKGROUND OF THE INVENTION

[002] Field of the Invention

[003] The present invention relates generally to methods and compositions that can be used to modulate inflammatory pathways associated with endothelial function and cardiovascular complications, including (1) TNF α mediated VCAM-1, E selectin and MCP-1 in endothelial cells (HAEC) and (2) TNF α mediated Monocyte-Endothelial interactions via protein kinase modulation. More specifically, the invention relates to methods and compositions that utilize substituted 1,3-cyclopentadione compounds.

[004] Description of the Related Art

[005] Monocyte activation and adhesion to the endothelium play critical roles in inflammatory and cardiovascular diseases. The process is further complicated by hyperglycemia leading to the complications in diabetes. Both TNF α and hyperglycemia activate many genes involved in the inflammatory responses (Shanmugam N, Gae Gonzalo IT, Natarajan R. Molecular mechanisms of high glucose-induced cyclooxygenase-2 expression in monocytes. Diabetes. 53(3):795-802, 2004.).

[006] MCP-1 is a potent chemoattractant for monocytes and plays pivotal role in early atherogenesis by promoting monocyte infiltration and adherence to the endothelium, leading to the formation atherosclerotic plaque (Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res. 29;95(9):858-66, 2004.).

[007] Matrix metalloproteinases (MMPs) are the primary proteolytic enzymes in the extracellular space, contributing to weakening of the plaque cap via their ability to cleave the extracellular matrix (ECM) (Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69:562-73.). Atherosclerotic plaque rupture, causally related to the majority of acute coronary syndromes, commonly occurs at sites of

continuous inflammation and collagen degradation (Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. *Arterioscler Thromb Vasc Biol* 2000;20:1262–75.).

[008] Clinical and experimental studies have implicated MMP-9 (gelatinase B) as a key determinant of atherosclerotic plaque stability (Gough PJ, Gomez IG, Wille PT, Raines EW. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. *J Clin Invest* 2006;116:59–69.; Fukuda D, Shimada K, Tanaka A, Kusuyama T, Yamashita H, Ehara S, et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. *Am J Cardiol* 2006;97:175–80.; Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. *Circulation* 2003;107:1579–85.). MMP-9 principally derives from monocytes/ macrophages (Chase AJ, Bond M, Crook MF, Newby AC. Role of nuclear factor kappa B activation in metalloproteinase-1, -3, and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. *Arterioscler Thromb Vasc Biol* 2002;22:765–71.; Stawowy P, Meyborg H, Stibenz D, Borges Pereira Stawowy N, Roser M, Thanabalasingam U, et al. Furin-like proprotein convertases are central regulators of the membrane type matrix metalloproteinase–promatrix metalloproteinase-2 proteolytic cascade in atherosclerosis. *Circulation* 2005;111:2820–7.), the major cell type involved in the initiation, progression and complications of atherosclerosis. In MNCs MMP- 9 is strongly inducible by a number of inflammatory mediators, including TNF- α (Stawowy P, Meyborg H, Stibenz D, Borges Pereira Stawowy N, Roser M, Thanabalasingam U, et al. Furin-like proprotein convertases are central regulators of the membrane type matrix metalloproteinase–promatrix metalloproteinase-2 proteolytic cascade in atherosclerosis. *Circulation* 2005;111:2820–7.).

[009] It has previously been shown that the anti-inflammatory compounds such as aspirin, glucocorticoids, and curcumin exert their effects through the inhibition of NF- κ B signaling pathways (Kopp E and Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. *Science*. 22: 270 (5244): 2017-9,1994.; De Bosscher K, Schmitz ML, Vanden Berghe W, Plaisance S, Fiers W, Haegeman G. Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation. *Proc Natl Acad Sci U S A*. 9;94(25):13504-9, 1997.; Pan MH, Lin-Shiau SY, Ho CT, Lin JH, Lin JK. Suppression of lipopolysaccharide-induced nuclear factor-kappaB activity by theaflavin-3,3'-digallate from black tea and other polyphenols through down-regulation of IkappaB kinase activity in macrophages. *Biochem Pharmacol*. 15;59(4):357-67, 2000.).

[0010] Inflammatory mediators, such as TNF α activate NF κ B, which regulate the expression of many genes involved in the inflammatory responses such as proinflammatory cytokines, adhesion molecules, chemokines including monocyte chemoattractant protein-1 (MCP-1) (Ueda A, Ishigatsubo Y, Okubo T, Yoshimura T. Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of two NF-kappaB sites and NF-kappaB/Rel subunit specificity. *J Biol Chem.* 5;272(49):31092-9, 1997.). It has been shown that hyperglycemia activate inflammation through the activation of PKC and NF-kB signaling pathways in monocytes (Devaraj S, Venugopal SK, Singh U, Jialal I. Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c- α and - β . *Diabetes.*;54(1):85-91, 2005.; Shanmugam N, Gae Gonzalo IT, Natarajan R. Molecular mechanisms of high glucose-induced cyclooxygenase-2 expression in monocytes. *Diabetes.* 53(3):795-802, 2004.)

[0011] Reversible phosphorylation of proteins regulates nearly all aspects of cell physiology. Chronic dysregulation of specific kinases and phosphatases exert their effects by altering the normal phosphorylation state of intracellular proteins, giving rise to a number of disorders including cancers and inflammatory diseases. Hence, protein kinases are a major therapeutic target.

[0012] The over-activation of specific kinases is particularly associated with many diseases and as expected, certain, targeted kinase inhibitors have been shown to be efficacious in normalizing cellular physiology and bringing about remission. For example, imatinib (tyrosine kinase inhibitor) is effective in the treatment of leukemia [Savage DG, *N Eng J Med* 2002]; erlotinib (Epidermal Growth Factor Receptor inhibitor) for lung cancer (Reviewed in *Expert Opin Pharmacother*, Gridelli, 2007); and ruboxistaurin (PKC-beta II inhibitor) for reducing microvascular complications for diabetic patients (Joy SV, et al. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications. *Ann Pharmacother.* 39(10): 1693-9, 2005).

[0013] Endothelial derived Nitric Oxide (NO) is a key determinant of cardiovascular homeostasis modulating vascular endothelial responsiveness and thus regulating systemic blood pressure, vascular remodeling and angiogenesis (Moncada S, Higgs A: The L-Arginine-Nitric Oxide pathway. *NEJM* 1993;329:2002-12). An important stimulus for the continuous production of NO is viscous drag related to blood flow across the endothelium. Endothelial NO synthase (eNOS) is under direct regulation by the protein kinase Akt. Shear stress and hyperglycemia through a series of mediating kinases directly activation Akt. (Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. *Nature* 1999;399:601-5). One of these kinases which actually inhibit Akt is PKC β . PKC β is activated by hyperglycemia. Hyperglycemia has been directly shown to inhibit endothelial dependent vasodilation (Ramos G, Peppas V, Zakopoulos N. Transient Insulin

Resistance in Normal Subjects: Acute Hyperglycemia inhibits Endothelial-Dependent Vasodilation in Normal Subjects. *Metabolic Syndrome and Related Disorders* 2008;6(3):159-170.). Roboxistaurin inhibits PKC β and thus normalizes endothelial function as measured by Flow Mediated Vasodilation (FMD) (Mehta NN, Sheetz M, Price K, Comiskey L, Amrutia S, Iqbal N, Mohler ER, Reilly MP. Selective PKC beta inhibition with roboxistaurin and endothelial function in type-2 diabetes mellitus. *Cardiovasc Drugs Ther* 2009;23(1):17-24). FMD is a non-invasive ultrasonographic technique for measuring brachial artery flow physiology after an induced hypoxemia (Corretti MC et al. Guidelines for the Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery – A Report of the International Brachial Artery Reactive Task Force. *J Am Coll Cardiol* 2002; 39(2): 257-65).

[0014] Previously, we reported that several compounds derived from hop cones, including humulones, lupulones, isohumulones, and reduced isohumulones (modified hop extract used as flavorings) potently inhibit lipopolysaccharide (LPS) stimulated PGE₂ formation in RAW 264.7 cells (Tripp M, Darland G, Lerman R, Lukaczer D, Bland J, Babish J: Hop and modified hop extracts have potent in vitro anti-inflammatory properties. *Acta Hort (ISHS)* 2005, 668:217-228). Among the most active are the substituted 1,3-cyclopentadione compounds derived from hops are the tetrahydro-isoalpha acids, collectively denoted herein as denoted Meta-060 or “THIAA. Meta-060 is a modified hop extract comprised of a mixture of three related analogs, tetrahydro-iso - humulone, -cohumulone, and –adhumulone at a ratio of 49:42:9. META-060 inhibits LPS induced PGE₂ production and COX-2 expression by inhibiting the NF κ B signaling pathway in RAW 264.7 cells (Desai A, Konda VR, Darland G, Austin M, Prabhu KS, Bland JS, et al. META060 inhibits multiple kinases in the NF- κ B pathway and suppresses LPS - mediated inflammation in vitro and ex vivo. *Inflamm Res* 2009).

[0015] Macrophage/monocyte activation participates pivotally in the pathophysiology of many chronic inflammatory diseases. The role of inflammation at all stages of the atherosclerotic process has become an active area of investigation, and there is a need for novel and innovative therapeutics to treat atherosclerosis. As such, the inventors have ascertained the inhibitory effects of Meta-060 on the NF κ B pathway acting via kinase inhibition against key kinases involved in NF κ B activation. Further, to assess specificity, the efficacy of META-060 was assessed against 85 different kinases.

[0016] Additionally, the inventors report on META-060's ability to inhibit other inflammatory markers under NF κ B regulation and associated with cardiovascular complications, including (1). TNF α mediated VCAM-1, E selectin and MCP-1 in endothelial cells (HAEC) and (2). TNF α mediated Monocyte-Endothelial interactions.

[0017] The present invention relates generally to methods and compositions that can be used to modulate inflammatory pathways associated with endothelial function and cardiovascular complications, including (1) TNF α mediated VCAM-1, E selectin and MCP-1 in endothelial cells (HAEC) and (2) TNF α mediated Monocyte-Endothelial interactions via protein kinase modulation. More specifically, the invention relates to methods and compositions that utilize substituted 1,3-cyclopentadione compounds.

[0018] A first embodiment of the invention describes methods for improving a cardiovascular risk factor in a subject in need. The methods comprise treating the subject with a therapeutically effective amount of a substituted 1,3-cyclopentadione compound where said amount modulates the expression of cardiovascular risk factor associated marker gene expression.

[0019] A second embodiment of the invention describes methods for promoting vascular elasticity in a subject in need, where the method comprises treating the subject with a therapeutically effective amount of a substituted 1,3-cyclopentadione compound where said amount increases vascular elasticity or dilation.

[0020] A third embodiment of the invention describes compositions promoting cardiovascular health in a subject. In this embodiment the compositions comprise a therapeutically effective amount of a substituted 1,3-cyclopentadione compound wherein such amount (a) modulates the expression of cardiovascular risk associated marker gene expression; or (b) increases vascular elasticity or dilation.

BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 graphically depicts the effects of substituted 1,3-cyclopentadione compounds on kinase activity y for kinases regulating inflammation and provides a showing of the specificity of the substituted 1,3-cyclopentadione compounds via Gini coefficient expression.

[0022] Figure 2 graphically depicts the effects of substituted 1,3-cyclopentadione compounds on the inhibition of selected endothelial inflammatory biomarkers.

[0023] Figure 3 graphically depicts the inhibitory effects of substituted 1,3-cyclopentadione compounds on endothelial-monocyte interactions.

[0024] Figure 4 depicts META-060 inhibition of THP-1 cell interactions to HAEC cells.

[0025] Figure 5 depicts META-060 inhibition of MCP-1 expression in THP-1 cells.

[0026] Figure 6 displays the inhibitory effect of META-060 on TNF α and LPS mediated MMP-9 levels in THP-1 cells. Panels A & B depict the respective effects of TNF α and LPS on MMP-9 levels while Panel C provides a zymograph displaying the effects on MMP-9 expression.

[0027] Figure 7 graphically displays the inhibitory effects of META-060 on LPS mediated NF κ B binding in THP-1 cells.

[0028] Figure 8 displays the inhibitory effects of META-060 on TNF α activated genes in THP-1 cells.

DETAILED DESCRIPTION OF THE INVENTION

[0029] The present invention relates generally to methods and compositions that can be used to modulate inflammatory pathways associated with endothelial function and cardiovascular complications, including (1) TNF α mediated VCAM-1, E selectin and MCP-1 in endothelial cells (HAEC) and (2) TNF α mediated Monocyte-Endothelial interactions via protein kinase modulation. More specifically, the invention relates to methods and compositions that utilize substituted 1,3-cyclopentadione compounds.

[0030] The patents, published applications, and scientific literature referred to herein establish the knowledge of those with skill in the art and are hereby incorporated by reference in their entirety to the same extent as if each was specifically and individually indicated to be incorporated by reference. Any conflict between any reference cited herein and the specific teachings of this specification shall be resolved in favor of the latter. Likewise, any conflict between an art-understood definition of a word or phrase and a definition of the word or phrase as specifically taught in this specification shall be resolved in favor of the latter.

[0031] Technical and scientific terms used herein have the meaning commonly understood by one of skill in the art to which the present invention pertains, unless otherwise defined. Reference is made herein to various methodologies and materials known to those of skill in the art. Standard reference works setting forth the general principles of recombinant DNA technology include Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory Press, New York (1989); Kaufman *et al.*, Eds., *Handbook of Molecular and Cellular Methods in Biology in Medicine*, CRC Press, Boca Raton (1995); McPherson, Ed., *Directed Mutagenesis: A Practical Approach*, IRL Press, Oxford (1991). Standard reference works setting forth the general principles of pharmacology include Goodman and Gilman's *The Pharmacological Basis of Therapeutics*, 11th Ed., McGraw Hill Companies Inc., New York (2006).

[0032] In the specification and the appended claims, the singular forms include plural referents unless the context clearly dictates otherwise. As used in this specification, the singular

forms "a," "an" and "the" specifically also encompass the plural forms of the terms to which they refer, unless the content clearly dictates otherwise. Additionally, as used herein, unless specifically indicated otherwise, the word "or" is used in the "inclusive" sense of "and/or" and not the "exclusive" sense of "either/or." The term "about" is used herein to mean approximately, in the region of, roughly, or around. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term "about" is used herein to modify a numerical value above and below the stated value by a variance of 20%.

[0033] As used herein, the recitation of a numerical range for a variable is intended to convey that the invention may be practiced with the variable equal to any of the values within that range. Thus, for a variable that is inherently discrete, the variable can be equal to any integer value of the numerical range, including the end-points of the range. Similarly, for a variable that is inherently continuous, the variable can be equal to any real value of the numerical range, including the end-points of the range. As an example, a variable that is described as having values between 0 and 2, can be 0, 1 or 2 for variables that are inherently discrete, and can be 0.0, 0.1, 0.01, 0.001, or any other real value for variables that are inherently continuous.

[0034] Reference is made hereinafter in detail to specific embodiments of the invention. While the invention will be described in conjunction with these specific embodiments, it will be understood that it is not intended to limit the invention to such specific embodiments. On the contrary, it is intended to cover alternatives, modifications, and equivalents as may be included within the spirit and scope of the invention as defined by the appended claims. In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention. The present invention may be practiced without some or all of these specific details. In other instances, well known process operations have not been described in detail, in order not to unnecessarily obscure the present invention.

[0035] Any suitable materials and/or methods known to those of skill can be utilized in carrying out the present invention. However, preferred materials and methods are described. Materials, reagents and the like to which reference are made in the following description and examples are obtainable from commercial sources, unless otherwise noted.

[0036] A first embodiment of the invention describes methods for improving a cardiovascular risk factor in a subject in need. The methods comprise treating the subject with a therapeutically effective amount of a substituted 1,3-cyclopentadione compound where said amount modulates the expression of cardiovascular risk factor associated marker gene expression.

[0037] In some aspects of this embodiment, the substituted 1,3-cyclopentadione compound is selected from the group comprising (+)-(4*R*,5*S*)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (-)-(4*S*,5*S*)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (+)-(4*R*,5*S*)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-(3-methylpropanoyl)cyclopent-2-en-1-one, (-)-(4*S*,5*S*)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-(3-methylpropanoyl)cyclopent-2-en-1-one, (+)-(4*R*,5*S*)-3,4-dihydroxy-2-(2-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one and (+)-(4*R*,5*S*)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-pentanoylcyclopent-2-en-1-one.

[0038] In other aspects the cardiovascular risk associated marker gene being modulated is selected from the group consisting of TNF α , MCP-1, VCAM-1, MMP-3, ICAM1 and SDF1.

[0039] In yet other aspects, the method further comprises lifestyle modification or pharmaceutical treatment wherein the lifestyle modification or pharmaceutical treatment is selected from the group consisting of blood pressure reduction, cholesterol level modulation, diabetes treatment, increased exercise, inflammation, obesity and weight reduction, prothrombotic factors treatment, reduction in serum homocysteine and lipoprotein (a), serum triglyceride reduction, smoking cessation, and stress reduction.

[0040] As used herein, “improving a cardiovascular risk factor” means stabilizing, reducing or eliminating an identified cardiovascular risk factor thereby promoting improved cardiovascular health. Representative, non-limiting examples of cardiovascular risk factors include tobacco usage, elevated blood pressure, elevated serum total (and LDL) cholesterol, diabetes, advancing age, obesity, physical inactivity, family history of premature cardiac heart disease, elevated serum triglycerides, small LDL particles, elevated serum homocysteine or lipoprotein (a), prothrombotic factors (e.g., fibrinogen), and inflammatory factors (e.g., C-reactive protein).

[0041] The phrase “modulates the expression of cardiovascular risk factor associated marker gene expression” means the up or down regulation of the expression of the gene, or its associated gene product production or activity. Non-limiting representative examples of genes identified or associated with various aspects of cardiovascular risk factors include AQP1, B3GAT3, BCL3, BTG2, C1ORF106, C1ORF38, C1ORF38, CACNA1A, CCDC75, CCL2, CCL8, CCND1, CD40, CD44, CD86, CLIP2, DDX58, DKFZP434H1419, DSC3, EHD1, EIF2AK2, FAM105A, FGD2, FKBP5, G3BP1, GPR153, HTR4, ICAM1, ICOSLG, IFI44, IFI44L, IFIH1, IFIT1, IFIT2, IFIT3, IGKC, IGKV1-5, IKBKE, IKZF1, IL10RA, IL18RAP, IL1B, IL7R, IRF7, ISG15, KIAA1731, KRT17, LHX, LIMD2, LTB, MARCKSL1, MCP-1, MMP3, MMP14, MMP9, MX1, MX2, NA, NAB1, NAB2, NOD2, NPTX1, OAS1, OAS2, OAS3, OASL, PDE4B, PIP5K1B, PRKCH, PTGIR, PTPN14, RASA, RASA4, RASSF4, REC8, RIN3, RSAD2, SAFB2, SAMD9,

SDF1, SEMA4C, SH3TC1, SH3TC, SIGLEC1, SLAMF8, SLC16A3, SLC1A3, SP110, SPI1, SPIB, SSPO, STAT1, TAP1, TAPBP, THBD, TNF α , TRAC, TRIM22, UBE2B, UBQLN4, UBQLN4P, UST, VCAM1, XAF1, ZFP2, ZMIZ2, and ZNF710.

[0042] In some aspects, the lifestyle modification or pharmaceutical treatment is selected from the group consisting of blood pressure reduction, cholesterol level modulation, diabetes treatment, increased exercise, inflammation, obesity and weight reduction, prothrombotic factors treatment, reduction in serum homocysteine and lipoprotein (a), serum triglyceride reduction, smoking cessation, and stress reduction.

[0043] As used herein, the phrase "lifestyle modification" means those activities which an individual may undertake to improve cardiovascular risk factors absent or in conjunction with a pharmaceutical treatment. Representative examples of lifestyle modification include, without limitation, diet modifications for weight reduction, blood pressure or cholesterol control; increased exercise for stress relief or weight reduction; or smoking cessation. "Pharmaceutical treatment", as used herein, refers to those agents obtained or prescribed by a health care provider which may be used in lieu of, or in conjunction with, lifestyle modifications to promote improved cardiovascular risk factors.

[0044] As used in this specification, whether in a transitional phrase or in the body of the claim, the terms "comprise(s)" and "comprising" are to be interpreted as having an open-ended meaning. That is, the terms are to be interpreted synonymously with the phrases "having at least" or "including at least". When used in the context of a process, the term "comprising" means that the process includes at least the recited steps, but may include additional steps. When used in the context of a compound or composition, the term "comprising" means that the compound or composition includes at least the recited features or compounds, but may also include additional features or compounds.

[0045] As used herein, the terms "derivatives" or a matter "derived" refer to a chemical substance related structurally to another substance and theoretically obtainable from it, *i.e.* a substance that can be made from another substance. Derivatives can include compounds obtained via a chemical reaction.

[0046] The term "pharmaceutically acceptable" is used in the sense of being compatible with the other ingredients of the compositions and not deleterious to the recipient thereof.

[0047] As used herein, "tetrahydro-isohumulone" shall refer to the *cis* and *trans* forms of (+)-(4*R*,5*S*)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one and (-)-(4*S*,5*S*)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one respectively.

[0048] “Tetrahydro-isocohumulone”, as used herein refers to the *cis* and *trans* forms of (+)-(4*R*,5*S*)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-(3-methylpropanoyl)cyclopent-2-en-1-one and (-)-(4*S*,5*S*)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-(3-methylpropanoyl)cyclopent-2-en-1-one respectively.

[0049] “Tetrahydro-adhumulone” shall be used herein to refer to the *cis* and *trans* forms of (+)-(4*R*,5*S*)-3,4-dihydroxy-2-(2-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one and (+)-(4*R*,5*S*)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-pentanoylcyclopent-2-en-1-one respectively.

[0050] As used herein, “tetrahydro-isoalpha acid” (see Table 1) or “Meta060” refers to any mixture of one or more of tetrahydro-adhumulone, tetrahydro-isocohumulone and tetrahydro-isohumulone.

Table 1

Tetrahydroisoalpha acids

Chemical Name	Synonym	Structure
(4 <i>R</i> ,5 <i>S</i>)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one	tetrahydro <i>cis n</i> iso-alpha acid	
(4 <i>S</i> ,5 <i>S</i>)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one	tetrahydro <i>trans n</i> iso-alpha acid	
(4 <i>S</i> ,5 <i>R</i>)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one	tetrahydro <i>cis n</i> iso-alpha acid	
(4 <i>R</i> ,5 <i>R</i>)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one	tetrahydro <i>trans n</i> iso-alpha acid	
(4 <i>R</i> ,5 <i>S</i>)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-(3-methylpropanoyl)cyclopent-2-en-1-one	tetrahydro <i>cis co</i> iso-alpha acid	
(4 <i>S</i> ,5 <i>S</i>)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-(3-methylpropanoyl)cyclopent-2-en-1-one	tetrahydro <i>trans co</i> iso-alpha acid	
(4 <i>S</i> ,5 <i>R</i>)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-(3-methylpropanoyl)cyclopent-2-en-1-one	tetrahydro <i>cis co</i> iso-alpha acid	
(4 <i>R</i> ,5 <i>R</i>)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-(3-methylpropanoyl)cyclopent-2-en-1-one	tetrahydro <i>trans co</i> iso-alpha acid	

(4 <i>R</i> ,5 <i>S</i>)-3,4-dihydroxy-2-(2-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one	tetrahydro <i>cis</i> ad iso-alpha acid	
(4 <i>S</i> ,5 <i>S</i>)-3,4-dihydroxy-2-(2-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one	tetrahydro <i>trans</i> ad iso-alpha acid	
(4 <i>S</i> ,5 <i>R</i>)-3,4-dihydroxy-2-(2-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one	tetrahydro <i>cis</i> ad iso-alpha acid	
(4 <i>R</i> ,5 <i>R</i>)-3,4-dihydroxy-2-(2-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one	tetrahydro <i>trans</i> ad iso-alpha acid	

[0051] As used herein, “compounds” may be identified either by their chemical structure, chemical name, or common name. When the chemical structure and chemical or common name conflict, the chemical structure is determinative of the identity of the compound. The compounds described herein may contain one or more chiral centers and/or double bonds and therefore, may exist as stereoisomers, such as double-bond isomers (*i.e.*, geometric isomers), enantiomers or diastereomers. Accordingly, the chemical structures depicted herein encompass all possible enantiomers and stereoisomers of the illustrated or identified compounds including the stereoisomerically pure form (*e.g.*, geometrically pure, enantiomerically pure or diastereomerically pure) and enantiomeric and stereoisomeric mixtures. Enantiomeric and stereoisomeric mixtures can be resolved into their component enantiomers or stereoisomers using separation techniques or chiral synthesis techniques well known to the skilled artisan. The compounds may also exist in several tautomeric forms including the enol form, the keto form and mixtures thereof. Accordingly, the chemical structures depicted herein encompass all possible tautomeric forms of the illustrated or identified compounds. The compounds described also encompass isotopically labeled compounds where one or more atoms have an atomic mass different from the atomic mass conventionally found in nature. Examples of isotopes that may be incorporated into the compounds of the invention include, but are not limited to, ^2H , ^3H , ^{13}C , ^{14}C , ^{15}N , ^{18}O , ^{17}O , *etc.* Compounds may exist in unsolvated forms as well as solvated forms, including hydrated forms and as N-oxides. In general, compounds may be hydrated, solvated or N-oxides. Certain compounds may exist in multiple

crystalline or amorphous forms. Also contemplated within the scope of the invention are congeners, analogs, hydrolysis products, metabolites and precursor or prodrugs of the compound. In general, unless otherwise indicated, all physical forms are equivalent for the uses contemplated herein and are intended to be within the scope of the present invention.

[0052] Compounds according to the invention may be present as salts. In particular, pharmaceutically acceptable salts of the compounds are contemplated. A “pharmaceutically acceptable salt” of the invention is a combination of a compound of the invention and either an acid or a base that forms a salt (such as, for example, the magnesium salt, denoted herein as “Mg” or “Mag”) with the compound and is tolerated by a subject under therapeutic conditions. In general, a pharmaceutically acceptable salt of a compound of the invention will have a therapeutic index (the ratio of the lowest toxic dose to the lowest therapeutically effective dose) of 1 or greater. The person skilled in the art will recognize that the lowest therapeutically effective dose will vary from subject to subject and from indication to indication, and will thus adjust accordingly.

[0053] A second embodiment of the invention describes methods for promoting vascular elasticity in a subject in need, the method comprising treating the subject with a therapeutically effective amount of a substituted 1,3-cyclopentadione compound wherein said amount increases vascular elasticity or dilation. In some aspects of this embodiment the substituted 1,3-cyclopentadione compound is selected from the group comprising (+)-(4*R*,5*S*)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (-)-(4*S*,5*S*)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (+)-(4*R*,5*S*)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-(3-methylpropanoyl)cyclopent-2-en-1-one, (-)-(4*S*,5*S*)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-(3-methylpropanoyl)cyclopent-2-en-1-one, (+)-(4*R*,5*S*)-3,4-dihydroxy-2-(2-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one and (+)-(4*R*,5*S*)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-pentanoylcyclopent-2-en-1-one.

[0054] Another embodiment describes a composition for promoting cardiovascular health in a subject in need, where the composition comprises a therapeutically effective amount of a substituted 1,3-cyclopentadione compound wherein said amount (a) modulates the expression of cardiovascular risk associated marker gene expression; or (b) increases vascular elasticity or dilation.

[0055] In some aspects, the substituted 1,3-cyclopentadione compound is selected from the group comprising (+)-(4*R*,5*S*)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (-)-(4*S*,5*S*)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (+)-(4*R*,5*S*)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-(3-methylpropanoyl)cyclopent-2-en-1-one, (-)-(4*S*,5*S*)-3,4-

dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-(3-methylpropanoyl)cyclopent-2-en-1-one, (+)-(4*R*,5*S*)-3,4-dihydroxy-2-(2-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one and (+)-(4*R*,5*S*)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-pentanoylcyclopent-2-en-1-one.

[0056] In yet other aspects of this embodiment the composition further comprises a pharmaceutically acceptable excipient wherein the pharmaceutically acceptable excipient is selected from the group consisting of coatings, isotonic and absorption delaying agents, binders, adhesives, lubricants, disintegrants, coloring agents, flavoring agents, sweetening agents, absorbants, detergents, and emulsifying agents. Additionally, in other aspects the composition further comprises one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, and carbohydrates.

[0057] In other aspects of this embodiment, the substituted 1,3-cyclopentadione compound utilized in the composition is greater than 50% pure, preferably greater than 75% pure, more preferably greater than 90% pure and most preferably greater than 95% pure for the identified stereoisomer (the remaining amount being the alternative isomeric form). In some aspects the composition comprises from about 50 mg to 10,000 mg, preferably 100 mg to 8,000 mg, or most preferably 150 mg to 6,000 mg of the substituted 1,3-cyclopentadione compound per dosage.

[0058] The compounds according to the invention are optionally formulated in a pharmaceutically acceptable vehicle with any of the well known pharmaceutically acceptable carriers, including diluents and excipients [see Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, Mack Publishing Co., Easton, PA 1990 and Remington: The Science and Practice of Pharmacy, Lippincott, Williams & Wilkins, 1995]. While the type of pharmaceutically acceptable carrier/vehicle employed in generating the compositions of the invention will vary depending upon the mode of administration of the composition to a mammal, generally pharmaceutically acceptable carriers are physiologically inert and non-toxic. Formulations of compositions according to the invention may contain more than one type of compound of the invention), as well as any other pharmacologically active ingredient useful for the treatment of the symptom/condition being treated.

[0059] The compounds of the present invention may be provided in a pharmaceutically acceptable vehicle using formulation methods known to those of ordinary skill in the art. The compositions of the invention can be administered by standard routes, though preferably administration is by inhalation routes. The compositions of the invention include those suitable for oral, inhalation, rectal, ophthalmic (including intravitreal or intracameral), nasal, topical (including buccal and sublingual), vaginal, or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, and intratracheal). In addition, polymers may be added according to standard methodologies in the art for sustained release of a given compound.

[0060] Formulations suitable for administration by inhalation include formulations that can be dispensed by inhalation devices known to those in the art. Such formulations may include carriers such as powders and aerosols. The present invention encompasses liquid and powdered compositions suitable for nebulization and intrabronchial use, or aerosol compositions administered via an aerosol unit dispensing metered doses ("MDI"). The active ingredient may be formulated in an aqueous pharmaceutically acceptable inhalant vehicle, such as, for example, isotonic saline or bacteriostatic water and other types of vehicles that are well known in the art. The solutions are administered by means of a pump or squeeze-actuated nebulized spray dispenser, or by any other conventional means for causing or enabling the requisite dosage amount of the liquid composition to be inhaled into the patient's lungs. Powder compositions containing the anti-inflammatory compounds of the present invention include, by way of illustration, pharmaceutically acceptable powdered preparations of the active ingredient thoroughly intermixed with lactose or other inert powders acceptable for intrabronchial administration. The powder compositions can be administered via a dispenser, including, but not limited to, an aerosol dispenser or encased in a breakable capsule which may be inserted by the patient into a device that punctures the capsule and blows the powder out in a steady stream. Aerosol formulations for use in the subject method typically include propellants, surfactants, and co-solvents and may be filled into conventional aerosol containers that are closed by a suitable metering valve.

[0061] Formulations of compositions of the present invention suitable for nasal administration, wherein the carrier is a solid, include a coarse powder having a particle size, for example, in the range of 20 to 500 microns which is administered in the manner in which snuff is administered, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations, wherein the carrier is a liquid, for administration, for example via a nasal spray, aerosol, or as nasal drops, include aqueous or oily solutions of the compound of the invention.

[0062] For oral administration, the compositions of the invention may be presented as discrete units such as capsules, caplets, gelcaps, cachets, pills, or tablets each containing a predetermined amount of the active ingredient as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil emulsion and as a bolus, etc. Alternately, administration of a composition of all of the aspects of the present invention may be effected by liquid solutions, suspensions or elixirs, powders, lozenges, micronized particles and osmotic delivery systems.

[0063] Formulations of compositions according to the aspects of the present invention suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain antioxidants, stabilizers, buffers, bacteriostats and solutes which render the

formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) conditions requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

[0064] A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent. Molded tablets may be made by molding, in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may be optionally coated or scored and may be formulated to provide a slow or controlled release of the active ingredient therein.

[0065] Formulations of compositions of the present invention for rectal administration may be prepared as a suppository with a suitable base comprising, such as, for example, cocoa butter.

[0066] Formulations of compositions of the present invention suitable for topical administration in the mouth include lozenges comprising the ingredients in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the ingredient to be administered in a suitable liquid carrier. Formulations of compositions of the present invention suitable for topical administration to the skin may be presented as ointments, creams, gels, lotions and pastes comprising the ingredient to be administered in a pharmaceutical acceptable carrier. A topical delivery system contemplated is a transdermal patch containing the ingredient to be administered.

[0067] Formulations of compositions according to the aspects of the present invention suitable for vaginal administration may be presented as pessaries, suppositories, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the compound of the invention such pharmaceutically acceptable carriers as are known in the art to be appropriate.

[0068] The term “modulate” or “modulation” is used herein to mean the up or down regulation of expression or activity of the gene by a compound, ingredient, *etc.*, to which it refers.

[0069] As used herein, the term “protein kinase” represents transferase class enzymes that are able to transfer a phosphate group from a donor molecule to an amino acid residue of a protein. See Kostich, M., *et al.*, Human Members of the Eukaryotic Protein Kinase Family, *Genome Biology*

3(9):research0043.1-0043.12, 2002 herein incorporated by reference in its entirety, for a detailed discussion of protein kinases and family/group nomenclature.

[0070] The methods and compositions of the present invention are intended for use with any mammal that may experience the benefits of the methods of the invention. Foremost among such mammals are humans, although the invention is not intended to be so limited, and is applicable to veterinary uses. Thus, in accordance with the invention, "mammals" or "mammal in need" include humans as well as non-human mammals, particularly domesticated animals including, without limitation, cats, dogs, and horses.

[0071] As used herein, by "treating" is meant reducing, preventing, and/or reversing the symptoms in the individual to which a compound of the invention has been administered, as compared to the symptoms of an individual not being treated according to the invention. A practitioner will appreciate that the compounds, compositions, and methods described herein are to be used in concomitance with continuous clinical evaluations by a skilled practitioner (physician or veterinarian) to determine subsequent therapy. Hence, following treatment the practitioners will evaluate any improvement in reducing cardiovascular risk factors or associated dyregularities according to standard methodologies. Such evaluation will aid and inform in evaluating whether to increase, reduce or continue a particular treatment dose, mode of administration, *etc.*

[0072] It will be understood that the subject to which a compound of the invention is administered need not suffer from a specific traumatic state. Indeed, the compounds of the invention may be administered prophylactically, prior to any development of symptoms. The term "therapeutic," "therapeutically," and permutations of these terms are used to encompass therapeutic, palliative as well as prophylactic uses. Hence, as used herein, by "treating or alleviating the symptoms" is meant reducing, preventing, and/or reversing the symptoms of the individual to which a compound of the invention has been administered, as compared to the symptoms of an individual receiving no such administration.

[0073] The term "therapeutically effective amount" is used to denote treatments at dosages effective to achieve the therapeutic result sought. Furthermore, one of skill will appreciate that the therapeutically effective amount of the compound of the invention may be lowered or increased by fine tuning and/or by administering more than one compound of the invention, or by administering a compound of the invention with another compound. See, for example, Meiner, C.L., "Clinical Trials: Design, Conduct, and Analysis," Monographs in Epidemiology and Biostatistics, Vol. 8 Oxford University Press, USA (1986). The invention therefore provides a method to tailor the administration/treatment to the particular exigencies specific to a given mammal. As illustrated in the following examples, therapeutically effective amounts may be easily determined for example

empirically by starting at relatively low amounts and by step-wise increments with concurrent evaluation of beneficial effect.

[0074] It will be appreciated by those of skill in the art that the number of administrations of the compounds according to the invention will vary from patient to patient based on the particular medical status of that patient at any given time including other clinical factors such as age, weight and condition of the mammal and the route of administration chosen.

[0075] As used herein, "symptom" denotes any sensation or change in bodily function that is experienced by a patient and is associated with a particular disease, *i.e.*, anything that accompanies "X" and is regarded as an indication of "X"'s existence. It is recognized and understood that symptoms will vary from disease to disease or condition to condition. By way of non-limiting examples, symptoms associated with autoimmune disorders include fatigue, dizziness, malaise, increase in size of an organ or tissue (for example, thyroid enlargement in Grave's Disease), or destruction of an organ or tissue resulting in decreased functioning of an organ or tissue (for example, the islet cells of the pancreas are destroyed in diabetes).

[0076] "Inflammation" or "inflammatory condition" as used herein refers to a local response to cellular injury that is marked by capillary dilatation, leukocytic infiltration, redness, heat, pain, swelling, and often loss of function and that serves as a mechanism initiating the elimination of noxious agents and of damaged tissue. Representative symptoms of inflammation or an inflammatory condition include, if confined to a joint, redness, swollen joint that's warm to touch, joint pain and stiffness, and loss of joint function. Systemic inflammatory responses can produce "flu-like" symptoms, such as, for instance, fever, chills, fatigue/loss of energy, headaches, loss of appetite, and muscle stiffness.

[0077] The following examples are intended to further illustrate certain preferred embodiments of the invention and are not limiting in nature. Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and procedures described herein.

EXAMPLES

Example 1

[0078] The purpose of this Example was to determine the effects of substituted 1,3-cyclopentadione compounds on protein kinase activity, especially that associated with the expression of selected cardiovascular risk associated markers and, additionally, on monocyte – endothelial cell interactions.

[0079] *The inhibition of META-060 on in vitro kinase activity:* In a final reaction volume of 25 μ l the kinase of interest (5-10 mU) was incubated with the specific buffer and peptide substrate, 10 mM MgAcetate and [γ -33P-ATP]. The reaction was initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction was stopped by the addition of 5 μ l of a 3% phosphoric acid solution. 10 μ l of the reaction was then spotted onto a P30 filtermat and washed three times for 5 minutes in 50 mM phosphoric acid and once in methanol prior to drying and scintillation counting.

[0080] *The inhibition of META-060 on TNFa induced VCAM1, E-selectin and MCP-1 in HAEC cells.* HAEC cells were pre-incubated with various concentrations of META-060 (10, 5 and 1 mg/ml) for 1 hr and stimulated with TNFa (10ng/ml) for 8 hrs. VCAM-/E-Selectin levels were measured by cell based ELISA method using antibodies for VCAM-1 and E-selectin and fold induction was calculated over unstimulated (control) cells. For MCP-1, the cell media were measured using human MCP-1 immunoassay kits (R&D Systems). Data represent Mean \pm SD of 8 individual samples.

[0081] *The inhibition of META-060 on TNFa induced Monocyte-Endothelial interactions:* The adhesion of fluorescently labeled human monocytic (THP-1) cells to confluent monolayers of HAECs was measured by using a microplate-based assay. HAEC or THP-1 cells were pre-incubated with META-060 (10mg/ml) and Parthenolide (10mM) for 1hr and stimulated with TNFa (10ng/ml) for 8 hrs. THP-1 cells were labeled with the fluorescent dye BCECF-AM (1 μ mM final concentration; Sigma) in HBSS medium for 30 min at 4 $^{\circ}$ C. Then cells were washed twice with (37 $^{\circ}$ C) HBSS medium and resuspended in EGM2 medium. 100,000 THP-1 cells were added to each well (96 well plate) and incubated for 30 min. Unbound THP-1 cells were washed twice with PBS by centrifugation by putting plate upside down with seal. Standard curve for BCECF-AM labeled THP-1 cells were generated. 200 μ l of PBS were added to each well, and fluorescence was measured using Vector2 (Perkin Elmer) fluorescent plate reader (excitation: 485 nm; emission: 535 nm). THP-1 stimulation (A). THP-1 cells without stimulation, (B). THP-1 cell with TNFa, (C) THP-1 cells with parthenolide (10ug/ml) and TNFa (D) THP-1 cells with META-060 (10ug/ml) and TNFa. Data represent Mean \pm SD of 6 individual samples.

[0082] Results – The results are presented in Figures 1 – 3 and Table 2 below.

Table 2.

Gini Coefficients and Hit Rate (>50% Inhibition) for 40 inhibitors against 85 Kinases

(see Supporting Information) at 10 μ M(G10)

Inhibitor	Concn (μ M)	G_{10}	hit rate
AG1024	10	0.568	11
AG1296	10	0.498	4
AG1478	10	0.500	25
AG18	10	0.680	1
AG183	10	0.460	14
AG538	10	0.417	17
Alsterpaullone	1	0.633	22
Calphostin C	10	0.606	2
Cdk2/5 inh.	10	0.555	7
Curcumin	50	0.417	38
EGCG	10	0.495	21
Genistein	10	0.582	0
H89	10	0.442	34
HA1077	10	0.650	19
Herbimycin A	10	0.534	0
Hispidin	10	0.790	2
Indirubin	10	0.291	52
JNK inh II	10	0.445	35
K252c	10	0.236	58
KT5720	1	0.423	33
Lavendustin A	1	0.726	0
Lavendustin B	1	0.515	0
LY294002	50	0.619	6
Olomoucine	50	0.556	13
PD153035	0.001	0.616	0
PD184352	10	0.802	1
PP1 analogue	1	0.758	15

PP2	1	0.722	14
PP3	1	0.634	0
Ro31-8220	1	0.432	39
Roscovitine	10	0.744	10
Rottlerin	10	0.595	3
SB202190	10	0.553	29
SB203580	10	0.621	17
ST638	10	0.568	14
Staurosporine	1	0.093	78
SU6656	1	0.607	19
Wortmannin	1	0.775	0
Y27632	10	0.628	13
ZM336372	10	0.635	11
Graczyk PP, Journal of Medicinal Chemistry, 2007			

[0083] The data presented show that Meta-060: a) inhibits TNF α mediated MCP-1, VCAM-1 and E-selectin expression in endothelial cells; b) inhibits TNF α mediated THP-1-HAEC cell interactions; c) inhibits kinases involved in inflammatory signaling pathways, such as, PKC β II, NF- κ B, PI3K and GSK3; and d) Gini-coefficient value of 0.81 at 13 μ M concentration, suggesting that META-060 shows high specificity for kinase inhibition.

[0084] The development of kinase inhibitors is complicated by their relative lack of specificity [Bain, Biochem J 2003, Graczek 2007] resulting in off-target side effects. In a review article, Graczek proposed the Gini-coefficient (0= lack specificity, 1=highest specificity), as a method to predict the specificity of kinase inhibitors against a panel of kinases. Forty commercially available inhibitors were tested for the inhibition of 85 kinases with Gini-coefficient ranging from 0.1 to 0.8. Here we add for comparison.

Example 2

[0085] The purpose of this study was to evaluate the effect of substituted 1,3-cyclopentadione compounds on monocyte-endothelial interactions, expression of MCP-1 and MMP-9 levels in monocytic cells, THP-1. Additionally evaluated was the expression of various

inflammatory genes in TNF α activated THP-1 cells and in vitro kinase screening of over 250 kinases in cell free enzyme assays

[0086] *THP-1 and HAEC cell interactions (A).* Human monocytic cell line, THP-1 were incubated with Low (5mM) and High (25mM) glucose for eight days. THP-1 cells were treated with THIAA for 8 hrs. B. THP-1 cells were activated with TNF α for 8 hrs in the presence and absence of test compound for 1 hr. Cells were labeled with BCECF for 30 min and added on monolayers of human endothelial cells (HAEC) for 30 min. Number of THP-1 cells bound to the wells were measured using standard curve from BCECF labeled THP-1 cells and fold induction was calculated from average of eight samples.

[0087] *MCP-1 Expression:* The inhibition of META-060 on TNF α (10ng/ml), LPS (1ug/ml) and cytokines (TNF α , Il-1b and IFN γ , 10ng/ml each) induced MCP-1 production in THP-1 cells. Cells were pre-incubated with various concentrations of META-060 for 1 hr and stimulated with TNF α (10ng/ml) for 24 hrs. MCP-1 levels were measured using human MCP-1 immunoassay kits (R&D Systems). Data represent Mean \pm SD of 8 samples.

[0088] *MMP-9 Expression:* The inhibition of META-060 on TNF α (10ng/ml) and LPS (1ug/ml) induced MMP-9 production in THP-1 cells. Cells were pre-incubated with various concentrations of META-060 for 1 hr and stimulated with A. TNF α (10ng/ml) or (B) LPS (1ug/ml) for 24 hrs. MMP-9 levels in the medium were measured using human MMP-9 immunoassay kits (GE Healthcare). Data represent Mean \pm SD of a representative experiment. For MMP-9 activity (C) LPS conditioned medium was mixed 1:1 with Novex buffer (Invitrogen) and electrophoresed in 10% SDS-PAGE containing 0.1% gelatin. Gels were renaturated by exchanging SDS for Triton X-100 (2.5%), followed by 24 h incubation at 37 °C in activation buffer (50 mmol/L Tris, pH 7.6; 5 mmol/L CaCl₂; 0.2 mol/L NaCl and 0.02% Brij). Gels were subsequently stained with Coomassie staining solution (0.5% Coomassie R250; 30% MeOH; 10% acetic acid) for 2 h, followed by destaining (50% MeOH and 10% acetic acid).

[0089] *Electrophoretic mobility shift assays (EMSA):* THP-1 cells were pre-incubated with test compounds for 1 hr and stimulated with LPS (1ug/ml) for 2 hrs. Nuclear extracts were prepared essentially as described by Dignam, *et al* [Nucl. Acids. Res 11:1475-1489) and NF-kB binding to DNA was assessed using electrophoretic mobility shift assay with labeled NF-kB consensus DNA probe (5' AGTTGAGGGGACTTCCAGGC).

[0090] *Regulation of protein phosphorylation in THP-1 cells:* THP-1 cells were seeded in 6 well plate, pre-incubated in the presence and absence of META-060 (20ug/ml) for 1 hr and stimulated with TNF α (10ng/ml) or LPS (10ug/ml) for 1 hr. Cell lysates were prepared as per the instructions from user manual from MILLIPLEX MAP technology (Millipore, Billerica, MA).

Multi-Pathway Signaling kit is used to detect changes in phosphorylated Erk/MAP kinase 1/2 (Thr185/Tyr187), STAT3 (Ser727), STAT5A/B (Tyr694/699), JNK (Thr183/Tyr185), p70 S6 kinase (Thr412) and p38 (Thr180/Tyr182) in cell lysates using the Luminex® system. Cell lysate (25ug/well) were used and phosphoproteins were measured in the lysates as per the instructions and fold inductions were calculated using unstimulated samples as a control (Table 3 & 4).

Table 3:

Effect of Meta060 on TNFa mediated protein phosphorylation in THP-1 cells

Phosphoproteins	Control (Unstimulated)	TNFa (10ng/ml)	Meta060 (ug/ml) + TNFa (10ng/ml)		
			20ug	10ug	5ug
Erk1/2	1.0	1.5	1.4	1.6	1.6
STAT3	1.0	1.4	1.2	1.2	1.4
JNK	1.0	1.3	1.0	0.8	1.1
p70 S6K	1.0	1.3	1.1	1.0	1.6
STAT5A/B	1.0	0.8	0.7	0.4	1.3
p38	1.0	2.0	1.5	1.4	1.6

Table 4:

Effect of Meta060 on LPS mediated protein phosphorylation in THP-1 cells.

Phosphoproteins	Control (Unstimulated)	LPS (10ug/ml)	Meta060 (ug/ml) + LPS (10ug/ml)		
			20ug	10ug	5ug
JNK	1.0	7.2	3.6	5.0	5.5
p70 S6K	1.0	1.5	0.7	0.9	1.5
STAT5A/B	1.0	1.5	1.4	1.1	1.0
p38	1.0	7.0	5.4	4.8	6.5

[0091] *Regulation of transcriptional factors in THP-1 cells:* THP-1 cells were seeded in 100mm dish, pre-incubated with META-060 (10mg/ml) for 1 hr and stimulated with TNFa (10ng/ml) or LPS (10ug/ml) for 2 hrs. Nuclear extracts were prepared as per the instructions from user manual (Panomics, CA). Transcriptional factors were measured using Procarta® Transcription Factor Plex panel 1 (Panomics, CA) according to the manufacturer instructions using Luminex 200. The fold induction was calculated from 3 measurements. TFIIID was used as an internal control and unstimulated samples used to calculate fold induction. The data is presented in Tables 5 & 6.

Table 5:

Effect of Meta060 on TNFa mediated transcriptional factors in THP-1 cells

	Control (unstimulated)	TNFa (10ng/ml)	Meta060 (20ug/ml) +TNFa (10ng/ml)
ELK-1	1.00	0.87	1.09
NFkB	1.00	1.86	1.40
FAST-1	1.00	1.40	1.21
OCT	1.00	1.21	0.98
P53	1.00	1.96	1.89
PAX-3	1.00	1.20	0.92
NF-E2	1.00	1.84	1.42
AP-2	1.00	1.35	1.11
NF-E1(YY1)	1.00	2.38	2.71
ATF-2	1.00	1.50	1.18
NF-1	1.00	2.13	1.77
ISRE	1.00	1.93	1.61
PAX-5	1.00	1.15	1.37
Nkx-2.5	1.00	1.60	1.25
AR	1.00	1.71	1.32
ETS/PEA	1.00	1.42	1.17
AP-1	1.00	1.91	1.18
E2F1	1.00	1.86	1.70

MyoD	1.00	1.67	1.48
PPAR	1.00	2.01	1.19
RUNX/AML	1.00	1.40	0.90
Brm3	1.00	0.44	0.75
NF-Y	1.00	2.44	1.87
c-myb	1.00	1.42	1.08
CREB	1.00	1.74	1.35
ER	1.00	1.60	1.30
GR/PR	1.00	1.43	1.25
HIF-1	1.00	1.74	1.45
FKHR	1.00	1.31	0.96
GATA	1.00	1.44	1.10
IRF	1.00	1.74	1.43
STAT-1	1.00	0.90	0.79
HNF1	1.00	1.11	1.07
STAT-4	1.00	1.32	1.09
STAT-5	1.00	1.27	1.19
MEF-2	1.00	1.24	0.97
NFAT	1.00	1.10	0.73

Table 6:

Effect of Meta060 on LPS mediated transcriptional factors in THP-1 cells

	Control (Unstimulated)	LPS (10ug/ml)	Meta060 (20ug/ml) +LPS (10ug/ml)
ELK-1	1.00	0.38	0.57
NFkB	1.00	3.20	0.83

FAST-1	1.00	1.24	1.45
OCT	1.00	0.72	0.69
P53	1.00	1.19	2.60
PAX-3	1.00	0.92	0.81
NF-E2	1.00	2.71	2.11
AP-2	1.00	0.91	1.05
NF-E1(Y Y1)	1.00	1.16	2.46
ATF-2	1.00	1.31	1.10
NF-1	1.00	1.46	1.86
ISRE	1.00	1.14	2.77
PAX-5	1.00	1.42	0.75
Nkx-2.5	1.00	0.97	1.47
AR	1.00	1.40	2.63
ETS/PEA	1.00	0.88	0.95
AP-1	1.00	4.06	1.42
E2F1	1.00	1.68	2.92
MyoD	1.00	0.88	1.65
PPAR	1.00	1.07	1.04
RUNX/AML	1.00	1.42	1.10
Brm3	1.00	0.22	0.13
NF-Y	1.00	1.68	2.02
c-myb	1.00	1.03	1.92
CREB	1.00	1.71	1.77
ER	1.00	1.31	2.36
GR/PR	1.00	0.69	1.75
HIF-1	1.00	1.54	2.45
FKHR	1.00	1.04	0.93
GATA	1.00	0.88	1.37

IRF	1.00	0.83	1.13
STAT-1	1.00	0.71	0.53
HNF1	1.00	0.77	1.42
STAT-4	1.00	0.81	1.07
STAT-5	1.00	1.09	0.94
MEF-2	1.00	0.75	0.79
NFAT	1.00	0.70	0.53

[0092] *Human Gene array analysis:* THP-1 cells were pre-incubated with META-060 (10mg/ml) or parthenolide (10mM) for 1 hr and stimulated with TNFa (10ng/ml) for 4 hrs. Genes were analyzed using Affymetrix human genome array U133A 2.0 and measured ~22,000 transcripts (by Expression Analysis Inc, North Carolina). Genes which are known to activate endothelial and monocyte interactions were shown. Each value represent Mean of 2 independent measurements.

[0093] Results – The results for this Example are presented in Figures 4 – 8 and Table 7 and indicate that META-060 inhibits: a) Hyperglycemia and TNFa mediated, THP- 1-HAEC cell interactions; b) Cytokines and LPS mediated MCP-1 secretion; c) TNFa and LPS activated MMP-9 levels; d) LPS mediated NF-kB binding; and e) TNFa mediated inflammatory genes including, MCP-1, VCAM, ICAM-1, MMP-9 and TNFa in THP-1 cells.

Table 7

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
209387_s_at	4071	TM4SF1	M90657	7.77	32.01	0.77	0.02	7.77	4.26	8.92	
216307_at	1607	DGKB	AB018261	1.77	22.51	0.71	0.03	1.77	2.84	5.19	
207837_at	11030	RBPMS	NM_006867	4.20	24.09	0.77	0.03	4.20	5.37	17.29	
208529_at	690	BTF3L1	NM_001208	4.85	26.42	0.99	0.04	4.85	3.48	0.80	
216923_at	6792	CDKL5	AL049684	8.08	34.36	1.35	0.04	8.08	20.57	33.50	
207679_at	5077	PAX3	NM_000438	9.48	40.46	2.02	0.05	9.48	25.09	2.74	0.11
215523_at	346157	RP1-153G14.3	AL031118	7.54	26.87	1.38	0.05	7.54	5.16	19.70	
211525_s_at	2814	GP5	L11238	6.37	18.86	0.98	0.05	6.37	3.45	15.65	
216787_at	2281	FKBP1B	AK026273	8.41	55.23	2.89	0.05	8.41	13.95	7.39	0.53
220820_at			NM_018539	21.18	39.60	2.19	0.06	21.18	14.35	31.81	
208045_at	9981	SPAR	NM_005129	16.48	25.57	1.44	0.06	16.48	16.54	4.07	
206446_s_at	63036	ELA2A	NM_001971	3.65	25.64	1.47	0.06	3.65	18.52	1.86	0.10
207527_at	3765	KCNJ9	NM_004983	8.00	53.09	3.08	0.06	8.00	18.72	11.49	0.61
220474_at	89874	SLC25A21	NM_030631	3.74	15.58	0.94	0.06	3.74	10.94	10.48	
211522_s_at	2798	GNRHR	L03380	0.71	22.66	1.41	0.06	0.71	1.92	3.48	
220187_at	79689	STEAP4	NM_024636	2.65	31.68	2.01	0.06	2.65	5.09	5.01	
221322_at	64111	NPVF	NM_022150	0.99	20.28	1.35	0.07	0.99	1.71	5.69	
219136_s_at	64788	TMEM112	NM_022773	7.70	35.86	2.40	0.07	7.70	3.74	4.74	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
205886_at	5968	REG1B	NM_006507	10.51	33.27	2.25	0.07	10.51	4.49	9.15	
217265_at	51090	PLLP	AL020989	2.32	23.95	1.62	0.07	2.32	1.62	4.05	
217213_at	6530	SLC6A2	AB022847	1.94	23.63	1.67	0.07	1.94	5.60	2.77	
209183_s_at	11067	C10orf10	AL136653	17.77	130.43	9.25	0.07	17.77	34.77	15.72	0.45
207912_s_at	1617 ///	DAZ1 /// DAZ3 /// DAZ2 /// DAZ	U21663	4.20	27.76	1.97	0.07	4.20	15.41	9.48	0.62
205430_at	653	BMP5	NM_021073	2.72	17.89	1.30	0.07	2.72	1.41	0.99	
220222_at	55472	C8orf39	NM_018608	3.66	30.66	2.30	0.07	3.66	4.12	4.62	
215117_at	5897	RAG2	AW058148	8.35	18.61	1.41	0.08	8.35	4.91	3.71	
209988_s_at	429	ASCL1	BC001638	8.11	14.39	1.09	0.08	8.11	1.55	9.42	
206941_x_at	9723	SEMA3E	NM_012431	4.04	19.31	1.49	0.08	4.04	1.01	3.56	
213197_at	460	ASTN1	AB006627	1.54	20.39	1.59	0.08	1.54	8.60	3.80	
216598_s_at	6347	CCL2	S69738	13.11	2860.66	222.78	0.08	13.11	430.87	121.62	0.28
216839_at	3908	LAMA2	AK026829	2.73	14.41	1.12	0.08	2.73	16.92	14.17	
216134_at	23150	FRMD4B	AK000244	14.80	26.35	2.07	0.08	14.80	12.75	8.25	
206300_s_at	5744	PTHLH	NM_002820	10.21	15.70	1.24	0.08	10.21	21.67	3.62	0.17
202196_s_at	27122	DKK3	NM_013253	2.32	18.77	1.50	0.08	2.32	3.00	6.94	
216986_s_at	3662	IRF4	D78261	30.30	58.93	4.80	0.08	30.30	28.46	13.55	
222258_s_at	23677	SH3BP4	AF015043	3.89	22.00	1.80	0.08	3.89	6.77	9.89	
210016_at	23040	MYT1L	BF223003	6.75	31.55	2.59	0.08	6.75	12.00	10.95	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
210116_at	4068	SH2D1A	AF072930	1.34	52.10	4.35	0.08	1.34	5.61	13.15	
215795_at	57644	MYH7B	AK000947	5.19	18.50	1.56	0.08	5.19	4.94	2.39	
204612_at	5569	PKIA	NM_006823	8.28	23.53	2.00	0.09	8.28	14.37	2.71	0.19
219803_at	27329	ANGPTL3	NM_014495	10.26	29.88	2.58	0.09	10.26	12.07	2.39	
206666_at	3003	GZMK	NM_002104	3.15	49.67	4.34	0.09	3.15	10.81	7.38	0.68
220807_at	3049	HBQ1	NM_005331	10.08	32.36	2.89	0.09	10.08	2.86	11.50	
220880_at			NM_018601	3.53	27.80	2.50	0.09	3.53	7.47	7.17	
205460_at	4862	NPAS2	NM_002518	14.34	30.55	2.75	0.09	14.34	38.35	16.29	0.42
219827_at	7352	UCP3	NM_003356	27.43	67.56	6.24	0.09	27.43	19.79	31.19	
221347_at	1133	CHRM5	NM_012125	3.09	21.42	1.98	0.09	3.09	15.25	4.10	0.27
208525_s_at	135948 /	OR2F1 /// OR2F2	NM_012369	1.30	28.88	2.68	0.09	1.30	3.15	4.84	
220314_at	51402 //	HSFX1 /// LOC728302	NM_016153	4.81	35.95	3.35	0.09	4.81	6.22	7.54	
220460_at	53919	SLCO1C1	NM_017435	17.61	26.61	2.50	0.09	17.61	4.89	6.94	
216003_at	374286	CDRT1	U43383	15.63	27.12	2.55	0.09	15.63	6.37	2.41	
207910_at	10648	SCGB1D1	NM_006552	0.73	14.86	1.40	0.09	0.73	1.70	0.92	
217412_at			AE000659	5.42	22.08	2.08	0.09	5.42	3.44	6.72	
216641_s_at	3898	LAD1	U58994	10.18	46.17	4.35	0.09	10.18	17.11	3.57	0.21
216939_s_at	3360	HTR4	Y08756	7.77	26.90	2.55	0.09	7.77	11.29	3.96	
207909_x_at	1617 ///	DAZ1 /// DAZ3 /// DAZ2	U21663	3.69	12.24	1.17	0.10	3.69	4.26	4.16	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		/// DAZ									
211044_at	9830	TRIM14	BC006333	15.45	59.97	5.79	0.10	15.45	27.99	5.98	0.21
217350_at	160313	LOC160313	AB041269	4.57	15.56	1.53	0.10	4.57	4.28	2.30	
204464_s_at	1909	EDNRA	NM_001957	14.40	26.56	2.64	0.10	14.40	6.32	7.03	
208497_x_at	4762	NEUROG1	NM_006161	19.48	61.49	6.14	0.10	19.48	74.79	87.44	
210713_at	6453	ITSN1	U61166	6.26	22.08	2.23	0.10	6.26	7.49	5.93	
207640_x_at	4917	NTN2L	NM_006181	11.60	58.01	5.88	0.10	11.60	13.16	10.71	
220010_at	23630	KCNE1L	NM_012282	29.49	48.71	4.94	0.10	29.49	26.70	28.21	
204878_s_at	9344	TAOK2	NM_004783	13.61	80.91	8.23	0.10	13.61	35.30	46.05	
204424_s_at	55885	LMO3	AL050152	19.24	31.57	3.22	0.10	19.24	24.51	7.04	
215784_at	913	CD1E	AA309511	6.86	43.27	4.45	0.10	6.86	9.32	1.24	
207070_at	5995	RGR	NM_002921	10.13	52.32	5.53	0.11	10.13	5.17	30.01	
203903_s_at	9843	HEPH	NM_014799	3.20	36.29	3.85	0.11	3.20	27.70	20.68	0.75
210850_s_at	2002	ELK1	AF000672	22.89	40.28	4.28	0.11	22.89	4.24	11.26	
212278_x_at	7337	UBE3A	BF588511	18.75	41.53	4.42	0.11	18.75	3.29	11.11	
215796_at			BF976764	3.69	20.46	2.20	0.11	3.69	3.52	14.70	
207077_at	51032	ELA2B	NM_015849	23.57	40.66	4.40	0.11	23.57	10.79	25.59	
206842_at	3750	KCND1	NM_004979	17.40	49.85	5.40	0.11	17.40	75.09	54.08	0.72
AFFX-r2-Bs-thr-M_s_at			AFFX-r2-Bs-thr-M	21.90	43.37	4.70	0.11	21.90	9.16	16.25	
215468_at	647070	LOC647070	AK001442	18.02	32.66	3.57	0.11	18.02	17.14	8.13	
220450_at	646593	LOC64	NM_0249	4.35	12.48	1.37	0.11	4.35	10.12	4.30	0.42

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		6593	14								
220916_at	80188	FLJ13310	NM_025118	12.10	33.61	3.69	0.11	12.10	16.15	19.97	
220506_at	2974	GUCY1B2	NM_004129	3.63	15.14	1.67	0.11	3.63	4.63	3.26	
214410_at	4308	TRPM1	N32151	10.51	18.87	2.09	0.11	10.51	6.91	4.05	
216927_at			AC003030	7.46	27.89	3.11	0.11	7.46	12.19	16.44	
216893_s_at	1285	COL4A3	U02519	10.39	29.16	3.26	0.11	10.39	11.40	15.20	
219167_at	51285	RASL12	NM_016563	44.41	69.87	7.86	0.11	44.41	6.60	25.12	
220619_at	55636	CHD7	NM_017783	3.84	20.71	2.34	0.11	3.84	9.81	27.35	
210823_s_at	5802	PTPRS	U40317	8.22	32.00	3.63	0.11	8.22	29.63	25.27	
214451_at	7021	TFAP2B	NM_003221	6.56	10.50	1.20	0.11	6.56	4.13	2.26	
220552_at	7224	TRPC5	NM_012471	2.04	25.60	2.92	0.11	2.04	5.31	3.71	
215225_s_at	2840	GPR17	Z94154	5.57	18.41	2.12	0.11	5.57	6.78	21.51	
214008_at	5756	TWF1	N25562	22.51	47.26	5.46	0.12	22.51	30.76	26.92	
221087_s_at	80833	APOL3	NM_014349	17.01	35.33	4.08	0.12	17.01	11.31	14.20	
214145_s_at	6710	SPTB	BG223341	9.29	47.02	5.44	0.12	9.29	10.10	6.43	
217119_s_at	2833	CXCR3	Z79783	61.47	134.49	15.64	0.12	61.47	13.05	12.26	
222174_at	4149	MAX	AU145025	11.80	31.26	3.64	0.12	11.80	6.18	20.16	
211843_x_at	1551	CYP3A7	AF315325	4.01	28.96	3.39	0.12	4.01	21.66	7.47	0.35
207846_at	5449	POU1F1	NM_000306	2.72	19.22	2.25	0.12	2.72	12.41	3.55	0.29
208059_at	1237	CCR8	NM_005201	8.05	38.33	4.49	0.12	8.05	16.31	10.86	0.67
206982_at	1411	CRYBA1	NM_005208	7.77	15.73	1.85	0.12	7.77	5.91	2.26	
216588_at	120872	RPL7	AL03157	10.70	16.25	1.92	0.12	10.70	21.61	7.10	0.33

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
	/	LOC120872 /// LOC1307	7								
210504_at	10661	KLF1	U65404	5.69	38.42	4.57	0.12	5.69	35.03	1.70	0.05
220214_at	7762	ZNF215	NM_013250	8.69	33.83	4.05	0.12	8.69	15.46	5.57	0.36
207255_at	3953	LEPR	NM_002303	15.52	35.32	4.24	0.12	15.52	9.79	10.04	
208139_s_at			NM_031269	3.66	31.29	3.79	0.12	3.66	1.55	5.67	
217409_at	4644	MYO5A	Z22957	5.67	10.30	1.25	0.12	5.67	2.68	1.50	
215835_at	949	SCARB1	AV708130	3.43	29.06	3.53	0.12	3.43	12.10	6.25	0.52
209047_at	358	AQP1	AL518391	129.69	1090.70	133.76	0.12	129.69	307.48	190.88	0.62
214502_at	8970	HIST1H2BJ	NM_021058	2.75	13.12	1.61	0.12	2.75	3.00	1.94	
216447_at			AK024525	1.80	19.69	2.43	0.12	1.80	3.39	14.05	
208533_at	6656	SOX1	NM_005986	5.71	17.16	2.12	0.12	5.71	1.80	2.81	
216363_at			S73614	26.46	66.54	8.24	0.12	26.46	30.88	21.77	
218656_s_at	10186	LHFP	NM_005780	4.45	22.24	2.77	0.12	4.45	2.79	2.51	
211920_at	629	CFB	AF349679	3.25	36.01	4.50	0.12	3.25	32.91	3.67	0.11
202086_at	4599	MX1	NM_002462	306.62	3062.73	389.68	0.13	306.62	4083.25	648.81	0.16
220228_at	23431	AP4E1	AB030653	4.96	20.77	2.65	0.13	4.96	2.35	1.31	
211164_at	2042	EPHA3	AF213460	1.05	18.86	2.44	0.13	1.05	2.42	2.73	
216687_x_at	7366	UGT2B15	U06641	8.05	24.52	3.19	0.13	8.05	17.44	8.77	0.50
220226_at	79054	TRPM8	NM_024080	20.22	56.93	7.45	0.13	20.22	14.18	23.50	
208143_s_at	10876	FAM12A	NM_006683	2.76	29.14	3.83	0.13	2.76	4.52	1.82	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
214939_x_at	4301	MLLT4	AB011399	10.19	16.08	2.12	0.13	10.19	9.34	14.66	
205106_at	4515	MTCP1	NM_014221	37.46	59.04	7.79	0.13	37.46	24.53	33.09	
214966_at	2901	GRIK5	S40369	3.18	25.09	3.33	0.13	3.18	9.21	9.25	
212224_at	216	ALDH1A1	NM_000689	15.84	54.38	7.21	0.13	15.84	43.36	21.96	0.51
219456_s_at	79890	RIN3	NM_024832	70.81	145.86	19.38	0.13	70.81	54.48	15.97	
217706_at	220074	LRRC51	AV742010	7.83	42.90	5.71	0.13	7.83	14.82	10.49	0.71
211745_x_at	3039	HBA1	BC005931	19.64	60.30	8.12	0.13	19.64	4.91	19.30	
221186_at			NM_025116	14.39	36.10	4.87	0.13	14.39	9.20	6.91	
213973_at	6238	RRBP1	BE646396	36.16	80.15	10.89	0.14	36.16	27.42	29.48	
209763_at	91851	CHRD L1	AL049176	6.88	29.60	4.05	0.14	6.88	18.04	25.39	
220556_at	23439	ATP1B4	NM_012069	4.40	21.10	2.91	0.14	4.40	9.06	8.98	
203930_s_at	4137	MAPT	NM_016835	3.50	24.27	3.35	0.14	3.50	13.37	21.10	
210354_at	3458	IFNG	M29383	3.80	24.89	3.46	0.14	3.80	7.75	8.95	
217316_at	390892	OR7A10	AC005255	4.05	35.52	4.95	0.14	4.05	8.15	2.83	
205772_s_at	9465	AKAP7	NM_004842	20.57	38.43	5.41	0.14	20.57	23.89	14.88	
214837_at	213	ALB	M12523	9.90	33.25	4.69	0.14	9.90	19.48	7.07	0.36
207580_at	4115	MAGEB4	NM_002367	5.24	15.23	2.15	0.14	5.24	10.97	14.43	
220491_at	57817	HAMP	NM_021175	26.85	58.18	8.26	0.14	26.85	44.03	38.80	
213722_at	6657	SOX2	AW007161	2.54	17.20	2.45	0.14	2.54	6.29	8.45	
220568_at			NM_018582	13.19	20.61	2.93	0.14	13.19	4.49	2.79	
206071_s_at	2042	EPHA3	AF21345	1.38	26.66	3.79	0.14	1.38	2.36	18.60	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			9								
210579_s_at	10107	TRIM10	AF220122	8.29	54.23	7.75	0.14	8.29	48.81	49.49	
204439_at	10964	IFI44L	NM_006820	62.17	663.59	94.85	0.14	62.17	681.10	109.27	0.16
207242_s_at	2897	GRIK1	NM_000830	3.57	36.81	5.26	0.14	3.57	8.45	7.77	
211472_at	23654	PLXNB2	AF336795	4.02	17.27	2.47	0.14	4.02	5.62	1.89	
212750_at	26051	PPP1R16B	AB020630	6.69	28.07	4.05	0.14	6.69	19.11	10.07	0.53
209597_s_at	10687	PNMA2	AB020690	21.05	41.90	6.05	0.14	21.05	15.98	6.85	
203838_s_at	10188	TNK2	AI146308	37.41	91.12	13.18	0.14	37.41	33.55	15.37	
210086_at	55806	HR	AF039196	6.55	19.01	2.75	0.14	6.55	18.18	11.24	0.62
208514_at	3753	KCNE1	NM_000219	3.98	16.90	2.45	0.15	3.98	3.92	12.77	
214772_at	25758	C11orf41	H08993	6.82	27.01	3.95	0.15	6.82	12.77	31.78	
204667_at	3169	FOXA1	NM_004496	3.55	46.41	6.86	0.15	3.55	26.09	19.78	
205388_at	7125	TNNC2	NM_003279	11.77	41.53	6.15	0.15	11.77	15.33	9.57	
206749_at	910	CD1B	NM_001764	11.77	27.68	4.12	0.15	11.77	10.87	13.60	
221697_at	440738	MAP1LC3C	AF276659	6.23	22.08	3.29	0.15	6.23	8.08	16.92	
218644_at	26499	PLEK2	NM_016445	63.35	140.84	21.03	0.15	63.35	100.88	95.53	
214067_at	115939	C16orf42	AL031709	4.09	21.02	3.14	0.15	4.09	8.77	13.53	
207393_at	3062	HCRTR2	NM_001526	17.49	33.30	5.03	0.15	17.49	4.39	6.84	
208422_at	4481	MSR1	NM_002445	2.61	11.37	1.73	0.15	2.61	12.31	5.96	0.48
207587_at	1418	CRYGA	NM_014617	4.73	30.31	4.61	0.15	4.73	2.50	16.76	
219764_at	11211	FZD10	NM_0071	7.21	14.71	2.24	0.15	7.21	8.61	5.14	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			97								
216193_at	440366	LOC440366	X69637	7.02	25.01	3.82	0.15	7.02	22.40	27.45	
211227_s_at	730420 /	PCDH11Y /// LOC730420	AF332216	12.95	25.45	3.90	0.15	12.95	27.12	24.97	
216418_at	215 ///	ABCD1 /// LOC642762 /// LOC648	AL133173	7.45	28.01	4.30	0.15	7.45	14.65	21.25	
207293_s_at	186	AGTR2	U16957	2.10	15.75	2.44	0.15	2.10	2.90	4.52	
206347_at	5165	PDK3	NM_005391	40.62	80.76	12.54	0.16	40.62	35.91	44.38	
221420_at			NM_005179	5.63	10.20	1.59	0.16	5.63	6.22	1.92	
221140_s_at	29933	GPR132	NM_013345	36.52	92.14	14.42	0.16	36.52	66.33	203.99	
208401_s_at	2740	GLP1R	U01157	7.03	29.03	4.55	0.16	7.03	5.22	7.44	
220854_at			NM_014123	8.49	19.50	3.06	0.16	8.49	1.44	2.51	
214453_s_at	10561	IFI44	NM_006417	79.18	689.10	108.37	0.16	79.18	632.18	153.77	0.24
219285_s_at	51199	NIN	NM_016350	2.10	14.68	2.33	0.16	2.10	4.65	4.66	
204856_at	10331	B3GNT3	NM_014256	13.44	40.89	6.50	0.16	13.44	24.93	13.30	0.53
216171_at	1937	EEF1G	AK025271	1.35	11.26	1.80	0.16	1.35	1.73	5.26	
209915_s_at	9378	NRXN1	AB035356	3.74	20.28	3.24	0.16	3.74	2.16	5.72	
208226_x_at	53616	ADAM22	NM_004194	13.66	24.39	3.90	0.16	13.66	21.56	11.11	0.52
208032_s_at	2892	GRIA3	NM_000828	2.63	18.61	2.98	0.16	2.63	5.72	2.65	
203587_at	379	ARL4D	U25771	9.71	26.35	4.24	0.16	9.71	10.06	9.08	
205108_s_at	338	APOB	NM_000384	6.65	23.09	3.73	0.16	6.65	3.21	5.11	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
206310_at	6691	SPINK2	NM_021114	7.24	26.12	4.22	0.16	7.24	15.04	8.47	0.56
211480_s_at	6579	SLCO1A2	AF085224	2.65	10.98	1.79	0.16	2.65	3.01	2.98	
210614_at	7274	TTPA	U21938	10.55	29.37	4.79	0.16	10.55	4.37	10.08	
208063_s_at	10753	CAPN9	NM_006615	7.64	35.56	5.82	0.16	7.64	9.83	5.86	
210659_at	1240	CMKLR1	U79526	7.99	59.40	9.72	0.16	7.99	18.35	17.88	
208392_x_at	3431	SP110	NM_004510	83.11	293.94	48.41	0.16	83.11	280.34	21.95	0.08
206811_at	114	ADCY8	NM_001115	2.79	26.34	4.36	0.17	2.79	26.63	12.96	0.49
222362_at	3268	HRBL	H07885	7.53	57.01	9.44	0.17	7.53	26.58	11.59	0.44
207206_s_at	239	ALOX12	NM_000697	14.18	43.89	7.27	0.17	14.18	12.68	7.35	
201185_at	5654	HTRA1	NM_002775	6.55	41.28	6.86	0.17	6.55	5.71	23.79	
220016_at	79026	AHNAK	NM_024060	11.01	52.73	8.79	0.17	11.01	20.63	18.55	
204698_at	3669	ISG20	NM_002201	6.50	24.33	4.08	0.17	6.50	315.07	146.78	0.47
214977_at	6503	SLA	AK023852	4.77	24.45	4.10	0.17	4.77	32.81	31.55	
220636_at	64446	DNAI2	NM_023036	8.55	46.43	7.80	0.17	8.55	14.24	5.23	0.37
207142_at	3760	KCNJ3	NM_002239	1.07	14.81	2.50	0.17	1.07	7.90	2.26	
215028_at	57556	SEMA6A	AB002438	5.37	13.68	2.32	0.17	5.37	5.32	31.18	
215774_s_at			AV650470	1.20	11.66	1.98	0.17	1.20	22.70	4.33	0.19
210182_at	1325	CORT	AB000263	16.34	46.81	7.96	0.17	16.34	37.50	20.88	0.56
221151_at	56979	PRDM9	NM_020227	4.44	27.14	4.63	0.17	4.44	4.60	12.30	
208606_s_at	54361	WNT4	NM_030761	3.95	20.76	3.55	0.17	3.95	6.18	6.72	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
208559_at	3651	PDX1	NM_013311	7.16	17.20	2.94	0.17	7.16	12.64	5.51	0.44
207409_at	3950	LECT2	NM_002302	7.49	15.66	2.68	0.17	7.49	6.38	1.43	
203475_at	1588	CYP19A1	NM_000103	30.55	83.20	14.26	0.17	30.55	79.24	84.70	
216929_x_at	28	ABO	U15197	17.66	37.04	6.35	0.17	17.66	36.60	10.58	0.29
216857_at			L48728	36.05	57.75	9.93	0.17	36.05	11.23	35.47	
210915_x_at	28568 //	TRBV19 /// TRBC1	M15564	16.84	34.84	6.00	0.17	16.84	14.86	11.93	
214883_at	7067	THRA	X55005	4.36	19.94	3.46	0.17	4.36	4.15	7.25	
209670_at	28755	TRAC	M12959	51.55	212.86	36.99	0.17	51.55	68.90	29.65	
204972_at	4939	OAS2	NM_016817	275.77	1007.17	175.54	0.17	275.77	955.50	240.13	0.25
213630_at	23148	KIAA0363	AB002361	6.20	15.38	2.69	0.17	6.20	4.14	14.27	
215295_at	1838	DTNB	Y15718	3.32	16.46	2.88	0.17	3.32	7.02	4.89	
208391_s_at	2740	GLP1R	NM_002062	4.03	11.14	1.95	0.17	4.03	5.25	2.39	
217705_at	5587	PRKD1	AW085172	1.71	18.82	3.31	0.18	1.71	17.69	0.89	0.05
209768_s_at	2812 ///	GP1BB /// SEPT5	AI860917	13.81	37.74	6.65	0.18	13.81	4.57	8.18	
206227_at	8483	CILP	NM_003613	17.85	49.71	8.80	0.18	17.85	22.56	28.21	
213004_at	23452	ANGPTL2	AI074333	20.60	54.18	9.63	0.18	20.60	19.17	28.22	
207267_s_at	53820	DSCR6	NM_018962	14.60	28.74	5.12	0.18	14.60	8.45	16.28	
215478_at	9699	RIMS2	AF007156	9.55	45.67	8.16	0.18	9.55	13.17	16.35	
215361_at			AK022242	3.15	16.21	2.90	0.18	3.15	1.62	1.33	
200939_s_at	473	RERE	AI920976	3.12	14.35	2.57	0.18	3.12	5.87	2.95	
207209_at	1068	CETN1	NM_004066	36.81	55.51	9.95	0.18	36.81	17.31	40.48	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
206416_at	7755	ZNF205	NM_003456	39.32	77.41	13.88	0.18	39.32	13.12	21.92	
220562_at	54905	CYP2W1	NM_017781	37.04	73.39	13.16	0.18	37.04	29.51	31.98	
216651_s_at	2572	GAD2	X69936	3.24	35.32	6.34	0.18	3.24	11.09	10.07	
211198_s_at	23308	ICOSLG	AF289028	12.92	114.47	20.57	0.18	12.92	147.71	172.98	
214393_at	8153	RND2	AI884814	8.89	40.89	7.35	0.18	8.89	17.19	21.45	
215703_at	1080	CFTR	W60595	13.92	38.36	6.89	0.18	13.92	18.69	15.56	
210199_at	1409	CRYAA	U66584	12.28	34.91	6.28	0.18	12.28	24.91	20.91	
203084_at	7040	TGFB1	NM_000660	41.41	91.16	16.41	0.18	41.41	38.49	11.22	
216790_at	9154	SLC28A1	AK026465	6.42	23.05	4.15	0.18	6.42	16.15	10.52	0.65
209277_at	7980	TFPI2	AL574096	5.96	13.68	2.47	0.18	5.96	164.41	445.38	
221292_at	8643	PTCH2	NM_003738	21.02	36.76	6.63	0.18	21.02	7.94	18.39	
207542_s_at	358	AQP1	NM_000385	78.24	562.65	101.82	0.18	78.24	138.56	121.71	
216805_at	50807	DDEF1	AK027254	2.26	24.10	4.36	0.18	2.26	15.19	13.08	
210008_s_at	6183	MRPS12	BC001617	38.78	84.69	15.34	0.18	38.78	73.25	59.12	
220559_at	2019	EN1	NM_001426	12.44	20.59	3.73	0.18	12.44	10.77	13.77	
222328_x_at	55384	MEG3	AI133721	7.82	30.86	5.63	0.18	7.82	4.12	10.67	
213537_at	3113	HLA-DPA1	AI128225	7.89	14.48	2.65	0.18	7.89	15.62	12.45	
216314_at	167	CRISP1	X95238	2.14	14.60	2.68	0.18	2.14	2.81	1.09	
203131_at	5156	PDGFR A	NM_006206	7.99	16.02	2.95	0.18	7.99	6.21	11.43	
210569_s_at	27180	SIGLEC9	AF247180	20.09	32.10	5.92	0.18	20.09	4.65	12.82	
206596_s_at	4901	NRL	M81840	5.03	40.72	7.52	0.18	5.03	3.10	10.56	
203888_at	7056	THBD	NM_0003	399.76	963.86	179.21	0.19	399.76	1715.58	491.61	0.29

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			61								
216821_at	149501 /	KRT8 /// LOC149501 /// LOC3443	AL137067	19.09	54.43	10.13	0.19	19.09	24.72	17.91	
205840_x_at	2688	GH1	NM_000515	4.95	17.81	3.32	0.19	4.95	13.28	14.15	
215941_at			D16471	4.71	19.57	3.65	0.19	4.71	1.92	5.43	
206242_at	9032	TM4SF5	NM_003963	8.09	19.69	3.69	0.19	8.09	11.08	7.52	
209752_at	5967	REG1A	AF172331	3.75	23.56	4.42	0.19	3.75	3.67	3.30	
206454_s_at	6010	RHO	AA058836	8.78	41.48	7.80	0.19	8.78	17.96	3.50	0.19
208007_at			NM_012122	15.22	23.18	4.37	0.19	15.22	4.61	16.67	
221438_s_at	56158	TEX12	NM_031275	3.55	11.57	2.18	0.19	3.55	11.24	6.70	0.60
203887_s_at	7056	THBD	NM_000361	729.02	1651.91	312.45	0.19	729.02	3541.42	894.93	0.25
215226_at	23086	EXPH5	AK000786	14.05	34.33	6.51	0.19	14.05	4.96	13.74	
221183_at			NM_025064	1.53	16.94	3.21	0.19	1.53	1.83	4.94	
214385_s_at	4586 ///	MUC5AC /// LOC730855	AI521646	2.20	22.52	4.28	0.19	2.20	9.30	2.79	
216690_at	26664	OR7C1	AC005255	3.57	21.89	4.16	0.19	3.57	5.94	8.16	
222224_at	342538	NACAL	AJ278883	19.79	36.46	6.93	0.19	19.79	9.71	4.58	
203009_at	4059	BCAM	NM_005581	18.07	55.85	10.62	0.19	18.07	29.07	15.04	0.52
207578_s_at	3360	HTR4	NM_000870	29.50	172.70	32.87	0.19	29.50	47.16	57.22	
220373_at	54798	DCHS2	NM_017639	3.99	14.50	2.77	0.19	3.99	5.26	3.45	
216708_x_at	3535	IGL@	D84143	11.02	29.20	5.57	0.19	11.02	8.06	7.85	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
219103_at	55616	DDEFL1	NM_017707	14.17	78.77	15.03	0.19	14.17	27.58	5.68	0.21
205266_at	3976	LIF	NM_002309	14.44	39.25	7.51	0.19	14.44	61.96	121.11	
220535_at	55138	FAM90A1	NM_018088	10.39	26.78	5.12	0.19	10.39	7.43	2.73	
205552_s_at	4938	OAS1	NM_002534	137.96	744.19	142.55	0.19	137.96	363.07	107.94	0.30
216709_at	400655	LOC400655	AL162040	9.34	36.70	7.03	0.19	9.34	7.20	7.33	
204684_at	4884	NPTX1	NM_002522	64.95	318.61	61.26	0.19	64.95	1104.38	533.67	0.48
215534_at			AL117546	17.98	56.95	11.02	0.19	17.98	60.54	14.84	0.25
210454_s_at	3763	KCNJ6	U24660	7.82	23.44	4.55	0.19	7.82	36.83	5.96	0.16
216722_at	139538	VENTXP1	AF164963	3.43	17.55	3.41	0.19	3.43	25.00	5.14	0.21
216626_at			AL050026	6.50	22.14	4.31	0.19	6.50	9.22	6.38	
211602_s_at	7220	TRPC1	U31110	21.05	39.13	7.65	0.20	21.05	5.40	24.02	
203325_s_at	1289	COL5A1	AI130969	8.42	13.96	2.73	0.20	8.42	8.56	2.05	
202869_at	4938	OAS1	NM_016816	165.01	762.84	149.48	0.20	165.01	722.61	133.48	0.18
217232_x_at	3043	HBB	AF059180	26.73	55.35	10.85	0.20	26.73	35.18	74.89	
207193_at	181	AGRP	NM_001138	10.75	46.71	9.17	0.20	10.75	17.91	16.59	
213541_s_at	2078	ERG	AI351043	4.58	33.06	6.49	0.20	4.58	23.23	30.75	
206155_at	1244	ABCC2	NM_000392	2.30	10.16	2.00	0.20	2.30	10.86	6.30	0.58
209559_at	9026	HIP1R	AB013384	12.55	50.86	10.02	0.20	12.55	13.89	5.17	
207944_at	4951	OCM	NM_006188	10.46	32.47	6.40	0.20	10.46	5.00	5.29	
207368_at	3352	HTR1D	NM_000864	1.23	37.50	7.40	0.20	1.23	4.58	13.42	
216875_x_at	55547	HAB1	X83412	18.50	33.24	6.57	0.20	18.50	20.61	24.45	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
202458_at	11098	PRSS23	NM_007173	15.23	45.10	8.91	0.20	15.23	157.75	161.56	
207460_at	3004	GZMM	NM_005317	15.65	38.99	7.71	0.20	15.65	12.47	8.42	
211608_at			U50073	3.99	26.51	5.26	0.20	3.99	20.38	4.28	0.21
204851_s_at	1641	DCX	BE551351	2.49	15.40	3.06	0.20	2.49	2.96	3.78	
214461_at	3929	LBP	NM_004139	4.72	13.83	2.75	0.20	4.72	2.55	4.53	
221409_at	56656	OR2S2	NM_019897	16.57	44.94	8.94	0.20	16.57	44.62	17.53	0.39
204395_s_at	2869	GRK5	NM_005308	4.85	39.76	7.93	0.20	4.85	13.18	3.49	0.26
206795_at	2151	F2RL2	NM_004101	5.69	24.09	4.81	0.20	5.69	11.45	1.02	0.09
205495_s_at	10578	GNLY	NM_006433	20.35	49.27	9.84	0.20	20.35	3.70	5.10	
219514_at	23452	ANGPTL2	NM_012098	5.02	35.13	7.02	0.20	5.02	13.05	4.40	0.34
220142_at	60484	HAPLN2	NM_021817	25.08	49.29	9.85	0.20	25.08	14.99	21.25	
208181_at	8365	HIST1H4H	NM_003543	1.92	18.25	3.65	0.20	1.92	2.67	15.62	
203596_s_at	24138	IFIT5	NM_012420	8.22	53.28	10.67	0.20	8.22	91.58	20.13	0.22
206883_x_at	2815	GP9	NM_000174	44.47	74.63	14.96	0.20	44.47	20.41	8.43	
206856_at	10990	LILRB5	NM_006840	6.75	16.31	3.28	0.20	6.75	7.61	12.82	
207349_s_at	7352	UCP3	NM_022803	18.73	84.10	16.96	0.20	18.73	27.32	31.07	
207638_at	5651	PRSS7	NM_002772	0.46	10.71	2.16	0.20	0.46	6.15	3.29	
208285_at	26659	OR7A5	NM_017506	8.56	27.54	5.59	0.20	8.56	3.30	2.75	
214059_at	10561	IFI44	BE049439	26.82	109.98	22.31	0.20	26.82	80.13	40.28	0.50
216854_at	10220	GDF11	AF028333	6.73	10.80	2.19	0.20	6.73	11.00	4.64	0.42

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
208281_x_at	1617 ///	DAZ1 /// DAZ3 /// DAZ2 ///DAZ	NM_020364	4.25	41.71	8.50	0.20	4.25	32.65	12.54	0.38
216487_at	3709	ITPR2	AL049988	4.02	13.51	2.76	0.20	4.02	2.23	3.70	
221149_at	27202	GPR77	NM_018485	2.75	25.88	5.30	0.20	2.75	51.40	37.04	0.72
207342_at	1258	CNGB1	NM_001297	3.35	11.94	2.45	0.20	3.35	3.50	2.02	
218400_at	4940	OAS3	NM_006187	193.77	989.10	203.04	0.21	193.77	715.99	284.58	0.40
220531_at	79907	FLJ14126	NM_024849	3.50	13.61	2.80	0.21	3.50	4.45	3.32	
211103_at	4647	MYO7A	U55209	10.66	36.22	7.46	0.21	10.66	5.69	8.66	
207569_at	6098	ROS1	NM_002944	13.54	40.21	8.28	0.21	13.54	10.51	13.64	
209992_at	5208	PFKFB2	AB044805	6.22	31.87	6.57	0.21	6.22	6.47	14.75	
207774_at	83734	ATG10	NM_025020	27.24	59.76	12.34	0.21	27.24	18.31	35.76	
211606_at			U43279	3.75	14.10	2.92	0.21	3.75	10.14	5.37	0.53
203842_s_at	22924	MAPRE3	NM_012326	8.33	26.12	5.40	0.21	8.33	18.46	7.12	0.39
220534_at	79097	TRIM48	NM_024114	22.18	44.07	9.13	0.21	22.18	33.60	12.66	0.38
214376_at			AI263044	6.65	12.21	2.53	0.21	6.65	11.63	13.39	
205506_at	7429	VIL1	NM_007127	2.43	11.39	2.37	0.21	2.43	1.70	12.49	
219153_s_at	79875	THSD4	BG163478	9.93	37.84	7.87	0.21	9.93	12.52	11.53	
208448_x_at	3449	IFNA16	NM_002173	17.33	36.83	7.67	0.21	17.33	11.22	7.85	
206343_s_at	3084	NRG1	NM_013959	3.46	11.68	2.45	0.21	3.46	10.32	98.74	
214987_at			AL049449	12.98	31.12	6.55	0.21	12.98	18.04	4.13	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
215214_at	3535	IGL@	H53689	15.76	26.23	5.52	0.21	15.76	36.35	46.53	
204874_x_at	8938	BAIAP3	NM_003933	4.70	23.75	5.00	0.21	4.70	4.92	9.80	
220245_at	51151	SLC45A2	NM_016180	34.04	72.99	15.37	0.21	34.04	30.18	31.16	
213816_s_at	4233	MET	AA005141	8.10	22.36	4.72	0.21	8.10	6.78	9.19	
213955_at	91977	MYOZ3	BE673151	9.73	24.84	5.25	0.21	9.73	6.89	4.61	
210267_at	57185	NPAL3	BC001265	5.35	35.89	7.59	0.21	5.35	14.82	15.15	
203990_s_at	7403	UTX	AI140752	3.30	10.49	2.23	0.21	3.30	9.39	5.38	
215010_s_at	9024	BRSK2	AJ006701	10.54	37.26	7.92	0.21	10.54	2.94	3.94	
220622_at	79782	LRRC31	NM_024727	3.02	10.62	2.26	0.21	3.02	13.15	10.31	
40524_at	11099	PTPN21	X79510	4.73	22.60	4.81	0.21	4.73	25.76	35.61	
205539_at	10677	AVIL	NM_006576	33.26	52.80	11.24	0.21	33.26	22.28	22.23	
214498_at	434	ASIP	NM_001672	2.35	17.56	3.75	0.21	2.35	18.51	4.35	0.23
208168_s_at	1118	CHIT1	NM_003465	5.09	15.71	3.36	0.21	5.09	3.62	2.89	
214200_s_at	1291	COL6A1	AI193744	4.27	25.62	5.49	0.21	4.27	25.50	7.40	0.29
214947_at			AF052146	173.91	458.82	98.30	0.21	173.91	100.82	30.97	
220957_at	64693	CTAGE1	NM_022663	10.02	46.85	10.10	0.22	10.02	15.60	18.19	
216472_at	6453	ITSN1	AF003737	8.07	52.67	11.39	0.22	8.07	25.37	37.51	
213905_x_at	10194 //	BGN /// TSHZ1	AA845258	3.46	15.70	3.39	0.22	3.46	12.08	19.73	
204845_s_at	2028	ENPEP	NM_001977	3.08	12.61	2.73	0.22	3.08	2.76	1.73	
211442_x_at	64816	CYP3A43	AF280111	6.49	24.68	5.34	0.22	6.49	6.58	5.42	
202997_s_at	4017	LOXL2	BE25121	3.18	10.97	2.38	0.22	3.18	3.93	3.30	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			1								
216612_x_at			AK021988	8.07	18.70	4.07	0.22	8.07	12.79	21.33	
219211_at	11274 //	USP18 /// LOC727996 /// LOC728	NM_017414	108.73	392.94	85.42	0.22	108.73	273.28	66.66	0.24
222178_s_at			AL133262	3.73	10.55	2.30	0.22	3.73	1.64	3.70	
204870_s_at	5126	PCSK2	NM_002594	12.30	33.16	7.22	0.22	12.30	13.17	5.12	
211832_s_at	4193	MDM2	AF201370	11.58	20.16	4.40	0.22	11.58	33.23	25.55	
221342_at	80739	C6orf25	NM_025260	8.88	28.62	6.26	0.22	8.88	4.78	13.74	
201438_at	1293	COL6A3	NM_004369	7.30	11.62	2.55	0.22	7.30	6.17	5.79	
206455_s_at	6010	RHO	NM_000539	21.22	38.08	8.36	0.22	21.22	41.58	10.28	0.25
208020_s_at	775	CACNA1C	NM_000719	8.53	22.08	4.85	0.22	8.53	3.30	13.32	
222254_at			AL034429	4.11	16.86	3.70	0.22	4.11	2.65	5.24	
208219_at	91	ACVR1B	NM_020328	8.45	45.25	9.95	0.22	8.45	18.74	12.83	0.68
208208_at	8735	MYH13	NM_003802	6.15	37.65	8.29	0.22	6.15	4.01	17.13	
209159_s_at	65009	NDRG4	AV724216	8.20	70.63	15.63	0.22	8.20	10.61	9.35	
208545_x_at	6874	TAF4	NM_003185	28.98	44.60	9.88	0.22	28.98	20.75	22.09	
217490_at			AL049301	11.98	47.84	10.61	0.22	11.98	21.29	23.32	
205914_s_at	2902 ///	GRIN1 /// LOC731701	D13515	4.39	11.05	2.47	0.22	4.39	9.71	9.90	
207034_s_at	2736	GLI2	NM_030379	3.03	37.90	8.46	0.22	3.03	2.71	4.92	
205018_s_at	10150	MBNL	NM_0057	4.63	18.46	4.14	0.22	4.63	16.00	5.20	0.33

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		2	57								
207420_at	10584	COLEC10	NM_006438	8.48	14.72	3.30	0.22	8.48	11.84	3.45	
217236_x_at	3500	IGHG1	S74639	4.47	60.17	13.48	0.22	4.47	25.60	30.56	
214492_at	6444	SGCD	NM_000337	3.20	23.26	5.24	0.23	3.20	9.28	22.52	
207151_at	117	ADCYAP1R1	NM_001118	24.36	39.56	8.96	0.23	24.36	11.34	11.52	
202270_at	2633	GBP1	NM_002053	3.58	17.81	4.03	0.23	3.58	7.29	7.94	
204802_at	6236	RRAD	NM_004165	1.53	77.18	17.53	0.23	1.53	249.55	639.77	
216245_at	3557	IL1RN	BE563442	4.56	23.85	5.42	0.23	4.56	6.81	25.37	
210159_s_at	11074	TRIM31	AF230386	8.30	24.94	5.69	0.23	8.30	11.07	9.49	
209850_s_at	10435	CDC42EP2	BC005406	22.00	71.03	16.22	0.23	22.00	32.79	21.64	
217428_s_at	1300	COL10A1	X98568	6.56	20.03	4.59	0.23	6.56	4.20	5.81	
206975_at	4049	LTA	NM_000595	3.72	18.73	4.30	0.23	3.72	58.43	26.95	0.46
212821_at	26030	PLEKHG3	AI738980	29.35	93.51	21.47	0.23	29.35	7.41	27.90	
215076_s_at	1281	COL3A1	AU144167	5.45	11.08	2.55	0.23	5.45	29.13	8.76	0.30
219761_at	51267	CLEC1A	NM_016511	12.48	37.32	8.57	0.23	12.48	30.77	14.58	0.47
214324_at	2813	GP2	BF222483	13.12	24.61	5.66	0.23	13.12	7.42	4.76	
218186_at	57111	RAB25	NM_020387	4.04	10.27	2.36	0.23	4.04	5.81	5.61	
211169_s_at	5506	PPP1R3A	AF024579	4.63	16.00	3.69	0.23	4.63	15.83	13.96	
209013_x_at	7204	TRIO	AF091395	12.35	18.84	4.35	0.23	12.35	9.26	8.74	
217688_at			AA224446	3.53	29.19	6.75	0.23	3.53	2.54	5.29	
207737_at			NM_0219	6.02	20.00	4.63	0.23	6.02	16.27	2.37	0.15

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			81								
206372_at	4618	MYF6	NM_002469	7.85	29.22	6.77	0.23	7.85	6.07	3.02	
214604_at	3237	HOXD11	NM_021192	3.35	19.53	4.53	0.23	3.35	19.69	11.06	0.56
207978_s_at	8013	NR4A3	NM_006981	6.57	62.28	14.50	0.23	6.57	139.87	137.78	
216581_at	441133	LOC41133	AL022068	3.70	33.06	7.71	0.23	3.70	8.64	4.16	
207656_s_at	51	ACOX1	NM_004035	3.97	18.29	4.27	0.23	3.97	6.86	3.38	
221914_at	6853	SYN1	H19843	4.35	24.00	5.60	0.23	4.35	7.60	6.39	
212489_at	1289	COL5A1	AI983428	2.67	13.99	3.28	0.23	2.67	8.97	15.19	
209789_at	10391	CORO2B	BF939649	11.86	20.38	4.78	0.23	11.86	32.55	7.48	0.23
208253_at	27181	SIGLEC8	NM_014442	7.55	25.65	6.04	0.24	7.55	2.42	24.75	
201235_s_at	7832	BTG2	BG339064	110.45	1093.07	257.99	0.24	110.45	709.50	1467.85	
215901_at	347344	ZNF81	X68011	5.87	34.73	8.20	0.24	5.87	3.30	10.64	
220289_s_at	55057 //	AIM1L /// FLJ38020	NM_017977	7.82	13.51	3.19	0.24	7.82	4.11	6.45	
217160_at	7258	TSPY1	M94893	3.58	13.64	3.22	0.24	3.58	4.89	5.05	
207427_at	49	ACR	NM_001097	3.24	16.20	3.84	0.24	3.24	8.57	4.94	
219364_at	79132	LGP2	NM_024119	12.91	56.98	13.50	0.24	12.91	36.47	9.26	0.25
210880_s_at	10278	EFS	AB001467	11.19	35.86	8.50	0.24	11.19	2.73	20.70	
214490_at	416	ARSF	NM_004042	17.84	35.68	8.48	0.24	17.84	17.39	10.11	
214799_at	23114	NFASC	AI821777	5.41	17.95	4.27	0.24	5.41	3.82	2.01	
207114_at	80740	LY6G6C	NM_025261	14.12	36.43	8.66	0.24	14.12	47.18	31.42	0.67
207900_at	6361	CCL17	NM_002987	3.85	21.82	5.19	0.24	3.85	22.03	36.17	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
207690_at	257	ALX3	NM_006492	11.07	18.24	4.34	0.24	11.07	7.42	9.50	
209671_x_at	28755 //	TRA@ /// TRAC	M12423	24.38	104.03	24.78	0.24	24.38	17.84	13.99	
207110_at	3768	KCNJ12	NM_021012	6.09	12.02	2.87	0.24	6.09	3.06	2.22	
217275_at			L77565	13.24	40.54	9.67	0.24	13.24	10.39	10.70	
205261_at	5225	PGC	NM_002630	33.37	62.29	14.92	0.24	33.37	61.82	39.44	0.64
206123_at	3996	LLGL1	D50550	17.03	44.07	10.59	0.24	17.03	8.65	22.49	
215647_at	64062	RBM26	AK021576	0.35	16.36	3.94	0.24	0.35	8.09	2.65	
203868_s_at	7412	VCAM1	NM_001078	8.54	412.52	99.55	0.24	8.54	498.26	82.10	0.16
217660_at	79784	MYH14	AW188214	3.59	17.44	4.22	0.24	3.59	11.95	20.39	
205998_x_at	1576	CYP3A4	NM_017460	81.17	152.61	37.01	0.24	81.17	99.79	134.07	
220158_at	56891	LGALS14	NM_020129	23.45	37.04	8.99	0.24	23.45	43.75	15.17	0.35
216312_at	492	ATP2B3	AW615612	12.39	26.54	6.45	0.24	12.39	34.49	5.68	0.16
217334_at	442186	OR2J3	AL022727	7.41	13.17	3.20	0.24	7.41	2.84	2.97	
208142_at	10876	FAM12A	NM_006683	6.33	10.44	2.54	0.24	6.33	4.73	2.79	
210684_s_at	1742	DLG4	AF028825	9.47	40.37	9.83	0.24	9.47	9.74	17.94	
48031_r_at	10826	C5orf4	H93077	12.87	28.02	6.84	0.24	12.87	15.35	17.71	
220639_at	79853	TM4SF20	NM_024795	8.65	14.86	3.63	0.24	8.65	12.17	2.57	
204912_at	3587	IL10RA	NM_001558	460.98	2093.69	512.21	0.24	460.98	3175.53	1078.66	0.34
215063_x_at	55631	LRRC40	AL390149	127.53	218.71	53.60	0.25	127.53	332.09	119.06	0.36
219416_at	51435	SCARA3	NM_016240	20.83	44.03	10.82	0.25	20.83	29.92	31.71	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
204018_x_at	3039 ///	HBA1 /// HBA2	NM_000558	26.22	50.79	12.49	0.25	26.22	11.05	11.47	
221170_at	59340	HRH4	AF312230	8.58	15.44	3.80	0.25	8.58	7.70	6.49	
211640_x_at	4917	NTN2L	L23519	3.85	10.12	2.49	0.25	3.85	3.25	3.96	
207434_s_at	4151 ///	FXVD2 ///MB	NM_021603	15.62	28.70	7.07	0.25	15.62	75.78	12.35	0.16
207967_at	11311	VPS45	NM_007258	14.12	49.68	12.26	0.25	14.12	9.45	15.67	
214228_x_at	7293	TNFRSF4	AJ277151	2.59	13.05	3.22	0.25	2.59	215.37	126.68	0.59
205483_s_at	9636	ISG15	NM_005101	404.40	2028.75	501.75	0.25	404.40	1879.17	752.00	0.40
202335_s_at	7320	UBE2B	NM_003337	27.08	65.10	16.12	0.25	27.08	33.41	25.60	
214720_x_at	151011	10-Sep	BF981643	5.14	16.24	4.02	0.25	5.14	1.41	5.50	
211046_at	81033	KCNH6	BC006334	8.79	18.09	4.49	0.25	8.79	6.46	19.86	
204237_at	51454	GULP1	NM_016315	5.54	11.53	2.86	0.25	5.54	66.23	15.16	0.23
203153_at	3434	IFIT1	NM_001548	48.44	560.68	139.17	0.25	48.44	703.99	149.53	0.21
201374_x_at	5516	PPP2CB	AI379894	30.08	48.17	11.97	0.25	30.08	27.87	30.29	
215815_at	8896	BUD31	AK001615	6.09	18.48	4.60	0.25	6.09	5.89	3.75	
215658_at			AK024897	2.77	12.42	3.09	0.25	2.77	4.54	7.99	
211157_at			AF119878	13.22	31.90	7.94	0.25	13.22	15.37	10.23	
217257_at			L37198	37.87	76.37	19.04	0.25	37.87	81.33	48.87	0.60
214400_at	3640	INSL3	AI991694	8.68	19.24	4.80	0.25	8.68	14.49	10.55	0.73
206318_at	57119	SPINLW1	NM_020398	11.11	35.45	8.85	0.25	11.11	14.15	21.68	
211670_x_at	10214	SSX3	S82471	5.16	25.54	6.41	0.25	5.16	5.96	6.45	
221091_at	10022	INSL5	NM_0054	17.80	41.97	10.54	0.25	17.80	15.50	12.30	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			78								
208111_at	554	AVPR2	NM_000054	7.29	11.61	2.92	0.25	7.29	12.39	6.95	0.56
207144_s_at	4435	CITED1	NM_004143	4.42	17.74	4.47	0.25	4.42	5.58	6.42	
205216_s_at	350	APOH	NM_000042	27.83	42.62	10.75	0.25	27.83	8.56	4.24	
208372_s_at	3984	LIMK1	AF134379	31.95	67.95	17.21	0.25	31.95	9.65	11.98	
207562_at	1609	DGKQ	NM_001347	42.97	76.12	19.32	0.25	42.97	55.44	30.29	
217110_s_at	4585	MUC4	AJ242547	8.32	17.23	4.37	0.25	8.32	9.78	3.27	
221331_x_at	1493	CTLA4	NM_005214	6.30	33.90	8.63	0.25	6.30	37.21	27.95	
221033_s_at	56163	RNF17	NM_031277	12.15	41.60	10.59	0.25	12.15	20.10	3.46	0.17
219962_at	59272	ACE2	NM_021804	4.67	23.24	5.92	0.25	4.67	4.18	4.42	
216734_s_at	643	BLR1	X68829	4.22	15.67	4.00	0.26	4.22	4.65	3.90	
206000_at	4224	MEP1A	NM_005588	4.05	11.34	2.90	0.26	4.05	58.09	8.08	0.14
215240_at	3690	ITGB3	AI189839	5.55	10.32	2.64	0.26	5.55	4.29	2.77	
217545_at	79784	MYH14	AW081820	3.56	17.60	4.50	0.26	3.56	5.91	4.04	
210745_at	3175	ONECUT1	U96173	9.74	34.52	8.83	0.26	9.74	10.51	4.19	
215304_at	79875	THSD4	U79293	11.88	45.27	11.60	0.26	11.88	13.82	3.30	
217004_s_at	4168	MCF2	X13230	10.93	16.91	4.36	0.26	10.93	5.96	13.11	
220469_at	11316	COPE	NM_025088	42.07	70.79	18.26	0.26	42.07	19.49	46.10	
204626_s_at	3690	ITGB3	NM_000212	9.87	32.67	8.44	0.26	9.87	17.27	15.12	
210085_s_at	8416	ANXA9	AF230929	4.13	33.94	8.77	0.26	4.13	5.88	8.34	
220426_at	79025	C20orf195	NM_024059	4.76	26.95	6.99	0.26	4.76	5.32	9.25	
209793_at	2890 ///	GRIA1 ///	AL56730	8.25	12.69	3.29	0.26	8.25	8.24	6.30	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		RGS12	2								
204964_s_at	8082	SSPN	AL136756	21.60	41.58	10.80	0.26	21.60	13.29	9.02	
210855_at	9687	GREB1	AF245390	10.75	36.31	9.44	0.26	10.75	31.19	26.24	
206602_s_at	3232	HOXD3	NM_006898	1.77	26.94	7.01	0.26	1.77	7.43	13.58	
209855_s_at	3817	KLK2	AF188747	6.04	17.55	4.57	0.26	6.04	4.04	6.82	
213230_at	30850	CDR2L	AI422335	6.04	39.05	10.22	0.26	6.04	8.31	18.48	
221852_at	408050	NOMO3	N39536	5.97	13.72	3.59	0.26	5.97	3.18	7.85	
213345_at	4776	NFATC4	AI624015	19.25	37.51	9.85	0.26	19.25	9.45	8.72	
206400_at	3963	LGALS7	NM_002307	6.36	12.72	3.35	0.26	6.36	3.16	11.72	
205348_s_at	1780	DYNC1I1	NM_004411	15.06	26.79	7.07	0.26	15.06	18.00	10.60	
206236_at	2828	GPR4	NM_005282	19.98	33.35	8.80	0.26	19.98	25.16	11.68	
207208_at	27288	HNRNPG-T	NM_014469	5.85	22.13	5.86	0.26	5.85	6.03	5.70	
210194_at	22925	PLA2R1	U17033	5.57	14.96	3.96	0.26	5.57	3.92	24.25	
212325_at	22998	DKFZP686A01247	AK026815	5.01	23.44	6.22	0.27	5.01	9.76	7.99	
203784_s_at	55794	DDX28	BG477502	33.90	72.78	19.33	0.27	33.90	6.27	38.39	
205867_at	5781	PTPN11	NM_002834	47.50	72.17	19.18	0.27	47.50	40.31	33.13	
208387_s_at	10893	MMP24	NM_006690	24.00	41.40	11.02	0.27	24.00	26.02	8.45	
207126_x_at	54657	UGT1A4	NM_000463	15.67	39.52	10.53	0.27	15.67	52.15	34.28	0.66
210179_at	3769	KCNJ13	AJ007557	4.20	20.78	5.55	0.27	4.20	20.00	3.32	0.17
220809_at	79972	FLJ14327	NM_024912	20.37	34.48	9.22	0.27	20.37	20.89	24.91	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
207398_at	3239	HOXD13	NM_000523	6.42	22.14	5.92	0.27	6.42	3.22	6.10	
206271_at	7098	TLR3	NM_003265	7.14	19.04	5.10	0.27	7.14	5.85	7.90	
206051_at	1996	ELAVL4	NM_021952	7.51	57.30	15.37	0.27	7.51	4.90	13.20	
203824_at	7103	TSPAN8	NM_004616	2.54	11.40	3.06	0.27	2.54	5.35	8.58	
221008_s_at	64850	AGXT2L1	NM_031279	5.21	24.33	6.53	0.27	5.21	24.32	7.31	0.30
211008_s_at	7329	UBE2I	BC000744	35.29	82.06	22.05	0.27	35.29	25.84	32.59	
209761_s_at	3431	SP110	AA969194	422.13	1021.62	274.72	0.27	422.13	445.52	193.77	
222346_at	284217	LAMA1	AI633741	10.50	21.15	5.69	0.27	10.50	3.99	3.35	
213783_at	4242	MFNG	AI760053	26.55	53.00	14.29	0.27	26.55	40.72	27.17	0.67
221295_at	1149 ///	CIDEA /// GGT1	NM_001279	5.34	47.52	12.82	0.27	5.34	11.70	6.95	0.59
219915_s_at	117247	SLC16A10	NM_018593	30.90	53.44	14.43	0.27	30.90	248.74	115.97	0.47
205883_at	7704	ZBTB16	NM_006006	11.54	32.27	8.72	0.27	11.54	30.38	3.64	0.12
214023_x_at	347733	TUBB2B	AL533838	1.73	14.85	4.01	0.27	1.73	14.14	33.14	
214528_s_at	7849	PAX8	NM_013951	9.12	34.34	9.29	0.27	9.12	12.86	26.81	
220626_at	51156	SERPINA10	NM_016186	7.15	25.23	6.83	0.27	7.15	11.54	28.40	
220979_s_at	81849	ST6GALNAC5	NM_030965	5.10	12.98	3.52	0.27	5.10	14.14	6.08	0.43
207602_at	9407	TMPRS11D	NM_004262	32.35	56.30	15.25	0.27	32.35	46.04	25.46	
216618_at			AL117520	7.07	11.29	3.06	0.27	7.07	7.09	7.76	
216827_at			AL355379	16.94	32.06	8.69	0.27	16.94	10.81	2.25	
211422_at	80036	TRPM3	AL136545	8.97	25.10	6.81	0.27	8.97	19.27	2.95	0.15

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
222085_at	400451	LOC400451	AW452357	11.89	26.00	7.07	0.27	11.89	9.88	6.06	
208006_at	2299	FOXJ1	NM_012188	5.22	27.86	7.60	0.27	5.22	8.94	18.28	
220131_at	53822	FXR1	NM_022006	10.07	34.61	9.45	0.27	10.07	11.60	10.75	
217222_at			S74639	8.78	20.57	5.64	0.27	8.78	8.73	8.55	
214762_at	534	ATP6V1G2	BF340635	25.32	44.89	12.33	0.27	25.32	18.58	14.67	
210323_at	27285	TEKT2	AB033823	4.58	39.12	10.75	0.27	4.58	9.93	9.21	
205666_at	2326	FMO1	NM_002021	8.79	28.09	7.73	0.28	8.79	17.62	27.75	
215247_at	440895	LOC440895	AI561253	30.64	60.12	16.57	0.28	30.64	21.20	15.50	
213651_at	27124	PIB5PA	AI935720	5.97	17.74	4.90	0.28	5.97	7.26	23.83	
216946_at	3111	HLA-DOA	M29335	6.56	19.83	5.49	0.28	6.56	33.45	9.10	0.27
217479_at	388336	FLJ45455	AL110201	3.67	25.71	7.16	0.28	3.67	13.97	11.27	
216611_s_at	6530	SLC6A2	AB022847	8.07	14.18	3.95	0.28	8.07	4.91	3.85	
215630_at	23180	RFTN1	AU147528	17.98	68.15	19.07	0.28	17.98	92.48	80.57	
208366_at	27328	PCDH11X	NM_014522	9.95	29.24	8.19	0.28	9.95	25.23	26.22	
214572_s_at	3640	INSL3	NM_005543	9.53	18.33	5.14	0.28	9.53	8.07	4.02	
221241_s_at	79370	BCL2L14	NM_030766	4.68	15.45	4.33	0.28	4.68	8.86	2.77	
204779_s_at	3217	HOXB7	NM_004502	32.81	66.69	18.71	0.28	32.81	14.88	16.60	
213797_at	91543	RSAD2	AI337069	131.05	296.80	83.36	0.28	131.05	197.36	72.89	0.37
216047_x_at	23544	SEZ6L	AL050253	27.19	44.58	12.53	0.28	27.19	21.70	28.99	
211830_s_at	8911	CACNA1I	AF211189	21.92	52.89	14.87	0.28	21.92	68.28	53.07	
220689_at			NM_0180	18.47	42.63	12.00	0.28	18.47	8.81	11.09	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			55								
202714_s_at	9692	KIAA0391	NM_014672	34.87	65.48	18.46	0.28	34.87	48.35	9.91	
214088_s_at	2525	FUT3	AW080549	31.31	47.46	13.39	0.28	31.31	14.12	22.92	
214371_at	23617	TSSK2	AI652441	23.19	40.13	11.34	0.28	23.19	4.53	9.47	
216043_x_at	9727	RAB11FIP3	AK024135	46.70	88.94	25.15	0.28	46.70	33.99	37.28	
208474_at	9074	CLDN6	NM_021195	13.31	35.38	10.04	0.28	13.31	16.34	26.80	
207531_at	1420	CRYGC	NM_020989	10.18	25.54	7.26	0.28	10.18	29.22	12.39	0.42
202988_s_at	5996	RGS1	NM_002922	5.07	16.67	4.74	0.28	5.07	22.11	9.52	0.43
210248_at	7476	WNT7A	D83175	5.65	22.72	6.47	0.28	5.65	7.33	25.92	
215542_at			AK023121	2.74	11.96	3.41	0.28	2.74	16.67	1.20	0.07
215857_at	56926	NCLN	AK022309	5.81	23.75	6.77	0.29	5.81	17.34	5.71	0.33
207660_at	1756	DMD	NM_004019	4.55	12.30	3.51	0.29	4.55	21.97	10.34	0.47
204834_at	10875	FGL2	NM_006682	235.09	447.31	128.08	0.29	235.09	443.74	52.00	0.12
217351_at	392479	LOC392479	AL024458	2.40	20.21	5.80	0.29	2.40	10.45	4.22	0.40
205226_at	5157	PDGFR L	NM_006207	9.81	39.25	11.28	0.29	9.81	137.33	59.71	0.43
207346_at	2054	STX2	NM_001980	30.26	56.81	16.33	0.29	30.26	26.17	14.27	
220817_at	7223	TRPC4	NM_016179	2.29	26.09	7.50	0.29	2.29	22.80	2.57	0.11
213592_at	187	AGTRL1	X89271	5.58	19.76	5.69	0.29	5.58	5.95	2.23	
218523_at	64077	LHPP	NM_022126	6.80	36.10	10.41	0.29	6.80	15.36	17.14	
213335_s_at	10402	ST3GAL6	AK001922	5.57	51.23	14.78	0.29	5.57	8.30	2.80	
214234_s_at	1577	CYP3A	X90579	7.84	22.21	6.43	0.29	7.84	59.75	17.90	0.30

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		5									
216740_at	55809	TRERF1	AK024851	12.83	21.32	6.18	0.29	12.83	22.35	10.56	0.47
220196_at	94025	MUC16	NM_024690	1.84	10.24	2.97	0.29	1.84	2.45	2.97	
214255_at	57194	ATP10A	N35112	175.94	339.96	98.64	0.29	175.94	191.53	120.37	
217583_at	5053	PAH	BG433489	3.84	22.23	6.45	0.29	3.84	4.17	2.55	
221297_at	55507	GPRC5D	NM_018654	17.02	53.14	15.51	0.29	17.02	12.50	6.35	
206404_at	2254	FGF9	NM_002010	9.63	42.36	12.37	0.29	9.63	8.19	6.64	
211844_s_at	8828	NRP2	AF022859	2.87	16.43	4.81	0.29	2.87	15.81	41.73	
221105_at			NM_018395	7.33	18.28	5.35	0.29	7.33	9.13	1.94	
213849_s_at	5521	PPP2R2B	AA974416	27.68	76.12	22.27	0.29	27.68	29.98	23.79	
209684_at	54453	RIN2	AL136924	4.45	31.01	9.08	0.29	4.45	25.64	11.26	0.44
206210_s_at	1071	CETP	NM_000078	6.85	11.17	3.27	0.29	6.85	4.45	8.82	
215906_at			S65921	5.40	12.11	3.55	0.29	5.40	4.61	4.01	
217182_at	4586	MUC5AC	Z34282	15.36	29.14	8.54	0.29	15.36	65.91	21.97	0.33
205031_at	1949	EFNB3	NM_001406	9.49	23.52	6.90	0.29	9.49	6.67	8.20	
208586_s_at	548313 /	SSX4 /// SSX4B	NM_005636	2.43	25.54	7.50	0.29	2.43	7.83	5.05	
206237_s_at	3084	NRG1	NM_013957	5.69	15.26	4.49	0.29	5.69	33.05	353.86	
215184_at	23604	DAPK2	AK026801	8.52	18.96	5.59	0.29	8.52	17.70	7.18	0.41
206906_at	7087	ICAM5	NM_003259	16.04	36.34	10.71	0.29	16.04	47.11	50.78	
221405_at	51190	LOC51190	NM_016317	17.54	27.35	8.06	0.29	17.54	11.82	8.66	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
210960_at	146	ADRA1D	M76446	7.97	14.80	4.36	0.29	7.97	6.61	13.19	
211193_at	8626	TP73L	AF061512	17.52	34.72	10.23	0.29	17.52	13.14	22.02	
213293_s_at	10346	TRIM22	AA083478	141.18	578.88	170.81	0.30	141.18	722.64	140.68	0.19
205201_at	2737	GLI3	NM_000168	39.46	86.24	25.46	0.30	39.46	52.78	75.97	
204678_s_at	3775	KCNK1	U90065	1.57	12.69	3.75	0.30	1.57	6.93	14.94	
217095_x_at	9437	NCR1	AJ006122	6.84	20.73	6.12	0.30	6.84	13.96	20.19	
216196_at	440366	LOC440366	X69637	17.85	45.99	13.63	0.30	17.85	21.40	6.17	
216181_at	8871	SYNJ2	AK026758	19.40	49.75	14.77	0.30	19.40	9.21	45.08	
208592_s_at	913	CD1E	NM_030893	3.05	22.83	6.78	0.30	3.05	10.77	11.82	
208260_at	553	AVPR1B	NM_000707	31.11	52.45	15.59	0.30	31.11	24.50	15.98	
221128_at	8728	ADAM19	NM_023038	12.63	19.33	5.75	0.30	12.63	23.18	20.16	
202312_s_at	1277	COL1A1	K01228	14.76	27.86	8.31	0.30	14.76	18.57	19.40	
215303_at			BE046461	1.69	14.59	4.36	0.30	1.69	2.69	9.78	
216344_at	261734	NPHP4	AL117405	8.37	29.12	8.71	0.30	8.37	20.27	20.35	
216007_at	64084	CLSTN2	AF052176	26.37	45.13	13.51	0.30	26.37	31.45	30.75	
214300_s_at	7156	TOP3A	AI676092	18.81	45.26	13.55	0.30	18.81	56.78	26.21	0.46
220901_at	80045	GPR157	NM_024980	12.24	37.33	11.20	0.30	12.24	35.85	41.54	
218943_s_at	23586	DDX58	NM_014314	142.59	612.93	183.90	0.30	142.59	569.23	191.35	0.34
205456_at	916	CD3E	NM_000733	8.46	31.35	9.42	0.30	8.46	28.21	15.42	0.55
217474_at			AL117652	20.76	33.63	10.10	0.30	20.76	15.31	41.40	
210521_s_at	26998	FETUB	AB01755	4.87	13.82	4.15	0.30	4.87	15.40	3.50	0.23

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			1								
211896_s_at	1634	DCN	AF138302	16.50	61.98	18.66	0.30	16.50	48.16	30.59	0.64
220851_at			NM_014095	4.72	21.20	6.38	0.30	4.72	21.07	3.69	0.17
AFFX-HUMISGF3A/M97935_5_at	6772	STAT1	AFFX-HUMISGF3A/M97935_5	163.93	393.76	118.62	0.30	163.93	188.44	124.21	
222223_s_at	26525	IL1F5	AF216693	12.17	35.41	10.67	0.30	12.17	22.90	54.22	
215651_at			AK026682	23.12	78.52	23.69	0.30	23.12	13.82	16.87	
207116_s_at	26330	GAPDHS	NM_014364	4.44	15.90	4.80	0.30	4.44	16.14	11.36	0.70
211095_at	4763	NF1	D12625	12.13	24.22	7.32	0.30	12.13	25.34	19.07	
213948_x_at	57863	IGSF4B	AI564838	3.25	23.97	7.24	0.30	3.25	9.17	6.36	
207064_s_at	314	AOC2	NM_009590	8.55	30.67	9.28	0.30	8.55	28.82	28.29	
213706_at	2819	GPD1	AI368018	5.45	18.19	5.51	0.30	5.45	5.37	4.42	
220129_at	54937	SOHLH2	NM_017826	5.02	38.90	11.79	0.30	5.02	9.76	15.42	
215956_at	5868	RAB5A	AK022065	24.75	48.08	14.60	0.30	24.75	22.56	37.72	
204562_at	3662	IRF4	NM_002460	33.88	93.40	28.43	0.30	33.88	62.68	78.51	
219466_s_at	336	APOA2	NM_001643	14.30	43.55	13.26	0.30	14.30	16.43	6.18	
207212_at	6550	SLC9A3	NM_004174	5.47	10.51	3.20	0.30	5.47	2.01	2.34	
220582_at			NM_025071	17.72	36.69	11.18	0.30	17.72	7.72	32.19	
220687_at			NM_018175	9.22	40.97	12.50	0.31	9.22	33.20	32.79	
205864_at	6545	SLC7A4	NM_004173	26.00	48.04	14.67	0.31	26.00	17.49	9.75	
207742_s_at	2649	NR6A1	NM_001489	7.62	21.90	6.69	0.31	7.62	26.80	39.67	
219039_at	54910	SEMA4	NM_0177	106.17	286.50	87.50	0.31	106.17	151.64	63.78	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		C	89								
208080_at	6790	AURKA	NM_003158	20.78	50.95	15.60	0.31	20.78	17.01	24.82	
208902_s_at	256949 /	RPS28 /// ANKR D47	BF431363	13.06	81.23	24.89	0.31	13.06	9.13	14.40	
218736_s_at	54873	PALMD	NM_017734	2.59	21.92	6.72	0.31	2.59	2.49	7.08	
221154_at	283116 /	TRIM49 /// LOC283116 /// LOC65	NM_020358	3.58	10.71	3.28	0.31	3.58	9.62	2.42	
207138_at	5253	PHF2	NM_005392	2.00	10.77	3.30	0.31	2.00	9.64	6.66	
215258_at	199731	IGSF4C	AC005525	13.35	26.98	8.28	0.31	13.35	16.16	6.75	
207907_at	8740	TNFSF14	NM_003807	244.50	469.67	144.24	0.31	244.50	9.70	98.35	
204931_at	6943	TCF21	NM_003206	3.93	13.46	4.14	0.31	3.93	11.16	4.05	0.36
210781_x_at	2902	GRIN1	AF015731	7.99	17.08	5.25	0.31	7.99	10.02	3.25	
203936_s_at	4318	MMP9	NM_004994	152.92	1272.48	391.26	0.31	152.92	1661.16	453.20	0.27
209125_at	140446 /	KRT6A /// KRT6C /// KRT6E	J00269	15.03	25.14	7.74	0.31	15.03	5.22	16.94	
208711_s_at	595	CCND1	BC000076	17.91	87.06	26.85	0.31	17.91	76.97	43.26	0.56
215372_x_at	9223	MAGI1	AU146794	20.71	77.29	23.88	0.31	20.71	28.71	3.47	
201565_s_at	3398	ID2	NM_002166	2022.60	3332.02	1030.00	0.31	2022.60	5470.79	4962.34	
214538_x_at	9628	RGS6	AF073921	3.00	14.82	4.58	0.31	3.00	4.90	3.30	
219685_at	59353	TMEM35	NM_021637	1.62	22.42	6.93	0.31	1.62	4.58	7.64	
215466_at			AF035314	19.20	32.80	10.15	0.31	19.20	5.74	26.25	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
210699_at			AF116679	10.24	45.32	14.04	0.31	10.24	46.75	6.85	0.15
220435_at	55532	SLC30A10	NM_018713	7.48	16.27	5.04	0.31	7.48	6.72	4.82	
222069_s_at			BF058311	3.91	14.94	4.63	0.31	3.91	6.95	8.17	
208468_at	11166	SOX21	NM_007084	8.43	19.47	6.04	0.31	8.43	9.45	26.33	
206996_x_at	782	CACNB1	NM_000723	27.97	46.33	14.38	0.31	27.97	56.34	25.34	0.45
214610_at	1584	CYP11B1	AV702430	9.55	17.53	5.46	0.31	9.55	12.44	7.17	
217651_at			BF512531	12.51	35.00	10.90	0.31	12.51	8.77	18.57	
210972_x_at	28517 //	TRA@ /// TRDV2 /// TRAV2 0 ///	M15565	12.56	32.98	10.29	0.31	12.56	10.13	23.94	
206553_at	4939	OAS2	NM_002535	97.30	226.30	70.68	0.31	97.30	201.61	83.85	0.42
210773_s_at	2358	FPRL1	U81501	17.52	50.31	15.72	0.31	17.52	26.55	16.36	0.62
216866_s_at	7373	COL14A1	M64108	2.40	12.32	3.85	0.31	2.40	2.51	1.94	
209227_at			AU158251	3.90	11.72	3.66	0.31	3.90	16.99	5.26	0.31
220904_at	80069	C6orf208	NM_025002	5.48	47.06	14.72	0.31	5.48	3.27	13.10	
211249_at	8111	GPR68	U35398	61.33	99.46	31.15	0.31	61.33	33.60	5.73	
205390_s_at	286	ANK1	M28880	3.52	10.86	3.41	0.31	3.52	2.87	4.57	
204582_s_at	354	KLK3	NM_001648	4.35	33.76	10.60	0.31	4.35	22.15	5.64	0.25
217462_at	745	C11orf9	AC004770	18.53	30.50	9.57	0.31	18.53	4.34	20.41	
200606_at	1832	DSP	NM_004415	3.38	18.42	5.79	0.31	3.38	15.98	8.00	0.50
207787_at	3884	KRT33B	NM_002279	6.33	14.14	4.45	0.31	6.33	5.25	3.89	
217936_at	394	ARHG	AW04463	2.90	19.94	6.27	0.31	2.90	8.39	10.36	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		AP5	1								
209573_s_at	753	C18orf1	AF009424	25.53	39.61	12.51	0.32	25.53	11.16	16.79	
206762_at	3741	KCNA5	NM_002234	5.05	22.65	7.16	0.32	5.05	2.47	1.79	
205580_s_at	3269	HRH1	D28481	32.54	63.41	20.05	0.32	32.54	397.39	358.02	
206614_at	8200	GDF5	NM_000557	16.19	49.52	15.67	0.32	16.19	11.98	23.70	
205660_at	8638	OASL	NM_003733	88.99	341.25	108.14	0.32	88.99	365.73	178.92	0.49
204631_at	4620	MYH2	NM_017534	10.24	18.93	6.00	0.32	10.24	6.33	5.12	
219430_at	56834	GPR137	NM_020155	34.07	59.77	18.96	0.32	34.07	5.67	40.13	
216414_at			AL136094	2.09	10.96	3.48	0.32	2.09	3.57	6.32	
204681_s_at	9771	RAPGEF5	NM_012294	4.61	15.65	4.97	0.32	4.61	1.66	3.45	
211736_at	6668	SP2	BC005914	7.59	18.90	6.00	0.32	7.59	19.43	17.64	
219955_at	54596	L1TD1	NM_019079	21.94	35.06	11.16	0.32	21.94	5.10	11.34	
210940_s_at	2911	GRM1	U31216	4.20	30.54	9.72	0.32	4.20	14.81	9.69	0.65
207588_at	8827	MYT2	NM_003871	2.86	13.14	4.20	0.32	2.86	6.94	15.55	
209038_s_at	10938	EHD1	AL579035	68.55	207.66	66.35	0.32	68.55	304.89	354.40	
221385_s_at	2865 ///	FFAR3 /// GPR42 /// LOC731823	NM_005305	6.86	17.35	5.55	0.32	6.86	1.79	21.84	
221359_at	2668	GDNF	NM_000514	7.77	20.60	6.60	0.32	7.77	2.79	8.03	
205798_at	3575	IL7R	NM_002185	25.72	372.24	119.37	0.32	25.72	10147.44	4107.25	0.40
213972_at	2297	FOXD1	AI080288	11.48	62.74	20.13	0.32	11.48	10.73	16.16	
208350_at	1446	CSN1S1	NM_001890	9.06	18.08	5.81	0.32	9.06	9.91	9.10	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
203404_at	9823	ARMCX2	NM_014782	13.42	27.70	8.91	0.32	13.42	10.45	2.40	
220704_at	10320	IKZF1	NM_018563	45.18	143.43	46.24	0.32	45.18	177.07	159.62	
203180_at	220	ALDH1A3	NM_000693	4.84	30.78	9.93	0.32	4.84	39.05	16.86	0.43
215042_at	654	BMP6	AI123471	3.86	30.84	9.97	0.32	3.86	5.90	8.18	
210056_at	27289	RND1	U69563	16.25	41.60	13.45	0.32	16.25	65.86	56.09	
221384_at	7350	UCP1	NM_021833	6.45	10.66	3.45	0.32	6.45	3.71	7.95	
215721_at	3500	IGHG1	X58397	7.93	13.41	4.35	0.32	7.93	2.45	2.82	
221162_at	10086	HHLA1	NM_005712	21.23	43.59	14.15	0.32	21.23	34.56	81.32	
217502_at	3433	IFIT2	BE888744	10.20	191.10	62.04	0.32	10.20	90.52	91.62	
205921_s_at	6533	SLC6A6	NM_003043	8.89	39.98	12.99	0.32	8.89	32.40	80.27	
205308_at	51101	C8orf70	NM_016010	7.04	21.89	7.13	0.33	7.04	11.29	12.61	
215730_at	51442	VGLL1	BE542323	15.71	30.24	9.86	0.33	15.71	25.82	16.11	0.62
206194_at	3221	HOXC4	AW299598	26.51	73.12	23.88	0.33	26.51	19.40	34.08	
220727_at	54207	KCNK10	NM_021161	16.31	29.32	9.58	0.33	16.31	13.18	42.57	
215449_at	222642	BZRPL1	AI052224	9.50	21.01	6.87	0.33	9.50	3.49	9.41	
211891_s_at	50649	ARHGEF4	AB042199	13.55	33.86	11.07	0.33	13.55	3.82	9.10	
212741_at	4128	MAOA	AA923354	7.77	38.91	12.74	0.33	7.77	37.80	12.63	0.33
219313_at	54762	GRAMD1C	NM_017577	17.55	29.80	9.76	0.33	17.55	3.81	3.25	
207571_x_at	9473	C1orf38	NM_004848	247.84	585.69	191.78	0.33	247.84	479.11	237.70	0.50
222080_s_at			AW188134	5.23	12.59	4.13	0.33	5.23	22.10	11.80	0.53
211869_at			AF04965	4.51	11.08	3.63	0.33	4.51	4.25	6.89	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			6								
219908_at	27123	DKK2	NM_014421	297.50	552.30	181.34	0.33	297.50	118.37	164.22	
206171_at	140	ADORA3	NM_000677	18.81	31.77	10.44	0.33	18.81	17.38	11.07	
202409_at	3481 ///	IGF2 /// INS-IGF2	X07868	9.43	36.56	12.02	0.33	9.43	100.24	40.12	0.40
216238_s_at	2244	FGB	BG545288	3.14	17.17	5.65	0.33	3.14	7.71	5.91	
208543_at	26538	OR10H2	NM_013939	2.93	12.83	4.23	0.33	2.93	2.72	1.59	
207351_s_at	9047	SH2D2A	NM_003975	91.41	152.14	50.15	0.33	91.41	255.43	76.03	0.30
205158_at	6038	RNASE4	NM_002937	8.41	16.86	5.56	0.33	8.41	2.15	6.69	
209524_at	50810	HDGFRP3	AK001280	12.15	27.90	9.21	0.33	12.15	19.95	4.50	0.23
204747_at	3437	IFIT3	NM_001549	85.86	453.16	149.61	0.33	85.86	428.18	165.86	0.39
207471_at			AF118086	12.05	18.79	6.21	0.33	12.05	12.80	14.03	
214616_at	5030	P2RY4	NM_003532	14.73	68.02	22.47	0.33	14.73	40.29	9.78	0.24
214927_at	9358	ITGBL1	AL359052	5.75	30.10	9.95	0.33	5.75	3.92	5.67	
215654_at	587	BCAT2	AK023909	36.62	63.94	21.18	0.33	36.62	32.84	47.95	
219457_s_at	79890	RIN3	NM_024832	145.15	326.81	108.28	0.33	145.15	154.47	69.03	
205067_at	3553	IL1B	NM_000576	51.79	821.35	272.30	0.33	51.79	14950.88	13257.54	
AFFX-PheX-3_at			AFFX-PheX-3	7.27	16.84	5.59	0.33	7.27	7.55	11.48	
214717_at	150967	DKFZp434H1419	AL137534	70.49	152.92	50.76	0.33	70.49	124.17	61.90	0.50
206867_at	2646	GCKR	NM_001486	15.39	35.59	11.82	0.33	15.39	26.71	94.01	
213917_at	7849	PAX8	BE46582	15.95	38.38	12.75	0.33	15.95	33.65	19.89	0.59

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			9								
215488_at	2495	FTH1	AF052095	8.88	25.41	8.45	0.33	8.88	8.82	8.35	
204939_s_at	5350	PLN	NM_002667	2.41	12.30	4.09	0.33	2.41	1.45	2.33	
207422_at	8748	ADAM20	NM_003814	5.74	21.40	7.13	0.33	5.74	3.32	10.99	
211199_s_at	23308	ICOSLG	AF199028	4.73	115.17	38.40	0.33	4.73	176.99	171.19	
215841_at	2979	GUCA1B	AL096814	38.35	93.95	31.35	0.33	38.35	54.23	58.61	
214477_at	4298	MLLT1	NM_005934	14.37	32.52	10.87	0.33	14.37	7.65	18.08	
209504_s_at	58473	PLEKH B1	AF081583	6.12	19.15	6.41	0.33	6.12	28.60	23.75	
222213_x_at			AU147800	14.35	38.34	12.83	0.33	14.35	29.79	11.54	0.39
214834_at	338427 /	SNRPN /// PAR5 /// SNORD108 //	AU118874	19.02	72.84	24.40	0.33	19.02	4.45	18.83	
219073_s_at	114884	OSBPL10	NM_017784	22.63	35.48	11.95	0.34	22.63	27.95	11.15	
206932_at	9023	CH25H	NM_003956	12.68	19.37	6.52	0.34	12.68	5.11	22.82	
215869_at	19	ABCA1	AK022254	12.25	31.02	10.46	0.34	12.25	15.61	12.90	
205766_at	8557	TCAP	NM_003673	11.35	28.86	9.74	0.34	11.35	62.73	15.68	0.25
205749_at	1543	CYP1A1	NM_000499	4.04	19.82	6.70	0.34	4.04	10.63	8.36	
220462_at	80034	TAIP-2	NM_024969	6.18	15.19	5.15	0.34	6.18	3.19	6.38	
203649_s_at	5320	PLA2G2A	NM_000300	16.27	24.82	8.41	0.34	16.27	11.45	7.08	
210785_s_at	9473	C1orf38	AB035482	337.82	690.32	234.69	0.34	337.82	707.56	298.39	0.42
220106_at	29881	NPC1L1	NM_013389	5.02	30.44	10.35	0.34	5.02	3.14	5.94	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
206149_at	63928	LOC63928	NM_022097	2.22	16.22	5.52	0.34	2.22	6.62	4.92	
206367_at	5972	REN	NM_000537	7.44	11.60	3.95	0.34	7.44	4.31	4.56	
220045_at	63974	NEUROD6	NM_022728	8.47	23.30	7.94	0.34	8.47	3.46	14.02	
213667_at	10847	SRCAP	AB002307	57.39	86.42	29.58	0.34	57.39	63.00	70.70	
201006_at	7001	PRDX2	NM_005809	45.18	94.32	32.29	0.34	45.18	60.88	55.25	
214591_at	56062	KLHL4	BF215673	4.00	20.10	6.88	0.34	4.00	7.89	16.22	
215255_at	22997	IGSF9B	AB028953	22.77	49.75	17.05	0.34	22.77	21.32	23.94	
216089_at	645927 /	LOC645927 /// LOC651111	BE877397	3.51	10.76	3.69	0.34	3.51	12.02	2.80	0.23
209723_at	5272	SERPINB9	BC002538	34.25	57.27	19.65	0.34	34.25	762.07	215.01	0.28
203631_s_at	51704	GPRC5B	NM_016235	5.60	12.60	4.33	0.34	5.60	20.73	13.58	0.66
205234_at	9122	SLC16A4	NM_004696	8.29	29.56	10.17	0.34	8.29	41.22	38.14	
216556_x_at			AL135926	23.21	66.49	22.88	0.34	23.21	7.10	31.24	
222187_x_at	10146	G3BP1	X78262	131.35	305.94	105.32	0.34	131.35	82.30	116.69	
201820_at	3852	KRT5	NM_000424	5.99	16.26	5.60	0.34	5.99	3.60	9.13	
219998_at	29094	HSPC159	NM_014181	13.89	33.82	11.65	0.34	13.89	14.65	24.13	
206560_s_at	8190	MIA	NM_006533	16.79	44.64	15.38	0.34	16.79	8.50	40.53	
206338_at	1995	ELAVL3	NM_001420	5.62	13.95	4.81	0.34	5.62	5.65	16.08	
211142_x_at	3111	HLA-DOA	M38056	10.13	30.64	10.57	0.34	10.13	23.39	32.02	
220621_at	2301	FOXO3	NM_012186	5.83	10.21	3.52	0.35	5.83	11.80	4.91	0.42
212515_s_at	1654	DDX3	BG49260	975.29	1688.85	582.96	0.35	975.29	948.43	1608.43	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		X	2								
206119_at	635	BHMT	NM_001713	12.35	40.03	13.84	0.35	12.35	6.24	7.79	
219840_s_at	27004	TCL6	NM_012468	2.19	26.04	9.02	0.35	2.19	16.14	20.37	
220066_at	64127	NOD2	NM_022162	100.06	518.34	179.49	0.35	100.06	160.53	72.19	0.45
216042_at	8718	TNFRSF25	AI275938	53.72	83.57	28.94	0.35	53.72	33.41	23.47	
44673_at	6614	SIGLEC1	N53555	110.33	240.92	83.44	0.35	110.33	133.53	58.42	
220409_at	157922	CAMSAP1	NM_018627	13.42	44.47	15.41	0.35	13.42	33.59	33.18	
206422_at	2641	GCG	NM_002054	3.30	12.49	4.33	0.35	3.30	1.14	2.57	
210090_at	23237	ARC	AF193421	5.62	11.23	3.90	0.35	5.62	8.31	10.06	
205503_at	5784	PTPN14	NM_005401	81.75	286.35	99.48	0.35	81.75	90.04	150.13	
208937_s_at	3397	ID1	D13889	38.28	58.63	20.38	0.35	38.28	38.87	47.81	
207109_at	25833	POU2F3	NM_014352	4.94	25.39	8.83	0.35	4.94	4.12	1.62	
213516_at	11214	AKAP13	AF126008	3.68	19.06	6.63	0.35	3.68	2.13	1.22	
210770_s_at	773	CACNA1A	AF004884	90.72	165.84	57.75	0.35	90.72	65.91	43.85	
221179_at			NM_025050	5.06	21.79	7.60	0.35	5.06	8.60	3.46	
211902_x_at	6955	TRA@	L34703	15.09	65.93	23.00	0.35	15.09	31.95	8.72	0.27
220779_at	51702	PADI3	NM_016233	6.69	21.45	7.48	0.35	6.69	8.76	6.24	
216575_at			AL035604	11.84	18.69	6.52	0.35	11.84	6.15	11.71	
211369_at			AF116689	8.41	15.47	5.40	0.35	8.41	5.22	25.02	
217394_at	6955	TRA@	AE000659	9.58	22.31	7.79	0.35	9.58	11.89	10.21	
207517_at	3918	LAMC2	NM_018891	7.34	13.44	4.70	0.35	7.34	4.53	2.97	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
216066_at	19	ABCA1	AK024328	17.06	60.72	21.23	0.35	17.06	51.27	100.81	
219659_at	51761	ATP8A2	NM_016529	8.08	16.98	5.94	0.35	8.08	8.76	5.69	
217158_at	728683	LOC728683	X97875	4.27	13.91	4.87	0.35	4.27	10.65	2.77	0.26
204751_x_at	1824	DSC2	NM_004949	116.12	183.32	64.28	0.35	116.12	47.95	83.23	
214963_at	23279	NUP160	AK026236	8.14	31.91	11.19	0.35	8.14	21.85	4.23	0.19
216219_at	363	AQP6	AL137716	20.19	58.03	20.36	0.35	20.19	53.01	32.39	0.61
207854_at	2996	GYPE	NM_002102	3.22	12.33	4.33	0.35	3.22	3.89	2.19	
214064_at	7018	TF	AI073407	10.02	33.26	11.70	0.35	10.02	9.73	10.28	
215125_s_at	54575 //	UGT1A10 /// UGT1A8 /// UGT1A7	AV691323	8.08	20.36	7.16	0.35	8.08	6.56	13.78	
219385_at	56833	SLAMF8	NM_020125	43.50	445.91	157.28	0.35	43.50	443.81	133.77	0.30
210229_s_at	1437	CSF2	M11734	5.89	13.16	4.64	0.35	5.89	7.30	51.72	
204623_at	7033	TFF3	NM_003226	14.34	52.14	18.42	0.35	14.34	46.35	50.03	
209914_s_at	9378	NRXN1	AW149405	10.64	25.39	9.00	0.35	10.64	4.60	30.18	
218820_at	56967	C14orf132	NM_020215	18.31	44.99	15.94	0.35	18.31	27.67	36.85	
215530_at	2175	FANCA	BG484069	47.32	71.26	25.26	0.35	47.32	38.10	32.15	
218600_at	80774	LIMD2	NM_030576	121.41	404.40	143.48	0.35	121.41	130.94	95.66	
208083_s_at	3694	ITGB6	NM_000888	5.63	10.16	3.61	0.35	5.63	0.88	1.25	
214650_x_at	4340	MOG	AL050328	19.10	41.04	14.58	0.36	19.10	19.66	25.20	
204642_at	1901	EDG1	NM_001400	7.29	24.67	8.79	0.36	7.29	7.02	7.62	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
213831_at	3117	HLA-DQA1	X00452	2.11	10.87	3.87	0.36	2.11	2.63	6.44	
214598_at	9073	CLDN8	AL049977	2.81	12.82	4.57	0.36	2.81	9.76	8.89	
213252_at	9644	SH3PX D2A	AI739005	55.00	88.12	31.43	0.36	55.00	37.93	34.67	
216017_s_at	4665	NAB2	AJ011081	150.35	501.93	179.05	0.36	150.35	410.79	1072.21	
203541_s_at	687	KLF9	NM_001206	8.85	14.30	5.11	0.36	8.85	18.30	17.67	
220749_at	79741	C10orf68	NM_024688	19.62	33.19	11.86	0.36	19.62	11.38	20.86	
AFFX-HUMISGF3A/M97935_MB_at	6772	STAT1	AFFX-HUMISGF3A/M97935_MB	333.13	792.85	283.54	0.36	333.13	356.02	297.74	
200795_at	8404	SPARCL1	NM_004684	8.32	18.73	6.70	0.36	8.32	8.98	4.29	
212448_at	23327	NEDD4L	AB007899	54.98	93.15	33.38	0.36	54.98	107.56	21.85	0.20
216892_at	3500	IGHG1	S65761	22.83	34.98	12.55	0.36	22.83	16.71	22.61	
220194_at	79730	NSUN7	NM_024677	4.84	12.38	4.44	0.36	4.84	3.35	4.21	
213873_at			D29810	26.79	41.92	15.04	0.36	26.79	20.44	24.28	
206650_at	55721	IQCC	NM_018134	22.11	48.73	17.51	0.36	22.11	41.53	20.04	0.48
214325_at	2813	GP2	BF046750	3.65	10.68	3.84	0.36	3.65	7.18	3.26	
213498_at	90993	CREB3L1	BG328407	15.99	40.69	14.65	0.36	15.99	38.50	21.47	0.56
219010_at	55765	C1orf106	NM_018265	397.55	1156.23	416.29	0.36	397.55	745.45	343.14	0.46
217629_at	2793	GNGT2	AA365670	19.33	31.12	11.21	0.36	19.33	26.85	15.35	
210887_s_at	2121	EVC	AF216185	10.29	23.25	8.38	0.36	10.29	17.78	32.87	
210146_x_at	10288 //	LILRB2 /// LILRA6 /// LOC65262	AF004231	32.40	56.81	20.47	0.36	32.40	125.79	14.82	0.12

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
204707_s_at	5596	MAPK4	BF115223	6.65	19.98	7.21	0.36	6.65	14.25	10.83	
206730_at	2892 ///	GRIA3 /// FLJ21839	NM_007325	11.00	18.63	6.74	0.36	11.00	12.47	3.01	
214856_at	6711	SPTBN1	BF434424	4.05	20.23	7.32	0.36	4.05	8.85	8.76	
1255_g_at	2978	GUCA1A	L36861	5.92	10.68	3.87	0.36	5.92	12.38	6.69	0.54
210106_at	5959	RDH5	U43559	29.55	65.32	23.68	0.36	29.55	25.65	13.68	
204288_s_at	8470	SORBS2	NM_021069	11.55	45.28	16.43	0.36	11.55	10.67	19.57	
211667_x_at			L34698	6.36	32.98	11.97	0.36	6.36	6.08	3.46	
219042_at	11178	LZTS1	NM_021020	7.89	17.88	6.49	0.36	7.89	15.80	3.25	0.21
210797_s_at	8638	OASL	AF063612	72.69	379.07	137.71	0.36	72.69	326.62	199.27	0.61
221303_at	29930	PCDHB1	NM_013340	9.73	17.04	6.21	0.36	9.73	26.11	22.12	
214775_at	23138	N4BP3	AW139448	19.41	45.72	16.67	0.36	19.41	42.11	55.89	
214821_at	291	SLC25A4	AF052119	17.95	37.73	13.76	0.36	17.95	22.55	22.74	
216136_at			AF113683	1.07	17.34	6.33	0.36	1.07	8.30	4.99	
214633_at	6658	SOX3	AI824954	6.56	18.61	6.80	0.37	6.56	3.37	3.67	
205116_at	3908	LAMA2	NM_000426	25.36	41.87	15.31	0.37	25.36	34.45	50.01	
216729_at			AK025388	14.14	22.32	8.16	0.37	14.14	20.26	7.24	
221462_x_at	55554	KLK15	NM_017509	10.37	20.99	7.68	0.37	10.37	6.76	4.62	
213961_s_at			AI077556	21.60	33.32	12.22	0.37	21.60	8.63	10.54	
215266_at	55567	DNAH3	AL096732	13.14	23.47	8.61	0.37	13.14	9.11	14.97	
217326_x_at	5644	PRSS1	AF009787	17.26	31.28	11.49	0.37	17.26	8.14	36.57	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
213071_at	1805	DPT	AL049798	3.99	10.14	3.72	0.37	3.99	9.40	8.16	
216390_at	3931	LCAT	X06537	14.96	37.53	13.80	0.37	14.96	11.49	9.37	
217217_at	10095 //	ARPC1B /// IGHA1	X95660	6.17	15.48	5.69	0.37	6.17	11.37	2.53	0.22
219249_s_at	60681	FKBP10	NM_021939	3.14	10.62	3.92	0.37	3.14	5.88	5.38	
206356_s_at	2774	GNAL	NM_002071	2.16	26.24	9.69	0.37	2.16	15.47	13.67	
215995_x_at	348094	ANKKD1A	AU147598	24.03	76.27	28.16	0.37	24.03	26.84	38.03	
202728_s_at	4052	LTBP1	AI986120	8.78	18.39	6.79	0.37	8.78	13.09	6.50	
204994_at	4600	MX2	NM_002463	401.48	1048.88	387.53	0.37	401.48	1233.73	323.72	0.26
211405_x_at	3451	IFNA17	M38289	46.09	101.45	37.49	0.37	46.09	27.81	12.90	
207777_s_at	11262	SP140	NM_007237	12.91	33.57	12.41	0.37	12.91	3.29	7.68	
220644_at			NM_014137	5.76	11.76	4.35	0.37	5.76	3.36	11.88	
205294_at	10458	BAIAP2	AB017120	118.85	178.85	66.12	0.37	118.85	331.06	321.61	
206894_at	337	APOA4	NM_000482	31.00	60.10	22.24	0.37	31.00	23.29	17.31	
220588_at	55653	BCAS4	NM_017843	13.75	29.11	10.79	0.37	13.75	34.75	29.20	
211719_x_at	2335	FN1	BC005858	3.41	30.07	11.15	0.37	3.41	71.30	59.05	
208441_at	3480	IGF1R	NM_015883	16.45	35.78	13.30	0.37	16.45	4.96	21.03	
215026_x_at	6337	SCNN1A	U81961	10.47	28.85	10.75	0.37	10.47	9.92	11.44	
220135_s_at	11136	SLC7A9	NM_014270	19.32	36.20	13.49	0.37	19.32	35.00	11.86	0.34
222285_at	3495	IGHD	AW134608	7.59	12.70	4.74	0.37	7.59	3.61	5.26	
219691_at	54809	SAMD9	NM_017654	181.38	431.12	160.89	0.37	181.38	224.11	63.18	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
220630_s_at	27159	CHIA	NM_021797	3.94	26.37	9.85	0.37	3.94	16.09	6.27	0.39
214603_at	266740 /	MAGE A2 /// MAGE A2B	U82671	2.18	22.06	8.24	0.37	2.18	12.12	16.08	
213294_at			AV755522	685.49	1711.91	639.85	0.37	685.49	2174.68	567.17	0.26
216127_at	64714	PDIA2	Z84717	2.37	11.67	4.36	0.37	2.37	4.45	6.00	
221911_at	2115	ETV1	BE881590	16.14	38.28	14.32	0.37	16.14	8.57	1.62	
206776_x_at	56	ACRV1	NM_001612	30.60	47.62	17.84	0.37	30.60	22.29	25.17	
209182_s_at	11067	C10orf10	AI302100	40.04	71.88	26.93	0.37	40.04	60.12	64.91	
206863_x_at			U76376	2.87	10.35	3.88	0.37	2.87	4.60	1.98	
202669_s_at	1948	EFNB2	U16797	11.10	23.81	8.93	0.38	11.10	31.06	59.31	
217668_at	388886	C22orf36	BF511164	5.79	14.46	5.43	0.38	5.79	15.40	11.49	0.75
214294_at	57235	KIAA0485	AI122905	13.83	35.13	13.20	0.38	13.83	13.10	18.86	
205559_s_at	5125	PCSK5	NM_006200	6.41	27.47	10.32	0.38	6.41	62.04	151.92	
219519_s_at	6614	SIGLEC1	NM_023068	78.10	195.87	73.63	0.38	78.10	99.53	57.39	
221631_at	8911	CACNA1I	AB032946	11.87	34.68	13.05	0.38	11.87	7.60	3.38	
217207_s_at	10917	BTNL3	AK025267	66.36	100.17	37.73	0.38	66.36	57.86	64.04	
216634_at	23007	PLCH1	AK022610	3.85	12.91	4.88	0.38	3.85	3.29	4.48	
217444_at			AL080086	7.09	26.70	10.10	0.38	7.09	8.08	20.65	
204401_at	3783	KCNN4	NM_002250	417.08	778.30	294.43	0.38	417.08	717.37	520.42	0.73
207658_s_at	2290 ///	FOXP1 B /// FOXG1 A	NM_004471	16.27	56.80	21.49	0.38	16.27	13.11	37.03	
217684_at	7298	TYMS	BG28167	22.41	46.19	17.50	0.38	22.41	9.52	11.89	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			9								
217374_x_at	6978	TRGV5	AC006033	65.25	106.69	40.46	0.38	65.25	11.64	33.41	
221386_at	4995	OR3A2	NM_002551	11.60	25.78	9.78	0.38	11.60	16.00	2.77	
214054_at	9046	DOK2	AI828929	1119.54	1794.24	681.22	0.38	1119.54	1676.34	597.50	
221174_at			NM_025039	5.86	10.14	3.85	0.38	5.86	3.58	7.40	
206196_s_at	10900	RPIP8	NM_006695	15.83	37.04	14.07	0.38	15.83	50.05	7.10	0.14
219412_at	23682	RAB38	NM_022337	51.61	250.31	95.08	0.38	51.61	367.63	94.16	0.26
217026_at	1080	CFTR	M96936	10.26	16.74	6.36	0.38	10.26	16.06	3.71	0.23
217328_at	5644	PRSS1	AF009787	6.76	10.47	3.98	0.38	6.76	5.11	26.32	
207470_at	54744	DKFZp566H0824	NM_017535	7.75	33.34	12.68	0.38	7.75	10.24	13.98	
221346_at	26476	OR10J1	NM_012351	11.04	82.22	31.33	0.38	11.04	39.70	15.43	0.39
209447_at	23345	SYNE1	AF043290	57.82	88.35	33.69	0.38	57.82	12.86	6.00	
39402_at	3553	IL1B	M15330	53.05	659.61	251.68	0.38	53.05	10198.17	10747.99	
221271_at	59067	IL21	NM_021803	4.88	25.84	9.86	0.38	4.88	8.13	6.52	
33304_at	3669	ISG20	U88964	56.23	136.14	51.99	0.38	56.23	280.62	206.24	0.73
209569_x_at	27065	D4S234E	BC001745	3.37	14.40	5.50	0.38	3.37	8.65	16.76	
202827_s_at	4323	MMP14	NM_004995	295.83	742.68	283.92	0.38	295.83	138.62	266.43	
207505_at	5593	PRKG2	NM_006259	15.99	29.45	11.26	0.38	15.99	14.12	11.02	
214542_x_at	8329	HIST1H2AI	NM_003509	42.02	74.04	28.34	0.38	42.02	12.67	26.61	
220267_at	192666	KRT24	NM_019016	9.22	17.45	6.68	0.38	9.22	10.09	17.24	
222059_at	63925	ZNF335	BE676476	5.30	31.65	12.13	0.38	5.30	45.87	6.36	0.14

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
220400_at	157680	VPS13B	NM_017890	55.25	135.30	51.84	0.38	55.25	29.10	55.10	
216546_s_at	1116	CH13L1	AJ251847	56.96	88.89	34.14	0.38	56.96	232.14	88.08	0.38
215018_at	85459	KIAA1731	AB051518	43.74	129.92	49.91	0.38	43.74	83.09	54.04	0.65
204400_at	10278	EFS	NM_005864	11.59	17.58	6.77	0.38	11.59	10.91	5.57	
206320_s_at	4093	SMAD9	NM_005905	4.12	17.46	6.74	0.39	4.12	23.63	13.28	0.56
216131_at	23150	FRMD4B	AK000244	5.35	10.39	4.01	0.39	5.35	26.15	19.49	0.75
215657_at	1811	SLC26A3	AK025044	3.27	25.17	9.73	0.39	3.27	6.79	2.90	
222257_s_at	59272	ACE2	AK026461	4.74	25.89	10.00	0.39	4.74	3.39	6.33	
209652_s_at	5228	PGF	BC001422	7.67	17.05	6.59	0.39	7.67	26.24	2.99	0.11
207757_at	80108	ZFP2	NM_030613	67.18	145.15	56.12	0.39	67.18	174.02	83.37	0.48
208600_s_at	2863	GPR39	NM_001508	5.14	17.35	6.72	0.39	5.14	7.59	9.14	
206360_s_at	9021	SOCS3	NM_003955	24.04	85.62	33.20	0.39	24.04	77.00	135.95	
215159_s_at	65220	NADK	AI239732	104.97	185.45	72.01	0.39	104.97	60.43	71.45	
209291_at	3400	ID4	AW157094	4.93	19.22	7.46	0.39	4.93	9.72	2.43	
214032_at	7535	ZAP70	AI817942	3.45	14.45	5.61	0.39	3.45	20.24	20.35	
210883_x_at	1949	EFNB3	U57001	32.26	66.56	25.87	0.39	32.26	54.90	46.17	
220498_at	10880	ACTL7B	NM_006686	6.35	12.88	5.01	0.39	6.35	9.72	10.31	
215617_at			AU145711	205.43	504.63	196.27	0.39	205.43	419.40	171.84	0.41
205685_at	942	CD86	BG236280	30.48	81.94	31.89	0.39	30.48	115.04	45.44	0.39
211374_x_at			AF116715	51.83	89.47	34.82	0.39	51.83	49.98	27.24	
204197_s_at	864	RUNX3	NM_004350	703.88	1070.81	416.78	0.39	703.88	1210.69	546.84	0.45

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
214899_at	163131	ZNF780B	AC007842	8.82	17.79	6.93	0.39	8.82	11.84	16.82	
206032_at	1825	DSC3	AI797281	76.10	230.70	89.88	0.39	76.10	156.10	163.08	
206985_at	3293	HSD17B3	NM_000197	8.11	44.81	17.48	0.39	8.11	6.01	7.71	
214669_x_at	3107	HLA-C	BG485135	12.06	123.66	48.25	0.39	12.06	30.48	45.50	
214084_x_at	29	ABR	AW072388	209.66	634.85	247.92	0.39	209.66	192.68	69.85	
214609_at	401	PHOX2A	AI469991	13.14	50.09	19.57	0.39	13.14	31.71	40.05	
209371_s_at	6452	SH3BP2	AI393190	112.60	236.00	92.21	0.39	112.60	125.14	101.81	
211325_x_at	171220	LOC171220	U72518	170.02	257.02	100.44	0.39	170.02	153.21	185.96	
216118_at			AU148024	20.52	35.35	13.82	0.39	20.52	52.25	15.01	0.29
202145_at	4061	LY6E	NM_002346	309.94	600.22	235.08	0.39	309.94	284.59	162.84	
211577_s_at	3479	IGF1	M37484	16.77	62.69	24.61	0.39	16.77	18.90	30.79	
213317_at	53405	CLIC5	AL049313	6.34	33.34	13.10	0.39	6.34	119.62	151.72	
207709_at	5563	PRKA2	NM_006252	10.29	34.74	13.66	0.39	10.29	32.52	8.62	0.27
222363_at			AW979018	12.38	124.76	49.10	0.39	12.38	36.51	35.86	
213559_s_at	168544	ZNF467	BF223401	4.10	13.65	5.37	0.39	4.10	3.74	2.50	
210441_at	8556	CDC14A	AF064102	42.69	67.52	26.60	0.39	42.69	48.45	40.23	
204549_at	9641	IKBKE	NM_014002	211.41	610.47	240.71	0.39	211.41	492.09	169.75	0.34
217101_at	22996	C1orf34	AB007921	6.03	21.09	8.32	0.39	6.03	4.42	3.17	
206639_x_at	3346	HTN1	NM_002159	12.95	23.78	9.39	0.39	12.95	4.78	12.14	
220101_x_at			NM_018628	24.49	49.27	19.46	0.40	24.49	38.90	20.71	0.53

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
218312_s_at	65982	ZNF447	NM_023926	3.67	29.94	11.84	0.40	3.67	5.22	6.35	
215068_s_at	80028	FBXL18	BC004228	103.91	161.23	63.87	0.40	103.91	93.60	55.45	
204211_x_at	5610	EIF2AK2	NM_002759	536.17	1173.56	465.02	0.40	536.17	846.82	467.26	0.55
216795_at			AK026847	5.08	37.28	14.78	0.40	5.08	16.70	3.61	0.22
221990_at	7849	PAX8	AI948472	6.46	12.60	5.00	0.40	6.46	11.75	4.10	0.35
206903_at			NM_005728	13.26	20.38	8.08	0.40	13.26	21.18	11.03	0.52
215717_s_at	2201	FBN2	X62009	37.77	64.85	25.72	0.40	37.77	44.55	24.92	
210751_s_at	9104	RGN	D31815	12.81	20.62	8.18	0.40	12.81	3.35	5.45	
211215_x_at	1734	DIO2	AB041843	12.09	21.26	8.44	0.40	12.09	8.02	8.57	
210583_at	84271	POLDIP3	AB055760	13.11	29.55	11.73	0.40	13.11	6.56	19.95	
218744_s_at	29763	PACSN3	NM_016223	7.19	16.23	6.45	0.40	7.19	5.03	12.05	
217190_x_at	2099	ESR1	S67777	7.98	32.15	12.79	0.40	7.98	6.06	13.38	
219883_at			NM_016611	36.71	67.19	26.73	0.40	36.71	46.04	20.34	
220861_at			NM_014093	11.40	22.11	8.80	0.40	11.40	16.59	29.43	
216743_at	112	ADCY6	AK024915	3.10	11.02	4.39	0.40	3.10	4.46	2.79	
207072_at	8807	IL18RAP	NM_003853	45.16	229.00	91.30	0.40	45.16	445.08	92.54	0.21
207561_s_at	9311	ACCN3	NM_020322	23.92	53.84	21.47	0.40	23.92	38.31	25.16	0.66
207715_at	1419	CRYGB	NM_005210	2.99	13.40	5.35	0.40	2.99	3.79	5.19	
215680_at	85368	KIAA1654	AB051441	6.82	22.18	8.85	0.40	6.82	15.12	17.30	
208134_x_at	5670	PSG2	NM_031246	3.32	22.18	8.85	0.40	3.32	3.18	31.50	
209697_at	5533	PPP3CC	BC004864	10.69	20.97	8.38	0.40	10.69	2.62	5.81	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
210767_at	4771	NF2	BC003112	7.55	20.00	7.99	0.40	7.55	22.47	14.39	0.64
221127_s_at	10530	RIG	NM_006394	2.03	15.06	6.02	0.40	2.03	5.55	1.17	
207652_s_at	1240	CMKLR1	NM_004072	5.77	13.59	5.43	0.40	5.77	5.34	6.39	
219947_at	50856	CLEC4A	NM_016184	1.37	29.36	11.75	0.40	1.37	17.45	13.29	
211771_s_at	5452	POU2F2	BC006101	80.85	363.75	145.69	0.40	80.85	551.98	530.55	
204248_at	2767	GNA11	NM_002067	61.62	126.80	50.88	0.40	61.62	96.45	27.12	0.28
215955_x_at	23092	ARHGAP26	Y10388	144.84	218.54	87.81	0.40	144.84	40.81	194.38	
203217_s_at	8869	ST3GAL5	NM_003896	200.17	321.04	129.03	0.40	200.17	297.64	97.14	
205942_s_at	6296	ACSM3	NM_005622	4.28	36.98	14.86	0.40	4.28	5.39	3.77	
214569_at	3442	IFNA5	NM_002169	7.73	19.89	8.00	0.40	7.73	2.75	17.81	
216374_at			AC006986	28.50	51.65	20.78	0.40	28.50	29.47	37.57	
205803_s_at	7220	TRPC1	NM_003304	19.99	50.43	20.31	0.40	19.99	16.57	31.48	
207639_at	8326	FZD9	NM_003508	39.73	68.93	27.76	0.40	39.73	39.09	42.81	
211457_at	23766	GABARAPL3	AF180519	4.35	25.70	10.35	0.40	4.35	16.09	3.95	0.25
208712_at	595	CCND1	M73554	43.20	115.86	46.75	0.40	43.20	67.62	70.85	
210304_at	5158	PDE6B	BC000249	5.05	47.16	19.03	0.40	5.05	11.49	10.98	
216736_at	53345	TM6SF2	AK024515	11.30	24.15	9.75	0.40	11.30	17.42	8.77	0.50
211314_at	8913	CACNA1G	AB012043	5.24	12.16	4.91	0.40	5.24	8.03	15.36	
AFFX-HUMISGF3A/M97935_MA_at	6772	STAT1	AFFX-HUMISGF3A/M97935_MA	445.10	1072.24	433.37	0.40	445.10	557.35	376.96	
217308_at	26184	OR1F2	AJ003145	2.89	15.87	6.42	0.40	2.89	3.11	22.98	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
212803_at	4665	NAB2	BF337329	254.48	796.94	322.72	0.40	254.48	944.78	1422.16	
220681_at	55267	C22orf26	NM_018280	23.29	73.80	29.90	0.41	23.29	18.00	32.96	
219958_at	55321	C20orf46	NM_018354	27.49	45.51	18.44	0.41	27.49	39.90	45.21	
221226_s_at	55515	ACCN4	NM_018674	6.49	14.31	5.80	0.41	6.49	6.15	6.05	
212706_at	10156	RASA4	AI738591	250.46	652.76	265.06	0.41	250.46	572.38	241.22	0.42
211300_s_at	7157	TP53	K03199	14.40	32.51	13.20	0.41	14.40	13.33	19.24	
221323_at	80329	ULBP1	NM_025218	7.96	43.18	17.53	0.41	7.96	11.10	70.11	
208851_s_at	7070	THY1	AL161958	31.49	66.80	27.13	0.41	31.49	10.19	20.89	
204803_s_at	6236	RRAD	NM_004165	12.44	107.26	43.64	0.41	12.44	266.20	688.02	
219091_s_at	79812	MMRN2	NM_024756	30.82	49.04	19.96	0.41	30.82	29.01	22.77	
210800_at	1678	TIMM8A	BC005236	17.06	33.69	13.74	0.41	17.06	12.81	10.08	
212921_at	56950	SMYD2	AF070592	39.59	83.90	34.23	0.41	39.59	52.73	45.12	
218410_s_at	283871	LOC283871	NM_024118	44.67	76.47	31.22	0.41	44.67	27.84	10.67	
214398_s_at	9641	IKBKE	AW340333	192.89	641.33	261.99	0.41	192.89	244.87	155.52	
206957_at	189	AGXT	NM_016236	1.69	22.37	9.14	0.41	1.69	11.70	3.88	0.33
216419_at	9696	CROC C	AK026910	18.87	49.78	20.34	0.41	18.87	37.46	8.61	0.23
203940_s_at	22846	VASH1	NM_014909	112.21	213.08	87.13	0.41	112.21	111.34	60.99	
206133_at	54739	BIRC4 BP	NM_017523	429.25	1584.83	648.08	0.41	429.25	830.56	290.18	0.35
213462_at	4862	NPAS2	AW000928	19.40	59.25	24.27	0.41	19.40	55.39	80.46	
206212_at	1358	CPA2	NM_001869	39.95	74.70	30.60	0.41	39.95	41.82	19.46	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
205009_at	7031	TFF1	NM_003225	6.32	23.62	9.68	0.41	6.32	14.42	3.85	0.27
219256_s_at	54436	SH3TC1	NM_018986	193.32	431.34	176.95	0.41	193.32	285.80	129.56	
AFFX-TrpnX-3_at			AFFX-TrpnX-3	2.57	11.24	4.62	0.41	2.57	5.13	3.89	
206186_at	4356	MPP3	NM_001932	43.70	79.92	32.88	0.41	43.70	39.10	79.49	
215477_at			H49077	22.60	35.27	14.51	0.41	22.60	2.77	13.86	
217601_at	23511	NUP188	AL523184	53.17	104.72	43.10	0.41	53.17	72.84	50.59	
221924_at	83637	ZMIZ2	AW444969	232.18	805.22	331.45	0.41	232.18	821.46	529.04	0.64
206317_s_at	11194	ABCB8	NM_007188	25.97	98.14	40.41	0.41	25.97	15.87	43.98	
210064_s_at	7348	UPK1B	NM_006952	14.42	22.55	9.29	0.41	14.42	22.60	16.50	0.73
214046_at			AA017721	17.22	25.97	10.72	0.41	17.22	14.30	17.89	
209834_at	9469	CHST3	AB017915	24.75	50.34	20.79	0.41	24.75	74.27	30.91	0.42
205391_x_at	286	ANK1	M28880	2.50	10.33	4.26	0.41	2.50	12.86	4.43	0.34
203071_at	7869	SEMA3B	NM_004636	6.04	10.60	4.38	0.41	6.04	7.89	5.95	
221106_at	51310	SLC22A17	NM_016609	13.05	42.50	17.57	0.41	13.05	32.31	29.55	
205293_x_at	10458	BAIAP2	AB017120	81.77	154.22	63.80	0.41	81.77	265.59	268.76	
213450_s_at	23308	ICOSLG	AI659611	141.14	445.28	184.26	0.41	141.14	855.53	713.61	
216670_at	26085	KLK13	AL050220	5.86	16.72	6.92	0.41	5.86	5.37	6.29	
216919_at	9537	TP53I1	U79302	28.48	56.21	23.28	0.41	28.48	47.67	41.85	
205568_at	366	AQP9	NM_020980	3.15	12.81	5.30	0.41	3.15	57.07	96.71	
215671_at	5142	PDE4B	AU144792	3.90	62.94	26.07	0.41	3.90	80.18	50.21	0.63

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
218704_at	54894	RNF43	NM_017763	7.69	15.77	6.53	0.41	7.69	13.71	12.34	
207921_x_at	7849	PAX8	NM_013952	14.83	34.92	14.47	0.41	14.83	17.68	19.77	
208436_s_at	3665	IRF7	NM_004030	352.89	1349.42	559.42	0.41	352.89	1434.35	576.39	0.40
204741_at	636	BICD1	NM_001714	59.33	142.85	59.24	0.41	59.33	115.28	91.33	
206378_at	4250	SCGB2A2	NM_002411	2.44	16.24	6.73	0.41	2.44	6.33	6.51	
209589_s_at	2048	EPHB2	AF025304	4.95	16.88	7.00	0.41	4.95	38.60	4.17	0.11
206504_at	1591	CYP24A1	NM_000782	3.82	20.09	8.34	0.41	3.82	14.40	6.96	0.48
204501_at	4856	NOV	NM_002514	16.91	43.40	18.02	0.42	16.91	15.13	20.71	
217220_at			AL050153	2.47	16.81	6.98	0.42	2.47	13.14	17.75	
201236_s_at	7832	BTG2	BG339064	504.34	3730.56	1551.96	0.42	504.34	5160.39	5204.92	
203088_at	10516	FBLN5	NM_006329	5.51	37.36	15.55	0.42	5.51	21.14	13.55	0.64
205693_at	7140	TNNT3	NM_006757	16.96	38.24	15.92	0.42	16.96	13.02	16.63	
216180_s_at	8871	SYNJ2	AK026758	20.07	55.74	23.22	0.42	20.07	43.87	138.70	
222336_at	201895	C4orf34	AW974915	8.31	24.32	10.14	0.42	8.31	20.02	15.58	
210634_at	27252	KLHL20	BC005253	4.10	60.74	25.34	0.42	4.10	25.74	6.05	0.24
220719_at	80079	FLJ13769	NM_025012	23.37	53.64	22.38	0.42	23.37	24.74	33.70	
217049_x_at	83259	PCDH11Y	AJ276803	29.07	49.70	20.75	0.42	29.07	57.68	36.85	0.64
216184_s_at	22999	RIMS1	AF263310	2.28	10.50	4.38	0.42	2.28	2.00	7.78	
217121_at	8658	TNKS	AF082559	15.14	29.29	12.24	0.42	15.14	3.52	12.40	
221357_at	1132	CHRM4	NM_000741	23.68	39.30	16.43	0.42	23.68	17.90	19.28	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
214768_x_at	3107	HLA-C	BG540628	38.74	87.89	36.75	0.42	38.74	47.79	15.63	
203980_at	2167	FABP4	NM_001442	5.97	35.60	14.89	0.42	5.97	139.54	8.74	0.06
207689_at	347853	TBX10	NM_005995	16.00	30.47	12.75	0.42	16.00	19.73	5.02	
204929_s_at	10791	VAMP5	NM_006634	56.53	88.95	37.24	0.42	56.53	33.09	35.23	
220692_at	246721	POLR2J2	NM_014147	122.96	284.17	119.05	0.42	122.96	236.10	107.81	0.46
201601_x_at	8519	IFITM1	NM_003641	763.85	1339.59	561.23	0.42	763.85	991.47	521.37	
213949_s_at	83475	DOHH	AI370867	5.39	15.21	6.38	0.42	5.39	28.56	10.13	0.35
221200_at			NM_022155	11.57	35.50	14.90	0.42	11.57	133.61	82.10	0.61
206179_s_at	11076	TPPP	NM_007030	13.85	30.12	12.66	0.42	13.85	27.82	41.06	
207389_at	2811	GP1BA	NM_000173	50.73	135.31	56.94	0.42	50.73	155.89	88.98	0.57
215583_at	9725	TMEM63A	AU148184	76.40	127.56	53.70	0.42	76.40	56.85	20.29	
214038_at	6355	CCL8	AI984980	4.39	202.95	85.48	0.42	4.39	1064.30	160.82	0.15
208397_x_at	3762	KCNJ5	U39195	6.90	15.97	6.73	0.42	6.90	6.32	6.81	
205728_at			AL022718	7.21	20.74	8.74	0.42	7.21	17.02	13.42	
221578_at	83937	RASSF4	AF260335	237.66	705.35	298.06	0.42	237.66	605.86	441.42	0.73
214223_at			AA427737	12.07	20.87	8.83	0.42	12.07	5.10	26.09	
215928_at	84448	ABLIM2	AK022192	4.87	12.70	5.38	0.42	4.87	15.15	21.61	
210237_at	9048	ARTN	AF120274	8.78	18.25	7.73	0.42	8.78	21.46	10.59	0.49
217302_at	135948	OR2F2	AC004853	18.04	53.83	22.82	0.42	18.04	32.41	26.16	
42361_g_at	54535	CCHCR1	AI588986	69.42	126.04	53.47	0.42	69.42	79.47	63.80	
221119_at	54848	FLJ201	NM_0177	12.86	31.29	13.28	0.42	12.86	23.69	8.38	0.35

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		84	00								
210772_at	2358	FPRL1	M88107	43.23	75.72	32.13	0.42	43.23	92.72	6.49	0.07
207339_s_at	4050	LTB	NM_002341	175.05	492.42	209.20	0.42	175.05	139.08	100.65	
217523_at	960	CD44	AV700298	65.00	330.57	140.49	0.42	65.00	1111.13	1674.02	
215485_s_at	3383	ICAM1	AA284705	52.06	355.68	151.18	0.43	52.06	315.11	268.32	
200785_s_at	4035	LRP1	NM_002332	13.80	24.68	10.51	0.43	13.80	26.69	19.12	0.72
220293_at	79820	C14orf161	NM_024764	14.18	21.38	9.10	0.43	14.18	20.25	13.64	
209491_s_at	272 ///	AMPD3 /// PPARA /// TRMU	AA919119	22.46	47.78	20.36	0.43	22.46	52.85	60.46	
216800_at			AK027069	13.56	22.16	9.45	0.43	13.56	10.90	7.51	
213688_at	801	CALM1	N25325	75.21	123.85	52.85	0.43	75.21	84.07	129.22	
216955_at	6872	TAF1	X07024	19.26	57.42	24.50	0.43	19.26	16.81	12.02	
206729_at	943	TNFRSF8	NM_001243	42.36	67.47	28.81	0.43	42.36	46.66	30.11	
219867_at	140578	CHODL	NM_024944	11.63	37.14	15.86	0.43	11.63	26.83	9.91	0.37
221029_s_at	81029	WNT5B	NM_030775	5.45	40.16	17.18	0.43	5.45	39.30	44.46	
211302_s_at	5142	PDE4B	L20966	42.56	694.41	297.31	0.43	42.56	785.18	723.06	
220280_s_at	51281	ANKMY1	NM_016552	20.15	30.77	13.19	0.43	20.15	7.98	17.60	
216019_x_at	23187	PHLDB1	AK021690	7.22	34.45	14.76	0.43	7.22	41.34	42.25	
206864_s_at	8739	HRK	NM_003806	16.85	42.67	18.31	0.43	16.85	7.68	17.84	
216155_at	89796	NAV1	AK024543	13.53	25.34	10.88	0.43	13.53	14.37	2.87	
211399_at	2263	FGFR2	AB030077	6.42	13.38	5.74	0.43	6.42	15.18	6.85	0.45

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
205912_at	5406	PNLIP	NM_000936	5.34	11.56	4.96	0.43	5.34	12.41	9.04	0.73
212654_at	122769 /	TPM2 /// PPIL5	AL566786	37.37	59.97	25.79	0.43	37.37	27.02	44.82	
222368_at			AW972351	77.14	124.37	53.52	0.43	77.14	65.70	67.96	
211031_s_at	7461	CYLN2	BC006259	106.20	314.64	135.40	0.43	106.20	1680.79	835.64	0.50
220683_at	50700	RDH8	NM_015725	17.71	28.18	12.13	0.43	17.71	4.07	24.89	
219503_s_at	55287	TMEM40	AI087937	18.25	42.85	18.44	0.43	18.25	19.57	20.62	
220207_at	541469	LOC541469	NM_022125	11.46	47.81	20.58	0.43	11.46	12.60	13.52	
221773_at	2004	ELK3	AW575374	539.20	858.25	369.85	0.43	539.20	866.34	237.59	0.27
209969_s_at	6772	STAT1	BC002704	182.75	975.92	420.63	0.43	182.75	1024.44	251.62	0.25
204259_at	4316	MMP7	NM_002423	4.44	14.69	6.33	0.43	4.44	8.81	33.19	
209641_s_at	8714	ABCC3	AF009670	6.47	11.48	4.95	0.43	6.47	66.70	82.57	
220733_at	10861	SLC26A1	NM_022042	6.30	10.59	4.57	0.43	6.30	5.69	7.52	
221072_at	57000	C9orf31	NM_020250	7.00	11.67	5.04	0.43	7.00	5.84	3.59	
204961_s_at	653361 /	NCF1 /// NCF1B /// NCF1C	NM_000265	176.02	536.94	231.99	0.43	176.02	178.48	58.28	
221134_at	51378	ANGPT4	NM_015985	18.36	46.80	20.26	0.43	18.36	32.58	46.40	
210348_at	5414	4-Sep	AF176379	4.64	32.31	14.00	0.43	4.64	2.40	12.91	
221122_at	54979	HRASLS2	NM_017878	6.52	13.21	5.72	0.43	6.52	35.01	9.47	0.27
213931_at	3398 ///	ID2 /// ID2B	AI819238	374.59	707.10	306.79	0.43	374.59	1599.99	626.43	0.39
220204_s_at	353500	BMP8A	NM_0247	12.62	19.16	8.32	0.43	12.62	7.06	10.70	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			32								
214403_x_at	25803	SPDEF	AI307915	33.45	93.08	40.42	0.43	33.45	61.99	29.06	0.47
211170_s_at	10846	PDE10A	AF127480	4.94	11.39	4.95	0.43	4.94	3.23	7.27	
215782_at	286526	LOC286526	Z95624	38.92	64.80	28.17	0.43	38.92	31.54	12.63	
204560_at	2289	FKBP5	NM_004117	345.23	708.34	308.31	0.44	345.23	501.04	544.14	
220501_at	10881	ACTL7A	NM_006687	11.38	17.22	7.50	0.44	11.38	16.65	7.05	
219093_at	55022	FLJ20701	NM_017933	24.06	45.92	19.99	0.44	24.06	312.11	118.09	0.38
205712_at	5789	PTPRD	NM_002839	15.72	29.99	13.08	0.44	15.72	6.14	9.42	
214025_at	55794	DDX28	AI922937	9.71	41.80	18.24	0.44	9.71	24.81	10.46	0.42
218978_s_at	51312	SLC25A37	NM_018586	61.04	107.49	46.92	0.44	61.04	40.60	25.61	
220283_at	79802	KIAA1822L	NM_024746	6.84	24.09	10.54	0.44	6.84	38.16	35.00	
218599_at	9985	REC8L1	NM_005132	175.87	455.17	199.13	0.44	175.87	315.80	188.42	0.60
211197_s_at	23308	ICOSLG	AL355690	82.89	197.58	86.46	0.44	82.89	583.18	517.54	
205850_s_at	2562	GABRB3	NM_000814	11.87	19.37	8.48	0.44	11.87	3.91	5.46	
212657_s_at	3557	IL1RN	AW083357	720.99	1159.37	508.51	0.44	720.99	2738.88	4547.59	
221730_at	1290	COL5A2	AL575735	7.38	14.21	6.24	0.44	7.38	234.04	114.89	0.49
200644_at	65108	MARCKSL1	NM_023009	265.69	552.74	243.42	0.44	265.69	1538.92	952.19	0.62
208012_x_at	3431	SP110	NM_004509	699.65	1152.86	508.05	0.44	699.65	990.50	276.84	
211819_s_at	10580	SORBS1	AF136381	36.13	64.25	28.32	0.44	36.13	37.83	42.91	
216809_at	1538	CYLC1	Z22780	23.47	37.70	16.63	0.44	23.47	34.92	41.50	
216701_at	553168	C1orf68	AF005081	10.18	24.21	10.68	0.44	10.18	9.12	12.10	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
214667_s_at	9537	TP53I1	AK026607	22.50	93.09	41.10	0.44	22.50	78.35	101.24	
202206_at	10123	ARL4C	AW450363	154.68	233.51	103.15	0.44	154.68	165.44	92.25	
217505_at	151230	KLHL23	BG403790	11.10	29.89	13.22	0.44	11.10	15.93	2.20	
222202_at	644213	LOC644213	AK024355	1.30	13.55	5.99	0.44	1.30	12.69	1.22	0.10
209603_at	2625	GATA3	AI796169	3.90	11.52	5.10	0.44	3.90	10.57	5.50	0.52
220920_at	23120	ATP10B	NM_025153	12.31	53.50	23.70	0.44	12.31	45.10	26.64	0.59
213033_s_at	4781	NFIB	AI186739	3.22	12.02	5.34	0.44	3.22	2.92	2.42	
210352_at	10902	BRD8	AL136823	3.52	39.59	17.61	0.44	3.52	8.22	13.35	
217074_at	54498	SMOX	AK025938	4.72	26.10	11.62	0.45	4.72	21.62	33.60	
215779_s_at	8339	HIST1H2BG	BE271470	35.37	91.29	40.64	0.45	35.37	55.16	59.76	
213413_at	11037	STON1	BG434174	7.75	13.60	6.06	0.45	7.75	18.09	9.58	0.53
205913_at	5346	PLIN	NM_002666	4.07	12.27	5.47	0.45	4.07	2.73	3.69	
211147_s_at	9127	P2RXL1	AF065385	6.45	14.73	6.57	0.45	6.45	7.05	15.91	
215141_at	317648	C4orf10	AA493300	14.54	43.10	19.25	0.45	14.54	9.24	9.62	
205696_s_at	2674	GFRA1	U97144	12.08	22.04	9.85	0.45	12.08	3.91	10.50	
204908_s_at	602	BCL3	NM_005178	164.74	2982.82	1333.44	0.45	164.74	2151.79	1227.55	0.57
216292_at	5797	PTPRM	AK024455	25.55	65.71	29.42	0.45	25.55	43.71	21.62	0.49
208136_s_at	81854	MGC3771	NM_030970	15.87	40.70	18.24	0.45	15.87	18.10	26.01	
215487_x_at	388358 /	RP13-401N8.2 /// LOC728882	AL096727	8.75	21.94	9.83	0.45	8.75	5.45	8.55	
206672_at	359	AQP2	NM_000486	20.72	98.99	44.38	0.45	20.72	62.52	50.65	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
210603_at	84779	MGC10646	BC004552	35.55	55.00	24.68	0.45	35.55	26.32	39.37	
205312_at	6688	SPI1	NM_003120	892.79	2323.94	1043.34	0.45	892.79	1948.44	1530.45	
210272_at	1556	CYP2B7P1	M29873	26.67	50.74	22.78	0.45	26.67	16.86	11.71	
213845_at	2898	GRIK2	AL355532	85.54	145.33	65.33	0.45	85.54	104.12	89.43	
205861_at	6689	SPIB	NM_003121	187.26	582.49	261.87	0.45	187.26	113.49	33.03	
212423_at	219654	C10orf56	AK024784	132.23	259.80	116.92	0.45	132.23	207.76	215.60	
207462_at	2742	GLRA2	NM_002063	13.25	21.78	9.81	0.45	13.25	15.28	37.06	
205605_at	3235	HOXD9	NM_014213	10.80	18.86	8.50	0.45	10.80	2.85	3.80	
221159_at			NM_016414	12.92	75.39	34.01	0.45	12.92	11.37	9.72	
213324_at	6714	SRC	AK024281	11.16	238.31	107.56	0.45	11.16	489.69	657.07	
206534_at	2903	GRIN2A	NM_000833	14.61	22.18	10.02	0.45	14.61	15.04	7.84	
220365_at	55821	ALLC	NM_018436	19.60	46.86	21.16	0.45	19.60	45.24	17.49	0.39
220303_at	79849	PDZD3	NM_024791	11.35	28.37	12.82	0.45	11.35	12.57	14.38	
213985_s_at	91304	C19orf6	H45660	18.95	42.38	19.16	0.45	18.95	20.74	23.64	
207407_x_at	1579	CYP4A11	NM_000778	10.17	16.57	7.49	0.45	10.17	4.98	23.32	
207881_at			NM_015887	14.31	23.19	10.50	0.45	14.31	19.25	3.75	
214521_at	54626	HES2	NM_019089	2.19	12.42	5.63	0.45	2.19	13.35	3.61	0.27
202953_at	713	C1QB	NM_000491	5.39	31.18	14.14	0.45	5.39	5.07	3.14	
206893_at	6299	SALL1	NM_002968	3.19	15.53	7.04	0.45	3.19	10.77	3.13	0.29
221975_s_at	755	C21orf2	AI539305	52.65	101.92	46.25	0.45	52.65	126.57	48.58	0.38

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
217465_at	10787	NCKA P1	AK001291	18.60	41.42	18.80	0.45	18.60	15.60	6.48	
219983_at	57110	HRASLS	NM_020386	5.68	13.48	6.12	0.45	5.68	6.77	7.42	
217867_x_at	25825	BACE2	AF178532	13.85	24.09	10.94	0.45	13.85	10.30	8.86	
210330_at	6444	SGCD	U58331	2.30	11.65	5.30	0.45	2.30	25.17	1.08	0.04
215331_at	22989	MYH15	BF062942	13.07	38.31	17.41	0.45	13.07	24.30	6.75	0.28
214421_x_at	1559	CYP2C9	AV652420	16.69	42.36	19.25	0.45	16.69	24.55	17.90	
221784_at	58525	WIZ	AI828531	16.16	41.37	18.80	0.45	16.16	38.04	63.61	
208017_s_at	4168	MCF2	NM_005369	3.22	15.88	7.22	0.45	3.22	12.11	7.74	0.64
207217_s_at	27035	NOX1	NM_013955	20.84	34.03	15.48	0.45	20.84	7.81	9.77	
217272_s_at	5275	SERPINB13	AJ001698	10.98	25.76	11.73	0.46	10.98	28.97	10.75	0.37
208344_x_at	3447	IFNA13	NM_006900	12.26	36.18	16.47	0.46	12.26	20.59	6.14	0.30
217253_at			L37198	83.15	179.63	81.80	0.46	83.15	214.50	79.03	0.37
221465_at	8590	OR6A2	NM_003696	4.47	10.29	4.69	0.46	4.47	5.20	7.49	
221415_s_at	81025	GJA10	NM_030772	16.11	64.23	29.28	0.46	16.11	37.27	36.01	
218952_at	27344	PCSK1N	NM_013271	21.06	65.45	29.86	0.46	21.06	13.22	36.47	
217180_at	96610	LOC96610	X79782	7.02	11.81	5.40	0.46	7.02	18.38	5.46	0.30
221184_at			NM_025089	10.05	50.83	23.29	0.46	10.05	19.95	39.95	
210839_s_at	5168	ENPP2	D45421	30.55	89.57	41.05	0.46	30.55	13.53	30.26	
215142_at	25763	CXorf27	AA815276	4.69	19.24	8.82	0.46	4.69	13.11	5.56	0.42
219775_s_at	594855	CPLX3	NM_024695	11.29	19.61	8.99	0.46	11.29	10.98	6.92	
206150_at	939	CD27	NM_001242	9.95	39.60	18.17	0.46	9.95	11.18	20.17	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
206876_at	6492	SIM1	AL121948	75.31	127.30	58.44	0.46	75.31	278.72	254.63	
218293_x_at	10762	NUP50	AF267865	32.63	77.95	35.80	0.46	32.63	27.97	16.46	
214349_at			AV764378	191.98	336.49	154.64	0.46	191.98	120.06	171.10	
204595_s_at	6781	STC1	AI300520	15.57	35.50	16.32	0.46	15.57	35.63	44.51	
205119_s_at	2357	FPR1	NM_002029	38.89	94.38	43.40	0.46	38.89	81.06	12.66	0.16
202454_s_at	2065	ERBB3	NM_001982	13.28	24.46	11.25	0.46	13.28	28.89	6.04	0.21
49306_at	83937	RASSF4	AI890191	360.79	1084.81	499.14	0.46	360.79	888.19	700.77	
203708_at	5142	PDE4B	NM_002600	58.60	1193.32	549.36	0.46	58.60	1737.58	1227.97	0.71
222033_s_at	2321	FLT1	AA058828	8.62	13.24	6.10	0.46	8.62	118.67	76.26	0.64
217227_x_at	3576	IL8	X93006	27.81	51.38	23.68	0.46	27.81	12.34	5.71	
211118_x_at	2100	ESR2	AF051428	10.30	23.55	10.87	0.46	10.30	17.60	12.40	0.70
215579_at	60489	APOBEC3G	AK022802	11.96	18.83	8.69	0.46	11.96	8.95	5.89	
220929_at	26290	GALNT8	NM_017417	39.63	71.97	33.23	0.46	39.63	19.37	43.00	
206803_at	5173	PDYN	NM_024411	8.32	17.96	8.30	0.46	8.32	5.30	8.56	
206222_at	8794	TNFRSF10C	NM_003841	14.71	41.28	19.10	0.46	14.71	6.75	7.71	
203280_at	9667	SAFB2	NM_014649	125.52	214.52	99.28	0.46	125.52	208.35	142.55	0.68
222326_at	5142	PDE4B	AW973834	18.87	176.42	81.76	0.46	18.87	279.14	119.85	0.43
205121_at	6443	SGCB	NM_000232	23.70	38.32	17.76	0.46	23.70	12.57	16.31	
209762_x_at	3431	SP110	AA969194	468.74	833.76	386.51	0.46	468.74	765.75	249.85	0.33
207452_s_at	53942	CNTN5	NM_014361	36.19	57.53	26.68	0.46	36.19	7.88	32.43	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
214022_s_at	8519	IFITM1	AA749101	874.90	1539.56	714.39	0.46	874.90	1337.05	635.82	0.48
206755_at	1555	CYP2B6	NM_000767	4.36	19.11	8.87	0.46	4.36	4.21	14.45	
213661_at	25891	DKFZP586H2123	AI671186	11.02	33.16	15.41	0.46	11.02	3.37	6.58	
215249_at	6165	RPL35A	AK021571	12.10	28.30	13.15	0.46	12.10	18.29	8.60	0.47
211219_s_at	9355	LHX2	U11701	225.70	630.33	293.00	0.46	225.70	460.75	278.41	0.60
220533_at			NM_024853	10.11	28.88	13.44	0.47	10.11	32.85	40.91	
217199_s_at	6773	STAT2	S81491	28.74	51.90	24.17	0.47	28.74	13.82	59.58	
221585_at	27092	CACNG4	BC004504	5.44	11.27	5.25	0.47	5.44	3.30	9.45	
201387_s_at	7345	UCHL1	NM_004181	5.97	16.79	7.85	0.47	5.97	7.00	17.94	
207449_s_at	23275	POFUT2	NM_015227	52.68	88.49	41.37	0.47	52.68	40.11	51.73	
211140_s_at	835	CASP2	AF314174	14.11	25.56	11.97	0.47	14.11	9.99	7.62	
210368_at	8641 ///	PCDHGB4 /// PCDHGA8	AB002325	73.20	135.23	63.35	0.47	73.20	50.61	35.91	
205775_at	26240	FAM50B	NM_012135	6.53	20.45	9.58	0.47	6.53	14.80	17.01	
216788_at			AK025564	13.55	40.07	18.78	0.47	13.55	6.93	14.29	
216144_at	57485	ATXN7L1	AL137378	47.45	137.80	64.62	0.47	47.45	36.09	65.50	
222221_x_at	10938	EHD1	AY007161	231.46	681.47	319.64	0.47	231.46	1957.26	1792.81	
215510_at	2116	ETV2	AV693985	8.22	21.71	10.19	0.47	8.22	4.96	12.44	
208218_s_at	91	ACVR1B	NM_020328	13.13	43.94	20.62	0.47	13.13	15.63	21.04	
217228_s_at	51666	ASB4	AC003079	7.17	23.45	11.01	0.47	7.17	8.87	25.70	
216056_at	960	CD44	AW85155	11.06	40.70	19.11	0.47	11.06	171.10	238.29	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			9								
202800_at	6507	SLC1A3	NM_004172	152.05	448.31	210.55	0.47	152.05	824.17	299.32	0.36
214443_at	5817	PVR	NM_006505	53.62	81.61	38.33	0.47	53.62	62.54	76.33	
216172_at			AK025114	36.25	123.25	57.94	0.47	36.25	61.07	22.09	0.36
210755_at	3082	HGF	U46010	16.65	34.61	16.28	0.47	16.65	8.40	4.12	
202908_at	7466	WFS1	NM_006005	34.00	59.20	27.85	0.47	34.00	39.81	28.46	
214767_s_at	126393	HSPB6	AL551046	24.47	44.62	20.99	0.47	24.47	27.92	15.75	
219386_s_at	56833	SLAMF8	NM_020125	64.32	442.58	208.66	0.47	64.32	584.05	158.27	0.27
209037_s_at	10938	EHD1	AW182860	139.26	404.70	190.85	0.47	139.26	1191.93	1352.43	
206671_at	6295	SAG	NM_000541	14.51	26.75	12.62	0.47	14.51	11.82	32.83	
215602_at	221472	FGD2	AK024456	49.51	118.97	56.19	0.47	49.51	98.39	53.13	0.54
216514_at			AF203728	21.53	46.21	21.85	0.47	21.53	30.44	19.56	
202856_s_at	9123	SLC16A3	NM_004207	1269.72	2800.24	1324.35	0.47	1269.72	7277.23	5376.38	0.74
220603_s_at	55784	MCTP2	NM_018349	18.73	33.13	15.67	0.47	18.73	32.04	22.74	0.71
214637_at	5008	OSM	BG437034	4.16	10.86	5.14	0.47	4.16	5.28	5.03	
214425_at	259	AMBP	AV645756	32.90	51.66	24.45	0.47	32.90	16.61	23.54	
205606_at	4040	LRP6	NM_002336	37.16	60.59	28.70	0.47	37.16	45.44	28.19	
219564_at	3773	KCNJ16	AF153815	2.83	13.33	6.32	0.47	2.83	17.45	3.98	0.23
206478_at	9834	KIAA0125	NM_014792	13.88	23.21	11.02	0.47	13.88	5.67	20.65	
215180_at			AL109703	16.61	25.31	12.02	0.47	16.61	9.66	11.54	
214996_at			AL07929	31.67	88.05	41.85	0.48	31.67	68.26	86.33	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			4								
220648_at	105	ADAR B2	NM_018702	7.46	19.12	9.09	0.48	7.46	11.36	8.22	0.72
210765_at	1434	CSE1L	AF053640	51.53	107.34	51.06	0.48	51.53	109.81	75.70	0.69
208100_x_at	10500	SEMA6C	NM_030913	6.34	11.80	5.61	0.48	6.34	6.15	6.80	
216415_at	55567	DNAH3	AK026793	9.20	17.60	8.38	0.48	9.20	3.82	4.66	
214563_at	5098	PCDHGC3	AF152524	29.47	49.54	23.62	0.48	29.47	14.72	47.38	
205524_s_at	1404	HAPLN1	NM_001884	5.65	17.18	8.20	0.48	5.65	14.55	5.42	0.37
214605_x_at	2825	GPR1	AL046992	32.48	80.34	38.37	0.48	32.48	79.88	48.37	0.61
220008_at	79834	KIAA2002	NM_024776	7.69	36.58	17.47	0.48	7.69	46.42	28.53	0.61
218687_s_at	56667	MUC13	AW451240	7.96	35.02	16.75	0.48	7.96	31.24	13.47	0.43
202855_s_at	9123	SLC16A3	AL513917	673.54	1409.55	674.24	0.48	673.54	2626.14	2682.65	
217104_at	400410	LOC400410	AL109714	109.68	166.79	79.83	0.48	109.68	190.54	158.92	
202485_s_at	8932	MBD2	NM_003927	12.05	44.48	21.29	0.48	12.05	10.55	29.58	
201649_at	9246	UBE2L6	NM_004223	567.27	926.03	443.91	0.48	567.27	477.43	372.63	
207327_at	2070	EYA4	NM_004100	12.06	18.39	8.81	0.48	12.06	8.07	7.44	
219209_at	64135	IFIH1	NM_022168	197.26	930.22	446.15	0.48	197.26	876.21	393.94	0.45
207826_s_at	3399	ID3	NM_002167	3.33	11.06	5.31	0.48	3.33	9.21	41.75	
222252_x_at	56893	UBQLN4	AK023354	104.84	283.27	135.97	0.48	104.84	142.02	111.97	
AFFX-M27830_3_at			AFFX-M27830_3	12.24	79.78	38.32	0.48	12.24	47.35	40.10	
219102_at	57333	RCN3	NM_020650	12.95	58.47	28.09	0.48	12.95	4.54	11.35	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
215682_at	440792	LOC440792	AB051440	10.12	93.67	45.00	0.48	10.12	21.62	16.61	
215590_x_at			AK025619	6.56	31.30	15.05	0.48	6.56	29.21	10.33	0.35
205088_at	10046	CXorf6	NM_005491	6.61	10.84	5.22	0.48	6.61	486.96	572.08	
204907_s_at	602	BCL3	AI829875	83.78	611.50	294.34	0.48	83.78	270.71	261.81	
206582_s_at	9289	GPR56	NM_005682	3.92	16.45	7.92	0.48	3.92	8.58	7.70	
216911_s_at	23119	HIC2	AL162003	9.93	16.44	7.92	0.48	9.93	4.52	2.50	
211053_at	3755	KCNG1	BC006367	2.55	10.37	5.00	0.48	2.55	10.62	24.18	
211343_s_at	1305	COL13A1	M33653	4.64	14.49	6.98	0.48	4.64	6.67	4.10	
215844_at	30000	TNPO2	AK022217	12.77	22.44	10.82	0.48	12.77	31.15	6.82	0.22
206187_at	5739	PTGIR	NM_000960	93.00	330.43	159.70	0.48	93.00	273.60	159.75	0.58
53991_at	27147	DENN2A	AA127623	12.23	40.51	19.59	0.48	12.23	39.59	22.72	0.57
221661_at	10864	SLC22A7	AF210455	5.72	19.06	9.24	0.48	5.72	12.38	7.52	0.61
205470_s_at	11012	KLK11	NM_006853	16.49	61.83	29.99	0.49	16.49	32.70	22.39	0.68
217585_at	51131	PHF11	BE502910	5.90	15.70	7.62	0.49	5.90	9.03	2.60	
205139_s_at	10090	UST	NM_005715	71.09	288.76	140.13	0.49	71.09	208.76	355.04	
207740_s_at	23636	NUP62	NM_012346	646.35	1052.53	511.34	0.49	646.35	552.88	618.76	
205833_s_at	25859	PART1	AI770098	4.56	11.18	5.44	0.49	4.56	15.27	8.63	0.56
201641_at	684	BST2	NM_004335	955.76	1772.88	862.77	0.49	955.76	797.12	534.68	
213731_s_at	6929	TCF3	AI871234	9.50	29.72	14.47	0.49	9.50	28.25	21.50	
222292_at	958	CD40	AW298127	60.18	340.59	165.89	0.49	60.18	178.71	214.24	
209419_at	8563	THOC5	AB02320	23.64	48.24	23.50	0.49	23.64	21.43	21.17	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			0								
64942_at	387509	GPR153	AI937160	144.39	224.86	109.61	0.49	144.39	246.18	158.83	0.65
205632_s_at	8395	PIP5K1B	NM_003558	141.80	413.77	201.74	0.49	141.80	80.53	201.85	
209176_at			AI332962	20.90	60.56	29.55	0.49	20.90	62.90	32.92	0.52
217610_at	246721	POLR2J2	AL047879	314.89	551.57	269.11	0.49	314.89	208.18	236.75	
220819_at	79981	FRMD1	NM_024919	15.27	23.37	11.41	0.49	15.27	8.10	6.30	
207094_at	3577	IL8RA	NM_000634	11.49	17.56	8.58	0.49	11.49	4.01	15.00	
221671_x_at	28299 //	IGKC /// IGKV1-5 /// IGKV2-24	M63438	27.09	348.99	170.52	0.49	27.09	113.73	22.17	0.19
217133_x_at	1555	CYP2B6	X06399	18.10	48.25	23.59	0.49	18.10	19.72	20.60	
206570_s_at	440533 /	PSG1 /// PSG4 /// PSG5 /// PSG	NM_002785	11.88	19.06	9.32	0.49	11.88	9.01	7.73	
217657_at	55973	BCAP29	AL583687	56.02	93.16	45.56	0.49	56.02	157.68	81.35	0.52
206901_at	79173	C19orf57	NM_024323	11.67	21.06	10.30	0.49	11.67	12.18	8.56	
207324_s_at	1823	DSC1	NM_004948	6.65	10.95	5.36	0.49	6.65	3.38	8.05	
214135_at	51208	CLDN18	BE551219	23.44	38.38	18.78	0.49	23.44	39.81	16.77	0.42
210294_at	6892	TAPBP	AF067286	80.57	303.94	148.78	0.49	80.57	150.09	149.13	
216535_at	57863	IGSF4B	AL050219	8.07	22.31	10.93	0.49	8.07	14.44	6.88	0.48
217003_s_at	255926	TMDCI1	AJ132823	7.30	44.10	21.62	0.49	7.30	21.59	19.46	
215575_at	9659	PDE4DIP	AU157078	2.77	18.79	9.22	0.49	2.77	15.56	5.20	0.33

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
210690_at	8302	KLRC4	U96845	3.22	12.34	6.05	0.49	3.22	3.38	2.30	
221171_at	728621	RP4-692D3.1	NM_025030	45.14	94.75	46.50	0.49	45.14	28.58	53.10	
221723_s_at	57835	SLC4A5	AF243499	19.17	38.68	18.99	0.49	19.17	31.53	31.28	
202307_s_at	6890	TAP1	NM_000593	549.39	2237.13	1098.51	0.49	549.39	965.28	591.09	0.61
220271_x_at	64800	FLJ23588	NM_022785	4.22	11.13	5.47	0.49	4.22	6.84	6.38	
208580_x_at	8362 ///	HIST1H4K /// HIST1H4J	NM_021968	26.88	73.75	36.27	0.49	26.88	23.42	12.78	
213051_at	56829	ZC3HAV1	AI133727	1144.26	2471.16	1215.72	0.49	1144.26	2873.27	1269.58	0.44
204677_at	1003	CDH5	NM_001795	2.77	24.82	12.23	0.49	2.77	14.30	13.89	
208060_at	5081	PAX7	NM_002584	19.66	30.54	15.05	0.49	19.66	12.61	28.66	
220213_at	128553	TSHZ2	NM_018692	3.84	11.41	5.62	0.49	3.84	6.28	3.43	
206675_s_at	6498	SKIL	NM_005414	7.55	68.20	33.65	0.49	7.55	88.44	197.32	
206503_x_at	5371	PML	NM_002675	102.22	171.85	84.92	0.49	102.22	161.85	67.69	0.42
217664_at	23030	JMJD2B	AA780524	5.04	20.00	9.88	0.49	5.04	7.97	28.25	
210226_at	3164	NR4A1	D85245	23.01	56.41	27.91	0.49	23.01	55.58	21.31	0.38
212977_at	57007	CXCR7	AI817041	31.39	87.50	43.31	0.49	31.39	88.25	56.13	0.64
216002_at	2342	FNTB	AU147200	26.61	46.15	22.88	0.50	26.61	14.33	20.52	
211731_x_at	10214	SSX3	BC005904	23.89	40.63	20.15	0.50	23.89	45.09	26.86	0.60
219914_at	9427	ECEL1	NM_004826	5.82	35.17	17.45	0.50	5.82	19.43	11.41	0.59
40560_at	6909	TBX2	U28049	9.36	23.42	11.65	0.50	9.36	65.63	55.42	
201269_s_at	23386	NUDCD3	AB028991	23.91	50.99	25.38	0.50	23.91	20.30	23.97	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
209266_s_at	64116	SLC39A8	AW134794	21.35	35.36	17.61	0.50	21.35	10.27	24.45	
217515_s_at	779	CACNA1S	AI391509	7.48	11.24	5.60	0.50	7.48	17.00	16.99	
221377_s_at	11317	RBPSUHL	NM_014276	7.14	13.83	6.89	0.50	7.14	3.75	11.79	
218223_s_at	51177	PLEKH01	NM_016274	393.57	1389.26	692.14	0.50	393.57	1535.10	1010.63	0.66
210683_at	4902	NRTN	AL161995	15.78	48.19	24.02	0.50	15.78	32.18	33.72	
220656_at			NM_018527	1.01	24.02	11.98	0.50	1.01	2.47	6.09	
218764_at	5583	PRKCH	NM_024064	144.61	308.76	154.17	0.50	144.61	184.83	270.13	
216248_s_at	4929	NR4A2	S77154	9.04	90.84	45.36	0.50	9.04	81.81	98.06	
221913_at	23410	SIRT3	AI492888	48.04	91.84	45.86	0.50	48.04	55.01	43.95	
216848_at	85374	KIAA1660	AB051447	6.70	10.32	5.16	0.50	6.70	4.77	3.20	
206955_at	364	AQP7	NM_001170	21.77	57.17	28.56	0.50	21.77	22.61	9.49	
211866_x_at	3077	HFE	AF079409	14.49	32.13	16.07	0.50	14.49	13.20	11.87	
209897_s_at	9353	SLIT2	AF055585	14.59	45.64	22.83	0.50	14.59	66.77	52.92	
205926_at	9466	IL27RA	NM_004843	164.31	324.13	162.14	0.50	164.31	876.65	395.74	0.45
216416_at	50807	DDEF1	AK027254	18.77	51.92	25.98	0.50	18.77	10.32	37.77	
209305_s_at	4616	GADD45B	AF078077	200.36	512.89	256.94	0.50	200.36	352.50	879.98	
212937_s_at	1291	COL6A1	M20776	69.99	126.27	63.26	0.50	69.99	148.85	131.90	
206720_at	4249	MGAT5	NM_002410	4.55	11.00	5.52	0.50	4.55	3.84	8.44	
219694_at	54491	FAM105A	NM_019018	494.90	775.91	389.17	0.50	494.90	307.64	58.14	
211660_at	5452	POU2F2	M36653	72.75	128.97	64.72	0.50	72.75	98.45	141.99	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
211661_x_at	5724	PTAFR	M80436	78.00	199.45	100.13	0.50	78.00	173.60	141.87	
215700_x_at	9362	CPNE6	AL050397	4.79	13.01	6.53	0.50	4.79	6.10	5.02	
222240_s_at	51477	ISYNA1	AL137749	18.57	36.01	18.08	0.50	18.57	24.49	38.29	
213458_at	317662	KIAA0974	AB023191	0.67	20.68	10.39	0.50	0.67	7.58	1.14	
215916_at	1145	CHRN E	AL157418	8.48	28.07	14.10	0.50	8.48	21.36	14.47	0.68
216173_at			AK025360	46.10	136.69	68.68	0.50	46.10	62.41	94.51	
222141_at	84861	KLHL22	AK024369	44.89	75.72	38.05	0.50	44.89	31.34	31.06	
205127_at	5742	PTGS1	NM_000962	17.10	61.50	30.91	0.50	17.10	56.42	64.33	
202446_s_at	5359	PLSCR1	AI825926	1441.49	2826.59	1420.85	0.50	1441.49	2777.81	1350.95	0.49
208301_at			NM_025033	41.19	70.16	35.29	0.50	41.19	80.98	101.32	
206341_at	3559	IL2RA	NM_000417	10.70	44.28	22.28	0.50	10.70	18.41	9.94	0.54
214613_at	2827	GPR3	AW024085	5.41	36.38	18.32	0.50	5.41	19.67	38.12	
210890_x_at	3802	KIR2DL1	U24078	4.51	12.15	6.12	0.50	4.51	2.79	3.99	
208569_at	8335	HIST1H2AB	NM_003513	46.33	91.91	46.28	0.50	46.33	62.17	40.51	
216349_at	341651	LOC341651	AL136527	57.66	88.59	44.61	0.50	57.66	61.40	56.83	
209811_at	835	CASP2	BC002427	81.74	126.69	63.81	0.50	81.74	68.43	29.30	
201422_at	10437	IFI30	NM_006332	224.38	359.58	181.11	0.50	224.38	321.71	226.05	
216502_at	81875	ISG20L2	AL096734	7.82	12.41	6.26	0.50	7.82	8.05	5.95	
215866_at	1937	EEF1G	AK024938	71.63	171.60	86.52	0.50	71.63	129.49	128.65	
210017_at	10892	MALT1	AF070528	71.24	164.15	82.79	0.50	71.24	267.72	123.84	0.46

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells (Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
205377_s_at	43	ACHE	AI190022	5.55	50.30	25.37	0.50	5.55	26.45	8.07	0.31
1438_at	2049	EPHB3	X75208	54.66	82.35	41.57	0.50	54.66	27.75	24.53	
60815_at	84820	MGC13098	AA601208	170.03	284.91	143.82	0.50	170.03	129.40	111.24	
202638_s_at	3383	ICAM1	NM_000201	41.96	1353.52	683.82	0.51	41.96	1508.23	1074.85	0.71
207538_at	3565	IL4	NM_000589	7.37	24.80	12.53	0.51	7.37	14.37	14.07	
214354_x_at	6439	SFTPB	T91506	11.95	60.19	30.41	0.51	11.95	18.06	31.76	
214557_at	10744	PTTG2	NM_006607	8.47	43.99	22.23	0.51	8.47	38.59	10.14	0.26
204927_at	8045	RASSF7	NM_003475	223.03	352.66	178.34	0.51	223.03	170.41	130.03	
211712_s_at	8416	ANXA9	BC005830	4.10	14.32	7.25	0.51	4.10	36.45	19.06	0.52
204879_at	10630	PDPN	NM_006474	43.25	127.99	64.79	0.51	43.25	24.06	50.10	
49049_at	196403	DTX3	N92708	10.96	24.73	12.52	0.51	10.96	5.77	4.24	
206223_at	22853	LMTK2	NM_014916	33.05	75.91	38.45	0.51	33.05	61.76	52.48	
207334_s_at	7048	TGFBR2	NM_003242	36.11	66.79	33.83	0.51	36.11	13.04	40.21	
207447_s_at	25834	MGAT4C	NM_013244	2.15	12.94	6.56	0.51	2.15	23.63	15.80	0.67
216370_s_at	8277	TKTL1	Z49258	5.13	10.24	5.19	0.51	5.13	6.95	4.77	
206125_s_at	11202	KLK8	NM_007196	6.98	23.67	12.01	0.51	6.98	16.02	11.44	0.71
219367_s_at	8828	NRP2	NM_018534	12.04	38.01	19.30	0.51	12.04	375.70	261.71	0.70
214185_at	10657	KHDRBS1	AW592227	34.55	68.05	34.56	0.51	34.55	82.11	67.59	
207050_at	781	CACNA2D1	NM_000722	6.33	14.14	7.18	0.51	6.33	8.90	9.45	
210618_at	5909	RAP1GAP	AB007943	21.45	38.37	19.53	0.51	21.45	9.35	10.69	
206970_at	6900	CNTN2	NM_005076	6.76	16.08	8.20	0.51	6.76	13.94	6.67	0.48

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
206193_s_at	1041	CDSN	NM_001264	8.09	19.62	10.00	0.51	8.09	3.99	12.05	
207779_at			NM_016344	28.62	95.09	48.52	0.51	28.62	15.36	37.54	
217142_at	442215	LOC442215	AL035687	55.76	158.82	81.04	0.51	55.76	72.88	145.15	
220037_s_at	10894	XLKD1	NM_016164	6.56	12.69	6.48	0.51	6.56	4.51	11.84	
216815_at			AL136306	4.70	26.52	13.54	0.51	4.70	2.68	5.74	
210799_at	3351	HTR1B	M81590	16.73	88.77	45.33	0.51	16.73	20.33	12.85	
219579_at	5866	RAB31L1	NM_013401	104.83	163.56	83.53	0.51	104.83	47.48	56.29	
218543_s_at	64761	PARP12	NM_022750	409.83	726.14	370.96	0.51	409.83	616.31	193.02	0.31
219257_s_at	8877	SPHK1	NM_021972	82.73	145.13	74.17	0.51	82.73	358.67	603.80	
222219_s_at	79816	TLE6	AC007766	7.19	25.99	13.29	0.51	7.19	4.94	21.03	
220210_at	57053	CHRNA10	NM_020402	28.16	61.66	31.56	0.51	28.16	40.00	58.84	
209012_at	7204	TRIO	AV718192	47.49	80.66	41.33	0.51	47.49	29.63	36.45	
214489_at	2488	FSHB	NM_000510	6.22	12.60	6.47	0.51	6.22	22.70	31.42	
218015_s_at	56897	WRNIP1	NM_020135	6.63	34.34	17.64	0.51	6.63	9.00	9.76	
205549_at	5121	PCP4	NM_006198	9.85	25.52	13.11	0.51	9.85	4.40	4.32	
216062_at	960	CD44	AW851559	10.10	41.48	21.34	0.51	10.10	34.89	36.40	
215922_at	85021	REPS1	AL049259	39.46	66.97	34.47	0.51	39.46	30.48	23.61	
219562_at	25837	RAB26	NM_014353	13.65	20.86	10.74	0.51	13.65	22.29	25.58	
206033_s_at	1825	DSC3	NM_001941	105.27	256.50	132.22	0.52	105.27	117.25	162.66	
217476_at	7067 ///	THRA /// NR1D1	M24900	7.74	12.50	6.44	0.52	7.74	6.69	14.37	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
216123_x_at	54879	ST7L	AK024158	42.11	68.45	35.30	0.52	42.11	35.28	18.38	
214689_at	60676	PAPPA2	BF435151	23.05	50.15	25.88	0.52	23.05	25.00	9.44	
214619_at	1394	CRHR1	X72304	11.85	37.23	19.21	0.52	11.85	40.54	41.73	
220168_at	55259	CASC1	NM_018272	3.79	11.99	6.20	0.52	3.79	8.01	13.79	
207354_at	6360	CCL16	NM_004590	4.37	15.99	8.26	0.52	4.37	5.71	12.10	
216465_at			AL110206	5.22	17.20	8.91	0.52	5.22	5.84	11.73	
215939_at			AU148005	7.97	22.86	11.85	0.52	7.97	2.85	12.83	
207296_at	79175	ZNF343	NM_024325	6.98	10.70	5.54	0.52	6.98	5.91	7.30	
211203_s_at	1272	CNTN1	U07820	16.70	34.79	18.04	0.52	16.70	28.76	18.01	0.63
211873_s_at	56107	PCDHGA9	AF152516	4.75	18.31	9.50	0.52	4.75	40.37	10.33	0.26
210355_at	5744	PTHLH	J03580	4.74	14.99	7.78	0.52	4.74	17.18	6.60	0.38
216773_at	150684	COMM1	AK025191	12.54	44.24	22.97	0.52	12.54	23.57	25.61	
208485_x_at	8837	CFLAR	NM_003879	397.61	1185.98	615.89	0.52	397.61	1197.52	1550.82	
201564_s_at	6624	FSCN1	NM_003088	1183.38	3054.04	1586.08	0.52	1183.38	1959.00	1655.62	
207113_s_at	7124	TNF	NM_000594	524.28	3499.34	1817.81	0.52	524.28	1597.18	2742.44	
210133_at	6356	CCL11	D49372	9.12	23.90	12.42	0.52	9.12	27.60	22.50	
213329_at	23380	SRGAP2	AA742261	323.54	543.95	282.78	0.52	323.54	260.56	197.79	
212939_at	1291	COL6A1	M20776	3.32	12.09	6.31	0.52	3.32	9.49	17.66	
208476_s_at	55691	FRMD4A	NM_018027	37.99	69.80	36.42	0.52	37.99	9.43	6.09	
211786_at	3604	TNFRSF9	BC006196	4.45	65.67	34.29	0.52	4.45	191.03	111.10	0.58
220337_at	58157	NGB	NM_021257	7.98	17.97	9.39	0.52	7.98	8.13	23.16	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
214289_at	5689	PSMB1	W86293	18.85	37.45	19.57	0.52	18.85	49.41	67.72	
217290_at			AL030995	6.61	12.03	6.29	0.52	6.61	7.72	4.60	
209138_x_at	3535	IGL@	M87790	41.80	71.68	37.53	0.52	41.80	59.67	28.54	
201631_s_at	8870	IER3	NM_003897	24.79	230.83	120.90	0.52	24.79	847.54	1453.11	
216365_x_at	3535 ///	IGL@ /// CPVL	AF047245	2.92	10.45	5.48	0.52	2.92	6.15	10.17	
219352_at	55008	HERC6	NM_017912	174.89	298.58	156.53	0.52	174.89	356.45	121.02	0.34
211817_s_at	3762	KCNJ5	L47208	8.40	36.77	19.28	0.52	8.40	36.80	3.87	0.11
216785_at	2281	FKBP1B	AK026273	5.02	15.17	7.96	0.52	5.02	2.52	16.17	
209699_x_at	1646	AKR1C2	U05598	8.15	41.79	21.92	0.52	8.15	76.63	203.90	
208047_s_at	4664	NAB1	NM_005966	90.73	196.23	103.05	0.53	90.73	105.29	366.13	
207169_x_at	780	DDR1	NM_001954	3.04	11.53	6.06	0.53	3.04	15.09	13.53	
47553_at	25861	DFNB31	AA813332	7.91	69.84	36.70	0.53	7.91	61.97	68.52	
216544_at	159162	RBMV2FP	AC007320	7.25	18.87	9.92	0.53	7.25	12.31	8.38	0.68
221376_at	8822	FGF17	NM_003867	19.98	48.53	25.52	0.53	19.98	52.78	27.56	0.52
216774_at			AK025325	32.59	50.41	26.51	0.53	32.59	34.02	29.30	
216157_at			AK024231	4.73	33.34	17.54	0.53	4.73	9.95	10.40	
213299_at	51341	ZBTB7A	AW027070	70.22	108.67	57.16	0.53	70.22	40.69	32.44	
219117_s_at	51303	FKBP11	NM_016594	225.15	376.30	197.96	0.53	225.15	248.89	180.36	
219432_at	2121	EVC	NM_014556	10.39	22.76	11.97	0.53	10.39	4.02	7.30	
209039_x_at	10938	EHD1	AF001434	331.25	1308.87	689.60	0.53	331.25	3816.89	2980.02	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
206459_s_at	7482	WNT2B	NM_024494	9.02	34.17	18.02	0.53	9.02	6.66	17.72	
201473_at	3726	JUNB	NM_002229	220.42	845.97	446.37	0.53	220.42	502.08	765.28	
216187_x_at	3831	KNS2	AF222691	1842.32	4024.28	2124.02	0.53	1842.32	2025.86	2088.13	
202995_s_at	2192	FBLN1	NM_006486	45.62	83.27	43.98	0.53	45.62	19.19	51.05	
208906_at	221092 /	BSCL2 /// HNRPU2	BC004911	234.80	397.20	209.88	0.53	234.80	321.30	214.35	
35147_at	23263	MCF2L	AB002360	6.16	20.79	10.99	0.53	6.16	13.67	7.39	0.54
211924_s_at	5329	PLAUR	AY029180	381.08	1022.12	540.21	0.53	381.08	1224.36	1708.63	
210222_s_at	6252	RTN1	BC000314	18.29	38.69	20.47	0.53	18.29	39.32	25.70	0.65
220958_at	54986	ULK4	NM_017886	9.09	15.24	8.07	0.53	9.09	4.03	9.08	
220167_s_at	24150 //	TP53TG3 /// LOC729264 /// LOC7	NM_015369	23.33	48.72	25.83	0.53	23.33	29.66	36.24	
219863_at	51191	HERC5	NM_016323	101.11	168.99	89.63	0.53	101.11	136.43	81.59	
202254_at	26037	SIPA1L1	AB007900	11.87	34.70	18.42	0.53	11.87	57.47	23.61	0.41
219993_at	64321	SOX17	NM_022454	8.76	35.15	18.67	0.53	8.76	20.92	30.74	
207547_s_at	11170	FAM107A	NM_007177	11.27	27.99	14.87	0.53	11.27	45.91	34.03	0.74
202914_s_at	9826	ARHGEF11	NM_014784	118.53	206.46	109.77	0.53	118.53	159.19	93.28	
219992_at	6866	TAC3	NM_013251	72.37	128.12	68.17	0.53	72.37	150.39	101.60	0.68
210845_s_at	5329	PLAUR	U08839	649.50	1163.57	619.52	0.53	649.50	1604.51	1884.17	
219196_at	29106	SCG3	NM_013243	3.94	15.34	8.17	0.53	3.94	18.72	2.40	0.13
219410_at	55076	TMEM	NM_0180	442.15	965.75	514.69	0.53	442.15	1335.48	1180.69	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		45A	04								
217557_s_at			AV710357	38.92	76.27	40.65	0.53	38.92	137.55	37.00	0.27
216167_at	10446	LRRN5	AK024867	2.86	13.71	7.31	0.53	2.86	8.82	2.15	
205288_at	8556	CDC14A	NM_003672	29.31	82.96	44.31	0.53	29.31	58.73	56.67	
213678_at	441151	C6orf137	F09448	28.04	42.44	22.67	0.53	28.04	26.23	28.17	
218686_s_at	64285	RHBDF1	NM_022450	170.51	261.98	139.95	0.53	170.51	203.45	155.07	
209119_x_at	7026	NR2F2	AV703465	3.53	25.01	13.36	0.53	3.53	59.63	34.63	0.58
117_at	3310	HSPA6	X51757	48.01	100.16	53.54	0.53	48.01	54.27	67.74	
208223_s_at	91	ACVR1B	NM_020327	28.94	56.75	30.34	0.53	28.94	35.26	17.15	
221651_x_at	28299 //	IGKC /// IGKV1-5 /// IGKV2-24	BC005332	56.33	325.62	174.17	0.53	56.33	131.91	31.89	0.24
208013_s_at	56	ACRV1	NM_020115	37.63	59.59	31.88	0.53	37.63	27.80	14.74	
214891_at	23014	FBXO21	U79257	8.02	14.28	7.65	0.54	8.02	7.88	4.75	
214417_s_at	26998	FETUB	N39010	21.05	48.29	25.86	0.54	21.05	24.61	42.55	
205080_at	5915	RARB	NM_000965	31.70	70.57	37.84	0.54	31.70	15.93	26.32	
221011_s_at	81606	LBH	NM_030915	75.88	125.33	67.22	0.54	75.88	80.47	125.37	
221902_at	387509	GPR153	AL567940	51.24	78.75	42.24	0.54	51.24	111.54	64.70	0.58
206841_at	5149	PDE6H	NM_006205	7.26	25.62	13.75	0.54	7.26	31.56	21.70	0.69
217600_at	222663	SCUBE3	BF511678	32.40	55.52	29.86	0.54	32.40	29.49	21.40	
203904_x_at	3732	CD82	NM_002231	190.04	419.57	225.84	0.54	190.04	1212.74	673.84	0.56
213172_at	23508	TTC9	AW23560	2.78	10.65	5.74	0.54	2.78	5.88	3.78	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			8								
210933_s_at	6624	FSCN1	BC004908	1177.05	2869.97	1548.32	0.54	1177.05	1368.41	1629.56	
217650_x_at	6483 ///	ST3GAL2 ///	AI088162	164.40	550.85	297.22	0.54	164.40	671.65	399.21	0.59
216315_x_at	387522 /	UBE2V1 ///	AL121873	49.77	89.94	48.58	0.54	49.77	83.11	60.79	0.73
210705_s_at	85363	TRIM5	AF220028	80.81	147.13	79.55	0.54	80.81	71.29	32.48	
213607_x_at	65220	NADK	BE551347	274.21	424.56	229.72	0.54	274.21	137.52	193.88	
218675_at	51310	SLC22A17	NM_020372	10.21	17.21	9.33	0.54	10.21	39.31	3.90	0.10
211965_at	677	ZFP36L1	BE620915	56.38	95.87	51.99	0.54	56.38	65.97	62.81	
215391_at	4130	MAP1A	AA633627	7.41	15.36	8.33	0.54	7.41	19.80	10.42	0.53
205976_at	22868	FASTKD2	NM_014929	48.86	80.50	43.68	0.54	48.86	73.66	54.61	0.74
206561_s_at	57016	AKR1B10	NM_020299	11.56	28.31	15.37	0.54	11.56	22.33	24.19	
209124_at	4615	MYD88	U70451	1576.46	2487.91	1351.39	0.54	1576.46	1687.04	587.50	
206382_s_at	627	BDNF	NM_001709	7.01	15.96	8.67	0.54	7.01	11.11	12.87	
203849_s_at	547	KIF1A	NM_004321	14.79	24.79	13.47	0.54	14.79	4.51	36.08	
AFFX-BioB-3_at			AFFX-BioB-3	447.16	784.04	426.26	0.54	447.16	424.02	283.64	
217433_at	6867	TACC1	AB029026	6.98	19.88	10.81	0.54	6.98	21.66	10.39	0.48
212611_at	23220	DTX4	AV728526	186.62	699.08	380.35	0.54	186.62	440.08	335.05	
210873_x_at	200315	APOBEC3A	U03891	4.78	44.43	24.18	0.54	4.78	165.32	25.92	0.16
215904_at	4301	MLLT4	AL049698	1.15	26.08	14.20	0.54	1.15	7.82	19.30	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
202662_s_at	3709	ITPR2	NM_002223	94.29	154.21	84.03	0.54	94.29	93.41	125.45	
205935_at	2294	FOXF1	NM_001451	27.17	45.28	24.67	0.54	27.17	77.08	64.65	
217277_at			AL008721	14.95	43.89	23.94	0.55	14.95	28.64	29.82	
211531_x_at	5542 ///	PRB1 /// PRB2	K03205	73.74	118.31	64.57	0.55	73.74	67.31	43.24	
220710_at	80035	C15orf28	NM_024970	87.22	207.09	113.09	0.55	87.22	91.82	117.64	
205569_at	27074	LAMP3	NM_014398	2.47	124.33	67.95	0.55	2.47	5996.80	1210.41	0.20
206255_at	640	BLK	NM_001715	2.15	10.69	5.84	0.55	2.15	3.75	2.77	
215811_at	6622	SNCA	AF238870	6.72	30.01	16.41	0.55	6.72	3.29	6.46	
207670_at	3891	KRT85	NM_002283	20.89	47.79	26.18	0.55	20.89	28.78	22.04	
215284_at	51429	SNX9	AF070575	23.02	53.74	29.46	0.55	23.02	17.55	22.15	
210578_at	10107	TRIM10	AF220122	24.21	50.62	27.75	0.55	24.21	26.88	20.04	
207526_s_at	9173	IL1RL1	NM_003856	10.85	18.10	9.93	0.55	10.85	6.03	3.98	
221905_at	1540	CYLD	BF516433	82.52	405.95	222.84	0.55	82.52	216.75	159.34	0.74
216499_at			AL137590	21.45	105.17	57.74	0.55	21.45	47.06	69.81	
215550_at	9901	SRGAP3	AL137457	23.64	84.50	46.42	0.55	23.64	17.94	40.98	
210433_at	23509	POFUT1	BC000582	13.87	54.44	29.91	0.55	13.87	23.05	42.46	
37512_at	8630	HSD17B6	U89281	14.46	29.98	16.48	0.55	14.46	29.73	20.67	0.70
217235_x_at			D84140	36.97	89.71	49.32	0.55	36.97	49.06	25.02	
210743_s_at	8556	CDC14A	AF064103	65.42	112.10	61.62	0.55	65.42	63.56	26.99	
205744_at	8448	DOC2A	NM_003586	49.94	77.70	42.74	0.55	49.94	55.52	55.74	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
AFFX-HUMRGE/M10098_5_at			AFFX-HUMRGE/M10098_5	100.84	176.11	96.90	0.55	100.84	51.70	212.23	
207928_s_at	8001	GLRA3	NM_006529	2.26	13.80	7.59	0.55	2.26	2.02	2.85	
205425_at	3092	HIP1	NM_005338	203.31	395.38	217.94	0.55	203.31	214.11	196.43	
204980_at	9575	CLOCK	NM_004898	271.80	435.45	240.07	0.55	271.80	464.62	220.13	0.47
213362_at	5789	PTPRD	N73931	17.26	31.03	17.12	0.55	17.26	8.46	21.60	
219480_at	6615	SNAI1	NM_005985	55.89	160.37	88.48	0.55	55.89	159.78	157.05	
216265_x_at	4625	MYH7	AI292276	1.73	13.20	7.28	0.55	1.73	3.32	10.19	
220073_s_at	55200	PLEKHG6	NM_018173	26.25	53.79	29.70	0.55	26.25	7.48	27.49	
206699_x_at	4861	NPAS1	NM_002517	8.54	18.47	10.20	0.55	8.54	21.49	5.57	0.26
221898_at	10630	PDPN	AU154455	66.68	153.19	84.64	0.55	66.68	19.34	43.79	
202222_s_at	1674	DES	NM_001927	29.18	62.95	34.80	0.55	29.18	20.71	37.45	
216372_at			AF103295	5.55	34.13	18.87	0.55	5.55	8.29	15.86	
219853_at	79147	FKRP	BC002612	12.33	67.30	37.22	0.55	12.33	47.93	55.53	
51226_at			N53536	26.09	42.12	23.29	0.55	26.09	13.40	11.21	
210197_at	3705	IIPK1	BC003622	11.15	24.41	13.50	0.55	11.15	8.20	8.34	
220752_at	51145	LOC51145	NM_016158	11.12	36.72	20.31	0.55	11.12	21.35	6.78	0.32
207461_at			NM_001272	15.57	27.78	15.37	0.55	15.57	16.05	3.46	
216984_x_at	3535	IGL@	D84143	4.91	13.58	7.51	0.55	4.91	7.88	15.03	
214904_at	7592	ZNF41	AI927984	28.59	53.02	29.34	0.55	28.59	35.44	25.29	
204363_at	2152	F3	NM_001993	224.43	764.37	423.36	0.55	224.43	371.32	748.25	
204958_at	1263	PLK3	NM_0040	55.80	180.65	100.24	0.55	55.80	298.27	1262.77	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			73								
211315_s_at	8913	CACNA1G	AB012043	4.82	23.79	13.20	0.55	4.82	11.24	12.00	
205888_s_at	23040 //	JAKMIP2 /// MYT1L	AI962693	5.51	17.36	9.64	0.56	5.51	4.54	2.70	
214516_at	8366	HIST1H4B	NM_003544	4.22	23.10	12.83	0.56	4.22	23.87	10.37	0.43
215221_at	27086	FOXP1	AK025064	226.27	401.58	223.02	0.56	226.27	180.79	183.70	
205262_at	3757	KCNH2	NM_000238	7.98	139.77	77.73	0.56	7.98	25.24	5.72	0.23
217024_x_at	140885	SIRPA	AC004832	69.21	194.86	108.36	0.56	69.21	85.81	170.74	
215387_x_at	10082	GPC6	AK021505	68.22	142.87	79.46	0.56	68.22	89.10	26.94	
220711_at			NM_024978	77.24	144.22	80.23	0.56	77.24	87.96	91.39	
210230_at	728965	LOC78965	BC003629	653.12	1704.32	948.25	0.56	653.12	1578.41	1354.99	
203394_s_at	3280	HES1	BE973687	11.64	26.95	15.01	0.56	11.64	41.23	28.61	0.69
202545_at	5580	PRKCD	NM_006254	1738.33	3145.25	1752.71	0.56	1738.33	2390.31	2411.49	
206973_at	8499	PPFIA2	NM_003625	15.84	124.67	69.49	0.56	15.84	76.28	98.64	
217179_x_at	96610	LOC96610	X79782	9.33	25.97	14.47	0.56	9.33	40.96	32.12	
218810_at	80149	ZC3H12A	NM_025079	120.05	822.86	458.68	0.56	120.05	1177.82	2182.59	
212091_s_at	1291	COL6A1	AI141603	135.96	364.34	203.09	0.56	135.96	674.75	506.24	
207987_s_at	2796	GNRH1	NM_000825	9.00	36.96	20.60	0.56	9.00	25.18	49.24	
214128_at	747	C11orf11	AB014559	72.53	114.27	63.79	0.56	72.53	129.18	104.34	
222114_x_at	54853	WDR55	BE409994	31.53	48.60	27.15	0.56	31.53	29.37	17.55	
206966_s_at	11278	KLF12	NM_016285	56.94	103.37	57.80	0.56	56.94	39.40	41.11	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
217270_s_at	9149	DYRK1B	AC005393	28.10	42.38	23.70	0.56	28.10	31.73	20.31	
206780_at	2572	GAD2	NM_000818	26.45	50.02	27.97	0.56	26.45	32.32	23.56	
219227_at	79616	CCNJL	NM_024565	3.73	29.44	16.48	0.56	3.73	79.41	75.44	
205346_at	6483	ST3GAL2	NM_006927	62.50	220.88	123.65	0.56	62.50	161.43	126.83	
216813_at			AL512728	3.95	22.37	12.53	0.56	3.95	7.16	28.67	
206100_at	1368	CPM	NM_001874	1155.85	3121.43	1748.94	0.56	1155.85	5890.11	2966.29	0.50
220374_at	54813	BTBD5	NM_017658	13.47	55.62	31.17	0.56	13.47	39.98	28.82	0.72
207025_at	57165	GJA12	NM_020435	16.01	37.12	20.81	0.56	16.01	25.71	35.71	
216812_at			AF308291	2.62	13.46	7.55	0.56	2.62	5.61	8.83	
215149_at			AF052109	14.42	29.68	16.64	0.56	14.42	14.76	14.35	
204621_s_at	4929	NR4A2	AI935096	33.55	73.04	40.95	0.56	33.55	127.15	80.23	0.63
216147_at	55752	11-Sep	AL353942	23.66	232.22	130.20	0.56	23.66	112.72	192.96	
38037_at	1839	HBEGF	M60278	53.04	83.15	46.62	0.56	53.04	148.66	126.52	
207093_s_at	4974	OMG	NM_002544	43.54	80.98	45.41	0.56	43.54	55.02	36.52	
206191_at	956	ENTPD3	NM_001248	9.27	17.66	9.91	0.56	9.27	20.77	9.67	0.47
218801_at	55757	UGCG L2	NM_020121	110.85	169.53	95.15	0.56	110.85	126.67	139.82	
219752_at	8437	RASAL1	NM_004658	31.29	66.68	37.43	0.56	31.29	13.95	20.90	
220137_at	54621	FLJ20674	NM_019086	76.53	137.23	77.05	0.56	76.53	74.70	67.30	
207630_s_at	1390	CREM	NM_001881	114.54	194.88	109.43	0.56	114.54	211.42	224.82	
207007_at	9970	NR1I3	NM_005122	7.81	57.54	32.33	0.56	7.81	23.95	18.69	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
217212_s_at	3581 ///	IL9R /// LOC72 9486	Z84723	35.78	81.25	45.65	0.56	35.78	57.74	51.02	
210726_at	1576	CYP3A 4	J04449	12.41	41.65	23.41	0.56	12.41	8.08	19.72	
219400_at	8506	CNTN AP1	NM_0036 32	20.59	41.58	23.37	0.56	20.59	47.40	23.08	0.49
221653_x_at	23780	APOL2	BC00439 5	69.69	106.76	60.03	0.56	69.69	49.07	20.89	
206648_at	51276	ZNF57 1	NM_0165 36	12.62	31.85	17.92	0.56	12.62	28.30	27.06	
217141_at	55727	BTBD7	AL04939 4	31.90	83.12	46.80	0.56	31.90	27.25	47.58	
206209_s_at	762	CA4	NM_0007 17	20.90	43.68	24.61	0.56	20.90	3.71	17.64	
221681_s_at	1834	DSPP	AF09450 8	17.38	57.96	32.67	0.56	17.38	25.33	27.25	
AFFX- HUMISGF3A /M97935_3_at	6772	STAT1	AFFX- HUMISG F3A/M97 935_3	1011.38	1734.07	978.40	0.56	1011.38	1278.43	866.67	
217541_x_at	125893 /	LOC12 5893 /// LOC73 1901	BG29053 2	82.50	138.83	78.39	0.56	82.50	70.12	41.45	
210601_at	1004	CDH6	BC00001 9	6.61	16.90	9.54	0.56	6.61	13.62	7.58	0.56
AFFX-r2-Ec- bioB-M_at			AFFX-r2- Ec-bioB- M	677.00	1126.52	636.20	0.56	677.00	628.74	410.49	
205723_at	1271	CNTFR	NM_0018 42	37.14	124.98	70.61	0.56	37.14	75.70	97.83	
37566_at	23349	KIAA1 045	AB02896 8	7.74	31.79	17.97	0.57	7.74	40.64	17.20	0.42
217778_at	27173	SLC39 A1	NM_0144 37	323.99	551.36	311.62	0.57	323.99	304.88	225.76	
214445_at	22936	ELL2	NM_0120 81	11.49	25.86	14.62	0.57	11.49	6.72	44.76	
205303_at	3764	KCNJ8	BF51415 8	3.75	14.59	8.26	0.57	3.75	5.67	9.91	
215513_at	57061	HYMA I	AF24153 4	88.17	181.76	102.86	0.57	88.17	181.58	199.14	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
AFFX-BioB-M_at			AFFX-BioB-M	733.24	1184.42	670.42	0.57	733.24	612.06	377.41	
216565_x_at	391020	LOC391020	AL121994	301.64	510.32	288.88	0.57	301.64	192.14	225.44	
214230_at	998	CDC42	R37664	5.92	22.80	12.92	0.57	5.92	5.70	21.06	
205265_s_at	10290	SPEG	NM_005876	15.45	30.76	17.42	0.57	15.45	14.02	26.29	
215421_at			AI821657	27.25	45.53	25.79	0.57	27.25	47.99	21.39	0.45
216810_at	85287	KRTAP4-7	AJ406939	4.49	15.30	8.67	0.57	4.49	19.39	19.83	
211549_s_at	3248	HPGD	U63296	6.87	10.78	6.11	0.57	6.87	3.08	21.19	
221978_at	3134	HLA-F	BE138825	43.93	80.39	45.71	0.57	43.93	60.69	61.09	
216322_at	965	CD58	D28586	29.83	46.82	26.63	0.57	29.83	74.55	33.15	0.44
215661_at	23139	MAST2	AK025352	12.29	40.70	23.15	0.57	12.29	15.76	24.58	
206286_s_at	6997 ///	TDGF1 /// TDGF3	NM_003212	12.89	20.90	11.90	0.57	12.89	20.82	5.05	0.24
211436_at			AF130053	4.74	11.97	6.81	0.57	4.74	9.80	1.09	
221329_at	23538	OR52A1	NM_012375	17.32	33.04	18.81	0.57	17.32	5.16	14.84	
210605_s_at	4240	MFG8	BC003610	49.85	90.54	51.56	0.57	49.85	33.15	20.67	
207868_at	1135	CHRNA2	NM_000742	58.88	89.58	51.01	0.57	58.88	64.98	52.14	
220232_at	79966	SCD5	NM_024906	116.44	257.09	146.48	0.57	116.44	112.90	121.68	
211232_x_at	2740	GLP1R	L23503	5.80	13.69	7.80	0.57	5.80	6.15	9.21	
210841_s_at	8828	NRP2	AF280546	47.60	97.39	55.50	0.57	47.60	98.87	135.69	
206682_at	10462	CLEC10A	NM_006344	46.54	84.46	48.17	0.57	46.54	28.26	18.35	
AFFX-BioB-5_at			AFFX-BioB-5	471.26	804.59	459.65	0.57	471.26	471.94	322.91	
214984_at	23049 //	SMG1 /// DKFZp	AC003007	13.67	40.98	23.43	0.57	13.67	28.19	11.93	0.42

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		547E087 /// LOC4									
214137_at	5795	PTPRJ	AI806482	12.88	33.65	19.24	0.57	12.88	26.53	25.52	
204438_at	414308 /	MRC1 /// MRC1L1	NM_002438	7.79	12.12	6.94	0.57	7.79	9.37	8.37	
218425_at	54476	TRIAD3	BC000787	363.64	594.58	340.41	0.57	363.64	374.30	369.69	
205092_x_at	22890	ZBTB1	NM_014950	18.37	37.65	21.56	0.57	18.37	42.10	59.26	
207575_at	342096 /	GOLGA /// GOLGA6 /// LOC653641	NM_018652	15.87	29.29	16.77	0.57	15.87	5.57	18.62	
216191_s_at	64919 //	TRA@ /// TRD@ /// BCL11B	X72501	0.96	17.62	10.10	0.57	0.96	7.13	5.41	
205153_s_at	958	CD40	NM_001250	264.54	1239.11	710.48	0.57	264.54	1797.70	1931.70	
210804_x_at	6546	SLC8A1	AF128524	42.68	67.98	38.99	0.57	42.68	16.40	14.98	
209525_at	50810	HDGFRP3	BG285017	3.78	10.56	6.06	0.57	3.78	1.75	3.52	
207194_s_at	3386	ICAM4	NM_001544	20.19	47.25	27.12	0.57	20.19	29.54	17.25	
206766_at	8515	ITGA10	AF112345	53.44	109.42	62.86	0.57	53.44	52.56	55.10	
AFFX-BioC-5_at			AFFX-BioC-5	1489.47	2318.83	1332.44	0.57	1489.47	1341.35	937.98	
204287_at	9145	SYNGR1	NM_004711	46.52	71.02	40.83	0.57	46.52	36.47	76.27	
203595_s_at	24138	IFIT5	N47725	27.91	198.45	114.11	0.58	27.91	239.63	98.57	0.41
206508_at	970	CD70	NM_001252	877.18	3190.96	1835.10	0.58	877.18	1948.79	1672.51	
201750_s_at	1889	ECE1	NM_001397	20.76	76.46	44.00	0.58	20.76	182.20	191.67	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
215498_s_at	5606	MAP2K3	AA780381	179.29	518.27	298.30	0.58	179.29	985.59	1021.49	
203242_s_at	10611	PDLIM5	BG054550	260.99	593.87	342.05	0.58	260.99	265.58	464.58	
217201_at	9462	RASAL2	AB007970	22.70	64.09	36.92	0.58	22.70	54.47	30.33	0.56
220771_at	51152	LOC51152	NM_016181	38.29	73.33	42.26	0.58	38.29	42.00	42.67	
220272_at	54796	BNC2	NM_017637	24.44	38.36	22.11	0.58	24.44	12.21	5.86	
220905_at			NM_025007	16.72	62.26	35.90	0.58	16.72	51.93	24.26	0.47
207312_at	5260	PHKG1	NM_006213	32.44	59.02	34.07	0.58	32.44	9.42	50.25	
211407_at	4713	NDUF B7	M33374	25.58	53.84	31.10	0.58	25.58	34.20	20.41	
206539_s_at	66002	CYP4F12	NM_023944	11.43	79.74	46.06	0.58	11.43	19.47	17.14	
210173_at	5795	PTPRJ	D37781	79.43	119.78	69.22	0.58	79.43	40.66	106.77	
204654_s_at	7020	TFAP2A	NM_003220	9.12	114.94	66.47	0.58	9.12	217.09	225.23	
216072_at	3275	PRMT2	AL050065	11.83	34.17	19.76	0.58	11.83	36.46	3.50	0.10
214707_x_at	7840	ALMS1	AB002326	100.13	414.70	239.87	0.58	100.13	127.94	81.47	
215627_at	440925	LOC440925	AK023515	19.11	53.40	30.93	0.58	19.11	48.09	14.09	0.29
208596_s_at	54575 //	UGT1A10 /// UGT1A8 /// UGT1A7	NM_019093	7.00	15.77	9.13	0.58	7.00	13.37	16.34	
207375_s_at	3601	IL15RA	NM_002189	71.76	121.46	70.36	0.58	71.76	245.72	303.93	
202637_s_at	3383	ICAM1	AI608725	37.89	1474.78	854.57	0.58	37.89	1749.04	1165.92	0.67
207718_x_at	1548 ///	CYP2A6 /// CYP2A7 /// CYP2A7P1	NM_000764	26.66	46.31	26.84	0.58	26.66	51.38	24.89	0.48

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
209785_s_at	8605	PLA2G4C	AF065214	128.84	631.78	366.27	0.58	128.84	654.05	528.35	
206999_at	3595	IL12RB2	NM_001559	1114.24	1860.35	1078.75	0.58	1114.24	1418.15	1004.03	
209886_s_at	4091	SMAD6	AF035528	20.93	52.85	30.66	0.58	20.93	13.94	17.92	
219869_s_at	64116	SLC39A8	AW139759	736.35	1327.90	770.56	0.58	736.35	1684.93	1731.26	
212503_s_at	22982	DIP2C	N22859	10.57	27.11	15.73	0.58	10.57	12.39	20.14	
211371_at	5607	MAP2K5	U71088	3.85	10.74	6.24	0.58	3.85	6.96	12.59	
214424_s_at			AV650852	4.23	11.25	6.53	0.58	4.23	7.40	4.06	
205241_at	9997	SCO2	NM_005138	454.58	968.47	562.22	0.58	454.58	1567.77	688.65	0.44
209493_at	23037	PDZD2	AF338650	4.64	22.46	13.04	0.58	4.64	17.01	5.43	0.32
207733_x_at	5678	PSG9	NM_002784	14.26	42.81	24.89	0.58	14.26	13.42	4.78	
215555_at	57035	C1orf63	AU158442	42.37	171.04	99.46	0.58	42.37	43.08	61.25	
207667_s_at	5606	MAP2K3	NM_002756	220.08	487.84	283.74	0.58	220.08	531.34	1158.48	
203729_at	2014	EMP3	NM_001425	2819.63	5234.38	3044.73	0.58	2819.63	5665.66	5895.52	
221866_at	7942	TFEB	AL035588	238.25	397.89	231.47	0.58	238.25	341.25	296.07	
211862_x_at	8837	CFLAR	AF015451	409.00	1233.50	717.66	0.58	409.00	1333.04	1749.55	
222040_at	3178 ///	HNRPA1 /// LOC728844 /// LOC73	AI144007	165.78	276.66	161.00	0.58	165.78	416.16	350.46	
205225_at	2099	ESR1	NM_000125	2.14	17.41	10.13	0.58	2.14	3.98	8.51	
219794_at	55275	VPS53	NM_018289	49.29	87.53	50.94	0.58	49.29	31.43	61.86	
217200_x_at	1534	CYB561	U06715	167.13	257.90	150.23	0.58	167.13	224.54	146.87	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
205801_s_at	25780	RASGRP3	NM_015376	3.46	13.15	7.66	0.58	3.46	3.17	1.50	
217208_s_at	1739 ///	DLG1 /// TNFRSF11B	AL121981	220.18	355.90	207.43	0.58	220.18	148.54	153.67	
217704_x_at	440423	SUZ12P	AI820796	289.95	583.77	340.31	0.58	289.95	258.87	278.56	
208965_s_at	3428	IFI16	BG256677	341.07	521.43	303.99	0.58	341.07	319.55	157.68	
206538_at	22808	MRAS	NM_012219	56.09	95.39	55.62	0.58	56.09	133.55	143.15	
211012_s_at	161527 /	PML /// LOC161527	BC000080	130.51	223.62	130.43	0.58	130.51	277.30	61.72	0.22
203882_at	10379	ISGF3G	NM_006084	553.66	1503.24	877.98	0.58	553.66	1354.94	1005.75	0.74
207998_s_at	776	CACNA1D	NM_000720	6.39	13.31	7.78	0.58	6.39	8.64	18.29	
206339_at	9607	CARTPT	NM_004291	28.40	49.14	28.75	0.58	28.40	40.01	24.85	
205174_s_at	25797	QPCT	NM_012413	60.94	236.11	138.15	0.59	60.94	309.07	161.82	0.52
204902_s_at	23192 //	ATG4B /// LOC727737	NM_013325	96.08	152.52	89.25	0.59	96.08	200.99	111.85	0.56
210282_at	7750	ZMYM2	AL136621	49.96	95.03	55.68	0.59	49.96	115.43	64.80	0.56
220484_at	55283	MCOLN3	NM_018298	374.54	824.00	482.88	0.59	374.54	615.67	1008.13	
211802_x_at	8913	CACNA1G	AF227750	17.00	34.12	20.00	0.59	17.00	17.98	18.23	
209016_s_at	3855	KRT7	BC002700	8.76	51.50	30.19	0.59	8.76	43.08	29.90	0.69
221755_at	254102	EHBP1L1	BG334196	381.85	698.02	409.19	0.59	381.85	124.69	219.63	
206995_x_at	8578	SCARF1	NM_003693	29.69	49.43	28.99	0.59	29.69	80.71	81.92	
204682_at	4053	LTBP2	NM_000428	41.55	69.71	40.90	0.59	41.55	25.89	46.87	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
221440_s_at	10741	RBBP9	NM_006606	8.25	18.93	11.12	0.59	8.25	19.01	18.60	
214058_at	4610	MYCL1	M19720	299.15	821.66	482.94	0.59	299.15	298.31	216.24	
211552_s_at	8659	ALDH4A1	U24267	25.77	40.80	23.99	0.59	25.77	14.35	24.14	
217054_at			AF007194	20.63	52.61	30.93	0.59	20.63	15.92	18.64	
206850_at	10633	RRP22	NM_006477	55.76	100.63	59.20	0.59	55.76	205.20	295.67	
215425_at	10950	BTG3	AL049332	20.75	44.40	26.13	0.59	20.75	30.33	21.44	
216432_at	9153	SLC28A2	AK025121	5.99	12.07	7.11	0.59	5.99	12.71	2.85	0.22
215496_at	23034	SAMD4A	AL117523	11.78	32.17	18.94	0.59	11.78	30.63	40.68	
210594_x_at	9019	MPZL1	AF239756	53.60	110.93	65.33	0.59	53.60	35.30	91.06	
219411_at	79767	ELMO3	NM_024712	63.48	103.14	60.74	0.59	63.48	117.35	113.52	
203441_s_at	1000	CDH2	NM_001792	56.46	87.33	51.56	0.59	56.46	53.16	80.65	
211653_x_at	1646	AKR1C2	M33376	25.79	59.50	35.14	0.59	25.79	62.69	198.51	
211571_s_at	1462	CSPG2	D32039	91.45	197.62	116.73	0.59	91.45	143.81	123.83	
214590_s_at	7321	UBE2D1	AL545760	25.37	41.26	24.37	0.59	25.37	36.59	44.37	
206830_at	57282	SLC4A10	NM_022058	8.17	18.16	10.72	0.59	8.17	10.63	2.69	
216745_x_at			AK024606	114.85	201.71	119.18	0.59	114.85	130.79	82.49	
211668_s_at	5328	PLAU	K03226	177.67	396.21	234.14	0.59	177.67	579.34	2489.29	
AFFX-r2-Ec-bioC-5_at			AFFX-r2-Ec-bioC-5	1801.29	2723.74	1610.18	0.59	1801.29	1638.71	976.91	
210364_at	6327	SCN2B	U87555	5.28	38.85	22.97	0.59	5.28	18.91	12.20	0.64
208504_x_at	56125	PCDHB11	NM_018931	10.82	21.09	12.47	0.59	10.82	7.45	5.04	
214068_at	146227	BEAN	AF07061	20.28	31.31	18.53	0.59	20.28	4.38	23.37	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			0								
203141_s_at	8546	AP3B1	NM_003664	161.30	242.06	143.30	0.59	161.30	100.15	153.71	
206132_at	4163	MCC	NM_002387	33.27	67.28	39.85	0.59	33.27	51.38	70.01	
221920_s_at	51312	SLC25A37	BE677761	209.09	337.45	200.01	0.59	209.09	78.66	217.19	
215868_x_at	6660	SOX5	AK026238	38.29	63.01	37.35	0.59	38.29	143.81	82.81	0.58
216964_at			AL162082	26.50	49.35	29.25	0.59	26.50	29.39	32.70	
215385_at	79068	FTO	AK022473	114.44	203.90	120.88	0.59	114.44	93.30	83.09	
218631_at	60370	AVPI1	NM_021732	59.68	108.10	64.08	0.59	59.68	252.57	159.91	0.63
214724_at	85458	DIXDC1	AF070621	101.05	314.69	186.64	0.59	101.05	991.37	525.56	0.53
217259_at			AL117549	24.30	40.75	24.18	0.59	24.30	12.24	20.98	
208167_s_at	4325	MMP16	NM_022564	6.60	22.80	13.54	0.59	6.60	5.44	7.73	
201308_s_at	55752	11-Sep	NM_018243	137.44	234.40	139.25	0.59	137.44	130.93	250.19	
204901_at	8945	BTRC	AA824369	6.95	34.26	20.36	0.59	6.95	16.62	30.25	
211208_s_at	8573	CASK	AB039327	40.01	96.46	57.33	0.59	40.01	24.58	64.81	
213693_s_at	4582	MUC1	AI610869	326.98	699.61	416.00	0.59	326.98	446.59	298.14	
200760_s_at	10550	ARL6IP5	N92494	2140.43	3933.07	2338.70	0.59	2140.43	2566.86	973.29	
216154_at	2262	GPC5	AF339787	7.03	33.40	19.88	0.60	7.03	2.65	5.02	
206423_at	10218	ANGPTL7	NM_021146	6.35	16.98	10.11	0.60	6.35	3.05	10.19	
221103_s_at	55779	WDR52	NM_018338	70.57	116.04	69.10	0.60	70.57	47.66	67.76	
216354_at			AL031669	56.16	96.11	57.29	0.60	56.16	95.15	87.22	
214873_at	91355	LRP5L	AL13765	16.41	42.77	25.51	0.60	16.41	39.00	13.15	0.34

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			1								
207211_at	9099	USP2	AF079564	6.52	10.00	5.97	0.60	6.52	7.24	9.44	
202971_s_at	8445	DYRK2	Y09216	387.05	585.88	349.80	0.60	387.05	623.69	238.02	0.38
217933_s_at	51056	LAP3	NM_015907	2126.63	4839.78	2891.17	0.60	2126.63	2787.93	2332.74	
213295_at	1540	CYLD	AA555096	181.04	590.06	352.62	0.60	181.04	438.26	382.32	
202897_at	140885	SIRPA	AB023430	702.89	1479.62	884.64	0.60	702.89	1787.89	1917.70	
214578_s_at	6093	ROCK1	AV683882	298.04	514.05	307.49	0.60	298.04	313.88	391.02	
220874_at			NM_018575	25.33	44.84	26.83	0.60	25.33	37.80	16.04	
203666_at	6387	CXCL12	NM_000609	34.89	82.37	49.36	0.60	34.89	115.21	169.19	
217542_at	1368	CPM	BE930512	30.13	51.25	30.72	0.60	30.13	98.01	70.73	0.72
216789_at			AK026439	5.94	14.12	8.47	0.60	5.94	23.56	2.65	0.11
217282_at	10905	MAN1A2	AK001970	34.88	53.83	32.31	0.60	34.88	50.06	36.78	
216165_at	84253	GARNL3	AK025650	6.93	12.48	7.49	0.60	6.93	3.79	4.12	
208242_at	30062	RAX	NM_013435	6.10	15.60	9.37	0.60	6.10	10.96	6.24	0.57
216751_at	284040	CDRT4	AK024879	39.91	69.31	41.61	0.60	39.91	38.04	27.35	
212364_at	4430	MYO1B	BF432550	29.60	47.70	28.68	0.60	29.60	238.94	298.92	
210539_at	23093	TLL5	AK024259	35.15	90.38	54.34	0.60	35.15	63.24	77.27	
213488_at	25992	SNED1	N73970	11.35	35.03	21.07	0.60	11.35	28.68	19.39	0.68
201150_s_at	7078	TIMP3	NM_000362	2147.20	3422.85	2058.64	0.60	2147.20	1655.18	3952.57	
209160_at	8644	AKR1C3	AB018580	5.27	16.10	9.68	0.60	5.27	43.53	16.81	0.39
220532_s_at	28959	TMEM176B	NM_014020	438.50	740.35	445.31	0.60	438.50	389.25	397.64	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
AFFX-HUMRGE/M10098_3_at			AFFX-HUMRGE/M10098_3	135.66	286.88	172.71	0.60	135.66	117.60	229.38	
205637_s_at	6457	SH3GL3	NM_003027	31.91	63.71	38.36	0.60	31.91	56.14	25.27	0.45
214909_s_at	23564	DDAH2	AK026191	225.56	347.32	209.48	0.60	225.56	225.55	176.27	
203300_x_at	8905	AP1S2	NM_003916	5225.34	9029.88	5446.98	0.60	5225.34	4677.36	5667.04	
209392_at	5168	ENPP2	L35594	21.35	77.30	46.63	0.60	21.35	21.59	46.53	
219788_at	29992	PILRA	NM_013439	21.06	48.36	29.18	0.60	21.06	43.82	56.30	
218986_s_at	55601	FLJ20035	NM_017631	256.69	451.79	272.81	0.60	256.69	549.85	467.75	
213954_at	26049	KIAA0888	AB020695	18.81	66.78	40.35	0.60	18.81	28.75	79.01	
208078_s_at	150094	SNF1LK	NM_030751	125.45	211.31	127.72	0.60	125.45	497.13	983.86	
205333_s_at	9986	RCE1	NM_005133	182.26	299.99	181.34	0.60	182.26	204.63	176.89	
221272_s_at	81563	C1orf21	NM_030806	18.45	83.54	50.53	0.60	18.45	100.12	192.92	
212813_at	83700	JAM3	AA149644	32.85	60.98	36.90	0.61	32.85	39.08	18.84	
213148_at	257407	LOC257407	AW156899	13.99	33.39	20.20	0.61	13.99	43.98	41.82	
205616_at			AW134812	9.33	28.11	17.02	0.61	9.33	8.20	16.11	
210499_s_at	10084	PQBP1	AB041834	83.01	156.38	94.75	0.61	83.01	93.77	120.50	
221496_s_at	10766	TOB2	AL008582	270.75	447.07	270.96	0.61	270.75	307.28	257.74	
217359_s_at	4684	NCAM1	M22094	6.80	29.72	18.02	0.61	6.80	25.25	18.10	0.72
203637_s_at	4281	MID1	NM_000381	24.68	41.22	25.00	0.61	24.68	50.22	23.04	0.46
200887_s_at	6772	STAT1	NM_007315	1429.05	3114.99	1890.80	0.61	1429.05	3209.97	1374.12	0.43
219780_at	51333	ZNF77	NM_0166	8.07	26.89	16.34	0.61	8.07	15.30	20.25	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		1	43								
AFFX-BioDn-5_at			AFFX-BioDn-5	3048.13	4817.97	2928.98	0.61	3048.13	2782.67	1846.70	
213075_at	169611	OLFM L2A	AL050002	21.79	46.54	28.30	0.61	21.79	35.70	15.66	0.44
216822_x_at			AL359763	45.36	80.49	48.94	0.61	45.36	52.86	53.90	
160020_at	4323	MMP14	Z48481	547.97	925.24	562.64	0.61	547.97	316.72	464.30	
207793_s_at	2035	EPB41	NM_004437	18.13	44.48	27.06	0.61	18.13	24.54	26.01	
207195_at	27255	CNTN6	NM_014461	3.92	12.13	7.38	0.61	3.92	3.84	5.70	
206450_at	1621	DBH	NM_000787	5.26	10.33	6.29	0.61	5.26	4.42	13.50	
216837_at	2044	EPHA5	L36644	11.84	21.23	12.93	0.61	11.84	24.23	15.12	0.62
204049_s_at	9749	PHACTR2	NM_014721	661.40	1322.14	805.65	0.61	661.40	1798.06	2022.93	
220906_at			NM_025016	8.92	40.75	24.85	0.61	8.92	21.42	7.53	0.35
208112_x_at	10938	EHD1	NM_006795	292.95	836.69	510.35	0.61	292.95	2309.52	1481.01	0.64
206911_at	7706	TRIM25	NM_005082	198.49	318.97	194.69	0.61	198.49	123.88	319.98	
205212_s_at	9744	CENTB1	NM_014716	22.41	37.36	22.82	0.61	22.41	5.03	32.16	
214284_s_at	8817	FGF18	AA022949	21.93	34.85	21.29	0.61	21.93	27.34	23.52	
217537_x_at			M78162	11.51	33.67	20.57	0.61	11.51	20.58	9.53	0.46
214028_x_at	81550	TDRD3	AU156998	38.03	80.42	49.14	0.61	38.03	52.37	52.62	
215797_at	348035	MGC40069	AE000659	15.84	35.77	21.85	0.61	15.84	28.28	27.43	
215852_x_at	140710	C20orf17	AK022023	32.52	60.04	36.69	0.61	32.52	39.85	30.73	
58780_s_at	55701	FLJ10357	R42449	502.95	777.06	475.08	0.61	502.95	1286.29	474.40	0.37
221392_at	50832	TAS2R4	NM_016944	17.85	32.03	19.59	0.61	17.85	27.80	13.99	0.50

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
220090_at	49860	CRNN	NM_016190	9.55	14.94	9.14	0.61	9.55	7.34	11.96	
204096_s_at	8178	ELL	AL136771	61.79	97.89	59.90	0.61	61.79	67.93	78.75	
219622_at	55647	RAB20	NM_017817	280.66	533.00	326.50	0.61	280.66	353.58	426.69	
206965_at	11278	KLF12	NM_016285	7.50	35.23	21.59	0.61	7.50	15.40	9.19	0.60
220364_at	54508	FLJ11235	NM_019033	11.10	24.76	15.17	0.61	11.10	6.53	13.74	
206487_at	23353	UNC84A	NM_025154	8.09	20.07	12.30	0.61	8.09	3.65	13.03	
220524_at	54566	EPB41L4B	NM_024823	3.99	10.81	6.62	0.61	3.99	8.00	5.31	
202273_at	5159	PDGFRB	NM_002609	27.54	49.04	30.07	0.61	27.54	15.71	7.50	
210424_s_at	23015 //	GOLGA8A /// GOLGA8B	AF164622	165.95	281.58	172.67	0.61	165.95	159.59	199.51	
211402_x_at	2649	NR6A1	AF004291	6.85	34.80	21.35	0.61	6.85	53.15	41.38	
222054_at	664727	LOC664727	BF511556	61.57	110.25	67.66	0.61	61.57	96.20	125.55	
215437_x_at	11176	BAZ2A	BE513659	37.23	79.45	48.76	0.61	37.23	42.10	44.56	
217691_x_at	9123	SLC16A3	AA853175	259.50	496.83	305.07	0.61	259.50	453.55	460.67	
221887_s_at	25861	DFNB31	BE045998	8.92	49.81	30.60	0.61	8.92	39.37	57.36	
211799_x_at	3107	HLA-C	U62824	1250.72	2051.02	1260.54	0.61	1250.72	1070.82	1619.81	
213924_at	65258	MPPE1	BF476502	6.82	14.22	8.74	0.61	6.82	11.07	24.41	
204891_s_at	3932	LCK	NM_005356	5.63	10.98	6.75	0.62	5.63	6.94	4.22	
202895_s_at	140885	SIRPA	D86043	110.67	206.40	127.01	0.62	110.67	105.38	191.50	
211681_s_at	10611	PDLIM5	AF116705	153.09	237.78	146.52	0.62	153.09	128.69	205.71	
204770_at	6891	TAP2	NM_000544	74.12	118.40	72.99	0.62	74.12	61.99	47.33	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
211139_s_at	4664	NAB1	AF045452	264.84	633.15	390.50	0.62	264.84	431.83	772.97	
215874_at	6482	ST3GAL1	AK026820	45.38	108.71	67.05	0.62	45.38	57.62	47.46	
210109_at	27099	NAG8	AF191492	97.09	229.39	141.67	0.62	97.09	167.40	199.58	
209935_at	27032	ATP2C1	AF225981	97.38	166.37	102.77	0.62	97.38	496.95	571.50	
207497_s_at	2206	MS4A2	D10583	4.70	38.40	23.72	0.62	4.70	33.23	9.25	0.28
211259_s_at	655	BMP7	BC004248	9.88	27.92	17.25	0.62	9.88	21.05	27.41	
206763_at	8468	FKBP6	NM_003602	16.91	26.85	16.59	0.62	16.91	31.50	18.80	0.60
201148_s_at	7078	TIMP3	AW338933	699.60	1285.56	794.53	0.62	699.60	758.77	2063.65	
219353_at	374354	NHLRC2	NM_017687	96.42	168.98	104.44	0.62	96.42	172.95	74.99	0.43
AFFX-r2-Ec-bioB-3_at			AFFX-r2-Ec-bioB-3	674.50	1038.38	641.82	0.62	674.50	635.36	415.27	
210564_x_at	8837	CFLAR	AF009619	220.24	702.70	434.38	0.62	220.24	729.67	1093.87	
205878_at	5463	POU6F1	NM_002702	4.24	44.00	27.21	0.62	4.24	44.54	14.65	0.33
210359_at	9788	MTSS1	AF116674	21.07	46.89	29.00	0.62	21.07	52.63	102.29	
220180_at	80323	CCDC68	NM_025214	6.00	35.74	22.10	0.62	6.00	90.64	116.81	
214971_s_at	6480	ST6GAL1	AV695711	37.97	81.03	50.12	0.62	37.97	22.60	86.03	
203233_at	3566	IL4R	NM_000418	279.19	505.68	312.95	0.62	279.19	842.42	452.06	0.54
205473_at	525	ATP6V1B1	NM_001692	29.82	46.35	28.69	0.62	29.82	41.51	11.88	
210461_s_at	3983	ABLIM1	BC002448	9.24	30.29	18.75	0.62	9.24	18.80	22.94	
215121_x_at	28786 //	IGL@ /// IGLV4-3 /// IGLV3-25	AA680302	50.69	83.03	51.46	0.62	50.69	61.94	46.91	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
212201_at	23141	KIAA0692	AW274877	463.04	714.47	443.48	0.62	463.04	913.05	1097.30	
216793_x_at			AK026856	12.86	21.40	13.28	0.62	12.86	8.43	23.38	
210925_at	4261	CIITA	U18288	18.82	59.46	36.91	0.62	18.82	42.50	30.85	0.73
220229_s_at	23431	AP4E1	AB030653	24.81	54.42	33.79	0.62	24.81	23.25	38.14	
206118_at	6775	STAT4	NM_003151	84.34	383.05	238.05	0.62	84.34	5306.00	3824.38	0.72
221028_s_at	81577	GFOD2	NM_030819	79.24	122.03	75.85	0.62	79.24	100.55	74.12	
202865_at	54788	DNAJB12	AI695173	47.05	73.85	45.91	0.62	47.05	70.06	72.33	
205947_s_at	7434	VIPR2	NM_003382	6.25	28.43	17.68	0.62	6.25	17.85	23.55	
207976_at	23276	KLHL18	NM_025010	11.95	62.85	39.10	0.62	11.95	36.86	14.11	0.38
202734_at	9322	TRIP10	NM_004240	188.84	413.86	257.63	0.62	188.84	1185.35	1386.27	
209084_s_at	9364	RAB28	BE504689	204.05	475.92	296.32	0.62	204.05	172.88	340.37	
207379_at	10085	EDIL3	NM_005711	25.90	47.37	29.50	0.62	25.90	11.98	20.84	
208520_at	26532	OR10H3	NM_013938	13.74	31.43	19.57	0.62	13.74	9.25	23.60	
219672_at	51327	ERAF	NM_016633	13.47	21.30	13.27	0.62	13.47	47.87	24.96	0.52
222142_at	1540	CYLD	AK024212	8.90	28.42	17.71	0.62	8.90	30.39	15.98	0.53
AFFX-r2-Ec-bioD-5_at			AFFX-r2-Ec-bioD-5	6369.45	9725.48	6063.32	0.62	6369.45	5914.31	4171.27	
203299_s_at	653653 /	AP1S2 /// LOC653653 /// LOC654	AF251295	1151.83	1852.40	1155.30	0.62	1151.83	1843.22	1410.88	
213135_at	7074	TIAM1	U90902	6.65	10.46	6.53	0.62	6.65	25.05	5.00	0.20
215029_at			AL117451	136.94	264.93	165.28	0.62	136.94	137.77	195.80	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
216368_s_at	1285	COL4A3	U02520	18.57	39.49	24.65	0.62	18.57	21.42	21.89	
215006_at	2146	EZH2	AK023816	161.19	356.14	222.37	0.62	161.19	294.09	224.74	
204858_s_at	1890	ECGF1	NM_001953	164.15	328.49	205.11	0.62	164.15	220.27	145.54	
35150_at	958	CD40	X60592	367.39	1633.92	1020.81	0.62	367.39	2347.53	2383.94	
217556_at			W26966	15.92	35.28	22.05	0.62	15.92	12.87	7.59	
219011_at	57664	PLEKH A4	NM_020904	5.33	12.80	8.00	0.63	5.33	10.41	3.98	0.38
206608_s_at	57096	RPGRI P1	NM_020366	19.76	58.99	36.88	0.63	19.76	34.04	60.21	
211619_s_at	250 ///	ALPP /// ALPPL 2	M13077	11.13	21.72	13.58	0.63	11.13	17.16	26.41	
221397_at	50839	TAS2R10	NM_023921	15.51	33.66	21.06	0.63	15.51	20.38	3.36	
204881_s_at	7357	UGCG	NM_003358	577.92	1184.67	741.69	0.63	577.92	2246.79	1180.95	0.53
205023_at	5888	RAD51	D14134	77.01	115.82	72.58	0.63	77.01	84.63	52.56	
208365_s_at	2868	GRK4	NM_005307	8.06	21.42	13.43	0.63	8.06	29.13	31.82	
220389_at	60494	CCDC81	NM_021827	7.68	42.33	26.54	0.63	7.68	26.54	28.73	
201789_at	51635	DHRS7	BC000637	1.18	19.32	12.12	0.63	1.18	12.37	9.44	
208919_s_at	65220	NADK	BC001709	900.45	1413.99	886.93	0.63	900.45	924.31	516.42	
212583_at	9716	AQR	AB011132	101.92	153.15	96.07	0.63	101.92	124.34	99.96	
201203_s_at	6238	RRBP1	NM_004587	68.61	127.48	80.08	0.63	68.61	44.36	76.03	
221466_at	5030	P2RY4	NM_002565	33.22	52.02	32.69	0.63	33.22	47.60	21.74	
AFFX-r2-Ec-bioD-3_at			AFFX-r2-Ec-bioD-3	7130.20	11037.18	6938.94	0.63	7130.20	7113.06	4857.27	
213825_at	10215	OLIG2	AA757419	177.42	397.25	250.20	0.63	177.42	647.08	471.46	0.73

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
213247_at	79987	SVEP1	AA716107	19.38	35.31	22.27	0.63	19.38	27.66	19.37	
219046_s_at	63876	PKNOX2	NM_022062	12.30	25.09	15.83	0.63	12.30	29.64	12.87	0.43
205847_at	64063	PRSS22	NM_022119	77.26	124.77	78.79	0.63	77.26	84.60	19.03	
206828_at	7294	TXK	NM_003328	58.25	93.71	59.24	0.63	58.25	88.35	70.68	
211222_s_at	9001	HAP1	AF040723	19.73	37.72	23.85	0.63	19.73	28.98	8.75	
201124_at	3693	ITGB5	AL048423	28.88	45.90	29.02	0.63	28.88	19.91	11.77	
221447_s_at	83468	GLT8D2	NM_031302	6.94	10.87	6.87	0.63	6.94	20.95	30.40	
212404_s_at	89910	UBE3B	AL096740	127.44	252.10	159.49	0.63	127.44	82.31	117.26	
210748_at			AF116696	19.49	39.78	25.17	0.63	19.49	50.46	7.42	0.15
210735_s_at	771	CA12	BC000278	37.66	57.90	36.65	0.63	37.66	25.17	40.37	
204685_s_at	491	ATP2B2	R52647	17.49	33.62	21.29	0.63	17.49	33.78	15.47	0.46
201251_at	5315	PKM2	NM_002654	4116.97	6968.84	4411.92	0.63	4116.97	8731.66	7064.40	
204844_at	2028	ENPEP	L12468	7.27	19.46	12.34	0.63	7.27	7.10	6.45	
219442_at	79014	C16orf67	NM_024048	130.89	342.36	217.13	0.63	130.89	216.35	88.77	0.41
208544_at	151	ADRA2B	NM_000682	10.78	28.32	17.97	0.63	10.78	22.18	29.97	
210754_s_at	4067	LYN	M79321	1603.33	2731.93	1735.29	0.64	1603.33	4974.01	7894.67	
217209_at			X16454	33.99	52.11	33.13	0.64	33.99	30.09	37.82	
220867_s_at	25769	SLC24A2	NM_020344	12.47	29.90	19.03	0.64	12.47	20.15	22.04	
204101_at	4534	MTM1	NM_000252	29.95	84.37	53.71	0.64	29.95	52.62	63.75	
207516_at	1143	CHRN B4	NM_000750	7.30	32.53	20.71	0.64	7.30	19.23	23.79	
221086_s_at	55079	FEZF2	NM_0180	2.39	11.54	7.35	0.64	2.39	6.01	6.06	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			08								
212294_at	55970	GNG12	BG111761	49.62	100.69	64.17	0.64	49.62	199.96	85.64	0.43
212707_s_at	10156 //	RASA4 /// FLJ21767	AI738591	167.72	381.62	243.36	0.64	167.72	354.83	261.21	0.74
221412_at	57191	VN1R1	NM_020633	44.07	84.16	53.67	0.64	44.07	23.25	25.14	
210669_at	7020	TFAP2A	M61156	15.56	27.33	17.43	0.64	15.56	37.30	28.93	
201015_s_at	3728	JUP	NM_021991	70.44	168.05	107.21	0.64	70.44	57.99	43.14	
208438_s_at	2268	FGR	NM_005248	345.06	645.11	411.87	0.64	345.06	1087.42	708.01	0.65
215377_at	1488	CTBP2	AK024129	25.33	58.74	37.50	0.64	25.33	30.86	35.84	
215825_at			AF070579	39.51	80.54	51.45	0.64	39.51	51.44	49.85	
220732_at	80243	DEPDC2	NM_025170	15.45	29.50	18.85	0.64	15.45	13.48	23.18	
212365_at	4430	MYO1B	BF215996	76.00	116.31	74.35	0.64	76.00	428.19	521.05	
213143_at	257407	LOC257407	BE856707	10.40	42.99	27.49	0.64	10.40	17.10	49.55	
207329_at	4317	MMP8	NM_002424	7.50	14.80	9.46	0.64	7.50	22.29	22.05	
34187_at	5939	RBMS2	D28483	26.05	66.50	42.54	0.64	26.05	66.53	78.57	
203902_at	9843	HEPH	AU148222	6.49	16.97	10.86	0.64	6.49	4.22	5.90	
206004_at	7053	TGM3	NM_003245	20.39	53.13	34.04	0.64	20.39	43.49	36.15	
218292_s_at	51422	PRKAG2	AF087875	193.43	294.73	188.90	0.64	193.43	189.82	330.38	
216112_at	5586	PKN2	AU157200	121.57	194.69	124.82	0.64	121.57	121.46	87.33	
203961_at	10529	NEBL	AL157398	46.52	87.50	56.10	0.64	46.52	84.83	44.14	0.52
202430_s_at	5359	PLSCR1	NM_021105	273.08	513.90	329.56	0.64	273.08	845.17	326.33	0.39

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
216004_s_at	5316	PKNOX1	AP001748	31.67	59.63	38.26	0.64	31.67	24.52	48.07	
212617_at	23060	ZNF609	AB002293	33.73	83.85	53.80	0.64	33.73	74.90	57.01	
206283_s_at	6886	TAL1	NM_003189	21.49	34.84	22.36	0.64	21.49	30.31	32.34	
220407_s_at	7042	TGFB2	NM_003238	5.47	37.06	23.80	0.64	5.47	9.87	7.58	
209156_s_at	1292	COL6A2	AY029208	217.33	433.74	278.89	0.64	217.33	1081.05	796.10	0.74
205518_s_at	8418	CMAH	NM_003570	22.59	38.51	24.78	0.64	22.59	7.27	19.58	
205870_at	624	BDKR B2	NM_000623	19.92	40.48	26.06	0.64	19.92	86.27	116.82	
203399_x_at	5671	PSG3	NM_021016	7.60	17.11	11.02	0.64	7.60	2.11	7.82	
219647_at	64091	POPDC2	NM_022135	22.61	52.03	33.52	0.64	22.61	47.62	69.30	
215805_at			BF574664	9.76	29.21	18.83	0.64	9.76	4.86	10.20	
215713_at	9839	ZFHXB	AK026778	4.56	38.66	24.93	0.64	4.56	26.10	14.02	0.54
212660_at	23338	PHF15	AI735639	576.96	1009.94	651.54	0.65	576.96	2432.97	977.41	0.40
220977_x_at	57669	EPB41L5	NM_020909	36.16	67.69	43.67	0.65	36.16	43.84	27.97	
215462_at	1263	PLK3	AI978990	72.42	120.29	77.62	0.65	72.42	126.22	142.78	
221901_at	85352	KIAA1644	BF516072	89.67	184.24	119.00	0.65	89.67	139.05	142.26	
216531_at	404281	YY2	U73479	56.91	95.22	61.53	0.65	56.91	83.46	42.28	
209304_x_at	4616	GADD45B	AF087853	272.11	534.74	345.60	0.65	272.11	703.61	1002.36	
217322_x_at			AL024509	80.30	180.68	116.85	0.65	80.30	85.42	125.58	
210029_at	3620	INDO	M34455	19.57	45.50	29.43	0.65	19.57	149.19	74.08	0.50
207820_at	124	ADH1A	NM_000667	4.69	19.47	12.60	0.65	4.69	20.26	10.12	0.50
215761_at	23312	DMXL2	AK000156	57.79	174.51	112.94	0.65	57.79	111.22	108.10	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
32088_at	8548	BLZF1	U79751	78.47	129.18	83.62	0.65	78.47	169.25	98.06	0.58
214272_at	1540	CYLD	AI362018	9.15	81.94	53.05	0.65	9.15	21.09	53.43	
221695_s_at	10746	MAP3 K2	AF239798	204.53	349.71	226.49	0.65	204.53	205.21	279.05	
205896_at	6583	SLC22 A4	NM_003059	102.96	162.72	105.48	0.65	102.96	147.16	219.11	
217237_at	23090	ZNF423	Y10615	7.58	15.55	10.08	0.65	7.58	6.09	5.46	
215755_at	51149	LOC51149	AK022006	28.89	47.14	30.58	0.65	28.89	34.06	36.84	
210193_at	4336	MOBP	D28114	13.75	29.91	19.41	0.65	13.75	27.28	19.52	0.72
220586_at	80205	CHD9	NM_025134	34.86	90.77	58.91	0.65	34.86	45.65	37.24	
215511_at	6942	TCF20	U19345	40.77	68.61	44.55	0.65	40.77	61.34	40.04	0.65
206910_x_at	3080	CFHR2	NM_005666	21.31	51.41	33.39	0.65	21.31	55.07	38.04	0.69
216474_x_at	7177	TPSAB1	AF206667	46.42	103.87	67.49	0.65	46.42	47.42	85.79	
220826_at	55264	C21orf77	NM_018277	23.39	40.19	26.12	0.65	23.39	30.92	28.53	
212655_at	23174	ZCCHC14	AB011151	541.29	811.99	527.88	0.65	541.29	720.52	826.97	
207851_s_at	3643	INSR	NM_000208	5.86	18.96	12.33	0.65	5.86	24.04	11.25	0.47
219593_at	51296	SLC15A3	NM_016582	128.93	261.56	170.14	0.65	128.93	216.13	125.41	0.58
205727_at	7011	TEP1	NM_007110	87.10	154.59	100.57	0.65	87.10	32.07	39.01	
206036_s_at	5966	REL	NM_002908	288.39	572.98	373.04	0.65	288.39	3020.79	3918.11	
216888_at	11155	LDB3	AJ133768	4.21	15.48	10.08	0.65	4.21	29.68	19.46	0.66
216373_at	202018	FLJ90013	AF189251	31.94	49.50	32.24	0.65	31.94	41.00	28.04	
214972_at	10724	MGEA5	AU144791	50.75	92.11	60.03	0.65	50.75	41.31	51.48	
222284_at	23094	SIPA1L3	AI734111	27.78	95.64	62.35	0.65	27.78	45.75	38.47	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
214357_at	92346	C1orf105	AL035295	9.21	39.89	26.05	0.65	9.21	43.65	41.23	
222281_s_at			AW517716	6.67	39.48	25.78	0.65	6.67	45.09	4.33	0.10
207009_at	8929	PHOX2B	NM_003924	11.20	34.54	22.56	0.65	11.20	30.64	3.63	0.12
207752_x_at	5542 ///	PRB1 /// PRB2	NM_005039	13.83	28.05	18.32	0.65	13.83	28.25	10.97	0.39
214066_x_at	4882	NPR2	AA565715	24.25	36.88	24.10	0.65	24.25	30.60	22.81	
203320_at	10019	SH2B3	NM_005475	708.53	2437.96	1593.10	0.65	708.53	3672.37	2311.01	0.63
217702_at	9466	IL27RA	AW295066	5.75	10.47	6.85	0.65	5.75	5.86	11.24	
215637_at	95681	TSGA14	AU155621	12.04	25.20	16.48	0.65	12.04	5.22	9.44	
207062_at	3375	IAPP	NM_000415	7.22	28.80	18.84	0.65	7.22	23.04	13.54	0.59
214844_s_at	55816	DOK5	AL050069	12.45	28.42	18.59	0.65	12.45	35.85	15.47	0.43
217019_at			AL137162	64.66	129.60	84.81	0.65	64.66	49.61	77.68	
AFFX-r2-Ec-bioB-5_at			AFFX-r2-Ec-bioB-5	764.61	1149.20	752.18	0.65	764.61	752.17	499.17	
220931_at	79024	MGC5590	NM_024058	15.69	39.04	25.56	0.65	15.69	19.40	22.77	
204727_at	11169	WDHD1	AW772140	40.69	71.36	46.75	0.66	40.69	57.06	52.92	
216679_at			AL137624	9.42	18.12	11.88	0.66	9.42	23.07	19.74	
220909_at	80128	TRIM46	NM_025058	35.35	54.50	35.76	0.66	35.35	3.32	3.51	
206169_x_at	23264	ZC3H7B	NM_025013	115.23	248.26	163.09	0.66	115.23	148.70	109.75	
212124_at	57178	ZMIZ1	AF070622	681.19	1160.43	762.78	0.66	681.19	2326.64	1756.20	
209636_at	4791	NFKB2	BC002844	34.99	322.88	212.26	0.66	34.99	617.38	671.08	
202626_s_at	4067	LYN	AI356412	1438.88	2329.78	1531.95	0.66	1438.88	5562.31	7279.54	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
201529_s_at	6117	RPA1	NM_002945	565.07	906.18	595.97	0.66	565.07	370.61	443.33	
207056_s_at	9498	SLC4A8	NM_004858	11.63	30.36	19.98	0.66	11.63	19.99	14.94	0.75
218815_s_at	55092	TMEM51	NM_018022	263.16	447.68	294.72	0.66	263.16	363.55	428.74	
220310_at	79861	TUBAL3	NM_024803	7.45	28.67	18.88	0.66	7.45	11.66	2.19	0.19
AFFX-r2-P1-cre-5_at			AFFX-r2-P1-cre-5	17179.16	26443.23	17413.63	0.66	17179.16	15993.52	12055.68	
216437_at	80314	EPC1	AK024949	6.46	31.89	21.01	0.66	6.46	23.12	20.84	
202504_at	23650	TRIM29	NM_012101	15.56	35.32	23.26	0.66	15.56	13.39	20.47	
217509_x_at	2901	GRIK5	BG151527	46.33	121.35	79.94	0.66	46.33	67.38	76.62	
203927_at	4794	NFKBIE	NM_004556	382.24	2087.41	1375.43	0.66	382.24	2383.78	1855.26	
AFFX-CreX-5_at			AFFX-CreX-5	14271.66	21688.15	14293.15	0.66	14271.66	13842.55	9433.75	
220269_at	79740	FLJ23049	NM_024687	2.30	20.39	13.45	0.66	2.30	78.87	63.00	
221875_x_at	3134	HLA-F	AW514210	1488.70	2288.67	1509.87	0.66	1488.70	1369.52	1841.85	
218835_at	6436 ///	SFTPA2 /// LOC729238	NM_006926	24.85	41.58	27.43	0.66	24.85	11.62	35.79	
205465_x_at	9957	HS3ST1	BF000296	6.96	11.78	7.78	0.66	6.96	7.72	7.20	
215531_s_at	2558 ///	GABRA5 /// LOC727729	BF966183	9.23	19.41	12.81	0.66	9.23	7.65	7.03	
201884_at	1048	CEACAM5	NM_004363	9.75	39.13	25.85	0.66	9.75	32.73	25.97	
201108_s_at	7057	THBS1	NM_003246	13.53	78.51	51.89	0.66	13.53	286.55	163.79	0.57
204790_at	4092	SMAD7	NM_005904	163.77	490.09	323.93	0.66	163.77	450.51	673.61	
215536_at	3120	HLA-	X87344	12.47	40.20	26.60	0.66	12.47	25.79	44.07	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells (Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		DQB2									
212200_at	23141	KIAA0692	AW274877	305.95	515.18	340.98	0.66	305.95	770.21	724.43	
200777_s_at	151579 /	BZW1 /// LOC151579	NM_014670	2959.96	4701.01	3113.34	0.66	2959.96	5836.96	5351.54	
216638_s_at	5618 ///	PRLR /// CLDN1	S78505	17.20	28.84	19.10	0.66	17.20	23.11	6.20	
201502_s_at	4792	NFKBIA	NM_020529	1349.53	15293.14	10129.70	0.66	1349.53	10601.20	11863.66	
215529_x_at	23181	DIP2A	AI590053	298.88	563.23	373.18	0.66	298.88	449.03	401.69	
210623_at	51035	LOC51035	BC001372	41.58	77.67	51.47	0.66	41.58	53.36	64.66	
217662_x_at	55973	BCAP29	AI393960	59.25	148.94	98.72	0.66	59.25	178.48	83.81	0.47
215156_at	80349	WDR61	AL109709	69.90	119.82	79.49	0.66	69.90	68.35	110.86	
212658_at	10184	LHFPL2	N66633	124.37	207.60	137.75	0.66	124.37	142.95	178.91	
221181_at	642452 /	LOC642452 /// LOC651791	NM_025062	8.40	12.78	8.48	0.66	8.40	5.53	6.84	
205802_at	7220	TRPC1	NM_003304	5.78	15.55	10.32	0.66	5.78	11.44	32.69	
211122_s_at	6373	CXCL11	AF002985	3.85	345.79	229.58	0.66	3.85	238.41	69.88	0.29
205964_at	79088	ZNF426	NM_024106	111.74	170.09	112.94	0.66	111.74	120.12	151.55	
216512_s_at	1638	DCT	AL139318	14.23	40.62	26.98	0.66	14.23	17.37	20.91	
210151_s_at	8444	DYRK3	AF186773	8.17	28.18	18.73	0.66	8.17	62.20	29.79	0.48
206322_at	8224	SYN3	NM_003490	24.27	38.25	25.44	0.66	24.27	7.80	8.83	
217628_at	53405	CLIC5	BF032808	8.09	22.63	15.05	0.66	8.09	35.52	35.14	
216250_s_at	9404	LPXN	X77598	383.36	687.48	457.32	0.67	383.36	3109.00	837.35	0.27

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
206306_at	6263	RYR3	NM_001036	7.70	16.97	11.29	0.67	7.70	11.05	9.63	
211883_x_at	634	CEACAM1	M76742	59.09	94.50	62.87	0.67	59.09	60.15	78.24	
AFFX-M27830_5_at			AFFX-M27830_5	404.65	737.51	490.80	0.67	404.65	658.49	737.56	
201786_s_at	103	ADAR	NM_001111	4417.18	7250.24	4827.70	0.67	4417.18	6909.82	3641.86	0.53
220599_s_at	79092	CARD14	NM_024110	28.08	49.68	33.08	0.67	28.08	39.54	11.72	
208221_s_at	6585	SLIT1	NM_003061	18.40	32.96	21.97	0.67	18.40	4.63	18.65	
219615_s_at	8645	KCNK5	NM_003740	135.71	205.14	136.73	0.67	135.71	450.17	409.57	
204793_at	9737	GPRASP1	NM_014710	49.09	74.57	49.72	0.67	49.09	69.12	44.06	
210001_s_at	8651	SOCS1	AB005043	46.09	79.23	52.85	0.67	46.09	66.05	49.38	
210403_s_at	3758	KCNJ1	U03884	3.22	17.46	11.65	0.67	3.22	13.88	8.36	0.60
205221_at	3081	HGD	NM_000187	16.25	81.03	54.08	0.67	16.25	288.86	209.61	0.73
205954_at	6258	RXRG	NM_006917	6.40	26.99	18.02	0.67	6.40	4.34	4.95	
221153_s_at			NM_020355	15.01	22.98	15.35	0.67	15.01	3.04	16.28	
216277_at	699	BUB1	AK023540	35.36	54.42	36.35	0.67	35.36	40.78	27.75	
220691_at	259230	TMEM23	NM_014114	57.55	88.51	59.13	0.67	57.55	58.22	55.49	
208288_at	8647	ABCB11	NM_003742	6.70	15.07	10.08	0.67	6.70	0.99	1.87	
211459_at			AF234262	18.55	47.38	31.68	0.67	18.55	28.50	22.51	
212736_at	89927	C16orf45	BE299456	42.03	69.82	46.68	0.67	42.03	64.33	39.84	0.62
207115_x_at	54799	MBTD1	NM_017643	115.01	215.85	144.37	0.67	115.01	104.26	121.70	
213870_at	1302	COL11A2	AL031228	26.53	41.65	27.87	0.67	26.53	43.95	49.04	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
53720_at	55337	FLJ11286	AI862559	274.92	414.86	278.08	0.67	274.92	374.88	143.18	
212463_at	966	CD59	BE379006	31.03	110.17	73.88	0.67	31.03	127.77	111.22	
211887_x_at	4481	MSR1	AF037351	3.67	16.64	11.16	0.67	3.67	9.83	3.29	
221071_at			NM_021651	58.63	107.90	72.42	0.67	58.63	88.54	68.52	
211964_at	1284	COL4A2	X05610	127.61	295.89	198.62	0.67	127.61	722.90	294.05	0.41
217077_s_at	9568	GABBR2	AF095723	16.77	54.73	36.74	0.67	16.77	6.92	23.36	
204105_s_at	4897	NRCAM	NM_005010	5.87	86.82	58.30	0.67	5.87	509.88	780.69	
222341_x_at	64770	CCDC14	AW973235	32.80	67.63	45.42	0.67	32.80	26.35	22.53	
215504_x_at	55608	ANKRD10	AF131777	253.88	462.49	310.69	0.67	253.88	417.14	261.90	0.63
222207_x_at	441258	LOC441258	AK024602	366.92	831.22	558.40	0.67	366.92	413.34	477.86	
209508_x_at	8837	CFLAR	AF005774	308.24	873.96	587.65	0.67	308.24	1200.33	1459.02	
207973_x_at	56	ACRV1	NM_020110	32.88	66.09	44.47	0.67	32.88	45.71	35.70	
209655_s_at	83604	TMEM47	AL136550	23.21	43.76	29.44	0.67	23.21	32.91	80.18	
209994_s_at	5243 ///	ABCB1 /// ABCB4	AF016535	145.68	251.85	169.48	0.67	145.68	132.14	178.21	
213389_at	9640	ZNF592	BF508616	147.72	234.99	158.13	0.67	147.72	216.83	162.18	
206812_at	155	ADRB3	NM_000025	15.09	34.26	23.08	0.67	15.09	4.60	15.91	
206673_at	11245	GPR176	NM_007223	9.50	49.00	33.03	0.67	9.50	17.19	10.05	0.58
205676_at	1594	CYP27B1	NM_000785	76.64	128.14	86.37	0.67	76.64	406.20	296.39	0.73
202597_at	3664	IRF6	AU144284	30.92	66.00	44.51	0.67	30.92	47.75	16.65	0.35
219334_s_at	64859	OBFC2	AU15754	11.78	40.74	27.48	0.67	11.78	425.71	373.06	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		A	1								
220458_at	55104	FLJ10246	NM_018038	90.06	143.96	97.27	0.68	90.06	62.89	93.47	
201005_at	928	CD9	NM_001769	235.01	367.10	248.04	0.68	235.01	208.11	245.69	
219730_at	54797	MED18	NM_017638	54.32	120.86	81.69	0.68	54.32	47.50	51.91	
220943_s_at	55471	PRO1853	NM_018607	55.91	89.90	60.78	0.68	55.91	80.23	56.71	
202724_s_at	2308	FOXO1A	NM_002015	56.81	96.81	65.46	0.68	56.81	222.43	81.28	0.37
204715_at	24145	PANX1	NM_015368	357.33	551.48	373.20	0.68	357.33	661.21	936.84	
214851_at	3172	HNF4A	X87870	14.90	32.65	22.10	0.68	14.90	14.21	37.81	
219847_at	79885	HDAC11	NM_024827	45.72	106.67	72.23	0.68	45.72	54.92	27.70	
208811_s_at	10049	DNAJB6	AF080569	707.33	1076.06	728.62	0.68	707.33	582.11	1436.08	
220841_s_at	54806	AHI1	NM_017651	62.67	138.62	93.87	0.68	62.67	93.44	82.63	
214964_at	84629	KIAA1856	AA554430	275.73	463.31	313.77	0.68	275.73	179.13	143.34	
217382_at	390363 /	LOC390363 /// LOC732322	U85978	12.97	49.25	33.36	0.68	12.97	36.11	6.55	0.18
214392_at	56269	IRGC	AA431984	16.75	35.66	24.17	0.68	16.75	3.69	6.71	
214888_at	824	CAPN2	AK023851	108.56	176.72	119.82	0.68	108.56	178.68	171.90	
211766_s_at	5408	PNLIPRP2	BC005989	5.67	17.43	11.82	0.68	5.67	9.67	7.10	
214091_s_at	2878	GPX3	AW149846	19.74	55.27	37.49	0.68	19.74	40.85	52.40	
206744_s_at	9205	ZMYM5	NM_014242	31.48	50.75	34.43	0.68	31.48	46.77	39.03	
216053_x_at	731501	LOC731501	AI143919	7.46	36.01	24.44	0.68	7.46	15.55	17.15	
39582_at	1540	CYLD	AL050166	99.81	306.63	208.15	0.68	99.81	254.18	235.07	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
203395_s_at	3280	HES1	NM_005524	18.30	52.79	35.84	0.68	18.30	60.77	81.60	
200880_at	3301	DNAJA1	AL534104	2771.33	4157.01	2823.89	0.68	2771.33	3513.12	4162.73	
211484_s_at	1826	DSCAM	AF023450	11.59	19.76	13.43	0.68	11.59	22.61	14.12	0.62
217497_at	1890	ECGF1	AW613387	141.27	597.75	406.19	0.68	141.27	528.61	247.50	0.47
217436_x_at	730399 /	LOC70399 /// LOC71974	M80469	1133.05	1809.86	1230.34	0.68	1133.05	1080.95	1477.65	
210286_s_at	9497	SLC4A7	AF053755	30.70	58.08	39.48	0.68	30.70	28.82	47.62	
218345_at	55365	TMEM176A	NM_018487	52.95	119.25	81.15	0.68	52.95	44.91	53.65	
221556_at	8555	CDC14B	BF792631	227.90	355.10	241.72	0.68	227.90	141.47	178.16	
205933_at	26040	SETBP1	NM_015559	29.98	47.57	32.39	0.68	29.98	76.14	61.58	
212817_at	25822	DNAJB5	AK023253	42.19	92.38	62.92	0.68	42.19	171.62	254.15	
215135_at	23549	DNPEP	AI690583	22.67	47.55	32.39	0.68	22.67	55.90	41.32	0.74
207882_at	55566	HSAJ2425	NM_017532	15.72	34.81	23.71	0.68	15.72	31.86	15.80	0.50
207031_at	579	BAPX1	NM_001189	279.73	425.74	290.04	0.68	279.73	234.35	119.73	
216746_at			AK024606	13.21	33.88	23.08	0.68	13.21	17.89	11.68	
214818_at	284001	CCDC57	AF007146	11.76	66.59	45.39	0.68	11.76	139.35	76.55	0.55
213748_at	9866	TRIM66	AW271713	81.36	139.78	95.35	0.68	81.36	67.68	71.22	
205003_at	9732	DOCK4	NM_014705	22.06	72.34	49.35	0.68	22.06	175.01	94.98	0.54
205925_s_at	5865	RAB3B	NM_002867	5.37	29.30	19.99	0.68	5.37	12.94	21.66	
220792_at	11107	PRDM5	NM_018699	34.77	59.18	40.40	0.68	34.77	29.53	29.85	
210077_s_at	6430	SFRS5	U30884	93.50	169.73	116.02	0.68	93.50	80.57	178.43	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
217639_at			BF674749	12.20	27.20	18.59	0.68	12.20	31.32	16.76	0.54
222074_at	4088 ///	SMAD3 /// UROD	AW614435	30.64	55.55	37.98	0.68	30.64	42.99	36.35	
215777_at			AW405975	7.08	18.26	12.48	0.68	7.08	21.42	19.79	
215849_x_at	118491	TTC18	AK022235	56.56	113.07	77.37	0.68	56.56	55.85	71.80	
207555_s_at	6915	TBXA2R	U27325	27.10	70.10	47.99	0.68	27.10	15.67	30.22	
202132_at	25937	WWTR1	AA081084	25.28	68.69	47.02	0.68	25.28	37.60	15.29	
221212_x_at	55193	PB1	NM_018313	7.87	20.15	13.80	0.68	7.87	6.13	23.64	
220580_at	80114	BICC1	NM_025044	14.04	38.40	26.31	0.69	14.04	34.35	19.74	0.57
201169_s_at	8553	BHLHB2	BG326045	51.47	195.62	134.05	0.69	51.47	113.56	529.80	
208849_at			AF118091	18.84	35.27	24.19	0.69	18.84	25.63	25.23	
220221_at	55187	VPS13D	NM_018156	26.24	91.20	62.57	0.69	26.24	40.97	52.36	
213620_s_at	3384	ICAM2	AA126728	156.89	254.36	174.67	0.69	156.89	105.03	106.01	
204760_s_at	7067 ///	THRA /// NR1D1	NM_021724	25.60	57.52	39.51	0.69	25.60	5.62	20.69	
220546_at	79951	FLJ11783	NM_024891	29.44	50.10	34.42	0.69	29.44	23.99	33.02	
216765_at	5607	MAP2K5	AK025177	42.07	85.02	58.42	0.69	42.07	28.79	7.33	
215066_at	5792	PTPRF	AU158443	51.32	86.06	59.18	0.69	51.32	77.06	38.82	0.50
214405_at	10659	CUGBP2	Z39557	32.89	50.92	35.04	0.69	32.89	40.18	3.17	
219275_at	9141	PDCD5	NM_004708	385.85	629.08	433.98	0.69	385.85	298.47	396.25	
39548_at	4862	NPAS2	U77970	13.34	35.64	24.59	0.69	13.34	45.56	26.10	0.57
211135_x_at	10288 //	LILRB	AF00964	91.64	151.04	104.25	0.69	91.64	164.72	36.60	0.22

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		2 /// LILRB3	4								
216347_s_at	23368	PPP1R13B	AK023188	65.18	124.91	86.23	0.69	65.18	119.13	129.16	
202181_at	9766	KIAA0247	NM_014734	735.40	1507.19	1041.22	0.69	735.40	1731.91	2576.81	
207930_at	3933	LCN1	NM_002297	14.44	24.72	17.09	0.69	14.44	9.34	17.46	
209458_x_at	3039 ///	HBA1 /// HBA2	AF105974	11.10	17.92	12.40	0.69	11.10	17.81	15.91	
204975_at	2013	EMP2	NM_001424	232.08	355.93	246.35	0.69	232.08	517.43	296.99	0.57
206107_at	8786	RGS11	NM_003834	4.01	11.10	7.68	0.69	4.01	1.75	4.99	
214212_x_at	10979	PLEKH C1	AI928241	19.85	52.50	36.36	0.69	19.85	30.61	45.65	
203548_s_at	4023	LPL	BF672975	461.02	988.96	685.13	0.69	461.02	4167.52	3450.99	
215898_at	23093	TTLL5	AK021879	56.91	120.39	83.42	0.69	56.91	91.67	88.85	
204679_at	3775	KCNK1	NM_002245	8.73	27.27	18.90	0.69	8.73	26.87	15.82	0.59
209967_s_at	1390	CREM	D14826	30.25	79.64	55.21	0.69	30.25	253.82	111.36	0.44
202153_s_at	23636	NUP62	NM_016553	1873.97	2816.31	1952.46	0.69	1873.97	3418.31	1641.28	0.48
207758_at	9647	PPM1F	NM_025056	26.35	89.57	62.25	0.69	26.35	44.72	34.09	
219288_at	57415	C3orf14	NM_020685	699.06	1097.64	763.02	0.70	699.06	1133.14	864.49	
217344_at	2229	FDPSL5	AL022163	17.20	79.57	55.32	0.70	17.20	47.86	78.75	
211734_s_at	2205	FCER1A	BC005912	17.35	28.27	19.66	0.70	17.35	22.27	18.70	
217578_at	7514	XPO1	AW576871	17.42	31.53	21.93	0.70	17.42	27.50	13.39	0.49
204116_at	3561	IL2RG	NM_000206	92.60	246.00	171.22	0.70	92.60	376.96	259.29	0.69
210556_at	4775	NFATC	U85430	77.19	148.23	103.21	0.70	77.19	82.31	90.46	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells (Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		3									
210408_s_at	9362	CPNE6	AB009288	4.49	12.99	9.05	0.70	4.49	4.85	3.57	
214618_at	8837	CFLAR	AF015452	9.87	31.97	22.28	0.70	9.87	5.81	31.64	
214343_s_at	222255 /	ATXN7 L1 /// ATXN7 L4	AI017382	52.37	91.80	63.98	0.70	52.37	49.84	38.69	
205237_at	2219	FCN1	NM_002003	3.99	29.59	20.63	0.70	3.99	10.70	14.67	
205414_s_at	9912	KIAA0672	NM_014859	48.82	78.12	54.50	0.70	48.82	47.12	63.57	
210271_at	4761	NEUROD2	AB021742	23.19	37.91	26.45	0.70	23.19	29.18	22.76	
202875_s_at	5089	PBX2	BE397715	294.09	465.56	324.89	0.70	294.09	357.83	439.61	
220113_x_at	84172	POLR1B	NM_019014	256.95	415.65	290.08	0.70	256.95	310.41	253.47	
208519_x_at	2797	GNRH2	NM_001501	24.16	62.16	43.40	0.70	24.16	8.30	22.42	
215996_at			AI446234	20.24	60.88	42.53	0.70	20.24	9.09	21.65	
204575_s_at	4327 ///	MMP19 /// LOC732415	NM_002429	40.59	153.74	107.44	0.70	40.59	115.04	142.93	
205810_s_at	8976	WASL	NM_003941	9.21	15.01	10.49	0.70	9.21	9.28	10.75	
213339_at	57212	KIAA0495	AB007964	4.85	14.33	10.02	0.70	4.85	3.39	15.79	
222367_at	123720 /	WHDC1 /// WHDC1L1 /// WHDC1L2	AI921841	27.52	49.30	34.49	0.70	27.52	47.56	37.50	
202612_s_at	9282	CRSP2	NM_004229	10.57	34.96	24.46	0.70	10.57	13.94	6.92	
208385_at	10002	NR2E3	NM_016346	12.25	27.65	19.35	0.70	12.25	10.73	31.10	
211524_at	4791	NFKB2	U09609	7.25	33.99	23.79	0.70	7.25	22.40	18.46	
202573_at	1455	CSNK1	AL53044	739.18	1157.56	811.77	0.70	739.18	783.40	701.67	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		G2	1								
219815_at	79690	GAL3ST4	NM_024637	7.79	34.14	23.95	0.70	7.79	28.10	11.07	0.39
214245_at	6208	RPS14	AI734124	38.44	62.38	43.82	0.70	38.44	50.88	69.66	
206888_s_at	398	ARHG DIG	NM_001176	43.64	79.24	55.66	0.70	43.64	10.95	46.39	
43934_at	56834	GPR137	AA479495	103.17	176.44	123.95	0.70	103.17	95.46	82.15	
209325_s_at	6004	RGS16	U94829	54.35	705.07	495.85	0.70	54.35	202.77	525.09	
200799_at	3303	HSPA1A	NM_005345	1731.57	3603.51	2534.45	0.70	1731.57	1558.32	3436.70	
215926_x_at	6621	SNAPC4	AK023513	173.53	390.00	274.39	0.70	173.53	415.34	401.38	
215491_at	4610	MYCL1	AI273812	32.29	82.32	57.93	0.70	32.29	46.20	41.30	
207979_s_at	926	CD8B	NM_004931	6.30	13.00	9.15	0.70	6.30	3.51	10.97	
203060_s_at	9060	PAPSS2	NM_004670	173.75	274.97	193.64	0.70	173.75	799.55	281.77	0.35
212466_at	200734	SPRED2	AW138902	88.45	137.26	96.72	0.70	88.45	141.53	148.36	
204687_at	25849	DKFZP564O0823	NM_015393	67.65	104.66	73.75	0.70	67.65	253.99	331.38	
216756_at			AK024995	14.65	47.22	33.29	0.70	14.65	36.12	33.85	
207749_s_at	5523	PPP2R3A	NM_002718	108.09	177.74	125.34	0.71	108.09	265.00	162.78	0.61
209700_x_at	9659	PDE4DIP	AB042555	16.02	27.28	19.26	0.71	16.02	46.00	81.08	
222082_at	51341	ZBTB7A	AI568395	36.44	57.42	40.55	0.71	36.44	23.16	58.37	
202828_s_at	4323	MMP14	NM_004995	177.23	397.93	281.14	0.71	177.23	123.47	160.18	
208526_at	26211	OR2F1	NM_012369	3.84	31.67	22.39	0.71	3.84	17.23	11.98	0.70
222272_x_at	85477	SCIN	BG283584	23.03	62.73	44.46	0.71	23.03	42.05	27.60	0.66
214102_at	116984	CENTD	AK02373	105.60	175.15	124.14	0.71	105.60	187.22	152.88	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		1	7								
220658_s_at	56938	ARNTL2	NM_020183	169.38	289.53	205.21	0.71	169.38	221.27	200.56	
208222_at	91	ACVR1B	NM_020327	26.84	51.57	36.58	0.71	26.84	36.30	10.73	
208729_x_at	3106	HLA-B	D83043	5128.16	8066.14	5723.93	0.71	5128.16	5663.19	7587.90	
210162_s_at	4772	NFATC1	U08015	225.35	448.14	318.04	0.71	225.35	460.85	474.70	
213060_s_at	1117	CH13L2	U58515	27.54	47.50	33.71	0.71	27.54	36.76	47.84	
206818_s_at	54805	CNNM2	NM_017649	42.84	77.56	55.06	0.71	42.84	69.79	58.98	
205707_at	23765	IL17RA	NM_014339	1085.55	1641.52	1165.83	0.71	1085.55	811.14	500.43	
209082_s_at	80781	COL18A1	AF018081	54.12	104.13	73.97	0.71	54.12	72.40	48.81	
213503_x_at	302	ANXA2	BE908217	2409.95	5924.72	4209.75	0.71	2409.95	9550.19	6945.62	0.73
206512_at	7310	U2AF1L1	NM_005083	42.28	88.95	63.22	0.71	42.28	82.91	156.40	
211544_s_at	2692	GHRHR	AB058895	19.35	52.71	37.48	0.71	19.35	18.42	26.14	
216738_at	3269	HRH1	AK024553	18.91	60.19	42.83	0.71	18.91	41.72	18.14	0.43
206023_at	10874	NMU	NM_006681	5.57	25.45	18.11	0.71	5.57	8.84	8.67	
207328_at	246	ALOX15	NM_001140	9.50	14.52	10.33	0.71	9.50	8.12	6.93	
216662_at	4648	MYO7B	AK000145	9.69	48.75	34.70	0.71	9.69	19.62	23.19	
220027_s_at	54922	RASIP1	NM_017805	22.59	38.03	27.10	0.71	22.59	10.95	23.04	
220762_s_at	54584	GNB1L	NM_022446	71.47	151.97	108.46	0.71	71.47	160.83	81.86	0.51
205479_s_at	5328	PLAU	NM_002658	328.74	609.31	435.17	0.71	328.74	1710.50	5039.60	
207644_at	8928	FOXH1	NM_003923	20.29	32.44	23.19	0.71	20.29	32.93	7.91	0.24
222038_s_at	51096	UTP18	AA993099	21.39	41.09	29.38	0.71	21.39	31.54	36.47	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
211317_s_at	8837	CFLAR	AF041461	422.39	932.17	666.58	0.72	422.39	1157.89	1851.36	
210538_s_at	330	BIRC3	U37546	30.89	602.11	430.60	0.72	30.89	1431.13	1068.78	0.75
217161_x_at	176	AGC1	X17406	15.56	63.17	45.22	0.72	15.56	36.67	47.88	
210412_at	2904	GRIN2B	U11287	25.81	46.16	33.06	0.72	25.81	5.87	5.68	
214486_x_at	8837	CFLAR	AF041459	218.81	575.70	412.73	0.72	218.81	900.37	851.11	
216683_at	6902	TBCA	AL353949	44.55	115.59	82.92	0.72	44.55	79.97	117.89	
211691_x_at	4946	OAZ1	AF293339	47.28	116.92	83.87	0.72	47.28	52.36	60.19	
202015_x_at			NM_006838	16.29	34.09	24.46	0.72	16.29	30.26	19.42	0.64
216182_at	8871	SYNJ2	AK026758	3.81	16.23	11.65	0.72	3.81	4.79	4.34	
221205_at			NM_018041	122.51	299.38	215.02	0.72	122.51	306.62	68.72	0.22
222137_at	54862	CC2D1A	AK023399	22.45	38.39	27.59	0.72	22.45	20.82	32.54	
209999_x_at	8651	SOCS1	AB005043	5.83	27.74	19.94	0.72	5.83	5.18	9.28	
204091_at	5147	PDE6D	NM_002601	451.23	703.39	505.73	0.72	451.23	443.35	448.02	
213665_at	6659	SOX4	AI989477	12.12	23.66	17.01	0.72	12.12	57.44	30.21	0.53
210997_at	3082	HGF	M77227	4.14	13.85	9.96	0.72	4.14	14.31	12.80	
212080_at	4297	MLL	AV714029	283.66	448.78	322.84	0.72	283.66	381.89	321.51	
211875_x_at	56106	PCDHGA10	AF152503	8.55	16.65	11.98	0.72	8.55	4.14	2.59	
214286_at	2779	GNAT1	X63749	12.71	20.17	14.52	0.72	12.71	13.90	15.13	
221085_at	9966	TNFSF15	NM_005118	8.80	20.63	14.85	0.72	8.80	24.56	10.05	0.41
209267_s_at	64116	SLC39A8	AB040120	1635.93	2844.81	2048.19	0.72	1635.93	4808.74	3856.87	
215648_at	23386	NUDCD3	AU144324	25.16	77.11	55.57	0.72	25.16	30.41	30.58	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
217525_at	283298	OLFM1	AW305097	5.75	19.19	13.83	0.72	5.75	2.08	8.02	
209210_s_at	10979	PLEKH C1	Z24725	56.67	118.90	85.72	0.72	56.67	100.19	167.64	
211195_s_at	8626	TP73L	AF116771	6.25	19.12	13.79	0.72	6.25	22.64	8.11	0.36
215499_at	5606	MAP2 K3	AA780381	182.54	460.47	332.07	0.72	182.54	617.86	825.58	
216290_x_at	1804	DPP6	AK000864	15.93	26.70	19.27	0.72	15.93	22.96	27.65	
206862_at	9534	ZNF254	NM_004876	46.65	70.24	50.71	0.72	46.65	56.73	30.82	
213428_s_at	1291	COL6A1	AA292373	438.55	938.69	677.63	0.72	438.55	3655.70	1864.75	0.51
215746_at	8602	C4orf9	L34409	8.12	25.55	18.44	0.72	8.12	13.67	8.54	0.62
208926_at	4758	NEU1	U84246	1604.71	2448.22	1767.75	0.72	1604.71	1619.31	3343.65	
207030_s_at	1466	CSRP2	NM_001321	48.31	111.01	80.19	0.72	48.31	149.19	159.50	
201590_x_at	302	ANXA2	NM_004039	2409.73	5747.46	4152.64	0.72	2409.73	9510.93	6896.18	0.73
207535_s_at	4791	NFKB2	NM_002502	139.41	902.97	652.74	0.72	139.41	1117.81	1464.21	
204261_s_at	5664	PSEN2	AA716657	50.50	85.16	61.64	0.72	50.50	12.15	36.70	
209098_s_at	182	JAG1	U73936	35.69	127.71	92.43	0.72	35.69	33.00	89.02	
211171_s_at	10846	PDE10A	AB026816	13.95	35.66	25.81	0.72	13.95	18.90	23.73	
207232_s_at	9666	DZIP3	NM_014648	38.22	105.69	76.53	0.72	38.22	18.12	27.74	
217377_x_at	4916	NTRK3	AF041811	39.30	66.21	47.95	0.72	39.30	50.71	43.68	
221996_s_at	1212	CLTB	AW170546	19.37	42.67	30.90	0.72	19.37	40.90	32.15	
207825_s_at	2692	GHRHR	NM_000823	6.05	10.50	7.60	0.72	6.05	3.71	7.87	
200986_at	710	SERPING1	NM_000062	15.14	44.75	32.42	0.72	15.14	25.12	24.94	
220338_at	55103	RALGP	NM_0180	26.80	53.88	39.03	0.72	26.80	33.05	32.84	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		S2	37								
211126_s_at	1466	CSRP2	U46006	52.36	91.81	66.53	0.72	52.36	85.38	72.83	
219474_at	79669	C3orf52	NM_024616	8.92	44.75	32.43	0.72	8.92	51.14	57.45	
215611_at	6938	TCF12	AU146580	222.71	340.01	246.53	0.73	222.71	304.64	180.51	
209683_at	81553	FAM49A	AA243659	44.97	92.36	67.02	0.73	44.97	40.93	92.65	
210427_x_at	302	ANXA2	BC001388	2547.05	6066.78	4402.80	0.73	2547.05	9806.56	7091.67	0.72
216832_at	862	RUNX1T1	AF018283	3.98	32.05	23.26	0.73	3.98	8.57	37.80	
205192_at	9020	MAP3K14	NM_003954	46.53	97.49	70.76	0.73	46.53	219.31	183.82	
208240_s_at	2246	FGF1	NM_013394	17.00	29.36	21.32	0.73	17.00	11.33	31.57	
207662_at	6899	TBX1	NM_005992	39.67	60.62	44.14	0.73	39.67	44.68	21.03	
206458_s_at	7482	WNT2B	NM_024494	5.76	11.09	8.07	0.73	5.76	11.49	10.21	
217192_s_at	639	PRDM1	AL022067	126.87	342.39	249.38	0.73	126.87	779.61	928.47	
214617_at	5551	PRF1	AI445650	29.24	71.34	51.97	0.73	29.24	73.46	36.46	0.50
202643_s_at	7128	TNFAIP3	AI738896	312.99	3082.51	2245.80	0.73	312.99	3593.12	3504.58	
205938_at	22843	PPM1E	NM_014906	33.99	65.46	47.69	0.73	33.99	13.33	56.25	
202339_at	8189	SYMPK	NM_004819	133.93	242.65	176.90	0.73	133.93	111.83	129.42	
215577_at	7324	UBE2E1	AU146791	180.70	374.26	272.86	0.73	180.70	235.88	267.04	
213248_at	221362 /	LOC221362 /// LOC730101	AL577024	123.28	284.56	207.53	0.73	123.28	135.07	79.46	
210831_s_at	5733	PTGER3	L27489	12.76	30.14	21.98	0.73	12.76	17.53	27.07	
201505_at	3912	LAMB1	NM_002291	23.77	38.44	28.08	0.73	23.77	208.19	279.87	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
204888_s_at	9148	NEURL	AF029729	36.39	54.96	40.14	0.73	36.39	37.50	6.15	
211175_at	11250	GPR45	U92642	7.68	15.92	11.63	0.73	7.68	6.61	2.47	
210717_at			AF116659	59.74	117.80	86.09	0.73	59.74	61.98	72.92	
213285_at	161291	TMEM30B	AV691491	1.17	25.10	18.35	0.73	1.17	21.13	7.88	0.37
219125_s_at	55974	RAG1A P1	NM_018845	168.92	278.15	203.41	0.73	168.92	156.94	175.81	
220514_at			NM_018568	7.93	16.45	12.03	0.73	7.93	6.32	6.59	
216166_at	399	RHOH	AK024909	11.46	23.08	16.90	0.73	11.46	14.07	39.95	
216961_s_at	219464 /	RPAIN /// OR5T2	M69039	13.06	23.82	17.44	0.73	13.06	10.66	20.69	
214449_s_at	23433	RHOQ	NM_012249	206.49	343.30	251.43	0.73	206.49	238.15	330.53	
210597_x_at	5542 ///	PRB1 /// PRB2	K03206	37.29	112.61	82.49	0.73	37.29	56.94	35.33	0.62
208597_at	1270	CNTF	NM_000614	4.15	21.29	15.59	0.73	4.15	7.40	12.45	
215754_at	950	SCARB2	AU148040	82.00	146.92	107.65	0.73	82.00	99.96	55.50	
212143_s_at	3486	IGFBP3	BF340228	74.80	3263.19	2391.41	0.73	74.80	5049.49	4818.18	
214878_at	256112 /	ZNF37A /// ZNF37B	AU118165	11.28	37.39	27.41	0.73	11.28	15.59	16.74	
218690_at	8572	PDLIM4	NM_003687	15.56	37.51	27.50	0.73	15.56	6.25	15.55	
204735_at	5141	PDE4A	NM_006202	176.91	293.85	215.50	0.73	176.91	397.51	260.30	0.65
203962_s_at	10529	NEBL	NM_006393	55.10	122.55	89.88	0.73	55.10	85.79	58.86	0.69
222351_at	5519	PPP2R1B	AW009884	37.76	81.19	59.55	0.73	37.76	39.04	62.35	
209604_s_at	2625	GATA3	AI796169	17.30	37.85	27.79	0.73	17.30	5.89	34.18	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
217239_x_at	54504	CPVL	AF044592	28.25	45.19	33.19	0.73	28.25	17.13	32.54	
206140_at	9355	LHX2	NM_004789	616.12	1806.76	1330.17	0.74	616.12	3969.65	1537.51	0.39
215540_at	6955	TRA@	AW950865	9.67	18.26	13.44	0.74	9.67	29.82	12.99	0.44
202509_s_at	7127	TNFAIP2	AI862445	75.77	308.86	227.45	0.74	75.77	298.03	231.05	
206380_s_at	5199	CFP	NM_002621	568.57	884.27	651.42	0.74	568.57	723.19	625.69	
211562_s_at	25802	LMOD1	BC001755	4.98	12.19	8.98	0.74	4.98	2.67	15.51	
210701_at	10428	CFDP1	D85939	114.69	264.71	195.15	0.74	114.69	136.68	192.28	
203125_x_at	4891	SLC11A2	AF046997	145.10	241.83	178.30	0.74	145.10	293.44	452.97	
215139_at	9639	ARHGEF10	AL137508	11.84	43.15	31.83	0.74	11.84	14.58	18.67	
209032_s_at	23705	IGSF4	AF132811	45.27	69.45	51.30	0.74	45.27	70.64	71.10	
215676_at	2972	BRF1	N91109	7.90	12.00	8.87	0.74	7.90	4.22	7.20	
204048_s_at	9749	PHACTR2	AA551142	1150.04	1904.21	1408.09	0.74	1150.04	2925.25	2638.90	
214980_at	7337	UBE3A	AF037219	78.69	124.24	91.94	0.74	78.69	75.95	103.58	
207730_x_at	84717	HDGF2	NM_017932	554.00	1070.47	792.80	0.74	554.00	634.45	604.72	
210911_at	84099	ID2B	M96843	6.20	21.77	16.13	0.74	6.20	45.87	35.87	
213935_at	51099	ABHD5	AF007132	49.01	76.15	56.43	0.74	49.01	81.02	80.62	
215287_at			AA975427	127.18	199.13	147.59	0.74	127.18	164.54	134.28	
213191_at	148022	TICAM1	AF070530	85.01	268.56	199.09	0.74	85.01	247.05	332.20	
201958_s_at	4660	PPP1R12B	NM_002481	9.53	27.57	20.46	0.74	9.53	3.26	4.25	
203915_at	4283	CXCL9	NM_002416	4.66	104.97	77.88	0.74	4.66	45.12	45.89	
215562_at	22996	C1orf34	AK00022	6.06	14.14	10.50	0.74	6.06	8.70	9.18	

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			0								
200706_s_at	9516	LITAF	NM_004862	925.98	1700.53	1262.37	0.74	925.98	2016.91	3255.18	
202625_at	4067	LYN	AI356412	784.60	1348.47	1001.54	0.74	784.60	3249.61	4428.80	
215887_at	11179	ZNF277P	AK027128	73.49	116.69	86.72	0.74	73.49	113.96	75.56	0.66
219235_s_at	65979	PHACTR4	NM_023923	423.25	687.48	511.22	0.74	423.25	582.92	293.31	
221281_at	6714	SRC	NM_005417	6.79	17.05	12.68	0.74	6.79	12.50	8.70	0.70
204174_at	241	ALOX5AP	NM_001629	2262.85	3704.92	2758.46	0.74	2262.85	1721.14	1584.03	
206938_at	6716	SRD5A2	NM_000348	26.96	44.81	33.37	0.74	26.96	33.12	32.28	
210654_at	8793	TNFRSF10D	AF021233	3.46	11.05	8.23	0.74	3.46	12.56	11.86	
207694_at	5456	POU3F4	NM_000307	8.90	29.11	21.69	0.75	8.90	36.13	21.15	0.59
206573_at	3786	KCNQ3	NM_004519	60.10	101.32	75.52	0.75	60.10	197.20	185.01	
210540_s_at	8702	B4GALT4	BC004523	70.20	107.49	80.16	0.75	70.20	169.52	215.59	
215556_at	57035	C1orf63	AU158442	20.90	51.01	38.06	0.75	20.90	25.14	33.10	
222214_at			AK024988	314.69	540.49	403.52	0.75	314.69	261.90	333.53	
210808_s_at	27035	NOX1	AF166327	5.40	35.62	26.64	0.75	5.40	33.74	32.98	
205603_s_at	1730	DIAPH2	NM_007309	464.65	897.67	671.33	0.75	464.65	680.31	801.99	
204864_s_at	3572	IL6ST	BE856546	71.14	127.89	95.75	0.75	71.14	66.71	69.86	
214104_at	23432	GPR161	AI703188	54.59	99.83	74.77	0.75	54.59	92.54	55.67	0.60
207795_s_at	3824	KLRD1	AB009597	3.96	11.53	8.64	0.75	3.96	6.67	29.06	
206268_at	10637	LEFTY1	NM_020997	7.01	39.24	29.40	0.75	7.01	36.79	23.25	0.63
205242_at	10563	CXCL1	NM_0064	2.93	6.96	2.00		2.93	1873.21	32.28	0.02

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		3	19								
207533_at	6346	CCL1	NM_002981	3.46	6.54	3.17		3.46	45.96	1.14	0.02
210815_s_at	10203	CALCR L	U17473	21.24	6.31	7.18		21.24	116.75	4.13	0.04
206526_at	26150	RIBC2	NM_015653	36.64	28.66	7.00		36.64	109.41	4.89	0.04
211533_at	5156	PDGFR A	M22734	1.41	5.14	8.82		1.41	24.09	1.22	0.05
213856_at	961	CD47	BG230614	1.53	8.03	5.38		1.53	36.17	1.86	0.05
220649_at			NM_024856	9.33	13.12	13.43		9.33	19.80	1.02	0.05
211064_at	284443	ZNF493	BC006408	4.81	1.20	24.79		4.81	20.29	1.10	0.05
215814_at	667	DST	AL049215	4.59	4.72	11.78		4.59	21.74	1.28	0.06
207901_at	3593	IL12B	NM_002187	4.24	13.40	10.51		4.24	1057.89	63.74	0.06
206298_at	58504	ARHG AP22	NM_021226	2.00	3.11	1.70		2.00	79.90	4.91	0.06
208547_at	3018	HIST1 H2BB	NM_021062	9.30	8.17	7.89		9.30	24.98	1.55	0.06
219935_at	11096	ADAM TS5	NM_007038	11.43	4.56	12.57		11.43	30.43	2.05	0.07
205112_at	51196	PLCE1	NM_016341	3.30	6.34	8.80		3.30	15.36	1.14	0.07
215420_at	3549	IHH	BE869172	9.72	7.00	9.08		9.72	33.48	2.50	0.07
208046_at	8359	HIST1 H4A	NM_003538	13.52	10.07	16.64		13.52	28.02	2.12	0.08
221288_at	2845	GPR22	NM_005295	26.31	31.34	28.77		26.31	55.91	4.35	0.08
208488_s_at	1378	CR1	NM_000651	15.88	28.28	26.11		15.88	44.78	3.56	0.08
221175_at	80111	C3orf36	NM_025041	8.41	6.91	13.14		8.41	30.48	2.44	0.08
215957_at	7321	UBE2D 1	AV731367	4.33	8.76	12.54		4.33	16.08	1.30	0.08

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
217020_at	5915	RARB	X04014	22.75	11.10	9.59		22.75	39.30	3.24	0.08
219230_at	55273	TMEM100	NM_018286	7.17	10.72	9.09		7.17	24.12	2.01	0.08
221182_at	80133	C1orf129	NM_025063	10.43	4.49	14.03		10.43	15.85	1.33	0.08
207016_s_at	8854	ALDH1A2	AB015228	2.05	4.47	4.39		2.05	66.58	5.58	0.08
210852_s_at	10157	AASS	AF229180	8.75	22.62	22.24		8.75	26.45	2.22	0.08
214370_at	6279	S100A8	AW238654	97.05	52.09	34.27		97.05	356.34	30.25	0.08
220218_at	55064	C9orf68	NM_017985	6.12	2.62	1.64		6.12	12.22	1.05	0.09
211238_at	8756	ADAM7	AF215824	8.93	10.69	23.62		8.93	30.85	2.65	0.09
207696_at	10690	FUT9	NM_006581	1.18	3.07	1.62		1.18	10.55	0.92	0.09
215465_at	26154	ABCA12	AL080207	2.34	7.60	14.22		2.34	11.92	1.04	0.09
216223_at	1370	CPN2	J05158	7.15	2.87	8.63		7.15	24.25	2.14	0.09
216405_at	3956	LGALS1	M14087	9.45	5.65	8.22		9.45	46.18	4.09	0.09
207861_at	6367	CCL22	NM_002990	161.27	125.24	74.15		161.27	7023.34	623.19	0.09
207615_s_at	750	C16orf3	NM_001214	2.65	5.63	11.28		2.65	21.92	1.98	0.09
215621_s_at	3495	IGHD	BG340670	3.63	5.24	7.05		3.63	46.24	4.21	0.09
203393_at	3280	HES1	BE973687	10.70	1.20	10.45		10.70	36.00	3.30	0.09
206645_s_at	190	NR0B1	NM_000475	12.07	3.16	1.94		12.07	38.55	3.53	0.09
207926_at	2814	GP5	NM_004488	12.79	6.12	7.19		12.79	31.92	2.95	0.09
210895_s_at	942	CD86	L25259	38.25	14.63	32.29		38.25	96.28	8.90	0.09
206165_s_at	9635	CLCA2	NM_006536	5.74	4.51	8.60		5.74	11.98	1.13	0.09
216764_at	150684	COMM	AK02519	11.06	11.57	3.97		11.06	19.86	1.89	0.10

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		D1	1								
217524_x_at			AA018923	5.50	7.34	1.44		5.50	17.40	1.66	0.10
220830_at	50939	IMPG2	NM_016247	2.81	6.70	8.75		2.81	25.59	2.44	0.10
207465_at			NM_014134	2.26	6.18	12.11		2.26	20.22	1.94	0.10
205267_at	5450	POU2AF1	NM_006235	12.46	26.93	24.31		12.46	23.23	2.24	0.10
214073_at	220	ALDH1A3	BG475299	3.88	2.97	7.21		3.88	13.96	1.38	0.10
210078_s_at	7881	KCNA B1	L39833	16.85	50.04	43.10		16.85	39.05	3.96	0.10
219857_at	79949	C10orf81	NM_024889	2.31	4.02	2.39		2.31	14.23	1.45	0.10
220653_at	23619	ZIM2	NM_015363	41.48	27.61	32.47		41.48	69.88	7.13	0.10
205960_at	5166	PDK4	NM_002612	2.59	2.75	6.29		2.59	44.19	4.57	0.10
207599_at	9313	MMP20	NM_004771	4.86	2.35	2.08		4.86	15.32	1.60	0.10
215619_at	473	RERE	AU148274	4.45	4.40	2.05		4.45	18.91	2.01	0.11
222353_at	8994	LIMD1	AV720842	4.06	10.20	12.37		4.06	23.29	2.50	0.11
215853_at	10806	SDCCA G8	AK021640	33.80	40.89	34.08		33.80	55.94	6.12	0.11
209101_at	1490	CTGF	M92934	23.07	5.24	26.98		23.07	368.37	40.43	0.11
214467_at	8477	GPR65	NM_003608	63.08	41.38	38.21		63.08	140.86	15.55	0.11
208458_at	6339	SCNN1D	NM_002978	7.51	4.50	9.77		7.51	29.51	3.26	0.11
212952_at	811	CALR	AA910371	1744.78	841.49	1191.85		1744.78	4006.99	446.49	0.11
210834_s_at	5733	PTGER3	AL031429	4.55	11.37	11.05		4.55	19.20	2.16	0.11
208394_x_at	11082	ESM1	NM_007036	2.24	2.12	6.74		2.24	17.43	1.96	0.11
212488_at	1289	COL5A	N30339	3.89	9.49	3.11		3.89	34.08	3.84	0.11

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells (Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		1									
202310_s_at	1277	COL1A1	K01228	5.86	13.13	19.21		5.86	80.30	9.13	0.11
217401_at			AL035555	5.60	8.79	3.42		5.60	11.74	1.35	0.11
203636_at	4281	MID1	BE967532	10.55	14.34	18.76		10.55	65.51	7.54	0.12
220877_at			NM_018580	7.74	9.89	2.24		7.74	17.99	2.10	0.12
208329_at	59351	PBOV1	NM_021635	4.46	5.91	3.64		4.46	27.69	3.25	0.12
214000_s_at	6001	RGS10	AI744627	46.17	25.13	39.60		46.17	101.85	12.00	0.12
220882_at			NM_018612	3.41	4.60	2.97		3.41	111.91	13.24	0.12
213755_s_at	137872	ADHFE1	BF431501	13.09	17.73	26.10		13.09	40.50	4.90	0.12
213964_x_at	79946	C10orf95	AI307586	2.10	1.66	6.98		2.10	21.40	2.60	0.12
214889_at	25854	DKFZP564J102	AL080065	14.32	3.25	3.82		14.32	27.91	3.41	0.12
206069_s_at	33	ACADL	NM_001608	2.39	2.05	3.28		2.39	10.40	1.30	0.12
210394_x_at	548313 /	SSX4 /// SSX4B	BC005325	1.87	8.11	6.97		1.87	17.25	2.16	0.13
216982_x_at	51412	ACTL6B	U50277	5.34	4.44	7.45		5.34	13.24	1.70	0.13
220759_at	64184	FAM12B	NM_022360	2.44	6.28	18.52		2.44	12.09	1.56	0.13
205834_s_at	25859	PART1	AI770098	11.84	16.34	23.40		11.84	27.34	3.55	0.13
217306_at	645749	LOC65749	AL031119	5.18	15.57	12.73		5.18	23.60	3.13	0.13
213871_s_at	10591	C6orf108	AA523444	46.45	25.19	44.27		46.45	83.50	11.44	0.14
210931_at	6049	RNF6	AF293342	3.24	4.89	1.85		3.24	12.59	1.73	0.14
216030_s_at	6407	SEMG2	AL049767	3.60	3.09	13.98		3.60	30.38	4.18	0.14

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
210339_s_at	3817	KLK2	BC005196	8.22	45.01	40.89		8.22	38.68	5.36	0.14
214026_s_at	200734	SPRED2	AI860246	2.26	4.87	1.27		2.26	23.31	3.24	0.14
206692_at	3766	KCNJ10	NM_002241	4.22	4.80	3.59		4.22	17.37	2.42	0.14
205764_at			NM_002932	4.35	5.28	3.09		4.35	21.96	3.08	0.14
205419_at	1880	EBI2	NM_004951	255.75	261.91	87.33		255.75	852.74	120.26	0.14
206331_at	10203	CALCR L	NM_005795	19.42	23.36	6.18		19.42	143.22	20.23	0.14
205343_at	6819	SULT1C1	NM_001056	5.74	2.18	15.63		5.74	24.45	3.46	0.14
201860_s_at	5327	PLAT	NM_000930	7.32	21.56	24.05		7.32	100.69	14.28	0.14
207473_at	4295	MLN	NM_002418	11.58	18.81	42.05		11.58	24.61	3.53	0.14
210631_at	4763	NF1	D42072	7.09	7.92	14.61		7.09	20.15	2.90	0.14
207811_at	3859	KRT12	NM_000223	1.73	3.85	1.57		1.73	19.20	2.77	0.14
207321_s_at	23457	ABCB9	NM_019625	5.23	7.04	3.46		5.23	16.01	2.31	0.14
216235_s_at	1909	EDNRA	S81545	20.10	18.68	28.08		20.10	43.48	6.33	0.15
207288_at	80161	CXYorf2	NM_025091	9.38	6.34	5.04		9.38	19.90	2.90	0.15
216435_at	5607	MAP2K5	AK025177	1.30	6.64	0.39		1.30	18.65	2.73	0.15
205374_at	6588	SLN	NM_003063	18.84	29.69	23.74		18.84	28.40	4.17	0.15
207864_at	6332	SCN7A	NM_002976	4.00	2.12	2.40		4.00	17.62	2.60	0.15
222350_at	607	BCL9	AW969913	14.66	7.42	10.98		14.66	30.87	4.56	0.15
212667_at	6678	SPARC	AL575922	7.43	9.22	7.46		7.43	18.63	2.75	0.15
217126_at			K00627	5.23	5.75	12.19		5.23	17.64	2.61	0.15

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
221180_at	80122	YSK4	NM_025052	14.60	25.74	39.06		14.60	57.17	8.47	0.15
201416_at	6659	SOX4	NM_003107	148.60	99.80	137.83		148.60	392.36	58.16	0.15
214074_s_at	2017	CTTN	BG475299	8.91	4.37	20.30		8.91	32.78	4.90	0.15
208162_s_at	55099	FLJ10232	NM_018033	2.39	5.20	4.16		2.39	14.20	2.15	0.15
205597_at	80736	SLC44A4	NM_025257	6.91	2.92	22.26		6.91	19.19	2.92	0.15
205399_at	9201	DCAMKL1	NM_004734	1.83	1.76	1.65		1.83	13.20	2.01	0.15
218002_s_at	9547	CXCL14	AF144103	3.00	2.86	4.84		3.00	589.79	90.26	0.15
213806_at	5813	PURA	BE222739	6.66	7.83	7.23		6.66	47.39	7.27	0.15
220428_at	50489	CD207	NM_015717	11.74	8.08	18.05		11.74	19.08	2.93	0.15
205620_at	2159	F10	NM_000504	7.12	15.80	15.94		7.12	14.59	2.24	0.15
205529_s_at	862	RUNX1T1	NM_004349	13.10	8.22	6.87		13.10	250.58	38.59	0.15
220401_at	79860	FLJ21369	NM_024802	8.28	5.68	4.34		8.28	17.77	2.75	0.15
207710_at	26239	LCE2B	NM_014357	1.60	6.93	5.57		1.60	14.66	2.30	0.16
208790_s_at	284119	PTRF	AF312393	17.21	10.92	28.04		17.21	36.43	5.73	0.16
219195_at	10891	PPARGC1A	NM_013261	3.79	4.92	4.29		3.79	16.01	2.53	0.16
215678_at	440792	LOC440792	AB051440	21.38	11.43	6.70		21.38	34.02	5.40	0.16
206048_at	58495	OVOL2	NM_021220	7.06	8.74	18.75		7.06	14.90	2.36	0.16
220551_at	57084	SLC17A6	NM_020346	8.16	3.85	19.98		8.16	22.01	3.50	0.16
206065_s_at	1807	DPYS	NM_001385	9.17	3.69	4.49		9.17	82.41	13.20	0.16
206909_at			AF068863	9.84	12.72	9.25		9.84	21.17	3.40	0.16

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
206144_at	9223	MAGI1	NM_004742	1.68	3.25	3.11		1.68	11.64	1.88	0.16
217169_at	3493	IGHA1	M31949	13.76	9.29	13.34		13.76	25.97	4.20	0.16
210993_s_at	4086	SMAD1	U54826	14.71	22.00	2.50		14.71	26.78	4.35	0.16
207178_s_at	2444	FRK	NM_002031	0.85	6.65	1.60		0.85	28.65	4.68	0.16
208131_s_at	5740	PTGIS	NM_000961	11.40	4.49	29.49		11.40	40.16	6.58	0.16
211274_at	6899	TBX1	AF012130	5.88	11.06	26.86		5.88	17.48	2.88	0.16
217426_at			L11372	7.25	6.86	23.14		7.25	36.10	5.95	0.16
207097_s_at	10246	SLC17A2	NM_005835	12.15	14.23	8.44		12.15	26.05	4.30	0.17
216462_at			X79200	2.04	5.32	9.55		2.04	10.20	1.70	0.17
208183_at	6870	TACR3	NM_001059	11.48	25.88	25.95		11.48	20.45	3.43	0.17
205908_s_at	4958	OMD	NM_005014	1.91	4.37	4.10		1.91	18.65	3.14	0.17
37892_at	1301	COL11A1	J04177	3.39	4.84	1.90		3.39	10.84	1.83	0.17
217689_at	5770	PTPN1	BG109555	6.99	3.74	2.80		6.99	17.35	2.93	0.17
216185_at	10690	FUT9	BC001879	5.09	4.00	4.70		5.09	11.52	1.96	0.17
208471_at	3250	HPR	NM_020995	5.06	23.85	17.93		5.06	22.71	3.91	0.17
206528_at	7225	TRPC6	NM_004621	6.90	4.37	15.12		6.90	14.83	2.57	0.17
205815_at	5068	REG3A	NM_002580	8.92	17.49	14.83		8.92	19.74	3.42	0.17
221846_s_at	57513	CASKI N2	AI970096	26.83	26.35	12.92		26.83	112.50	19.50	0.17
219614_s_at	54716	SLC6A20	NM_020208	3.56	3.79	4.21		3.56	16.12	2.79	0.17
205863_at	6283	S100A12	NM_005621	66.09	59.11	38.25		66.09	515.83	89.58	0.17
213397_x_at	6038	RNASE	AI761728	2.07	2.88	5.52		2.07	12.87	2.24	0.17

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		4									
213747_at			AA047234	315.44	147.79	570.49		315.44	1067.62	186.27	0.17
210836_x_at	5144	PDE4D	AF012073	29.15	39.13	28.28		29.15	60.45	10.63	0.18
213757_at			AA393940	2393.48	1651.77	2565.92		2393.48	8391.34	1487.69	0.18
201744_s_at	4060	LUM	NM_002345	0.37	1.17	0.63		0.37	25.70	4.56	0.18
220231_at	10842	C7orf16	NM_006658	13.68	49.24	42.07		13.68	193.09	34.45	0.18
208105_at	2696	GIPR	NM_000164	14.84	8.24	7.34		14.84	31.72	5.67	0.18
211959_at	3488	IGFBP5	AW007532	5.17	18.35	16.85		5.17	218.01	39.11	0.18
214176_s_at	57326	PBXIP1	AI348545	196.90	92.43	162.05		196.90	459.56	83.74	0.18
202835_at	10907	TXNL4A	BC001046	38.95	27.16	56.43		38.95	124.33	22.75	0.18
200865_at			AI001896	4.64	2.75	3.44		4.64	15.74	2.89	0.18
205163_at	29895	MYLPF	NM_013292	23.78	21.01	8.06		23.78	57.41	10.58	0.18
210640_s_at	2852	GPR30	U63917	11.00	8.27	18.88		11.00	20.53	3.80	0.19
208098_at	442192 /	OR5V1 /// OR12D 3 /// LOC442192	NM_030876	1.24	3.03	5.65		1.24	13.79	2.55	0.19
207631_at	10230	NBR2	NM_005821	22.40	32.64	58.94		22.40	34.25	6.36	0.19
214935_at	23636 //	NUP62 /// IL4I1	BE794962	8.23	12.22	9.93		8.23	38.87	7.22	0.19
220111_s_at	57101	TMEM16B	NM_020373	6.22	5.82	8.71		6.22	11.75	2.19	0.19
206328_at	1013	CDH15	NM_004933	3.35	2.94	3.93		3.35	11.87	2.22	0.19
206407_s_at	6357	CCL13	NM_005408	32.00	21.50	33.31		32.00	64.22	12.12	0.19
216649_at	6239	RREB1	AF07282	3.17	5.68	5.50		3.17	11.98	2.26	0.19

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			6								
214217_at	2915	GRM5	D60132	3.19	2.08	1.47		3.19	17.57	3.34	0.19
210373_at	10641	TUSC4	AF040708	11.47	12.99	14.43		11.47	23.87	4.55	0.19
220433_at	79057	PRRG3	NM_024082	8.64	6.28	12.15		8.64	19.81	3.78	0.19
205101_at	4261	CIITA	NM_000246	9.09	6.20	7.09		9.09	34.78	6.66	0.19
216987_at	3662	IRF4	D78261	2.16	1.84	0.62		2.16	19.18	3.69	0.19
214644_at	8330	HIST1H2AK	BF061074	8.10	6.77	4.53		8.10	19.06	3.69	0.19
209547_s_at	57794	SF4	BC001043	25.31	20.05	16.50		25.31	66.37	12.99	0.20
207489_at	80052	FLJ12331	NM_024986	12.21	13.81	27.22		12.21	29.52	5.79	0.20
206705_at	7287	TULP1	NM_003322	11.15	12.61	14.49		11.15	39.08	7.67	0.20
219728_at	9499	MYOT	NM_006790	3.09	3.62	13.34		3.09	22.62	4.45	0.20
215183_at			AF090886	10.72	7.42	20.86		10.72	39.25	7.74	0.20
221395_at	50838	TAS2R13	NM_023920	3.30	4.05	3.70		3.30	13.83	2.73	0.20
214776_x_at	9942	XYLB	AA777793	5.12	14.72	24.05		5.12	28.33	5.61	0.20
220265_at	57720	GPR107	NM_020960	20.75	31.14	34.05		20.75	32.82	6.52	0.20
218517_at	79960	PHF17	NM_024900	671.89	541.57	620.61		671.89	3234.03	645.07	0.20
213991_s_at	9957	HS3ST1	BF940710	16.80	9.92	5.45		16.80	31.00	6.19	0.20
208339_at	353515 /	XKRY /// XKRY2	NM_004677	1.77	6.40	9.09		1.77	15.95	3.19	0.20
219768_at	79679	VTCN1	NM_024626	7.04	26.08	19.70		7.04	26.59	5.33	0.20
218974_at	55084	FLJ10159	NM_018013	222.38	310.14	140.60		222.38	485.33	97.37	0.20
206618_at	8809	IL18R1	NM_0038	6.10	156.73	122.43		6.10	214.33	43.08	0.20

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			55								
217345_at			U91640	2.59	8.63	19.63		2.59	16.96	3.41	0.20
210049_at	462	SERPINC1	D29832	8.65	11.33	4.76		8.65	19.46	3.92	0.20
207024_at	1144	CHRN D	NM_000751	21.20	3.50	11.38		21.20	35.01	7.10	0.20
215768_at	6660	SOX5	AL049337	261.96	376.89	230.64		261.96	1435.56	292.59	0.20
215181_at	64405	CDH22	AF035300	4.05	9.69	4.56		4.05	24.42	4.98	0.20
220332_at	10686	CLDN16	NM_006580	6.96	10.59	9.02		6.96	18.69	3.82	0.20
220330_s_at	64092	SAMSN1	NM_022136	299.66	283.79	140.95		299.66	4794.99	979.81	0.20
215618_at	6251	RSU1	AK024109	13.95	15.40	32.54		13.95	34.33	7.05	0.21
220418_at	51098 //	IFT52 /// UBASH3A	NM_018961	1.80	6.21	2.53		1.80	20.92	4.30	0.21
209985_s_at	429	ASCL1	BC001638	11.20	13.94	6.81		11.20	26.33	5.45	0.21
220984_s_at	81796	SLCO5A1	NM_030958	5.65	4.67	14.49		5.65	32.62	6.77	0.21
201286_at	6382	SDC1	Z48199	6.04	6.77	1.92		6.04	12.55	2.61	0.21
207748_at			NM_014122	15.39	16.95	43.66		15.39	56.06	11.66	0.21
208413_at	5915	RARB	NM_015854	2.15	4.01	3.06		2.15	10.33	2.15	0.21
207703_at	22829	NLGN4Y	NM_014893	79.40	98.88	108.46		79.40	564.37	118.03	0.21
211083_s_at	9175	MAP3K13	Z25428	1.33	2.63	6.52		1.33	12.08	2.54	0.21
214375_at	440091 /	PPFIBP1 /// LOC440091 /// LOC7	AI962377	69.98	62.54	97.33		69.98	178.23	37.50	0.21
219064_at	80760	ITIH5	NM_030569	5.73	3.79	9.11		5.73	18.69	3.94	0.21

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
217082_at			U82306	4.93	2.01	8.21		4.93	15.90	3.37	0.21
207688_s_at	3626	INHBC	NM_005538	327.66	191.98	326.23		327.66	619.35	131.36	0.21
213774_s_at			AW614578	4.03	6.26	6.70		4.03	14.53	3.10	0.21
206344_at	5444	PON1	U53784	10.98	11.36	7.03		10.98	16.90	3.61	0.21
220717_at	80070	ADAMTS20	NM_025003	7.96	8.10	13.19		7.96	23.35	5.00	0.21
207744_at			NM_014124	1.74	0.95	5.13		1.74	11.11	2.39	0.21
215514_at			AL080072	5.34	9.83	11.46		5.34	16.28	3.51	0.22
216558_x_at			AF044595	8.61	4.05	14.62		8.61	26.20	5.69	0.22
208512_s_at	4301	MLLT4	NM_005936	5.48	6.08	12.11		5.48	16.17	3.52	0.22
220959_s_at	29989 //	OBP2B /// OBP2A	NM_014581	12.73	9.84	7.55		12.73	30.86	6.75	0.22
216704_at	6902	TBCA	AL353949	4.35	10.14	13.34		4.35	21.21	4.65	0.22
204388_s_at	4128	MAOA	NM_000240	1.23	3.23	7.34		1.23	13.35	2.95	0.22
219529_at	9022 ///	CLIC3 /// RABEP1	NM_004669	3.99	9.37	0.95		3.99	20.79	4.60	0.22
220313_at	54112	GPR88	NM_022049	140.60	189.27	109.25		140.60	688.55	152.32	0.22
217561_at	796	CALCA	BF447272	10.92	8.14	4.82		10.92	17.97	3.98	0.22
215307_at	57711	ZNF529	AL109722	16.02	10.53	26.57		16.02	25.91	5.74	0.22
220392_at	64641	EBF2	NM_022659	3.92	3.87	3.17		3.92	10.08	2.24	0.22
210664_s_at	7035	TFPI	AF021834	6.05	10.38	31.32		6.05	34.95	7.80	0.22
203432_at	7112	TMPO	AW272611	775.83	593.57	714.25		775.83	1280.81	287.30	0.22
208075_s_at	6354	CCL7	NM_0062	3.14	12.34	9.73		3.14	26.25	5.90	0.22

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			73								
220616_at			NM_006448	19.78	8.07	48.79		19.78	57.14	12.87	0.23
203295_s_at	477	ATP1A2	NM_000702	24.20	7.78	9.26		24.20	37.13	8.38	0.23
208416_s_at	6710	SPTB	NM_000347	21.16	16.14	46.95		21.16	55.42	12.57	0.23
213979_s_at	1487	CTBP1	BF984434	766.52	549.77	790.85		766.52	1794.22	407.70	0.23
201340_s_at	8507	ENC1	AF010314	71.63	61.36	7.00		71.63	120.85	27.48	0.23
221765_at			AI378044	167.05	244.29	252.38		167.05	1035.54	237.06	0.23
215036_at			AI952772	10.40	7.19	15.22		10.40	33.59	7.71	0.23
216995_x_at	23609	MKRN2	X06409	2.68	7.51	5.44		2.68	17.02	3.92	0.23
220825_s_at	55243	KIRREL	NM_018240	4.23	3.87	6.69		4.23	10.05	2.32	0.23
207731_at			NM_020118	5.86	7.35	3.54		5.86	11.27	2.61	0.23
220502_s_at	6561	SLC13A1	AF260824	3.52	4.09	12.12		3.52	17.15	3.97	0.23
214101_s_at	728896	LOC728896	BG153399	137.38	136.88	180.71		137.38	533.68	123.56	0.23
210382_at	6344	SCTR	U13989	8.09	6.06	6.03		8.09	36.49	8.46	0.23
207256_at	4153	MBL2	NM_000242	2.50	1.33	4.14		2.50	10.44	2.44	0.23
221529_s_at	83483	PLVAP	AF326591	11.30	7.18	25.72		11.30	28.83	6.76	0.23
209690_s_at	55715	DOK4	BC003541	6.83	10.54	8.79		6.83	27.09	6.41	0.24
210861_s_at	8838	WISP3	AF143679	2.09	1.21	7.79		2.09	13.25	3.17	0.24
220657_at	55175	KLHL11	NM_018143	7.81	6.55	6.63		7.81	23.72	5.69	0.24
209290_s_at	4781	NFIB	BC001283	5.22	5.72	13.05		5.22	26.40	6.33	0.24
210356_x_at	931	MS4A1	BC002807	7.05	9.75	23.10		7.05	11.77	2.83	0.24

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
214587_at	1295	COL8A1	BE877796	10.90	16.26	6.51		10.90	19.94	4.80	0.24
213565_s_at	4091	SMAD6	AI193899	10.35	12.84	13.06		10.35	28.61	6.91	0.24
216456_at	5101	PCDH9	AL162044	7.61	10.97	6.21		7.61	21.07	5.09	0.24
220334_at	26575	RGS17	NM_012419	4.67	18.44	27.58		4.67	45.54	11.02	0.24
216124_at	54879	ST7L	AK024158	13.20	8.80	12.57		13.20	22.08	5.34	0.24
215927_at	10564	ARFGEF2	AV657604	6.00	8.79	12.23		6.00	23.67	5.73	0.24
214142_at	123887	ZG16	AI732905	6.01	6.78	8.19		6.01	22.17	5.37	0.24
206080_at	9651	PLCH2	NM_014638	5.81	5.60	4.44		5.81	17.57	4.27	0.24
205326_at	10268	RAMP3	NM_005856	30.47	13.41	35.39		30.47	46.09	11.22	0.24
222062_at	9466	IL27RA	AI983115	193.02	338.97	259.12		193.02	2386.38	583.92	0.24
209888_s_at	4632	MYL1	M20643	3.85	5.66	4.67		3.85	10.77	2.64	0.24
220595_at	29951	PDZRN4	NM_013377	7.48	10.67	3.92		7.48	13.90	3.41	0.25
205572_at	285	ANGPT2	NM_001147	8.61	7.15	15.35		8.61	28.81	7.10	0.25
215432_at	116285	ACSM1	AC003034	6.62	5.97	13.02		6.62	12.53	3.09	0.25
210080_x_at	10136	ELA3A	D00306	14.51	8.79	4.88		14.51	25.96	6.44	0.25
203398_s_at	2591	GALNT3	NM_004482	7.66	38.18	29.55		7.66	30.22	7.50	0.25
206439_at	1833	EPYC	NM_004950	6.75	3.28	1.90		6.75	15.50	3.85	0.25
206598_at	3630	INS	NM_000207	3.02	2.70	2.00		3.02	18.42	4.57	0.25
220676_at	11095	ADAMTS8	NM_007037	5.35	4.47	16.73		5.35	25.79	6.41	0.25
210665_at	7035	TFPI	AF021834	5.80	8.57	5.04		5.80	22.17	5.51	0.25
213655_at	5048	PAFAH1B1	AA502643	2539.35	1808.95	2842.37		2539.35	7026.66	1754.25	0.25

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
218875_s_at	26271	FBXO5	NM_012177	594.34	574.83	520.55		594.34	1893.84	473.23	0.25
207145_at	2660	GDF8	NM_005259	2.84	2.28	4.17		2.84	10.33	2.58	0.25
218574_s_at	29995	LMCD1	NM_014583	23.55	4.03	17.24		23.55	46.87	11.73	0.25
207038_at	9120	SLC16A6	NM_004694	6.97	34.06	28.86		6.97	23.55	5.89	0.25
206721_at	57821	C1orf114	NM_021179	10.31	2.87	6.29		10.31	22.21	5.57	0.25
207669_at	3889	KRT83	NM_002282	5.60	6.60	6.45		5.60	18.63	4.67	0.25
202969_at			AI216690	284.42	326.45	231.60		284.42	616.25	155.30	0.25
221872_at	5918	RARRES1	AI669229	0.95	7.19	22.24		0.95	13.73	3.46	0.25
204198_s_at	864	RUNX3	AA541630	804.37	1177.81	431.84		804.37	1672.19	424.29	0.25
211161_s_at	1281	COL3A1	AF130082	3.16	3.75	5.35		3.16	20.76	5.27	0.25
221698_s_at	64581	CLEC7A	AF313468	42.75	59.27	51.05		42.75	173.71	44.19	0.25
215360_at			AK022063	1.37	1.37	4.89		1.37	13.55	3.45	0.25
211348_s_at	8555	CDC14B	AF064105	21.81	5.56	12.85		21.81	33.15	8.45	0.25
221884_at	2122	EVI1	BE466525	8.67	5.58	14.16		8.67	15.88	4.05	0.25
200761_s_at	10550	ARL6IP5	NM_006407	2021.41	2829.28	2410.96		2021.41	3837.72	980.80	0.26
205102_at	7113	TMPRS2	NM_005656	10.49	5.08	19.42		10.49	21.90	5.60	0.26
214418_at	196993	LOC196993	AI656822	5.48	6.03	2.89		5.48	10.05	2.57	0.26
214862_x_at			AL080082	2.29	6.41	4.25		2.29	13.63	3.50	0.26
217194_at	9462	RASAL2	AB007970	2.86	9.03	13.06		2.86	10.85	2.79	0.26
218413_s_at	51193	ZNF639	NM_016331	9.14	5.19	20.07		9.14	39.77	10.24	0.26

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
206027_at	6274	S100A3	NM_002960	28.61	28.50	13.55		28.61	81.06	20.98	0.26
205674_x_at	486	FXVD2	NM_001680	22.37	29.36	27.36		22.37	85.81	22.41	0.26
205809_s_at	8976	WASL	BE504979	111.25	90.27	153.75		111.25	240.88	62.99	0.26
213868_s_at	51635	DHRS7	AW243128	2.80	7.04	6.93		2.80	11.65	3.05	0.26
206167_s_at	395	ARHGAP6	NM_001174	3.65	19.02	20.45		3.65	64.74	16.96	0.26
210025_s_at	29775	CARD10	AW205153	16.25	22.02	35.74		16.25	60.78	16.00	0.26
205629_s_at	1392	CRH	BC002599	11.88	16.57	4.74		11.88	25.96	6.84	0.26
209854_s_at	3817	KLK2	AF188747	5.18	3.03	2.57		5.18	14.86	3.92	0.26
221997_s_at	122704	MRPL52	AI560951	110.57	75.97	120.11		110.57	183.34	48.45	0.26
206824_at	51716	CES4	NM_016280	4.98	5.15	2.55		4.98	17.68	4.67	0.26
207925_at	1473	CST5	NM_001900	8.59	3.74	31.35		8.59	15.42	4.08	0.26
216600_x_at			AK026411	50.51	67.20	54.99		50.51	76.01	20.11	0.26
209335_at	1634	DCN	BC005322	9.45	16.25	20.72		9.45	30.15	7.98	0.26
207395_at	696	BTN1A1	NM_001732	4.95	5.50	8.07		4.95	15.30	4.06	0.27
217481_x_at	388336	FLJ45455	AL110201	15.87	20.39	16.45		15.87	31.98	8.49	0.27
214468_at	4624	MYH6	D00943	3.84	6.60	8.61		3.84	24.96	6.63	0.27
206616_s_at	53616	ADAM22	AF155382	5.67	3.75	3.53		5.67	11.44	3.04	0.27
206683_at	7718	ZNF165	NM_003447	16.95	23.59	18.69		16.95	46.90	12.48	0.27
220862_s_at	23326	USP22	NM_014093	13.23	8.50	4.20		13.23	28.35	7.57	0.27
220872_at	55415	PRO2964	NM_018547	44.15	37.40	33.91		44.15	124.12	33.27	0.27

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
1320_at	11099	PTPN21	X79510	4.10	14.79	17.18		4.10	20.28	5.44	0.27
207929_at	2925	GRPR	NM_005314	12.63	23.86	37.49		12.63	35.34	9.48	0.27
220114_s_at	55576	STAB2	NM_017564	30.48	20.22	30.38		30.48	50.95	13.67	0.27
202489_s_at	5349	FXVD3	BC005238	7.01	4.63	5.16		7.01	49.52	13.29	0.27
210750_s_at	9229	DLGAP1	AB000277	13.66	6.37	36.86		13.66	52.95	14.24	0.27
212533_at	7465	WEE1	X62048	740.96	666.06	664.70		740.96	1614.33	435.31	0.27
206021_at	54581	SCAND2	NM_022050	9.69	11.16	8.56		9.69	19.97	5.39	0.27
208247_at	711	C3orf51	NM_001213	4.74	1.98	4.78		4.74	14.60	3.98	0.27
206392_s_at	5918	RARRES1	NM_002888	8.04	1.67	6.79		8.04	28.04	7.67	0.27
214388_at	10443	PFAAP5	AI732885	56.87	77.68	82.68		56.87	134.22	36.79	0.27
215145_s_at	26047	CNTNAP2	AC005378	7.58	4.27	4.30		7.58	11.89	3.26	0.27
202600_s_at	8204	NRIP1	AI824012	695.26	743.82	853.54		695.26	3249.25	892.90	0.27
203424_s_at	3488	IGFBP5	AW157548	3.79	22.29	21.70		3.79	72.37	19.93	0.28
207799_x_at			NM_015437	24.85	18.13	6.90		24.85	49.19	13.56	0.28
201242_s_at	481	ATP1B1	BC000006	751.38	1068.01	600.04		751.38	11642.50	3222.21	0.28
216217_at	23228	PLCL2	AK023546	9.08	14.39	39.09		9.08	20.86	5.77	0.28
207315_at	10666	CD226	NM_006566	8.96	7.90	8.80		8.96	16.30	4.53	0.28
216240_at	5820	PVT1	M34428	5.56	9.88	18.54		5.56	34.97	9.71	0.28
206035_at	5966	REL	NM_002908	24.22	12.38	20.40		24.22	331.30	92.07	0.28
221795_at	4915	NTRK2	AA707199	4.24	3.95	3.10		4.24	14.43	4.01	0.28
207415_at	22925	PLA2R	NM_0073	5.81	3.64	2.72		5.81	13.21	3.69	0.28

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		1	66								
216864_at			U05589	8.67	4.20	2.79		8.67	13.95	3.89	0.28
211567_at			J04168	2.33	5.41	4.93		2.33	11.84	3.32	0.28
216190_x_at	3688	ITGB1	AA215854	6.44	4.31	25.88		6.44	15.82	4.43	0.28
211131_s_at	1896	EDA	AF061193	4.77	26.98	25.43		4.77	20.71	5.81	0.28
208303_s_at	64109	CRLF2	NM_022148	16.51	7.18	8.63		16.51	1356.51	381.58	0.28
208232_x_at	3084	NRG1	L12260	12.44	43.25	33.69		12.44	37.46	10.54	0.28
216642_at	6397	SEC14L1	AL110190	22.54	25.08	13.40		22.54	37.62	10.60	0.28
212827_at	3507	IGHM	X17115	15.53	21.19	13.40		15.53	65.44	18.48	0.28
204591_at	10752	CHL1	NM_006614	4.95	8.02	7.14		4.95	20.37	5.75	0.28
208004_at	58503	PROL1	NM_021225	14.22	36.53	29.12		14.22	40.19	11.40	0.28
207887_s_at	799	CALCR	AB022177	5.05	14.08	11.84		5.05	26.49	7.56	0.29
204814_at	8618	CADPS	NM_003716	8.11	5.96	23.10		8.11	29.57	8.46	0.29
37996_s_at	1760	DMPK	L08835	72.89	100.17	52.84		72.89	110.11	31.49	0.29
218350_s_at	51053	GMNN	NM_015895	870.50	736.93	698.81		870.50	1727.31	494.58	0.29
219804_at	79933	SYNPO2L	NM_024875	2.59	1.83	1.02		2.59	13.90	3.99	0.29
221273_s_at	727800	LOC727800	NM_031297	21.10	21.42	15.67		21.10	36.39	10.46	0.29
209816_at	5727	PTCH1	AL044175	10.00	5.16	10.88		10.00	24.92	7.17	0.29
216803_at	10611	PDLIM5	AK027217	5.28	14.04	16.42		5.28	11.18	3.22	0.29
205828_at	4314	MMP3	NM_002422	13.63	13.06	21.41		13.63	23.26	6.71	0.29
220249_at	23553	HYAL4	NM_012269	7.20	7.28	2.48		7.20	28.92	8.37	0.29
211201_at	2492	FSHR	M95489	6.10	3.63	2.28		6.10	19.21	5.56	0.29

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
219739_at	54546	RNF186	NM_019062	7.82	5.51	8.38		7.82	18.93	5.49	0.29
211403_x_at	26609 //	VCY /// VCX /// VCX2 /// VCX3A	AF167079	15.03	10.65	26.10		15.03	30.62	8.91	0.29
209924_at	6362	CCL18	AB000221	5.01	8.22	3.71		5.01	35.20	10.24	0.29
205514_at	55786	ZNF415	NM_018355	1.70	1.56	1.47		1.70	15.58	4.54	0.29
219585_at	79140	CCDC28B	NM_024296	7.89	8.44	7.73		7.89	17.29	5.04	0.29
206109_at	2523	FUT1	NM_000148	19.28	38.51	53.68		19.28	62.90	18.33	0.29
204184_s_at	157	ADRBK2	NM_005160	135.61	147.65	260.75		135.61	215.58	62.91	0.29
209740_s_at	8228	PNPLA4	U03886	11.84	14.37	40.29		11.84	31.67	9.26	0.29
213765_at	8076	MFAP5	AW665892	5.45	6.98	3.18		5.45	21.59	6.31	0.29
207331_at	1063	CENPF	NM_016343	39.68	61.25	58.36		39.68	60.75	17.78	0.29
216108_at			AU147017	12.31	2.04	9.10		12.31	19.45	5.70	0.29
216784_at			AK025422	17.39	4.52	29.39		17.39	38.10	11.18	0.29
215748_at	283212	FLJ33790	AL050370	6.42	9.30	23.55		6.42	36.45	10.70	0.29
222337_at	114883	OSBPL9	AW968210	25.07	35.61	27.75		25.07	50.29	14.80	0.29
211148_s_at	285	ANGPT2	AF187858	4.10	3.82	12.64		4.10	12.25	3.62	0.30
216778_s_at	1538	CYLC1	Z22780	3.82	15.76	13.38		3.82	14.75	4.37	0.30
212923_s_at	221749	C6orf145	AK024828	61.65	189.49	144.47		61.65	1582.04	469.53	0.30
205805_s_at	4919	ROR1	NM_005012	12.55	13.97	9.88		12.55	19.30	5.75	0.30
213906_at	4603	MYBL1	AW592266	363.55	455.99	206.56		363.55	611.58	182.64	0.30

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
214077_x_at	4213	MEIS3 P1	H15129	189.79	245.42	198.01		189.79	381.83	114.12	0.30
207982_at	3010	HIST1 H1T	NM_005323	19.26	14.47	17.82		19.26	54.57	16.36	0.30
221204_s_at	55118	CRTAC 1	NM_018058	17.94	20.34	31.82		17.94	45.97	13.89	0.30
206093_x_at	7148	TNXB	NM_007116	6.80	15.62	13.63		6.80	21.78	6.58	0.30
209074_s_at	11170	FAM107A	AF089853	3.00	7.21	1.94		3.00	17.86	5.40	0.30
208389_s_at	6506	SLC1A2	NM_004171	10.38	7.55	35.09		10.38	46.41	14.04	0.30
214464_at	8476	CDC42 BPA	NM_003607	15.67	10.70	13.80		15.67	23.78	7.19	0.30
219602_s_at	63895	FAM38B	AW269818	58.88	86.45	36.48		58.88	115.47	34.99	0.30
213962_s_at	23141	KIAA0692	AI924382	16.60	9.97	34.09		16.60	38.22	11.58	0.30
217206_at			D00267	13.50	9.39	17.16		13.50	34.63	10.50	0.30
208265_at	56918	DKFZp547H025	NM_020161	2.47	4.08	6.57		2.47	16.82	5.12	0.30
207500_at	838	CASP5	NM_004347	11.33	15.19	12.14		11.33	69.59	21.32	0.31
213350_at	6205	RPS11	BF680255	522.85	650.26	632.61		522.85	1583.80	485.58	0.31
217460_at	7142	TNP2	X63759	4.90	5.01	17.20		4.90	20.34	6.24	0.31
220907_at	266977	GPR110	NM_025048	10.97	23.38	19.46		10.97	19.55	6.02	0.31
208382_s_at	11144	DMC1	NM_007068	5.84	16.49	25.88		5.84	26.24	8.08	0.31
213573_at			AA861608	513.04	429.35	294.03		513.04	925.56	285.39	0.31
213306_at	8777	MPDZ	AA917899	7.02	3.95	2.60		7.02	30.84	9.52	0.31
214182_at	382	ARF6	AA243143	651.99	537.07	751.31		651.99	2197.77	679.05	0.31
217332_at	647288 /	LOC647288 /// LOC73	AL133018	9.71	9.52	9.16		9.71	30.15	9.32	0.31

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		0587									
206946_at	10021	HCN4	NM_005477	13.59	4.80	10.52		13.59	24.47	7.58	0.31
214944_at	23035	PHLPP1	AK001854	5.05	3.85	12.01		5.05	34.90	10.81	0.31
215417_at	23233	EXOC6B	AI803703	8.77	12.13	9.54		8.77	16.96	5.26	0.31
210498_at	1213	CLTC	AF130062	5.41	4.41	7.39		5.41	25.68	7.97	0.31
203844_at	7428	VHL	NM_000551	2.39	10.46	9.02		2.39	24.05	7.46	0.31
213705_at			AW301861	127.37	89.65	121.65		127.37	276.88	86.04	0.31
213258_at	7035	TFPI	BF511231	15.91	39.97	30.15		15.91	82.52	25.70	0.31
211266_s_at	2828	GPR4	U35399	11.30	12.25	16.11		11.30	25.51	7.97	0.31
208229_at	2263	FGFR2	NM_022975	81.11	68.49	96.56		81.11	141.64	44.29	0.31
215298_at			U79300	6.89	9.82	17.53		6.89	27.16	8.51	0.31
214391_x_at	5731	PTGER1	AI762344	14.66	11.33	10.32		14.66	28.55	8.97	0.31
204871_at	7978	MTERF	NM_006980	132.49	135.92	147.33		132.49	309.83	97.41	0.31
217554_at			AV719355	61.28	69.60	87.23		61.28	252.86	79.69	0.32
210374_x_at	5733	PTGER3	D38300	20.97	26.75	27.04		20.97	38.35	12.10	0.32
211413_s_at	23569	PADI4	AF229067	2.14	6.32	6.88		2.14	10.50	3.32	0.32
212372_at	4628	MYH10	AK026977	333.25	341.82	245.40		333.25	752.49	237.95	0.32
220923_s_at	29944	PNMA3	NM_013364	21.89	37.09	45.05		21.89	42.88	13.60	0.32
204069_at	4211	MEIS1	NM_002398	3.14	3.09	5.46		3.14	21.60	6.85	0.32
219900_s_at	55663	ZNF446	NM_017908	29.67	25.80	54.96		29.67	47.50	15.07	0.32
211848_s_at	1087	CEACAM7	AF006623	12.22	2.08	9.93		12.22	20.52	6.52	0.32

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
202191_s_at	8522	GAS7	BE439987	259.02	363.60	322.08		259.02	549.39	175.24	0.32
203863_at			NM_001103	7.32	5.41	4.31		7.32	15.23	4.88	0.32
221131_at	51146	A4GNT	NM_016161	23.52	13.63	44.66		23.52	51.14	16.42	0.32
209905_at	3205	HOXA9	AI246769	1336.86	1328.69	1205.90		1336.86	2314.70	744.44	0.32
220316_at	64067	NPAS3	NM_022123	6.17	4.88	23.19		6.17	34.56	11.11	0.32
214253_s_at	1838	DTNB	AI672185	7.17	12.94	15.91		7.17	12.10	3.89	0.32
206915_at	4821	NKX2-2	NM_002509	5.74	8.40	7.53		5.74	15.61	5.03	0.32
209640_at	5371	PML	M79462	103.93	152.75	52.72		103.93	161.12	52.02	0.32
214071_at	65258	MPPE1	AI082827	4.98	4.67	21.53		4.98	13.49	4.37	0.32
217384_x_at	3576	IL8	AJ275374	5.03	3.46	3.73		5.03	29.54	9.58	0.32
204134_at	5138	PDE2A	NM_002599	5.69	8.74	16.12		5.69	13.72	4.46	0.32
216566_at			D84140	7.95	8.95	5.72		7.95	17.59	5.72	0.33
219493_at	79801	SHCBP1	NM_024745	909.34	971.91	874.17		909.34	1517.50	494.29	0.33
213609_s_at	23544	SEZ6L	AB023144	13.11	23.86	19.65		13.11	33.07	10.78	0.33
200938_s_at	473	RERE	AI920976	7.75	7.65	2.65		7.75	25.51	8.32	0.33
202517_at	1400	CRMP1	NM_001313	15.83	22.69	26.13		15.83	31.26	10.20	0.33
216609_at	7295	TXN	AF065241	300.13	264.66	432.34		300.13	866.37	283.09	0.33
221222_s_at	54964	C1orf56	NM_017860	161.08	189.41	223.25		161.08	581.43	190.02	0.33
209529_at	8612	PPAP2C	AF047760	6.36	5.52	5.90		6.36	36.40	11.90	0.33
217504_at	23460	ABCA6	AA099357	15.12	15.97	15.05		15.12	44.34	14.49	0.33
207977_s_at	1805	DPT	NM_001937	4.94	3.09	12.24		4.94	27.25	8.92	0.33
213387_at	54454	ATAD2	AB03306	432.35	479.83	550.43		432.35	1079.37	353.82	0.33

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		B	6								
221682_s_at	56100	PCDH GB6	AF135156	3.09	3.29	3.87		3.09	15.01	4.93	0.33
208003_s_at	10725	NFAT5	NM_006599	111.69	183.35	294.93		111.69	1165.92	384.13	0.33
217526_at	84901	NFATC2IP	AI478300	908.12	990.46	727.01		908.12	1459.88	481.18	0.33
205839_s_at	9256	BZRAP1	NM_004758	116.03	105.86	46.45		116.03	216.00	71.22	0.33
213872_at	81688	C6orf62	BE465032	4467.07	3291.94	4231.06		4467.07	12032.13	3979.21	0.33
207386_at	9420	CYP7B1	NM_004820	56.11	104.17	87.13		56.11	695.28	230.00	0.33
209071_s_at	8490	RGS5	AF159570	140.34	118.62	82.31		140.34	233.03	77.16	0.33
215450_at			W87901	639.72	381.40	669.98		639.72	987.74	327.24	0.33
217115_at			AL031686	9.70	9.55	3.21		9.70	16.53	5.48	0.33
216058_s_at	1557	CYP2C19	X65962	8.87	19.70	17.86		8.87	34.18	11.42	0.33
214057_at	4170	MCL1	H71805	195.42	199.20	194.76		195.42	326.34	109.24	0.33
214640_at	54346	UNC93A	AL021331	0.99	6.45	21.82		0.99	17.46	5.86	0.34
201996_s_at	23013	SPEN	AL524033	381.63	394.58	479.29		381.63	942.35	316.24	0.34
213344_s_at	3014	H2AFX	H51429	120.93	133.97	157.21		120.93	223.29	74.95	0.34
201645_at	3371	TNC	NM_002160	6.94	31.79	29.12		6.94	131.77	44.27	0.34
205934_at	5334	PLCL1	NM_006226	5.30	5.74	14.52		5.30	51.15	17.21	0.34
205978_at	9365	KL	NM_004795	25.59	8.20	23.07		25.59	39.47	13.28	0.34
216972_at	6677	SPAM1	L13779	2.62	9.30	15.14		2.62	17.41	5.88	0.34
208610_s_at	23524	SRRM2	AI655799	1427.12	1168.86	1364.26		1427.12	2409.21	814.03	0.34
208417_at	2251	FGF6	NM_020996	36.94	54.61	51.29		36.94	84.36	28.67	0.34
220326_s_at	55701	FLJ103	NM_0180	429.44	555.41	333.11		429.44	736.94	250.54	0.34

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		57	71								
212524_x_at	3014	H2AFX	AA760862	23.77	11.49	21.80		23.77	36.95	12.56	0.34
219912_s_at			NM_005021	11.29	15.07	20.40		11.29	17.42	5.93	0.34
205507_at	22899	ARHG EF15	NM_014958	23.23	26.16	14.73		23.23	36.70	12.51	0.34
215951_at	23102	TBC1D 2B	AL137303	11.55	14.61	23.73		11.55	19.07	6.50	0.34
208377_s_at	778	CACN A1F	NM_005183	5.04	4.45	5.17		5.04	10.57	3.61	0.34
222183_x_at	22938	SNW1	AL390153	82.73	103.80	73.58		82.73	236.25	80.60	0.34
215198_s_at	800	CALD1	AU147402	18.54	4.85	9.83		18.54	30.40	10.38	0.34
204515_at	3283	HSD3B 1	NM_000862	4.44	11.33	13.05		4.44	17.76	6.08	0.34
210357_s_at	54498	SMOX	BC000669	66.63	86.93	75.62		66.63	524.99	179.82	0.34
206897_at	8712	PAGE1	NM_003785	8.41	40.30	32.65		8.41	34.41	11.79	0.34
216792_at			AK026867	18.65	33.57	31.05		18.65	49.35	16.93	0.34
214329_x_at	8743	TNFSF 10	AW474434	151.51	178.28	68.69		151.51	433.65	148.93	0.34
60794_f_at	400721 /	LOC400721 /// LOC730051	AI400621	356.46	239.02	331.46		356.46	623.85	214.26	0.34
208465_at	2912	GRM2	NM_000839	7.79	16.53	14.58		7.79	14.96	5.14	0.34
212732_at	55384	MEG3	AI950273	15.23	25.15	28.80		15.23	31.46	10.81	0.34
208155_x_at	2543 ///	GAGE1 /// GAGE4 /// GAGE5 ///	NM_001476	9.84	8.04	30.01		9.84	49.98	17.22	0.34
210483_at	254896	MGC31 957	BC005043	19.25	9.94	14.77		19.25	49.42	17.04	0.34
207181_s_at	840	CASP7	NM_001227	199.41	273.14	181.19		199.41	439.34	151.80	0.35

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
217195_at			L42230	17.67	25.91	25.78		17.67	32.57	11.26	0.35
215103_at	1562	CYP2C18	AW192911	9.33	3.30	3.14		9.33	19.68	6.81	0.35
222161_at	10003	NAALAD2	AJ012370	1.77	1.26	1.96		1.77	15.60	5.41	0.35
215674_at	85373	KIAA1659	AB051446	8.80	12.26	16.16		8.80	15.42	5.35	0.35
216550_x_at	23253	ANKRD12	X80821	196.14	195.58	256.91		196.14	371.92	129.14	0.35
221387_at	64106	NPF1R1	NM_022146	27.32	30.67	40.07		27.32	60.87	21.14	0.35
218963_s_at	25984	KRT23	NM_015515	5.73	2.59	5.20		5.73	19.36	6.75	0.35
215058_at	160518	MGC24039	AU144041	33.68	35.36	15.58		33.68	71.97	25.15	0.35
214495_at	10369	CACNG2	NM_006078	4.65	4.70	3.04		4.65	14.24	4.98	0.35
216285_at	8220	DGCR14	AL137713	3.98	10.95	17.29		3.98	12.68	4.44	0.35
201893_x_at	1634	DCN	AF138300	19.80	13.96	30.66		19.80	89.35	31.29	0.35
213710_s_at			AL523275	348.81	270.83	187.51		348.81	637.83	223.75	0.35
209587_at	5307	PITX1	U70370	10.52	3.90	5.44		10.52	18.31	6.43	0.35
216910_at	7512	XP2NP2	AF195953	17.00	4.10	3.52		17.00	27.17	9.55	0.35
202023_at	1942	EFNA1	NM_004428	4.86	3.99	14.49		4.86	19.13	6.72	0.35
214316_x_at	811	CALR	AI378706	199.68	206.15	199.34		199.68	370.83	130.51	0.35
216834_at	5996	RGS1	S59049	7.14	9.99	3.55		7.14	93.55	32.97	0.35
217303_s_at	155	ADRB3	X70812	3.75	6.15	3.42		3.75	10.34	3.65	0.35
206986_at	728985 /	LOC728985 /// LOC732125	AB007422	16.61	15.65	18.93		16.61	34.67	12.25	0.35
208327_at	1553	CYP2A13	NM_000766	6.81	7.84	8.79		6.81	14.40	5.09	0.35
213002_at	4082	MARC	AA77059	370.19	489.58	1055.64		370.19	2017.85	714.48	0.35

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		KS	6								
215282_at	25847	ANAPC13	BE677493	5.91	5.95	6.73		5.91	13.08	4.63	0.35
217006_x_at			U52428	10.10	8.02	10.17		10.10	17.38	6.16	0.35
210718_s_at	51326	ARL17P1	AF119889	14.94	24.37	24.62		14.94	28.28	10.03	0.35
205665_at	10867	TSPAN9	NM_006675	10.18	13.77	28.16		10.18	22.39	7.95	0.36
220017_x_at	1559	CYP2C9	NM_000771	7.86	8.50	5.59		7.86	28.00	9.96	0.36
206555_s_at	55623	THUMPD1	NM_017736	940.98	866.21	958.89		940.98	1978.37	703.71	0.36
201890_at	6241	RRM2	BE966236	3071.14	3710.39	2785.24		3071.14	8099.15	2881.88	0.36
221968_s_at	51333	ZNF771	AW014373	4.06	8.94	3.05		4.06	14.87	5.29	0.36
206794_at	2066	ERBB4	NM_005235	9.87	16.07	24.06		9.87	22.16	7.92	0.36
217258_x_at	3712	IVD	AF043583	4.47	5.58	3.34		4.47	15.85	5.67	0.36
205523_at	1404	HAPLN1	U43328	5.27	3.68	3.97		5.27	16.08	5.75	0.36
205179_s_at	101	ADAM8	AI814527	9.57	9.98	11.66		9.57	25.65	9.19	0.36
220422_at	50613	UBQLN3	NM_017481	4.26	5.90	8.50		4.26	13.85	4.96	0.36
222237_s_at	7771	ZNF228	AC084239	10.39	5.86	1.98		10.39	15.89	5.70	0.36
213904_at			AL390170	6.41	7.16	2.18		6.41	29.24	10.49	0.36
221334_s_at	50943	FOXP3	NM_014009	13.69	17.98	14.22		13.69	42.24	15.24	0.36
204511_at	9855	FARP2	NM_014808	19.61	22.92	43.63		19.61	40.91	14.76	0.36
220563_s_at	50944	SHANK1	NM_016148	5.28	7.48	22.93		5.28	17.38	6.28	0.36
212924_s_at	25804	LSM4	N37057	19.72	22.11	16.08		19.72	40.62	14.72	0.36
220318_at	55040	EPN3	NM_017957	3.63	4.45	22.15		3.63	10.33	3.75	0.36

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
214676_x_at	57876	MUC3B	AF113616	5.04	9.67	20.68		5.04	21.70	7.88	0.36
201205_at			AF006751	74.84	86.79	59.19		74.84	114.24	41.55	0.36
204863_s_at	3572 ///	IL6ST /// MAGEA4	BE856546	76.81	107.86	161.33		76.81	126.00	45.85	0.36
202743_at	8503	PIK3R3	BE622627	180.26	182.78	177.64		180.26	303.90	110.66	0.36
208475_at	55691	FRMD4A	NM_018027	10.54	8.48	22.45		10.54	40.18	14.64	0.36
211010_s_at	259197	NCR3	AF031138	5.40	3.95	3.98		5.40	10.75	3.92	0.37
205378_s_at	43	ACHE	NM_015831	13.73	3.61	7.30		13.73	26.60	9.73	0.37
204636_at	1308	COL17A1	NM_000494	4.91	4.80	5.16		4.91	10.80	3.95	0.37
211813_x_at	1634	DCN	AF138303	4.70	9.69	2.65		4.70	22.83	8.38	0.37
203443_at	256364	EML3	AB012922	3.94	6.30	8.37		3.94	14.74	5.42	0.37
219692_at	79412	KREMEN2	NM_024507	11.95	19.09	29.50		11.95	86.90	31.96	0.37
213048_s_at	6418	SET	W26593	9208.00	6033.37	8658.77		9208.00	15146.32	5612.76	0.37
209297_at	6453	ITSN1	AF114488	86.55	18.49	30.93		86.55	168.69	62.52	0.37
217681_at	647836 /	WNT7B /// LOC647836 /// LOC649	BE736994	7.96	4.86	19.28		7.96	29.00	10.77	0.37
209869_at	150	ADRA2A	AF284095	11.63	3.30	30.99		11.63	27.61	10.28	0.37
211867_s_at	56139	PCDH A10	AF152475	4.45	8.98	38.48		4.45	14.66	5.47	0.37
218829_s_at	55636	CHD7	AI475906	326.71	342.47	271.31		326.71	836.14	313.27	0.37
201372_s_at	8452	CUL3	AU145232	26.77	44.53	44.71		26.77	49.16	18.50	0.38
220411_x_at	79883	PODNL	NM_0248	49.87	66.89	76.29		49.87	84.49	31.84	0.38

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		1	25								
217061_s_at	2115	ETV1	AC004857	6.46	9.05	7.30		6.46	21.22	8.00	0.38
221383_at	10316	NMUR1	NM_006056	6.97	7.96	7.68		6.97	13.07	4.94	0.38
211726_s_at	2327	FMO2	BC005894	25.42	16.53	27.82		25.42	44.26	16.87	0.38
213928_s_at	3267	HRB	AI742626	32.74	16.92	30.17		32.74	71.28	27.23	0.38
209613_s_at	125	ADH1B	M21692	6.29	1.79	2.03		6.29	12.06	4.62	0.38
207244_x_at	1548	CYP2A6	NM_000762	14.24	34.95	94.24		14.24	56.36	21.59	0.38
205814_at	2913	GRM3	NM_000840	6.86	6.00	11.54		6.86	19.30	7.42	0.38
207015_s_at	8854	ALDH1A2	AB015228	4.60	3.38	6.32		4.60	31.35	12.06	0.38
208410_x_at	265	AMELX	NM_001142	8.39	2.14	7.54		8.39	19.05	7.33	0.38
209773_s_at	6241	RRM2	BC001886	1867.24	2216.54	1532.67		1867.24	3367.85	1299.07	0.39
209633_at	5523	PPP2R3A	AL389975	131.13	294.89	253.58		131.13	764.33	294.90	0.39
203535_at	6280	S100A9	NM_002965	1263.49	1163.30	1045.22		1263.49	3171.00	1225.31	0.39
207610_s_at	30817	EMR2	NM_013447	94.47	125.29	59.34		94.47	249.34	96.83	0.39
214052_x_at	23215	BAT2D1	AW238632	149.09	158.40	262.06		149.09	382.59	148.64	0.39
207931_s_at	5208	PFKFB2	NM_006212	12.56	50.71	56.20		12.56	58.13	22.64	0.39
205576_at	3053	SERPIN1	NM_000185	9.86	5.57	4.10		9.86	43.03	16.80	0.39
215151_at	55619	DOCK10	AB014594	24.13	71.37	55.78		24.13	57.01	22.28	0.39
205180_s_at	101	ADAM8	NM_001109	16.30	61.13	50.65		16.30	99.62	38.95	0.39
220246_at	57118	CAMK1D	NM_020397	9.06	24.85	40.97		9.06	30.15	11.81	0.39
215725_at	25786	DGCR11	L77561	15.18	71.39	78.99		15.18	75.80	29.69	0.39

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
213171_s_at	10893	MMP24	AL121753	6.12	7.71	4.79		6.12	16.87	6.61	0.39
220729_at			NM_014092	31.59	11.78	32.52		31.59	66.41	26.05	0.39
217439_at			AL122122	2.70	13.68	22.54		2.70	23.61	9.30	0.39
220803_at	57559	STAMBPL1	NM_017597	3.00	3.98	5.83		3.00	16.53	6.51	0.39
221018_s_at	56165	TDRD1	NM_031278	2.90	6.63	11.57		2.90	13.84	5.46	0.39
203407_at	5493	PPL	NM_002705	2.92	5.10	7.59		2.92	11.66	4.60	0.39
205099_s_at	1230	CCR1	AI421071	804.75	1012.48	541.74		804.75	1440.10	570.64	0.40
207775_at	79150	MGC4859	NM_024304	4.36	9.06	8.16		4.36	10.46	4.15	0.40
211428_at	5265	SERPINA1	AF119873	4.03	3.20	5.74		4.03	16.60	6.58	0.40
203058_s_at	9060	PAPSS2	AW299958	79.27	90.71	68.55		79.27	375.47	149.15	0.40
60084_at	1540	CYLD	AI453099	12.53	23.80	18.53		12.53	35.76	14.21	0.40
209632_at	5523	PPP2R3A	AI760130	75.46	154.21	142.61		75.46	400.92	159.37	0.40
215552_s_at	2099	ESR1	AI073549	4.14	2.41	15.34		4.14	10.02	3.98	0.40
205034_at	9134	CCNE2	NM_004702	1116.62	1437.07	698.33		1116.62	2004.21	797.88	0.40
203687_at	6376	CX3CL1	NM_002996	10.84	8.12	4.80		10.84	22.94	9.18	0.40
206430_at	1044	CDX1	NM_001804	12.44	32.40	31.28		12.44	31.23	12.51	0.40
210575_at	10726	NUDC	AF241788	7.05	7.31	5.79		7.05	20.65	8.30	0.40
213808_at			BE674466	1.09	4.72	3.15		1.09	20.31	8.18	0.40
210550_s_at	5923	RASGRF1	L26584	94.20	111.73	56.90		94.20	143.98	58.08	0.40
210026_s_at	29775	CARD10	AW205153	21.18	30.96	17.66		21.18	118.17	47.70	0.40
205098_at	1230	CCR1	AI421071	1280.61	1340.44	761.52		1280.61	2817.21	1137.51	0.40

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
206297_at	11330	CTRC	NM_007272	51.41	60.91	49.80		51.41	80.42	32.50	0.40
202436_s_at	1545	CYP1B1	AU144855	1273.78	1404.79	570.44		1273.78	3487.26	1411.86	0.40
207985_at	26237	ENO1B	NM_014355	10.30	9.33	3.42		10.30	17.10	6.93	0.41
212883_at	10452	TOMM40	AI358867	4.36	4.49	12.30		4.36	22.58	9.15	0.41
212616_at	80205	CHD9	BF668950	1390.38	1491.23	1262.55		1390.38	2361.22	956.76	0.41
211980_at	1282	COL4A1	AI922605	475.72	286.61	365.89		475.72	882.69	357.69	0.41
201348_at	2878	GPX3	NM_002084	20.47	20.58	20.86		20.47	41.39	16.77	0.41
208789_at	284119	PTRF	BC004295	19.22	10.73	12.27		19.22	129.45	52.49	0.41
217922_at			BE543064	741.45	838.83	535.61		741.45	1578.20	640.41	0.41
216439_at	10188	TNK2	AK024904	17.26	8.49	7.98		17.26	31.64	12.87	0.41
221796_at	4915	NTRK2	AA707199	3.64	6.73	5.77		3.64	12.98	5.28	0.41
222068_s_at	123872	LRRCS0	AW663632	4.83	25.80	27.87		4.83	249.46	101.58	0.41
221994_at	10611	PDLIM5	AA196325	16.49	36.08	32.58		16.49	33.85	13.79	0.41
204115_at	2791	GNG11	NM_004126	32.07	14.31	5.25		32.07	56.54	23.06	0.41
205302_at	3484	IGFBP1	NM_000596	5.25	6.77	20.29		5.25	23.84	9.73	0.41
216408_at	81697	OR2B2	AJ302584	6.46	1.47	3.61		6.46	14.37	5.87	0.41
214164_x_at	771	CA12	BF752277	42.49	49.48	12.32		42.49	108.50	44.31	0.41
208123_at	9312	KCNB2	AF338730	5.82	8.54	13.80		5.82	24.41	9.97	0.41
204762_s_at	2775	GNAO1	NM_020988	19.28	28.64	13.84		19.28	33.05	13.52	0.41
214345_at			BF058643	24.69	9.90	13.55		24.69	38.84	15.94	0.41

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
210343_s_at	9356	SLC22A6	AF124373	9.97	11.76	7.50		9.97	15.70	6.45	0.41
207519_at	6532	SLC6A4	NM_001045	10.05	6.24	13.68		10.05	28.59	11.75	0.41
221030_s_at	83478	ARHGAP24	NM_031305	17.03	21.38	19.82		17.03	89.13	36.67	0.41
216494_at	645468 /	LOC645468 /// LOC651107	AL023775	13.30	7.00	6.72		13.30	21.64	8.92	0.41
205184_at	2786	GNG4	NM_004485	116.95	138.87	77.98		116.95	529.58	218.43	0.41
213582_at	23250	ATP11A	BF439472	62.30	89.60	72.02		62.30	138.39	57.12	0.41
201130_s_at	999	CDH1	NM_004360	1.20	4.97	4.07		1.20	15.70	6.48	0.41
218044_x_at	5763	PTMS	M24398	18.05	21.39	33.02		18.05	30.50	12.59	0.41
205625_s_at	793	CALB1	AW014927	0.92	2.19	3.47		0.92	12.19	5.03	0.41
202437_s_at	1545	CYP1B1	NM_000104	625.40	780.26	321.65		625.40	2128.34	880.49	0.41
205765_at	1577	CYP3A5	NM_000777	2.51	6.23	3.78		2.51	21.03	8.72	0.41
216842_x_at	159163 /	RBMY1A1 /// RBMY1F /// RBMY1B	U38460	29.69	13.64	23.56		29.69	53.36	22.13	0.41
211002_s_at	23650	TRIM29	AF230389	4.84	8.94	3.99		4.84	15.29	6.35	0.42
219520_s_at	55841	WWC3	NM_018458	207.01	252.15	208.72		207.01	428.87	178.48	0.42
207222_at	8399	PLA2G10	NM_003561	14.38	47.25	38.13		14.38	26.77	11.14	0.42
219636_s_at	80210	ARMC9	NM_025139	5.75	19.00	31.84		5.75	49.45	20.59	0.42
203917_at	1525	CXADR	NM_001338	39.30	41.28	30.52		39.30	77.08	32.10	0.42
204491_at	5144	PDE4D	R40917	133.25	174.31	211.33		133.25	452.65	188.74	0.42
209648_x_at	9655	SOCS5	AL13689	174.11	197.15	205.62		174.11	308.15	128.78	0.42

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			6								
220378_at	6954	TCP11	NM_018679	11.33	5.72	2.44		11.33	21.25	8.91	0.42
203921_at	9435	CHST2	NM_004267	79.60	498.72	401.55		79.60	1003.43	420.69	0.42
214660_at	53918	PELO	X68742	16.48	4.64	7.45		16.48	30.51	12.80	0.42
215894_at	5729	PTGDR	AI460323	7.42	5.46	10.82		7.42	11.56	4.85	0.42
205528_s_at	862	RUNX1 T1	X79990	3.53	4.30	20.47		3.53	91.06	38.29	0.42
210610_at	634	CEACAM1	M69176	13.88	20.35	15.83		13.88	53.82	22.65	0.42
200618_at	3927	LASP1	NM_006148	2009.27	2011.50	1515.01		2009.27	3899.85	1645.64	0.42
217244_at			AL021327	2.80	2.10	1.70		2.80	13.67	5.77	0.42
201417_at	6659	SOX4	AL136179	340.42	399.80	350.07		340.42	899.40	380.77	0.42
215321_at	154661	RPIB9	AI825798	32.51	9.19	55.07		32.51	64.21	27.20	0.42
207454_at	2899	GRIK3	NM_000831	3.38	4.62	8.93		3.38	10.83	4.59	0.42
206002_at	10149	GPR64	NM_005756	10.15	30.78	31.88		10.15	29.61	12.55	0.42
206151_x_at	23436	ELA3B	NM_007352	7.00	7.53	5.59		7.00	12.58	5.34	0.42
218856_at	27242	TNFRSF21	NM_016629	652.00	768.42	677.72		652.00	2467.23	1048.09	0.42
213443_at	8717	TRADD	N36774	3.48	8.92	6.89		3.48	15.94	6.78	0.43
211675_s_at	29969	MDFIC	AF054589	1419.27	1260.63	1322.18		1419.27	7904.07	3364.37	0.43
208484_at	3024	HIST1H1A	NM_005325	3.38	3.93	1.77		3.38	10.48	4.47	0.43
203354_s_at	23362	PSD3	NM_015310	112.90	188.34	253.36		112.90	707.21	302.01	0.43
220208_at	11093	ADAMTS13	NM_017587	33.95	41.07	57.04		33.95	62.92	26.91	0.43
203063_at	9647	PPM1F	NM_014634	383.51	489.93	381.53		383.51	621.16	266.36	0.43

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
204603_at	9156	EXO1	NM_003686	625.28	614.87	484.97		625.28	1128.18	484.19	0.43
215252_at	7266	DNAJC7	AW814026	330.12	346.32	484.63		330.12	627.49	269.31	0.43
207311_at	8447	DOC2B	NM_003585	8.97	16.99	34.64		8.97	35.37	15.20	0.43
206137_at	9699	RIMS2	NM_014677	23.93	45.32	86.23		23.93	38.87	16.71	0.43
215822_x_at	4661	MYT1	M96980	8.95	16.17	17.17		8.95	56.78	24.44	0.43
214420_s_at	1559	CYP2C9	AV657878	7.92	5.49	10.96		7.92	13.54	5.83	0.43
205286_at	7022	TFAP2C	U85658	38.85	28.24	24.65		38.85	113.24	48.79	0.43
209540_at	3479	IGF1	M29644	11.09	6.04	7.71		11.09	27.62	11.91	0.43
219855_at	55190	NUDT11	NM_018159	5.61	8.07	5.64		5.61	21.56	9.30	0.43
212927_at	23137	SMC5	AW183677	221.82	271.10	221.26		221.82	445.92	192.87	0.43
215675_at	7008	TEF	AB051442	4.94	5.16	7.99		4.94	26.37	11.43	0.43
206336_at	6372	CXCL6	NM_002993	7.54	2.50	26.49		7.54	1643.05	714.11	0.43
212013_at	7837	PXDN	D86983	9.40	6.95	14.24		9.40	14.55	6.33	0.43
206765_at	3759	KCNJ2	AF153820	127.19	124.00	196.39		127.19	531.69	231.32	0.44
203477_at	1306	COL15A1	NM_001855	80.00	59.46	62.52		80.00	138.69	60.37	0.44
210596_at			AF130104	454.39	374.73	527.00		454.39	755.48	329.13	0.44
205966_at	6884	TAF13	NM_005645	20.01	12.80	22.70		20.01	45.51	19.84	0.44
210303_at	10586	MAB21L2	AF262032	5.40	3.92	10.70		5.40	19.36	8.46	0.44
35776_at	6453	ITSN1	AF064243	117.00	129.34	114.72		117.00	190.05	83.12	0.44
214386_at	3166	HMX1	AI939402	4.40	10.88	17.53		4.40	11.89	5.21	0.44
213277_at	677	ZFP36L1	AI344045	7.92	5.59	12.63		7.92	18.80	8.25	0.44

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
215538_at	730062 /	LOC730062 /// LOC731972	BF057493	10.95	11.98	6.18		10.95	26.97	11.85	0.44
216891_at			U00956	4.77	5.53	11.17		4.77	22.36	9.83	0.44
215277_at	5097	PCDH1	AA481656	9.69	3.38	6.78		9.69	41.92	18.44	0.44
207784_at	414	ARSD	NM_009589	4.60	6.05	36.57		4.60	14.49	6.38	0.44
202688_at	8743	TNFSF10	NM_003810	412.50	502.19	210.74		412.50	775.60	341.63	0.44
210163_at	6373	CXCL11	AF030514	11.28	89.98	73.90		11.28	74.88	32.99	0.44
204146_at	10635	RAD51AP1	BE966146	508.40	392.56	578.83		508.40	890.24	392.25	0.44
205187_at	4090	SMAD5	AF010601	95.62	69.51	93.56		95.62	171.06	75.40	0.44
219896_at	50632	DRD1IP	NM_015722	4.03	6.84	12.02		4.03	11.75	5.18	0.44
215698_at	5927	JARID1A	AF007135	98.34	80.27	93.60		98.34	165.22	72.99	0.44
220362_at	170679	PSORS1C1	NM_014068	13.00	10.64	25.72		13.00	19.56	8.66	0.44
205505_at	2650	GCNT1	NM_001490	232.59	229.26	217.79		232.59	426.47	188.95	0.44
206660_at	3543	IGLL1	NM_020070	8.10	4.03	3.89		8.10	31.18	13.82	0.44
205931_s_at	9586	CREB5	NM_004904	16.50	5.89	5.71		16.50	37.16	16.47	0.44
202285_s_at	4070	TACSTD2	NM_002353	8.02	17.65	18.13		8.02	39.00	17.31	0.44
212077_at	800	CALD1	AL583520	9.65	19.45	16.60		9.65	19.71	8.76	0.44
208701_at	334	APLP2	BC000373	210.25	207.51	224.80		210.25	356.38	158.69	0.45
218995_s_at	1906	EDN1	J05008	5.90	10.77	10.13		5.90	14.55	6.49	0.45
218399_s_at	55038	CDCA4	NM_017955	909.74	1088.69	908.84		909.74	1836.61	819.95	0.45
212477_at	23527	CENTB2	D26069	38.01	38.65	49.77		38.01	64.81	28.94	0.45

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
221816_s_at	158852 /	PHF11 /// RP13-36C9.1 ///RP13	BF05547 4	760.35	1093.60	863.09		760.35	1141.83	510.50	0.45
207501_s_at	2257	FGF12	NM_0041 13	1.88	7.00	6.63		1.88	14.42	6.45	0.45
213866_at	201191	SAMD 14	AL13445 3	21.47	68.44	60.23		21.47	78.33	35.11	0.45
221960_s_at	5862	RAB2	AI189609	132.04	104.98	154.40		132.04	213.39	95.87	0.45
215547_at	9819	TSC2 D2	AF20129 1	13.78	37.76	39.86		13.78	33.46	15.04	0.45
215610_at	728263 /	LOC72 8263 /// LOC73 1183	AK02203 8	52.22	68.45	28.01		52.22	98.87	44.62	0.45
208388_at	10002	NR2E3	NM_0142 49	9.26	7.12	7.75		9.26	27.39	12.36	0.45
206447_at	63036	ELA2A	NM_0019 71	2.69	6.57	1.64		2.69	16.10	7.27	0.45
216856_s_at			AF26478 7	35.94	19.42	61.68		35.94	107.46	48.57	0.45
217163_at	2099	ESR1	X63118	5.38	2.41	12.26		5.38	10.05	4.54	0.45
203745_at	3052	HCCS	AI801013	356.54	380.83	345.60		356.54	814.86	368.71	0.45
206020_at	9306	SOCS6	NM_0163 87	115.84	116.66	104.12		115.84	202.24	91.57	0.45
221912_s_at	79140	CCDC2 8B	AL04979 5	31.72	36.80	62.87		31.72	56.43	25.55	0.45
222330_at	5140	PDE3B	AW97499 5	8.56	64.82	63.97		8.56	59.50	26.95	0.45
214704_at	22980	TCF25	AK02467 9	9.35	9.88	11.30		9.35	14.99	6.80	0.45
215204_at	26054	SENP6	AU14729 5	280.16	518.45	510.30		280.16	473.39	214.66	0.45
217183_at	3949	LDLR	S70123	8.35	9.65	12.06		8.35	23.01	10.44	0.45
217575_s_at	6655	SOS2	BF69295 8	2.55	4.81	5.58		2.55	15.29	6.95	0.45
219806_s_at	56935	C11orf7 5	NM_0201 79	813.80	868.61	1189.71		813.80	1426.85	648.44	0.45
203425_s_at	3488	IGFBP5	M65062	27.36	27.39	47.86		27.36	69.42	31.57	0.45

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
213832_at			AA530995	23.92	4.85	1.79		23.92	43.91	20.00	0.46
209121_x_at	7026	NR2F2	M64497	64.03	69.03	48.15		64.03	145.52	66.30	0.46
213087_s_at	1936	EEF1D	BF690020	79.37	48.97	70.10		79.37	132.63	60.58	0.46
208942_s_at	7095	TLOC1	U93239	2339.60	2197.18	2676.33		2339.60	5369.52	2454.47	0.46
221559_s_at	79003	MIS12	BC000229	287.87	302.62	325.60		287.87	617.00	282.21	0.46
210906_x_at	361	AQP4	U34846	3.92	2.75	5.10		3.92	10.50	4.81	0.46
206919_at	2005	ELK4	NM_021795	4.63	25.69	32.95		4.63	38.85	17.81	0.46
202687_s_at	8743	TNFSF10	NM_003810	216.68	253.09	115.06		216.68	338.68	155.25	0.46
213437_at	22902	RUFY3	AA861784	17.65	24.37	38.78		17.65	56.41	25.93	0.46
213951_s_at	29893	PSMC3IP	BE964655	249.95	319.91	280.94		249.95	559.59	257.29	0.46
222070_at	373863	DND1	AW090043	160.67	169.26	127.16		160.67	245.61	112.96	0.46
213092_x_at	23234	DNAJC9	AW241779	382.02	292.84	320.19		382.02	636.50	292.89	0.46
220627_at	10047	CST8	NM_005492	12.36	12.60	5.89		12.36	19.00	8.75	0.46
219973_at	79642	ARSJ	NM_024590	1.61	7.93	18.04		1.61	18.20	8.39	0.46
202792_s_at	9701	SAPS2	NM_014678	146.47	217.94	90.70		146.47	225.64	104.08	0.46
220859_at			NM_014136	5.44	9.37	2.72		5.44	23.20	10.71	0.46
203544_s_at	8027	STAM	NM_003473	218.80	200.55	256.16		218.80	419.30	193.54	0.46
206813_at	1489	CTF1	NM_001330	5.75	7.96	9.63		5.75	10.60	4.90	0.46
219229_at	28232	SLCO3A1	NM_013272	344.12	546.43	561.62		344.12	782.05	361.57	0.46
209501_at	1039	CDR2	AL582414	406.72	480.56	528.64		406.72	797.87	369.33	0.46
212620_at	23060	ZNF60	AW16597	70.02	92.79	93.35		70.02	142.24	65.85	0.46

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		9	9								
211441_x_at	64816	CYP3A43	AF280113	6.46	8.14	0.73		6.46	13.15	6.09	0.46
222304_x_at	26628	OR7E47P	AW514038	13.29	9.56	11.52		13.29	27.80	12.88	0.46
219609_at	79446	WDR25	NM_024515	19.82	11.57	12.34		19.82	36.03	16.70	0.46
221516_s_at	54471	SMCR7L	BC002587	1051.50	967.40	934.79		1051.50	1937.54	899.75	0.46
202892_at	8697	CDC23	NM_004661	764.29	768.29	640.18		764.29	1204.26	559.41	0.46
213523_at	898	CCNE1	AI671049	493.85	602.45	399.25		493.85	1201.18	558.12	0.46
220420_at	79748	LMAN1L	NM_021819	9.01	6.96	4.92		9.01	17.17	7.98	0.46
215871_at	5322	PLA2G5	AL158172	2.20	4.35	9.63		2.20	23.94	11.14	0.47
218623_at	51617	HMP19	NM_015980	15.56	3.63	3.13		15.56	24.20	11.27	0.47
214677_x_at	28786 //	IGL@ /// IGLV4-3 /// IGLV3-25	X57812	13.39	17.75	8.11		13.39	20.51	9.55	0.47
211652_s_at	3929	LBP	M35533	11.66	24.39	20.69		11.66	53.50	24.95	0.47
206545_at	940	CD28	NM_006139	1.37	11.63	9.81		1.37	17.41	8.12	0.47
204068_at	6788	STK3	NM_006281	609.39	661.92	1145.95		609.39	1394.06	650.54	0.47
207719_x_at	9859	CEP170	NM_014812	971.09	936.59	1042.16		971.09	1480.30	691.59	0.47
220013_at	79852	ABHD9	NM_024794	5.32	8.11	22.55		5.32	17.75	8.29	0.47
206578_at	1482	NKX2-5	NM_004387	10.81	7.42	9.58		10.81	23.51	10.99	0.47
212759_s_at	6934	TCF7L2	AI703074	15.90	11.57	15.01		15.90	42.71	20.02	0.47
204753_s_at	3131	HLF	AI810712	5.84	2.18	14.68		5.84	10.81	5.08	0.47
213913_s_at	23329	KIAA0984	AW134976	23.11	17.80	19.53		23.11	38.51	18.10	0.47

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
216846_at	3535	IGL@	AF234254	6.09	2.99	8.14		6.09	10.78	5.08	0.47
213219_at	108	ADCY2	AB028983	6.52	11.00	9.57		6.52	13.02	6.13	0.47
201330_at	5917	RARS	NM_002887	1949.10	1463.27	1700.46		1949.10	3004.78	1415.94	0.47
203753_at	6925	TCF4	NM_003199	145.94	114.22	158.65		145.94	258.80	121.99	0.47
207840_at	11126	CD160	NM_007053	19.05	12.04	10.09		19.05	38.49	18.15	0.47
206838_at	9095	TBX19	NM_005149	86.99	123.34	89.60		86.99	137.86	65.08	0.47
206933_s_at	9563	H6PD	NM_004285	4.94	7.38	8.02		4.94	13.62	6.45	0.47
208615_s_at	8073	PTP4A2	AF208850	1057.30	1306.62	1139.73		1057.30	2562.19	1217.48	0.48
203414_at	23531	MMD	NM_012329	604.70	836.25	733.27		604.70	1332.71	633.42	0.48
216286_at	9331	B4GALT6	AV760769	28.57	34.12	44.78		28.57	42.95	20.43	0.48
214257_s_at	9554	SEC22B	AA890010	2185.00	1534.51	2935.81		2185.00	4901.57	2331.41	0.48
205923_at	5649	RELN	NM_005045	3.60	16.30	38.60		3.60	21.45	10.25	0.48
217168_s_at	9709	HERPUD1	AF217990	1669.26	2386.03	3476.03		1669.26	6156.64	2948.91	0.48
218249_at	64429	ZDHC6	NM_022494	580.61	726.38	550.70		580.61	1058.00	506.88	0.48
205159_at	1439	CSF2RB	AV756141	673.88	846.20	718.47		673.88	1162.18	558.04	0.48
211984_at	801	CALM1	AI653730	1080.10	1123.86	811.09		1080.10	2044.09	981.64	0.48
209250_at	8560	DEGS1	BC000961	2245.39	3471.41	3212.51		2245.39	9207.58	4424.00	0.48
202256_at	10421	CD2BP2	BF793888	178.58	267.73	123.49		178.58	312.71	150.39	0.48
200685_at	9295	SFRS11	AU146237	236.45	158.40	186.72		236.45	371.71	178.88	0.48
37547_at	27241	PTHB1	U85995	3.19	5.31	5.62		3.19	10.37	4.99	0.48

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
210057_at	23049	SMG1	U32581	95.85	141.25	119.54		95.85	224.41	108.10	0.48
213956_at	9857	CEP350	AW299294	593.86	738.43	786.34		593.86	905.12	436.09	0.48
202751_at	24144	TFIP11	NM_012143	46.26	54.31	49.87		46.26	103.54	49.90	0.48
214481_at	8336	HIST1H2AM	NM_003514	15.80	4.47	33.89		15.80	28.52	13.75	0.48
204729_s_at	6804	STX1A	NM_004603	33.67	66.32	84.46		33.67	103.82	50.06	0.48
206708_at	3344	FOXN2	NM_002158	75.68	70.40	90.70		75.68	168.35	81.27	0.48
216117_at	27085	MTBP	AK025114	10.22	38.67	36.82		10.22	42.34	20.50	0.48
217012_at			AL080233	1.50	6.99	15.85		1.50	18.26	8.86	0.49
208176_at	26584	DUX1	NM_012146	22.57	24.42	5.20		22.57	35.70	17.33	0.49
201451_x_at	6009	RHEB	D78132	10.51	14.12	30.45		10.51	75.64	36.72	0.49
221278_at	3218	HOXB8	NM_024016	4.08	2.57	15.70		4.08	17.14	8.34	0.49
202599_s_at	8204	NRIP1	NM_003489	645.40	663.59	609.51		645.40	1479.20	719.89	0.49
209043_at	9061	PAPSS1	AF033026	467.40	584.83	371.60		467.40	830.78	405.25	0.49
216596_at	26082	DKFZP434L187	AL117445	9.06	7.00	7.87		9.06	26.69	13.03	0.49
216557_x_at	2537 ///	IFI6 /// IGHA1 /// IGHG1 /// I	U92706	6.06	24.01	25.75		6.06	44.38	21.68	0.49
201899_s_at	7319	UBE2A	NM_003336	1836.90	1907.49	1727.04		1836.90	3167.95	1549.17	0.49
201213_at			AI090331	116.62	133.61	110.86		116.62	194.86	95.57	0.49
220510_at	57127	RHBG	NM_020407	11.17	8.74	9.79		11.17	16.85	8.27	0.49
217599_s_at	29969	MDFIC	BE910600	118.63	81.89	90.10		118.63	574.23	281.77	0.49
218962_s_at	64418	TMEM	NM_0224	643.50	629.20	654.83		643.50	1087.93	534.50	0.49

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		168	84								
205038_at	10320	IKZF1	BG540504	317.07	308.68	163.79		317.07	1541.16	757.29	0.49
207490_at	80086	TUBA4	NM_025019	48.59	62.15	32.35		48.59	76.47	37.58	0.49
217663_at			AW264320	23.76	36.95	47.22		23.76	55.26	27.17	0.49
209555_s_at	948	CD36	BE968792	273.65	331.19	282.13		273.65	423.74	208.36	0.49
216453_at	57336	ZNF287	AL359578	10.13	10.64	25.14		10.13	19.72	9.71	0.49
204695_at	993	CDC25A	AI343459	351.24	493.20	225.60		351.24	879.42	433.11	0.49
204789_at	752	FMNL1	NM_005892	468.33	458.86	410.11		468.33	886.29	437.39	0.49
216877_at	401014	DKFZp686O1327	U80770	25.52	55.39	53.03		25.52	66.72	32.93	0.49
221439_at	10741	RBBP9	NM_006606	6.43	7.52	8.89		6.43	12.53	6.19	0.49
205894_at	415	ARSE	NM_000047	17.55	11.97	7.02		17.55	35.06	17.32	0.49
211085_s_at	6789	STK4	Z25430	152.17	142.55	158.54		152.17	232.05	114.64	0.49
208086_s_at	1756	DMD	M92650	8.43	4.87	7.26		8.43	27.15	13.42	0.49
211646_at			L14453	2.65	1.09	0.45		2.65	16.03	7.95	0.50
206737_at	7481	WNT11	NM_004626	4.49	3.92	4.48		4.49	17.09	8.49	0.50
218324_s_at	65244	SPATS2	NM_023071	50.62	101.66	79.55		50.62	93.85	46.64	0.50
208110_x_at	81857	MED25	NM_030973	6.75	7.90	6.33		6.75	12.53	6.25	0.50
219790_s_at	4883	NPR3	NM_000908	7.82	11.53	3.49		7.82	17.26	8.61	0.50
215059_at	79625	C4orf31	AA053967	1.62	2.22	1.96		1.62	13.63	6.82	0.50
200914_x_at	3895	KTN1	NM_004986	1049.11	752.35	1272.78		1049.11	1823.45	912.58	0.50
212027_at	58517	RBM25	AI925305	860.97	770.64	725.45		860.97	1467.98	734.70	0.50

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
215685_s_at	1746	DLX2	BE792224	26.96	20.58	44.08		26.96	54.20	27.13	0.50
204461_x_at	5810	RAD1	NM_002853	782.00	679.22	754.59		782.00	1292.64	647.02	0.50
203487_s_at	25852	ARMC8	NM_015396	414.33	380.06	354.70		414.33	676.69	338.88	0.50
202976_s_at	22836	RHOB TB3	NM_014899	276.77	258.23	187.81		276.77	471.05	236.38	0.50
204235_s_at	51454	GULP1	AF200715	22.41	28.98	8.00		22.41	62.21	31.22	0.50
208502_s_at	5307	PITX1	NM_002653	34.58	27.12	28.72		34.58	72.79	36.57	0.50
213406_at	26118	WSB1	AA521269	66.97	43.60	68.43		66.97	103.27	51.89	0.50
204080_at	114034	TOE1	NM_025077	456.78	527.99	410.73		456.78	812.13	408.13	0.50
212766_s_at	81875	ISG20L2	AW294587	1031.22	1130.36	940.51		1031.22	2546.09	1281.83	0.50
221458_at	3355	HTR1F	NM_000866	14.83	9.25	15.93		14.83	28.25	14.24	0.50
217005_at	3949	LDLR	M28219	3.22	6.70	6.22		3.22	19.65	9.93	0.51
204268_at	6273	S100A2	NM_005978	46.22	20.03	31.12		46.22	70.24	35.50	0.51
210111_s_at	23008	KIAA0265	AF277175	773.86	707.52	768.96		773.86	1300.30	658.08	0.51
217643_x_at	440295	LOC440295	AA443771	37.82	45.53	46.48		37.82	57.83	29.31	0.51
220388_at	80307	FER1L4	NM_024777	9.67	10.23	8.71		9.67	23.53	11.94	0.51
205596_s_at	64750	SMURF2	AY014180	752.88	766.27	1137.30		752.88	2313.63	1174.48	0.51
207675_x_at	9048	ARTN	NM_003976	73.79	48.25	51.77		73.79	111.22	56.49	0.51
215474_at	286053	NSMC E2	AK022094	9.63	60.47	84.58		9.63	60.80	30.89	0.51
221177_at	117153	MIA2	NM_025043	3.56	3.87	18.59		3.56	21.10	10.73	0.51
221367_at	4342	MOS	NM_005372	17.57	13.01	26.89		17.57	27.29	13.88	0.51

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
217280_x_at	727729	LOC727729	AF061785	8.02	7.00	10.31		8.02	18.62	9.47	0.51
205386_s_at	4193	MDM2	NM_002392	50.74	45.02	48.74		50.74	113.69	57.97	0.51
218874_s_at	79969	C6orf134	NM_024909	27.90	17.85	33.20		27.90	55.88	28.50	0.51
216454_at	55621	TRMT1	AL390133	19.82	25.00	32.11		19.82	30.54	15.61	0.51
206805_at	10371	SEMA3A	NM_006080	20.97	15.88	24.74		20.97	86.67	44.30	0.51
221731_x_at	1462	CSPG2	BF218922	259.21	481.92	388.87		259.21	618.55	316.16	0.51
204256_at	79071	ELOVL6	NM_024090	8.47	2.53	8.35		8.47	15.05	7.70	0.51
209572_s_at	8726	EED	AF080227	1103.80	1447.37	1270.60		1103.80	2735.45	1399.15	0.51
210170_at	27295	PDLIM3	BC001017	6.07	1.30	6.38		6.07	13.08	6.69	0.51
212182_at	11163 //	NUDT4 /// NUDT4 P1	AB007956	36.36	47.89	35.39		36.36	55.54	28.45	0.51
203947_at	1479	CSTF3	NM_001326	1509.35	1518.13	884.81		1509.35	2596.15	1331.39	0.51
210929_s_at	197	AHSG	AF130057	8.10	7.87	16.73		8.10	27.44	14.08	0.51
220674_at	79978	FLJ22814	NM_024916	2.92	4.52	8.35		2.92	13.62	7.00	0.51
204688_at	8910	SGCE	NM_003919	19.25	29.06	27.11		19.25	30.48	15.67	0.51
205438_at	11099	PTPN21	NM_007039	3.20	5.14	2.34		3.20	36.57	18.80	0.51
203910_at	9411	ARHGAP29	NM_004815	11.30	21.65	25.04		11.30	18.86	9.72	0.52
204763_s_at	2775	GNAO1	NM_020988	5.44	15.02	23.25		5.44	10.86	5.60	0.52
218333_at	51009	DERL2	NM_016041	361.25	381.83	491.98		361.25	697.53	359.57	0.52
219823_at	79727	LIN28	NM_024674	9.11	12.82	37.37		9.11	19.35	9.98	0.52

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
220375_s_at			NM_024752	95.23	90.24	76.40		95.23	163.20	84.23	0.52
212696_s_at	6047	RNF4	BF968633	1606.31	1349.15	1241.86		1606.31	2520.53	1301.46	0.52
214857_at	79946	C10orf95	AL050035	58.45	78.22	47.86		58.45	179.88	93.26	0.52
215591_at	23314	SATB2	AK025127	281.19	495.35	379.61		281.19	543.96	282.09	0.52
211556_at	10982	MAPRE2	AB016823	3.61	1.65	1.96		3.61	17.01	8.82	0.52
214751_at	90333	ZNF468	BE541042	267.41	308.40	303.11		267.41	610.48	316.98	0.52
207290_at	5362	PLXNA2	NM_025179	3.00	2.04	5.63		3.00	21.53	11.19	0.52
202011_at	7082	TJP1	NM_003257	31.56	14.89	16.59		31.56	59.10	30.72	0.52
214237_x_at	5074	PAWR	AI760470	19.62	42.67	35.14		19.62	44.00	22.88	0.52
216319_at			AK022686	7.52	1.90	7.57		7.52	29.75	15.50	0.52
216110_x_at			AU147017	46.58	109.60	84.39		46.58	135.38	70.62	0.52
217604_at			AI086530	90.69	91.95	104.00		90.69	210.65	109.92	0.52
216469_at	727867	LOC727867	AL163202	1.33	5.73	11.38		1.33	25.81	13.48	0.52
207369_at			Z97632	12.09	24.32	26.20		12.09	25.45	13.29	0.52
213907_at	9521	EEF1E1	N32257	32.45	38.59	42.42		32.45	50.17	26.23	0.52
222042_x_at	399664	RKHD1	BF056534	11.91	8.76	12.25		11.91	23.85	12.47	0.52
208605_s_at	4914	NTRK1	NM_002529	3.05	6.12	1.55		3.05	74.43	38.94	0.52
214661_s_at	8602	C4orf9	R06783	831.88	560.56	779.27		831.88	1279.38	669.46	0.52
221038_at			NM_018610	29.15	46.72	39.31		29.15	64.99	34.09	0.52
205030_at	2173	FABP7	NM_001446	7.56	9.22	19.31		7.56	27.41	14.38	0.52
210673_x_at	7080	TITF1	D50740	12.40	10.73	8.65		12.40	19.09	10.02	0.52

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
209764_at			AL022312	24.66	24.31	17.34		24.66	41.41	21.79	0.53
204481_at	7862	BRPF1	NM_004634	624.18	645.33	571.52		624.18	995.56	524.54	0.53
204244_s_at	10926	DBF4	NM_006716	777.92	754.74	1146.76		777.92	1236.63	651.74	0.53
212804_s_at	26130	GAPVD1	AI797397	625.29	624.61	590.20		625.29	1050.10	553.71	0.53
215213_at	53371	NUP54	AU146949	10.37	28.70	26.00		10.37	26.43	13.94	0.53
207043_s_at	6536	SLC6A9	NM_006934	25.77	30.65	45.00		25.77	39.89	21.05	0.53
206087_x_at	3077	HFE	NM_000410	23.96	30.90	25.87		23.96	49.91	26.35	0.53
204885_s_at	10232	MSLN	NM_005823	5.85	4.68	9.92		5.85	15.39	8.13	0.53
208843_s_at	26003	GORASP2	BC001408	1166.36	913.23	1102.22		1166.36	2140.69	1130.79	0.53
213515_x_at	3047 ///	HBG1 /// HBG2	AI133353	7.55	17.08	17.43		7.55	14.75	7.81	0.53
219698_s_at	64863	METTL4	NM_022840	229.77	268.51	217.64		229.77	357.49	189.32	0.53
212646_at	23180	RFTN1	D42043	598.16	797.78	1154.46		598.16	2992.35	1590.21	0.53
201519_at	9868	TOMM70A	NM_014820	1139.68	1130.48	1445.11		1139.68	2462.65	1309.62	0.53
203185_at	9770	RASSF2	NM_014737	918.83	1236.44	624.67		918.83	1444.26	768.21	0.53
206083_at	575	BAI1	NM_001702	5.80	15.93	12.27		5.80	15.98	8.50	0.53
210050_at	7167	TPI1	M10036	37.52	52.62	69.45		37.52	60.98	32.47	0.53
212606_at	23001	WDFY3	AL536319	641.82	875.31	829.18		641.82	1007.42	536.39	0.53
201542_at	56681	SAR1A	AY008268	723.66	797.87	823.10		723.66	1172.98	625.20	0.53
216162_at	55206	SBNO1	AK024128	5.34	3.04	22.00		5.34	38.42	20.52	0.53
213351_s_at	23023	TMCC1	AB018322	165.36	179.59	174.97		165.36	319.85	171.06	0.53

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
213567_at			BF431965	551.09	504.28	556.12		551.09	1373.65	735.42	0.54
213409_s_at	6009	RHEB	BF593727	67.27	60.90	98.52		67.27	125.95	67.43	0.54
205217_at	1678	TIMM8A	NM_004085	126.84	90.15	96.93		126.84	194.50	104.30	0.54
219053_s_at	55048	VPS37C	NM_017966	1198.05	1276.55	1540.24		1198.05	2476.83	1329.01	0.54
213637_at			BE503392	438.11	436.35	477.85		438.11	937.19	503.07	0.54
218707_at	55311	ZNF444	NM_018337	91.95	95.72	117.76		91.95	179.84	96.70	0.54
204010_s_at	3845	KRAS	NM_004985	33.72	33.88	43.86		33.72	50.86	27.38	0.54
213165_at	9857	CEP350	AI041204	1539.30	1494.91	1673.92		1539.30	2332.14	1255.70	0.54
213560_at	4616	GADD45B	AV658684	11.79	35.24	58.52		11.79	107.99	58.20	0.54
206235_at	3981	LIG4	NM_002312	117.38	160.36	118.74		117.38	222.17	119.80	0.54
AFFX-r2-Bs-lys-3_at			AFFX-r2-Bs-lys-3	2.24	8.15	3.04		2.24	18.75	10.11	0.54
205825_at	5122	PCSK1	NM_000439	7.09	9.22	8.50		7.09	17.48	9.43	0.54
208135_at	6928	TCF2	NM_006481	5.83	9.21	10.04		5.83	17.97	9.70	0.54
202445_s_at	4853	NOTCH2	NM_024408	92.07	118.35	84.60		92.07	181.68	98.05	0.54
209945_s_at	2932	GSK3B	BC000251	490.15	495.20	559.85		490.15	803.29	433.67	0.54
203347_s_at	22823	MTF2	NM_007358	599.35	632.99	579.21		599.35	1402.04	757.01	0.54
209422_at	51230	PHF20	AY027523	1019.85	1234.74	1533.52		1019.85	2319.53	1254.73	0.54
219146_at	79736	C17orf42	NM_024683	542.17	645.81	600.70		542.17	959.75	519.55	0.54
202435_s_at	1545	CYP1B1	AU154504	624.04	857.21	318.42		624.04	1683.84	912.77	0.54
201997_s_at	23013	SPEN	NM_015001	1294.84	1381.87	1278.71		1294.84	2117.06	1147.92	0.54

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
207935_s_at	3860	KRT13	NM_002274	3.38	1.85	6.36		3.38	11.03	5.99	0.54
209957_s_at	4878	NPPA	M30262	23.43	34.34	31.17		23.43	79.99	43.45	0.54
212176_at	25957	C6orf111	AA902326	1542.05	1485.49	1514.14		1542.05	2351.72	1277.42	0.54
214957_at	81569	ACTL8	BF594459	6.95	8.16	27.85		6.95	16.82	9.15	0.54
212090_at	2907	GRINA	AL571424	908.66	1500.60	1270.25		908.66	1519.22	826.93	0.54
207476_at	50618	ITSN2	NM_018512	7.50	4.27	8.31		7.50	18.44	10.04	0.54
212435_at	51592	TRIM33	AA205593	565.79	554.14	538.25		565.79	878.07	478.06	0.54
218170_at	51015	ISOC1	NM_016048	609.14	797.72	811.27		609.14	1734.46	944.32	0.54
221917_s_at	2926	GRSF1	BF058465	46.94	42.56	48.07		46.94	72.49	39.50	0.54
216884_at	5782	PTPN12	S69182	7.44	12.68	36.09		7.44	91.33	49.77	0.54
218757_s_at	65109	UPF3B	NM_023010	646.34	759.28	895.07		646.34	1205.29	657.07	0.55
203346_s_at	22823	MTF2	AF072814	1463.65	1632.74	1331.98		1463.65	2687.47	1465.67	0.55
210495_x_at	2335	FN1	AF130095	17.03	59.51	49.75		17.03	99.64	54.35	0.55
214744_s_at	9349	RPL23	AK021960	73.88	116.48	94.19		73.88	161.75	88.25	0.55
221870_at	30846	EHD2	AI417917	21.04	29.86	12.01		21.04	129.40	70.60	0.55
204073_s_at	745	C11orf9	NM_013279	32.85	39.30	32.69		32.85	51.60	28.16	0.55
206386_at	6906	SERPINA7	NM_000354	5.41	19.84	21.03		5.41	19.51	10.65	0.55
212888_at	23405	DICER1	BG109746	532.23	608.67	501.68		532.23	798.74	436.21	0.55
211168_s_at	5976	UPF1	D86988	503.32	554.73	450.32		503.32	925.90	506.53	0.55
210542_s_at	28232	SLCO3A1	BC000585	57.56	64.09	50.14		57.56	122.36	66.97	0.55
208298_at	7813	EVI5	NM_0056	7.93	3.06	2.90		7.93	12.68	6.95	0.55

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			65								
44822_s_at	54531	MIER2	AW003889	192.34	196.07	136.93		192.34	295.84	162.46	0.55
204686_at	3667	IRS1	NM_005544	41.93	50.71	16.99		41.93	131.26	72.11	0.55
211678_s_at	55905	ZNF313	AF090934	1296.20	1152.15	1341.12		1296.20	2414.30	1326.73	0.55
219567_s_at	64789	C1orf176	NM_022774	936.37	1313.36	1059.32		936.37	1463.09	804.25	0.55
210155_at	4653	MYOC	D88214	48.84	49.97	42.84		48.84	74.98	41.22	0.55
219448_at	54968	TMEM70	BC002748	65.56	57.68	70.05		65.56	136.50	75.08	0.55
213457_at	9258	MFHAS1	BF739959	620.68	643.62	571.84		620.68	1174.55	646.13	0.55
213544_at	3622	ING2	AI186701	22.40	14.76	35.39		22.40	64.74	35.62	0.55
219624_at	9530	BAG4	NM_004874	130.48	128.96	142.46		130.48	202.16	111.28	0.55
214718_at	57798	GATA D1	AK026142	421.81	467.90	544.32		421.81	788.14	434.36	0.55
218783_at	25896	INTS7	AL133049	307.52	316.47	258.88		307.52	474.68	261.64	0.55
203575_at	1459	CSNK2A2	NM_001896	402.45	415.51	340.72		402.45	803.90	443.29	0.55
206164_at	9635	CLCA2	NM_006536	5.90	7.51	3.32		5.90	11.06	6.10	0.55
202073_at	10133	OPTN	AV757675	173.40	450.81	407.47		173.40	441.30	243.39	0.55
215128_at			AV704232	116.39	162.95	132.27		116.39	285.39	157.51	0.55
208287_at	10255	HCG9	NM_005844	11.72	6.94	23.96		11.72	22.89	12.63	0.55
207815_at	5197	PF4V1	NM_002620	3.99	18.84	17.84		3.99	23.36	12.91	0.55
201794_s_at	9887	SMG7	NM_014837	858.91	791.45	990.44		858.91	1352.73	748.10	0.55
215457_at	10552	ARPC1A	AF070647	23.57	4.00	31.40		23.57	39.62	21.94	0.55
213734_at			BG260658	374.34	370.20	554.06		374.34	962.96	533.48	0.55

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
204909_at	1656	DDX6	NM_004397	63.64	81.28	63.34		63.64	100.97	55.96	0.55
202565_s_at	6840	SVIL	NM_003174	141.61	96.43	148.47		141.61	357.23	198.04	0.55
220651_s_at	55388	MCM10	AB042719	261.54	280.33	216.37		261.54	412.86	228.91	0.55
213500_at	9276	COPB2	AI307760	217.20	244.58	156.09		217.20	330.78	183.41	0.55
209558_s_at	728014 /	HIP1R /// LOC728014	AB013384	24.53	51.29	43.98		24.53	73.28	40.67	0.56
216504_s_at	64116	SLC39A8	AL049963	48.40	78.75	62.89		48.40	166.93	92.66	0.56
206208_at	762	CA4	NM_000717	5.51	24.52	18.78		5.51	10.62	5.90	0.56
216142_at			AL137403	44.77	60.59	56.74		44.77	82.88	46.06	0.56
209120_at	7026	NR2F2	AL037401	29.67	56.19	56.29		29.67	106.88	59.45	0.56
202230_s_at	10523	CHERP	NM_006387	1955.62	1567.98	1532.63		1955.62	3126.88	1739.84	0.56
205335_s_at	6728	SRP19	NM_003135	2107.55	2076.69	2037.09		2107.55	3826.84	2132.52	0.56
204533_at	3627	CXCL10	NM_001565	12.53	3433.73	4050.06		12.53	1996.92	1112.92	0.56
219719_at	51751	HIGD1B	NM_016438	7.60	10.61	8.46		7.60	15.40	8.59	0.56
201110_s_at	7057	THBS1	NM_003246	2.69	49.97	64.93		2.69	644.40	359.39	0.56
217400_at	392454	LOC392454	AL034410	12.30	4.15	9.35		12.30	19.04	10.64	0.56
202295_s_at	1512	CTSH	NM_004390	3602.55	5815.13	4593.58		3602.55	6007.85	3361.13	0.56
222107_x_at	11178	LZTS1	BE312985	8.73	37.20	35.80		8.73	30.31	16.96	0.56
214133_at	4588	MUC6	AI611214	16.68	36.64	51.79		16.68	64.05	35.85	0.56
216725_at	166614	DCAMKL2	AL359602	5.30	5.23	3.99		5.30	10.41	5.83	0.56
210383_at	6323	SCN1A	AF225985	5.32	9.15	8.31		5.32	12.37	6.93	0.56

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
214860_at	84679	SLC9A7	AL022165	5.63	8.81	3.45		5.63	12.57	7.04	0.56
204812_at	9183	ZW10	NM_004724	383.66	380.50	389.53		383.66	588.00	329.62	0.56
205709_s_at	1040	CDS1	U65887	125.58	113.83	107.86		125.58	209.70	117.59	0.56
210419_at	8538	BARX2	AF031924	9.57	14.74	16.75		9.57	19.18	10.77	0.56
220886_at	55879	GABRQ	NM_018558	16.38	2.86	6.70		16.38	28.47	16.00	0.56
218956_s_at	26024	PTCD1	NM_015545	270.00	270.28	268.69		270.00	575.45	323.52	0.56
201667_at	2697	GJA1	NM_000165	2.13	20.51	15.90		2.13	102.85	57.84	0.56
203358_s_at	2146	EZH2	NM_004456	1011.21	1048.92	1116.89		1011.21	2182.16	1227.15	0.56
217828_at	79811	SLTM	NM_024755	1018.28	888.35	884.24		1018.28	1653.10	930.70	0.56
203066_at	51363	GALNAC4S-6ST	NM_014863	11.67	6.84	24.21		11.67	24.13	13.60	0.56
208016_s_at	185	AGTR1	NM_004835	6.06	7.07	15.78		6.06	10.77	6.07	0.56
209705_at			BG033764	615.53	648.43	718.05		615.53	1163.32	655.88	0.56
221982_x_at	8270	LAGE3	AA034498	12.66	7.30	6.93		12.66	21.49	12.13	0.56
213076_at	80271	IIPKC	D38169	72.56	81.20	98.58		72.56	121.95	68.86	0.56
220939_s_at	54878	DPP8	NM_017743	1150.90	1296.89	1132.00		1150.90	1771.65	1000.55	0.56
220121_at	55180	LINS1	NM_018148	80.59	84.47	92.25		80.59	143.84	81.29	0.57
215092_s_at	10725	NFAT5	AJ005683	126.73	287.38	240.81		126.73	611.89	345.88	0.57
201934_at	80335	TMEM113	N92524	1911.34	1566.53	1812.90		1911.34	4097.14	2317.02	0.57
203038_at	5796	PTPRK	NM_002844	534.39	648.97	742.03		534.39	1149.32	650.04	0.57
216655_s_at			AF041811	4.20	5.23	3.73		4.20	21.65	12.24	0.57

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
218447_at	56942	C16orf61	NM_020188	815.60	958.90	934.89		815.60	1911.90	1081.77	0.57
216336_x_at	4499	MT1M	AL031602	771.07	469.15	498.68		771.07	1218.16	689.54	0.57
221169_s_at	59340	HRH4	AF312230	6.60	13.81	16.80		6.60	13.76	7.79	0.57
221168_at	59336	PRDM13	NM_021620	26.10	33.88	25.79		26.10	57.25	32.44	0.57
222047_s_at	51593	ARS2	AI523895	3175.02	3036.78	2857.66		3175.02	4881.85	2767.32	0.57
201558_at	8480	RAE1	NM_003610	1308.92	1246.68	1264.18		1308.92	2214.87	1256.22	0.57
216814_at			AL353587	6.18	15.59	30.87		6.18	22.78	12.94	0.57
204176_at	27252	KLHL20	AA808694	171.63	221.34	206.44		171.63	258.85	147.07	0.57
37152_at	5467	PPARD	L07592	816.89	1283.54	1017.45		816.89	1808.92	1027.89	0.57
209115_at	9039	UBE1C	AL117566	1143.90	1476.21	1511.58		1143.90	2027.89	1152.50	0.57
201109_s_at	7057	THBS1	AV726673	8.37	54.04	71.48		8.37	585.69	332.94	0.57
213673_x_at	29937	NENF	AA156251	23.67	12.40	64.29		23.67	56.48	32.14	0.57
202429_s_at	5530	PPP3CA	AL353950	2546.81	2925.70	2581.92		2546.81	4408.70	2510.26	0.57
214743_at	1523	CUTL1	BE046521	517.17	815.05	750.95		517.17	1328.98	756.84	0.57
214175_x_at	8572	PDLIM4	AI254547	111.09	132.61	106.52		111.09	1380.21	786.14	0.57
203255_at	80204	FBXO11	NM_018693	467.30	553.26	512.44		467.30	1039.36	593.22	0.57
200995_at	10527	IPO7	AI741392	898.97	728.95	761.91		898.97	1456.93	831.65	0.57
201678_s_at	56941	C3orf37	AI937543	294.64	327.53	346.71		294.64	538.95	307.69	0.57
220203_at	353500	BMP8A	NM_024732	11.78	7.99	13.24		11.78	24.62	14.06	0.57
203963_at	771	CA12	NM_001218	30.62	37.85	27.85		30.62	70.78	40.44	0.57
210068_s_at	361	AQP4	U63622	2.55	3.55	6.04		2.55	11.20	6.40	0.57

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
219801_at	80778	ZNF34	NM_030580	105.12	90.95	82.85		105.12	161.75	92.45	0.57
210500_at			BC001957	9.70	27.09	31.23		9.70	26.52	15.17	0.57
206207_at	1178	CLC	NM_001828	4.34	5.02	2.67		4.34	10.98	6.28	0.57
211221_at	10474	TADA3L	AL117487	14.41	28.17	41.59		14.41	21.97	12.57	0.57
218888_s_at	81831	NETO2	AI335263	620.42	694.17	411.07		620.42	1162.49	665.59	0.57
205962_at	5062	PAK2	NM_002577	5.10	6.52	4.52		5.10	10.55	6.04	0.57
209005_at	26234	FBXL5	AF157323	402.10	489.15	494.98		402.10	611.07	350.09	0.57
221506_s_at	30000	TNPO2	BG258639	523.21	581.43	517.79		523.21	926.33	531.48	0.57
221654_s_at	9960	USP3	AF077040	1046.89	1022.30	1404.66		1046.89	2334.51	1339.48	0.57
216170_at	1937	EEF1G	AK025271	62.43	129.40	107.42		62.43	158.64	91.09	0.57
205016_at	7039	TGFA	NM_003236	31.45	26.63	46.20		31.45	72.23	41.52	0.57
218939_at	3954	LETM1	NM_012318	61.30	48.56	97.44		61.30	104.34	60.07	0.58
211071_s_at	10962	MLLT11	BC006471	80.14	87.38	86.95		80.14	159.72	92.03	0.58
205525_at	800	CALD1	NM_018495	20.67	18.24	25.10		20.67	36.63	21.13	0.58
204449_at	5082	PDCL	NM_005388	214.13	210.87	480.31		214.13	345.82	199.64	0.58
218833_at	51776	ZAK	NM_016653	81.01	82.76	82.80		81.01	134.45	77.67	0.58
203355_s_at	23362	PSD3	NM_015310	507.92	624.18	948.42		507.92	3142.40	1815.89	0.58
203481_at	55719	C10orf6	AI655902	235.56	196.06	205.55		235.56	392.47	227.09	0.58
215363_x_at	2346	FOLH1	AW168915	19.13	19.05	11.89		19.13	44.97	26.04	0.58
204620_s_at	1462	CSPG2	NM_004385	272.63	479.87	383.43		272.63	597.02	345.69	0.58

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
204926_at	3624	INHBA	NM_002192	15.48	7.96	1.44		15.48	27.03	15.67	0.58
211339_s_at	3702	ITK	D13720	17.30	11.10	13.78		17.30	27.76	16.10	0.58
213122_at	85453	TSPYL5	AI096375	891.44	626.71	650.82		891.44	1365.32	792.27	0.58
212412_at	10611	PDLIM5	AV715767	1104.80	1587.77	1280.50		1104.80	1993.22	1157.15	0.58
221974_at	63968	PWCR1	AW770748	163.05	222.80	210.50		163.05	267.26	155.19	0.58
215045_at	11189	TNRC4	BC004145	6.94	7.96	11.89		6.94	18.72	10.87	0.58
210047_at	4891	SLC11A2	AF064484	25.04	12.54	34.35		25.04	105.56	61.33	0.58
202457_s_at	5530	PPP3CA	AA911231	1878.67	2067.17	1969.82		1878.67	3811.17	2214.15	0.58
218859_s_at	51575	ESF1	NM_016649	405.27	316.59	411.38		405.27	687.15	399.25	0.58
219792_at	79814	AGMAT	NM_024758	17.48	32.52	33.58		17.48	48.63	28.26	0.58
218279_s_at	8337	HIST2H2AA3	BC001629	29.81	72.00	54.01		29.81	94.79	55.10	0.58
221569_at	54806	AHI1	AL136797	258.34	338.49	282.42		258.34	546.72	317.96	0.58
203673_at	7038	TG	NM_003235	38.30	31.98	10.90		38.30	115.66	67.27	0.58
202655_at	7873	ARME1T	NM_006010	1387.14	2019.70	1247.65		1387.14	2130.75	1239.48	0.58
201566_x_at	3398 ///	ID2 /// ID2B	NM_002166	383.92	461.04	156.05		383.92	1336.35	777.63	0.58
215750_at	85373	KIAA1659	AB051446	86.88	114.23	125.76		86.88	132.43	77.08	0.58
202843_at	4189	DNAJB9	NM_012328	56.63	74.98	149.09		56.63	366.95	214.10	0.58
221729_at	1290	COL5A2	AL575735	20.18	11.28	22.13		20.18	307.15	179.24	0.58
217947_at	54918	CMTM6	NM_017801	5067.56	5746.33	5613.70		5067.56	7918.64	4621.34	0.58
222308_x_at	9984	THOC1	AV700403	17.44	13.13	9.93		17.44	34.68	20.25	0.58

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
218649_x_at	9147	SDCCA G1	NM_004713	690.20	739.86	832.53		690.20	1344.82	785.54	0.58
204204_at	1318	SLC31 A2	NM_001860	69.78	160.89	124.61		69.78	269.65	157.60	0.58
220765_s_at	55679	LIMS2	NM_017980	104.77	130.97	110.48		104.77	454.49	265.64	0.58
208816_x_at	304	ANXA 2P2	M62898	1277.14	1657.98	1732.89		1277.14	2493.57	1457.84	0.58
209704_at			AL523380	411.75	465.01	465.04		411.75	939.24	549.57	0.59
213044_at	6093	ROCK1	N22548	2153.60	2018.87	2398.84		2153.60	3533.11	2068.97	0.59
206652_at	9205	ZMYM 5	NM_016384	107.50	145.22	182.96		107.50	215.98	126.50	0.59
32032_at	8220	DGCR1 4	L77566	491.02	466.07	592.26		491.02	865.24	507.43	0.59
217464_at			L48784	27.50	40.30	21.12		27.50	49.38	28.96	0.59
220520_s_at	54830	NUP62 CL	NM_017681	3.38	2.63	10.86		3.38	10.11	5.93	0.59
203476_at	7162	TPBG	NM_006670	1547.74	1859.00	1448.97		1547.74	2461.87	1445.51	0.59
217992_s_at	79180	EFHD2	AW664179	2087.89	2742.68	1521.53		2087.89	4132.64	2427.90	0.59
216357_at	6642	SNX1	AL050148	3.46	11.61	25.37		3.46	13.89	8.16	0.59
207058_s_at	5071	PARK2	NM_004562	20.26	30.54	37.07		20.26	34.28	20.16	0.59
220962_s_at	29943	PADI1	NM_013358	28.98	76.92	62.85		28.98	94.95	55.88	0.59
204042_at	10810	WASF3	AB020707	8.08	8.35	9.49		8.08	16.34	9.62	0.59
219290_x_at	27071	DAPP1	NM_014395	699.32	1441.05	1434.34		699.32	1269.02	747.23	0.59
201054_at	10949	HNRPA0	BE966599	2367.56	2412.44	1967.07		2367.56	3839.74	2262.69	0.59
219902_at	23743	BHMT 2	NM_017614	9.25	12.98	8.28		9.25	14.57	8.59	0.59
209161_at	9128	PRPF4	AI184802	1263.94	1229.26	1127.79		1263.94	2497.99	1475.02	0.59
205664_at	22944	KIN	NM_0123	223.92	193.14	225.06		223.92	341.81	201.90	0.59

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			11								
219049_at	55790	ChGn	NM_018371	38.51	26.81	31.40		38.51	197.61	116.77	0.59
212989_at	259230	TMEM23	AI377497	31.60	40.87	45.39		31.60	54.14	32.00	0.59
219747_at	79625	C4orf31	NM_024574	44.69	44.20	55.00		44.69	124.89	73.81	0.59
206442_at	6406	SEMG1	NM_003007	78.87	70.34	69.75		78.87	163.27	96.60	0.59
212522_at	5151	PDE8A	W73272	123.91	182.94	229.48		123.91	584.71	346.00	0.59
207279_s_at	10529	NEBL	NM_016365	12.47	19.33	16.29		12.47	38.60	22.85	0.59
203562_at	9638	FEZ1	NM_005103	274.24	1270.93	1430.17		274.24	3040.29	1800.35	0.59
218358_at	8812	CCNK	NM_024324	2082.26	2626.58	1781.27		2082.26	3180.78	1883.74	0.59
203620_s_at	9873	FCHSD2	NM_014824	351.87	398.56	367.25		351.87	597.74	354.69	0.59
206028_s_at	10461	MERTK	NM_006343	39.27	43.70	41.43		39.27	67.32	39.95	0.59
202660_at	3709	IIPR2	AA834576	66.59	98.91	79.22		66.59	131.94	78.37	0.59
218131_s_at	54815	GATA D2A	AK024670	568.29	661.47	600.94		568.29	1127.27	670.07	0.59
205946_at	7434	VIPR2	NM_003382	6.03	8.98	25.12		6.03	13.15	7.81	0.59
222106_at	23627	PRND	AL133396	4.92	8.82	26.67		4.92	20.22	12.03	0.59
208462_s_at	10060	ABCC9	NM_005691	13.41	11.27	7.50		13.41	22.00	13.09	0.60
205527_s_at	50628	GEMIN4	NM_015487	175.68	183.32	140.97		175.68	350.20	208.47	0.60
220476_s_at	55924	C1orf183	NM_019099	24.14	12.49	25.01		24.14	49.36	29.39	0.60
209296_at	5495	PPM1B	AF136972	1521.64	1397.15	1972.36		1521.64	2494.04	1485.51	0.60
210335_at	9182	PAMCI	AF056209	10.06	7.72	21.71		10.06	19.88	11.84	0.60
212972_x_at			AL08013	16.33	30.31	39.88		16.33	29.54	17.63	0.60

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			0								
203898_at	27297	RCP9	AU154853	153.56	181.76	191.90		153.56	294.30	175.82	0.60
207812_s_at	26003	GORASP2	NM_015530	1356.37	1316.83	1221.07		1356.37	2195.98	1312.22	0.60
212643_at	93487	C14orf32	AI671747	3791.63	3457.95	3260.05		3791.63	6364.90	3803.72	0.60
204296_at	1639	DCTN1	NM_021196	28.07	28.90	59.15		28.07	62.64	37.49	0.60
203419_at	9757	MLL4	NM_014727	306.37	458.27	260.17		306.37	500.38	299.54	0.60
204655_at	6352	CCL5	NM_002985	1774.54	2421.70	2736.70		1774.54	13645.23	8170.20	0.60
205255_x_at	6932	TCF7	NM_003202	279.46	339.40	216.17		279.46	540.90	323.87	0.60
219743_at	23493	HEY2	NM_012259	3.36	7.80	6.20		3.36	11.12	6.67	0.60
219128_at	54980	C2orf42	NM_017880	198.95	205.65	231.04		198.95	327.95	196.67	0.60
211149_at	7404	UTY	AF000994	69.65	100.26	99.90		69.65	131.54	78.95	0.60
212726_at	5253	PHF2	AB014562	500.61	479.08	465.57		500.61	793.54	477.15	0.60
216731_s_at	389768	LOC389768	AK023690	3.28	4.84	2.50		3.28	12.82	7.71	0.60
213275_x_at	1508	CTSB	W47179	658.11	663.52	549.73		658.11	1041.07	626.45	0.60
220667_at			NM_018540	11.65	7.88	23.12		11.65	24.81	14.95	0.60
217579_x_at	64225	ARL6IP2	AW301806	210.96	165.28	403.77		210.96	375.05	226.03	0.60
220895_at	57663	USP29	NM_020903	10.72	7.70	6.64		10.72	16.14	9.73	0.60
222270_at	57223	SMEK2	BG540048	27.47	48.27	47.65		27.47	70.22	42.33	0.60
213479_at	4885	NPTX2	U26662	259.79	365.58	240.72		259.79	1620.57	977.75	0.60
218984_at	54517	PUS7	NM_019042	533.43	367.17	404.26		533.43	1091.49	658.54	0.60
221680_s_at	51513	ETV7	AF147782	25.25	47.37	37.06		25.25	57.60	34.77	0.60

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
215454_x_at	6440	SFTPC	AI831055	8.18	5.80	6.03		8.18	13.10	7.91	0.60
219441_s_at	79705	LRRK1	NM_024652	123.60	100.35	116.42		123.60	232.30	140.48	0.60
212846_at	23076	KIAA0179	AA811192	1082.23	830.79	848.05		1082.23	1756.32	1062.20	0.60
203345_s_at	22823	MTF2	AI566096	2207.34	2366.26	2104.05		2207.34	3740.22	2265.45	0.61
212083_at	113419	TEX261	AV759552	836.12	751.67	794.43		836.12	1282.77	777.36	0.61
221244_s_at			NM_031268	44.60	46.48	48.65		44.60	67.31	40.81	0.61
206878_at	1610	DAO	NM_001917	20.21	38.40	31.06		20.21	36.77	22.31	0.61
220323_at	79935	CNTD2	NM_024877	54.39	87.58	77.82		54.39	83.78	50.84	0.61
201594_s_at	9989	PPP4R1	NM_005134	761.99	1024.43	802.41		761.99	1481.98	899.34	0.61
203464_s_at	22905	EPN2	NM_014964	57.63	91.85	72.60		57.63	95.79	58.14	0.61
204493_at	637	BID	NM_001196	382.02	933.59	809.83		382.02	2783.34	1690.01	0.61
207844_at	3596	IL13	NM_002188	24.38	46.53	40.21		24.38	45.47	27.61	0.61
219531_at	55722	CEP72	NM_018140	167.53	173.60	200.58		167.53	300.73	182.67	0.61
214706_at	7752	ZNF200	AU149447	376.85	445.79	419.95		376.85	651.74	395.92	0.61
220961_s_at	9238	TBRG4	NM_030900	102.97	124.95	97.25		102.97	224.01	136.09	0.61
216247_at			AF113008	40.65	59.63	25.48		40.65	80.87	49.13	0.61
217757_at	2	A2M	NM_000014	71.81	69.95	64.21		71.81	113.55	69.01	0.61
205150_s_at	9865	KIAA0644	AV724192	14.91	17.40	14.12		14.91	31.84	19.36	0.61
212940_at	1291	COL6A1	BE350145	18.11	25.09	35.21		18.11	52.97	32.20	0.61
207860_at	9437	NCR1	NM_004829	3.17	3.24	1.89		3.17	10.70	6.50	0.61

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
209459_s_at	18	ABAT	AF237813	140.40	75.56	98.52		140.40	519.06	315.70	0.61
221552_at	57406	ABHD6	BC001698	93.69	117.93	165.66		93.69	263.25	160.35	0.61
212458_at	200734	SPRED2	H97931	831.60	1203.64	1317.60		831.60	4278.55	2607.09	0.61
211445_x_at	389240 /	NACA P1 /// LOC389240	AF315951	5704.31	6411.03	9891.98		5704.31	9755.78	5944.85	0.61
200673_at	9741	LAPT M4A	NM_014713	1716.40	1531.08	1677.57		1716.40	2675.01	1630.72	0.61
217897_at	53826	FXVD6	NM_022003	69.25	36.73	48.36		69.25	209.49	127.73	0.61
206239_s_at	6690	SPINK1	NM_003122	9.50	14.67	21.22		9.50	20.58	12.55	0.61
217574_at	1006	CDH8	T65123	2.00	7.87	15.49		2.00	32.22	19.66	0.61
214841_at	149111	CNIH3	AF070524	35.88	5.37	41.10		35.88	154.61	94.40	0.61
206712_at	79774	GRTP1	NM_024719	5.53	6.30	11.56		5.53	11.69	7.14	0.61
217618_x_at	3364	HUS1	AW007988	133.90	130.20	136.67		133.90	243.64	148.93	0.61
203840_at	8548	BLZF1	NM_003666	173.30	194.33	166.51		173.30	306.20	187.28	0.61
213037_x_at	6780	STAU1	AJ132258	2281.36	1958.66	2554.56		2281.36	3630.45	2220.53	0.61
218042_at	51138	COPS4	NM_016129	895.30	791.04	896.08		895.30	1469.97	899.50	0.61
205994_at	2005	ELK4	NM_001973	42.83	27.01	42.98		42.83	80.40	49.20	0.61
204653_at	7020	TFAP2A	BF343007	62.25	352.23	341.09		62.25	1355.87	829.89	0.61
208780_x_at	9218	VAPA	AF154847	5331.27	5276.47	6669.87		5331.27	9326.57	5712.03	0.61
215775_at	7057	THBS1	BF084105	8.33	41.92	44.68		8.33	45.12	27.64	0.61
207480_s_at	4212	MEIS2	NM_020149	327.69	256.31	279.73		327.69	1017.66	623.66	0.61
218236_s_at	23683	PRKD3	NM_005813	533.29	623.45	771.24		533.29	1030.95	633.16	0.61

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
207570_at	6473	SHOX	NM_000451	3.25	7.56	7.05		3.25	26.59	16.33	0.61
211269_s_at	3559	IL2RA	K03122	6.10	3.35	6.99		6.10	17.80	10.94	0.61
213732_at	6929	TCF3	AI871234	18.93	21.71	22.02		18.93	36.10	22.19	0.61
218819_at	26512	INTS6	NM_012141	904.26	1274.85	1041.84		904.26	1658.35	1019.46	0.61
202842_s_at	4189	DNAJB9	AL080081	396.07	479.83	595.35		396.07	1556.19	956.83	0.61
209430_at	9044	BTAF1	AJ001017	540.74	557.37	604.34		540.74	1010.70	621.56	0.61
217264_s_at	6337	SCNN1A	U81961	4.44	11.93	14.34		4.44	18.99	11.69	0.62
216192_at	2173	FABP7	AL512688	8.19	10.96	6.39		8.19	38.90	23.95	0.62
209802_at	7262	PHLDA2	BC005034	33.05	20.28	26.10		33.05	61.38	37.81	0.62
202054_s_at	224	ALDH3A2	NM_000382	155.79	156.50	145.58		155.79	275.61	169.83	0.62
217371_s_at	3600	IL15	Y09908	13.08	18.82	18.19		13.08	32.69	20.15	0.62
218263_s_at	58486	ZBED5	NM_021211	1325.33	1337.89	1414.79		1325.33	2247.35	1388.28	0.62
216038_x_at	1616	DAXX	BE965715	335.63	285.30	302.23		335.63	620.78	383.80	0.62
202720_at	26136	TES	NM_015641	993.94	889.84	1123.07		993.94	1646.51	1018.15	0.62
204619_s_at	1462	CSPG2	BF590263	27.86	9.59	43.59		27.86	57.19	35.36	0.62
214314_s_at	9669	EIF5B	BE138647	329.67	289.82	284.70		329.67	566.31	350.57	0.62
213352_at	23023	TMCC1	AB018322	106.92	161.57	137.23		106.92	214.45	132.80	0.62
219022_at	64897	C12orf43	NM_022895	348.72	354.57	362.11		348.72	596.55	369.52	0.62
208469_s_at	80864	EGFL8	NM_030652	21.30	62.19	62.15		21.30	53.36	33.05	0.62
217550_at	22926	ATF6	AA576497	222.62	315.80	284.91		222.62	404.33	250.54	0.62
204722_at	55800	SCN3B	AW007335	10.53	13.04	14.60		10.53	31.26	19.42	0.62

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
220996_s_at	81626	C1orf14	NM_030933	7.22	4.00	4.45		7.22	12.89	8.01	0.62
206417_at	1259	CNGA1	NM_000087	23.28	12.07	32.35		23.28	46.24	28.75	0.62
204516_at	6314	ATXN7	BG390306	360.88	448.85	406.68		360.88	617.16	383.77	0.62
202255_s_at	26037	SIPA1L1	NM_015556	70.22	83.38	76.14		70.22	266.24	165.66	0.62
208948_s_at	6780	STAU1	BC000830	1935.73	1827.41	2306.62		1935.73	3498.32	2176.79	0.62
210135_s_at	6474	SHOX2	AF022654	3460.15	4612.13	4402.03		3460.15	8271.93	5147.53	0.62
216830_at	730909	LOC730909	AC004460	3.44	7.04	7.39		3.44	14.18	8.82	0.62
200028_s_at	56910	STARD7	NM_020151	3322.02	3987.67	5578.30		3322.02	5058.23	3148.26	0.62
205173_x_at	965	CD58	NM_001779	1039.87	2046.09	2432.88		1039.87	2577.48	1604.72	0.62
200765_x_at	1495	CTNNA1	NM_001903	1333.37	1579.45	1452.13		1333.37	2113.12	1315.90	0.62
222063_s_at	1040	CDS1	AI991484	8.41	31.67	28.21		8.41	18.70	11.65	0.62
203556_at	22882	ZHX2	NM_014943	119.00	133.57	110.55		119.00	615.44	383.72	0.62
204349_at	9443	CRSP9	BC005250	180.17	139.89	326.86		180.17	333.79	208.15	0.62
209065_at	7381	UQCRB	BC005230	481.62	422.25	445.20		481.62	735.25	458.52	0.62
201352_at	10730	YME1L1	NM_014263	1525.93	1264.93	1815.25		1525.93	2877.65	1796.07	0.62
215011_at	8420	SNHG3	AJ006835	60.04	75.78	38.54		60.04	139.09	86.90	0.62
218050_at	51569	UFM1	NM_016617	692.72	719.87	1187.22		692.72	2208.74	1380.11	0.62
216132_at	23245	ASTN2	AK021992	6.29	18.19	20.26		6.29	10.28	6.43	0.63
209798_at	4863	NPAT	D83243	320.67	306.07	351.91		320.67	498.47	312.15	0.63
221193_s_at	54819	ZCCHC10	NM_017665	463.67	457.06	544.79		463.67	1000.85	626.77	0.63
205103_at	10485	C1orf61	NM_0063	73.74	102.20	65.12		73.74	154.86	97.00	0.63

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			65								
218677_at	57402	S100A14	NM_020672	13.70	17.72	27.49		13.70	36.21	22.69	0.63
204593_s_at	54471	SMCR7L	AA046752	621.68	593.59	607.69		621.68	1025.19	642.44	0.63
220966_x_at	81873	ARPC5L	NM_030978	1914.80	2009.32	2351.08		1914.80	2981.97	1868.80	0.63
219844_at	55088	C10orf18	NM_018017	20.21	30.40	25.63		20.21	32.29	20.25	0.63
205437_at	10520	ZNF211	NM_006385	235.16	313.25	289.22		235.16	466.66	292.72	0.63
216086_at	22987	SV2C	AB028977	29.52	16.62	29.61		29.52	100.11	62.81	0.63
219540_at	10308	ZNF267	NM_003414	514.71	544.69	753.59		514.71	1470.33	922.84	0.63
201190_s_at	5306	PIIPNA	H15647	429.23	572.34	461.82		429.23	1791.54	1125.31	0.63
216113_at	10152	ABI2	AF070566	17.41	10.75	15.16		17.41	27.82	17.48	0.63
213359_at	3184	HNRPD	W74620	554.16	734.55	636.69		554.16	1436.56	902.80	0.63
46323_at	124583	CANT1	AL120741	792.96	791.03	798.35		792.96	1373.99	863.60	0.63
202365_at	84747	MGC5139	BC004815	914.38	872.52	937.04		914.38	1446.69	909.35	0.63
215810_x_at	667	DST	AL049215	11.98	25.79	46.93		11.98	60.62	38.13	0.63
45653_at	253980	KCTD13	AW026481	289.71	276.32	362.53		289.71	440.68	277.48	0.63
1405_i_at	6352	CCL5	M21121	1821.38	2494.79	2775.85		1821.38	13200.54	8314.36	0.63
202193_at	3985	LIMK2	NM_005569	197.52	265.61	274.95		197.52	417.67	263.27	0.63
203812_at			AB011538	26.86	58.74	62.88		26.86	64.33	40.57	0.63
215086_at	25998	IBTK	AB037838	30.19	36.89	51.24		30.19	51.15	32.27	0.63
213222_at	23236	PLCB1	AL049593	80.40	73.11	121.00		80.40	132.89	83.86	0.63
221741_s_at	54915	YTHDF	AL09682	1411.69	1390.49	1433.95		1411.69	2711.22	1711.48	0.63

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
		1	8								
217921_at			BE543064	190.20	195.75	162.92		190.20	389.90	246.42	0.63
210702_s_at	5740	PTGIS	D38145	6.39	5.00	1.54		6.39	13.11	8.29	0.63
205854_at	7289	TULP3	AK024246	167.54	248.46	286.62		167.54	362.71	229.74	0.63
206670_s_at	253782 /	GAD1 /// LASS6	NM_013445	4.24	5.43	4.17		4.24	10.29	6.52	0.63
204780_s_at	355	FAS	NM_000043	26.39	33.87	40.50		26.39	53.76	34.12	0.63
210636_at	5467	PPARD	BC002715	26.93	69.25	56.95		26.93	52.71	33.46	0.63
211028_s_at	3795	KHK	BC006233	18.42	19.93	16.58		18.42	30.64	19.46	0.64
204781_s_at	355	FAS	NM_000043	16.62	35.30	29.61		16.62	31.02	19.73	0.64
208841_s_at	9908	G3BP2	AB014560	1452.94	1479.71	1338.12		1452.94	2487.86	1582.42	0.64
205100_at	9945	GFPT2	NM_005110	24.06	34.37	31.69		24.06	190.76	121.38	0.64
217935_s_at	55245	C20orf44	NM_018244	367.57	388.98	356.64		367.57	623.00	396.43	0.64
218313_s_at	51809	GALNT7	NM_017423	685.51	813.24	616.16		685.51	1333.29	849.43	0.64
202723_s_at	2308	FOXO1A	AW117498	69.08	78.66	55.05		69.08	162.03	103.24	0.64
212599_at	26053	AUTS2	AK025298	19.64	20.60	25.17		19.64	40.25	25.65	0.64
221208_s_at	79684	C11orf61	NM_024631	132.94	188.70	173.23		132.94	294.70	187.84	0.64
216874_at	401014	DKFZp686O1327	U80770	66.91	175.68	200.55		66.91	206.56	131.67	0.64
211210_x_at	4068	SH2D1A	AF100539	5.43	7.71	5.37		5.43	19.02	12.14	0.64
202293_at	10274	STAG1	NM_005862	309.76	346.82	356.80		309.76	481.01	307.06	0.64
202271_at	23219	FBXO28	AB007952	1350.05	1452.41	1483.51		1350.05	2591.69	1654.61	0.64

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
216993_s_at	1302	COL11A2	U32169	67.02	84.79	72.25		67.02	106.06	67.73	0.64
204661_at	1043	CD52	NM_001803	579.06	587.07	457.80		579.06	972.91	621.71	0.64
203508_at	7133	TNFRSF1B	NM_001066	572.31	801.24	236.66		572.31	1149.71	735.84	0.64
203341_at	10153	CEBPZ	NM_005760	1314.48	1239.38	1179.44		1314.48	2203.97	1411.09	0.64
201983_s_at	1956	EGFR	NM_005228	12.28	24.96	27.80		12.28	34.35	22.00	0.64
202987_at	10758	TRAF3IP2	NM_015524	21.83	10.52	29.84		21.83	80.46	51.59	0.64
214581_x_at	27242	TNFRSF21	BE568134	179.96	215.92	135.04		179.96	489.11	313.70	0.64
222048_at	157	ADRBK2	AA536000	57.47	78.29	98.63		57.47	97.18	62.44	0.64
218851_s_at	55339	WDR33	NM_018383	69.73	77.84	112.19		69.73	128.53	82.68	0.64
209033_s_at	1859	DYRK1A	D86550	2329.08	2284.34	3123.43		2329.08	3691.16	2377.82	0.64
209031_at	23705	IGSF4	AL519710	144.00	176.61	140.94		144.00	430.57	277.60	0.64
217767_at	653879	LOC653879	NM_000064	773.37	1495.52	1178.52		773.37	1752.15	1131.92	0.65
212950_at	221395	GPR116	BF941499	5.28	20.47	15.58		5.28	20.02	12.93	0.65
221538_s_at	5361	PLXNA1	T16388	186.40	295.26	224.93		186.40	687.09	444.55	0.65
219377_at	64762	FAM59A	NM_022751	133.94	155.88	209.60		133.94	218.04	141.17	0.65
205284_at	9816	KIAA0133	NM_014777	305.13	369.25	283.02		305.13	682.23	442.04	0.65
215289_at	388567	ZNF749	BE892698	2.08	17.62	16.87		2.08	18.09	11.73	0.65
213618_at	116984	CENTD1	AB011152	62.37	97.06	112.50		62.37	263.80	171.11	0.65
220623_s_at	80705	TSGA10	NM_025244	30.14	38.70	12.04		30.14	56.68	36.78	0.65
219848_s_at	9668	ZNF432	NM_014650	194.30	141.73	254.84		194.30	311.26	202.01	0.65

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
213278_at	66036	MTMR9	AW014788	475.20	517.24	698.96		475.20	898.98	583.99	0.65
204529_s_at	9760	TOX	AI961231	17.75	24.41	35.72		17.75	60.72	39.55	0.65
210946_at	8611	PPAP2A	AF014403	97.48	130.98	203.41		97.48	195.26	127.21	0.65
204136_at	1294	COL7A1	NM_000094	60.72	55.28	78.62		60.72	162.49	105.89	0.65
218691_s_at	8572	PDLIM4	NM_003687	4.55	4.89	5.20		4.55	151.08	98.47	0.65
217544_at	729806 /	LOC729806 /// LOC730619	AA768909	112.17	190.34	162.62		112.17	274.56	178.99	0.65
213861_s_at	25895	FAM119B	N67741	215.39	202.33	158.00		215.39	351.94	229.48	0.65
45297_at	30846	EHD2	AI417917	95.74	87.00	71.45		95.74	144.40	94.16	0.65
213692_s_at	79053	ALG8	AA904259	3.89	3.57	4.70		3.89	20.32	13.26	0.65
200069_at	9733	SART3	AI656011	582.33	526.70	618.52		582.33	944.87	616.77	0.65
215067_x_at	7001	PRDX2	AU147942	198.01	368.59	300.37		198.01	329.30	215.14	0.65
204230_s_at	57030	SLC17A7	NM_020309	62.54	78.99	57.21		62.54	135.06	88.27	0.65
222197_s_at			AF131813	4.96	8.77	15.30		4.96	11.17	7.31	0.65
202220_at	22889	KIAA0907	NM_014949	2158.94	3002.45	1957.96		2158.94	3789.31	2483.99	0.66
220270_at	56163	RNF17	NM_019038	7.77	3.66	5.55		7.77	19.52	12.80	0.66
214471_x_at	3972	LHB	NM_000894	13.71	5.86	7.49		13.71	57.04	37.39	0.66
208660_at	1431	CS	BC000105	2968.51	2552.89	2743.70		2968.51	5865.14	3845.51	0.66
214138_at	7633	ZNF79	AA284829	106.60	106.92	107.51		106.60	171.74	112.61	0.66
215087_at	56905	C15orf39	AL109730	95.46	110.41	121.80		95.46	174.64	114.62	0.66
213585_s_at	5134	PDCD2	AA764988	30.02	58.73	53.27		30.02	59.62	39.17	0.66

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
823_at	6376	CX3CL1	U84487	5.74	7.30	22.08		5.74	48.30	31.74	0.66
220608_s_at			NM_014106	36.90	44.48	59.57		36.90	90.25	59.31	0.66
205724_at	5317	PKP1	NM_000299	22.49	12.92	9.37		22.49	42.36	27.84	0.66
216693_x_at	50810	HDGFRP3	AL133102	21.71	47.74	39.87		21.71	52.67	34.62	0.66
214656_x_at	4641	MYO1C	BE790157	173.29	327.17	269.11		173.29	412.61	271.33	0.66
215082_at	55000 //	TUG1 /// ELOVL5	BF973387	163.51	118.99	150.38		163.51	286.97	188.74	0.66
211764_s_at	7321	UBE2D1	BC005980	101.20	156.08	178.95		101.20	238.38	156.79	0.66
221062_at	9953	HS3ST3B1	NM_006041	10.40	8.33	4.04		10.40	49.34	32.46	0.66
213876_x_at	8233	ZRSR2	AW089584	288.13	421.13	376.38		288.13	456.03	300.00	0.66
40016_g_at	23227	MAST4	AB002301	52.75	54.34	65.26		52.75	142.91	94.10	0.66
216691_at			AL137705	6.99	2.59	4.47		6.99	13.48	8.88	0.66
212852_s_at	6738	TROVE2	AL538601	2410.62	2740.92	2451.15		2410.62	3727.41	2454.72	0.66
209598_at	10687	PNMA2	AB020690	62.45	98.10	105.80		62.45	128.01	84.35	0.66
209403_at	414060 /	TBC1D3 /// TBC1D3C /// LOC6533	AL136860	356.98	312.13	314.68		356.98	546.19	359.92	0.66
214112_s_at	541578 /	CXorf40A /// CXorf40B	AA543076	689.74	601.70	673.93		689.74	1073.97	708.60	0.66
219500_at	23529	CLCF1	NM_013246	35.07	29.74	13.52		35.07	102.82	67.87	0.66
214372_x_at	10595	ERN2	AI732416	109.55	201.02	223.42		109.55	223.09	147.47	0.66
215614_at	644974	LOC64974	AK022038	12.63	12.40	12.05		12.63	50.87	33.63	0.66

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
201602_s_at	4659	PPP1R1 2A	NM_002480	215.44	287.20	298.78		215.44	388.08	256.86	0.66
214866_at	5329	PLAUR	X74039	153.90	213.29	96.43		153.90	329.94	218.47	0.66
201409_s_at	5500	PPP1C B	W67887	546.52	512.06	671.00		546.52	836.89	555.22	0.66
204721_s_at	9829	DNAJC 6	NM_014787	4.28	3.77	4.86		4.28	14.26	9.47	0.66
222234_s_at	79007	DBND D1	AK022644	6.22	12.23	19.51		6.22	43.98	29.19	0.66
202127_at	8899	PRPF4 B	AB011108	264.99	306.02	286.71		264.99	622.74	413.31	0.66
213221_s_at	23235	SNF1L K2	AB018324	110.53	156.13	99.85		110.53	204.87	136.04	0.66
219194_at	57715	SEMA4 G	NM_017893	28.58	53.46	52.64		28.58	63.92	42.45	0.66
209593_s_at	27348	TOR1B	AF317129	483.60	692.12	572.37		483.60	807.28	536.51	0.66
213704_at	5876	RABG GTB	AA129753	197.33	177.45	219.25		197.33	366.85	243.81	0.66
208989_s_at	22992	FBXL1 1	AF179221	162.99	267.67	236.95		162.99	299.12	199.08	0.67
214260_at	10920	COPS8	AI079287	69.54	97.49	105.14		69.54	119.44	79.52	0.67
214688_at	7091	TLE4	BF217301	41.94	49.52	47.01		41.94	66.86	44.53	0.67
215978_x_at	152719	LOC15 2719	AK021514	1806.07	2790.17	3474.09		1806.07	2924.90	1949.14	0.67
204740_at	10256	CNKSR 1	NM_006314	20.78	24.14	26.97		20.78	46.39	30.91	0.67
212761_at	6934	TCF7L 2	AI703074	172.85	151.25	269.32		172.85	328.32	218.86	0.67
213128_s_at	7337	UBE3A	AA527499	533.93	525.26	656.50		533.93	1469.59	979.70	0.67
202405_at	7073	TIAL1	BF432532	98.64	140.10	130.96		98.64	150.71	100.50	0.67
206836_at	6531	SLC6A 3	NM_001044	32.57	47.75	67.11		32.57	65.59	43.80	0.67
204566_at	8493	PPM1D	NM_003620	639.99	481.26	854.60		639.99	1094.05	730.95	0.67

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
213410_at	26098	C10orf137	AL050102	443.56	429.34	435.58		443.56	693.36	463.29	0.67
213229_at	23405	DICER1	BF590131	589.34	796.84	751.13		589.34	1257.70	840.42	0.67
202324_s_at	64746	ACBD3	NM_022735	1564.09	1347.60	1960.89		1564.09	2512.28	1680.94	0.67
201712_s_at	5903	RANBP2	NM_006267	264.00	289.96	271.50		264.00	431.95	289.25	0.67
205054_at	4703	NEB	NM_004543	93.61	109.65	94.01		93.61	220.07	147.41	0.67
201038_s_at	8125	ANP32A	T67821	568.73	749.56	643.22		568.73	941.00	630.35	0.67
218947_s_at	55149	PAPD1	NM_018109	285.78	249.08	237.07		285.78	490.12	328.33	0.67
212158_at	6383	SDC2	AL577322	784.59	589.45	861.24		784.59	1824.34	1222.69	0.67
217373_x_at	4193	MDM2	AJ276888	111.98	170.16	130.59		111.98	204.89	137.35	0.67
218566_s_at	26973	CHORDC1	NM_012124	828.63	1258.04	1179.87		828.63	2132.94	1430.73	0.67
210837_s_at	5144	PDE4D	AF012074	29.95	21.81	28.93		29.95	53.52	35.92	0.67
219363_s_at	51001	MTERFD1	NM_015942	1244.05	1473.56	1572.44		1244.05	2732.43	1834.85	0.67
216273_at	10794	ZNF460	X78931	21.22	23.52	22.80		21.22	48.25	32.43	0.67
208200_at	3552	IL1A	NM_000575	55.13	110.54	99.32		55.13	113.12	76.07	0.67
213810_s_at			AW007137	72.66	71.00	135.01		72.66	124.79	83.95	0.67
201952_at	214	ALCAM	AA156721	2044.41	3613.90	3693.11		2044.41	6244.65	4201.66	0.67
201984_s_at	1956	EGFR	NM_005228	24.71	35.65	15.96		24.71	56.33	37.91	0.67
218053_at	55660	PRPF40A	NM_017892	3256.96	3735.16	3812.97		3256.96	5228.97	3518.93	0.67
210965_x_at	8621	CDC2L5	BC001274	78.95	110.34	108.81		78.95	123.86	83.37	0.67
221077_at	55130	ARMC4	NM_018076	34.21	60.53	49.11		34.21	60.89	40.99	0.67

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
218496_at	246243	RNASEH1	BG534527	640.72	655.75	653.07		640.72	1224.76	824.85	0.67
222203_s_at	57665	RDH14	AK023625	430.76	452.66	377.55		430.76	713.33	480.74	0.67
216480_x_at	8028	MLLT10	AF060927	32.27	39.01	44.30		32.27	55.76	37.65	0.68
214024_s_at	85359	DGCR6L	AA631156	3.04	13.54	12.89		3.04	26.19	17.69	0.68
50400_at	196743	PAOX	AI743990	27.46	33.83	16.08		27.46	54.67	36.95	0.68
208581_x_at	4501	MT1X	NM_005952	876.45	500.40	601.35		876.45	2203.33	1489.46	0.68
201496_x_at	4629	MYH11	NM_022844	10.07	9.74	10.26		10.07	33.15	22.42	0.68
217845_x_at	25994	HIGD1A	NM_014056	1832.29	1853.31	1904.64		1832.29	3290.28	2225.17	0.68
210652_s_at	22996	C1orf34	BC004399	3.79	25.91	40.94		3.79	84.15	56.95	0.68
205737_at	3785	KCNQ2	NM_004518	17.68	32.00	27.10		17.68	27.84	18.85	0.68
46270_at	51271	UBAP1	AL039447	342.24	380.31	413.58		342.24	649.74	440.14	0.68
221649_s_at	56342	PPAN	BC000535	312.43	366.94	234.87		312.43	675.36	457.55	0.68
203769_s_at	412	STS	NM_000351	10.57	15.22	10.18		10.57	34.55	23.41	0.68
215134_at	55361	PI4KII	H84390	26.18	29.67	36.22		26.18	52.67	35.71	0.68
218761_at	54778	RNF111	NM_017610	706.35	648.47	898.79		706.35	1126.75	763.98	0.68
219383_at	79899	FLJ14213	NM_024841	15.95	20.81	9.16		15.95	25.82	17.51	0.68
215373_x_at	80047	FLJ12151	AK022213	286.84	486.56	443.36		286.84	449.99	305.38	0.68
201889_at	10447	FAM3C	NM_014888	676.05	797.67	690.68		676.05	1529.69	1038.27	0.68
213903_s_at	9125	RQCD1	AI380850	10.49	13.73	63.23		10.49	58.80	39.94	0.68
215877_at	89919	C14orf56	AK024445	7.32	9.83	6.32		7.32	15.64	10.62	0.68
200884_at	1152	CKB	NM_0018	228.03	304.10	238.74		228.03	1445.47	982.33	0.68

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			23								
218614_at	55196	C12orf35	NM_018169	804.52	1513.93	1308.08		804.52	3148.79	2140.21	0.68
211977_at	57720	GPR107	AK024651	217.94	269.29	272.32		217.94	386.14	262.55	0.68
202345_s_at	2171 ///	FABP5 /// LOC728641 /// LOC729	NM_001444	4523.51	3366.88	3513.20		4523.51	16384.06	11146.49	0.68
218708_at	29107	NXT1	NM_013248	778.31	1166.08	763.95		778.31	1400.02	952.50	0.68
216989_at	6677	SPAM1	L13779	13.11	19.24	28.62		13.11	28.25	19.22	0.68
221919_at	10076	PTRU	AW450929	251.98	301.98	195.53		251.98	400.23	272.58	0.68
212668_at	57154	SMURF1	AI654869	20.74	21.17	35.19		20.74	36.29	24.72	0.68
206693_at	3574	IL7	NM_000880	12.25	6.30	2.16		12.25	22.86	15.57	0.68
206139_at	5298	PIK4CB	NM_002651	213.39	239.42	201.75		213.39	425.61	290.40	0.68
205956_x_at	29893	PSMC3IP	NM_013290	316.31	400.51	344.65		316.31	495.96	338.41	0.68
213181_s_at	4337	MOCS1	AL583528	29.77	26.74	25.30		29.77	67.62	46.15	0.68
217063_x_at	6955	TRA@	X61079	2.72	9.23	18.29		2.72	23.34	15.93	0.68
215986_at	64430	C14orf135	AU146999	19.83	18.51	47.63		19.83	53.83	36.75	0.68
33148_at	51663	ZFR	AI459274	115.02	141.65	152.28		115.02	184.56	126.04	0.68
221677_s_at	29980	DONS ON	AF232674	565.80	758.88	535.20		565.80	891.79	609.29	0.68
202076_at	329	BIRC2	NM_001166	1990.37	2073.34	2233.86		1990.37	3604.44	2463.37	0.68
200071_at	10285	SMND C1	BF224259	908.25	733.38	1170.30		908.25	1573.19	1075.36	0.68
208424_s_at	57019	CIAPIN1	NM_020313	445.08	432.13	457.50		445.08	682.47	466.70	0.68
220344_at	56673	C11orf16	NM_020643	6.98	11.69	12.15		6.98	10.82	7.40	0.68

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
209568_s_at	23179	RGL1	AF186779	146.44	1099.56	1182.05		146.44	2480.91	1697.81	0.68
202388_at	5997	RGS2	NM_002923	446.40	463.76	501.12		446.40	839.25	574.37	0.68
219047_s_at	79759	ZNF668	NM_024706	101.56	111.58	135.23		101.56	180.00	123.19	0.68
219062_s_at	54877	ZCCHC2	BE676543	266.43	339.99	333.79		266.43	747.35	511.64	0.68
222239_s_at	26512	INTS6	AL117626	466.70	675.29	449.82		466.70	796.00	545.04	0.68
214056_at	4170	MCL1	BF981280	115.20	143.89	147.31		115.20	224.16	153.55	0.68
214985_at			AF070571	4.89	8.75	7.84		4.89	13.75	9.42	0.69
204973_at	2705	GJB1	NM_000166	24.10	20.54	28.13		24.10	50.42	34.59	0.69
221639_x_at	3192	HNRPU	AF068846	10.18	49.40	46.67		10.18	42.15	28.97	0.69
222182_s_at	4848	CNOT2	BG105204	1543.44	1189.76	1716.16		1543.44	2422.67	1666.06	0.69
202228_s_at	27020	NPTN	NM_017455	2921.44	3196.32	2764.11		2921.44	5025.08	3456.04	0.69
211966_at	1284	COL4A2	AA909035	81.19	106.34	79.25		81.19	182.30	125.38	0.69
217880_at			NM_001256	615.00	638.24	1089.08		615.00	998.24	686.60	0.69
210346_s_at	57396	CLK4	AF212224	841.00	1016.99	925.71		841.00	1415.61	973.80	0.69
209004_s_at	26234	FBXL5	AF142481	1612.23	2097.63	2522.88		1612.23	2599.68	1789.14	0.69
220308_at	25790	CCDC19	NM_012337	24.68	18.43	35.70		24.68	49.55	34.11	0.69
215888_at	23047	APRIN	AK026889	179.53	309.06	287.54		179.53	358.20	246.99	0.69
202205_at	7408	VASP	NM_003370	607.69	646.02	574.87		607.69	1055.66	728.22	0.69
222118_at	55839	CENPN	AK023669	254.76	350.51	256.95		254.76	449.58	310.14	0.69
219092_s_at	64768	IPPK	NM_022755	116.77	183.23	164.92		116.77	231.85	159.96	0.69

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
205039_s_at	10320	IKZF1	BG540504	962.44	752.19	433.36		962.44	2080.00	1436.83	0.69
211129_x_at	1896	EDA	AF061192	19.57	12.86	17.66		19.57	32.45	22.41	0.69
200784_s_at	4035	LRP1	BF304759	9.51	13.00	17.38		9.51	15.26	10.55	0.69
206043_s_at	9914	ATP2C2	NM_014861	12.10	9.27	19.04		12.10	24.72	17.09	0.69
213225_at	5495	PPM1B	AJ271832	140.21	161.08	170.43		140.21	242.34	167.59	0.69
213701_at	91298	C12orf29	AW299245	609.18	529.79	616.46		609.18	1011.04	699.53	0.69
203161_s_at	9025	RNF8	NM_003958	3.22	8.17	13.48		3.22	17.84	12.35	0.69
208091_s_at	81552	ECOP	NM_030796	953.79	1353.88	1177.53		953.79	2878.56	1992.10	0.69
221743_at	10658	CUGBP1	AI472139	2387.50	2660.11	3511.98		2387.50	4046.64	2802.07	0.69
209958_s_at	27241	PTHB1	AF095771	18.21	51.40	44.45		18.21	39.14	27.10	0.69
215546_at	5711	PSMD5	AK001065	7.82	7.01	7.63		7.82	12.89	8.93	0.69
204308_s_at	9895	KIAA0329	NM_014844	140.43	215.94	201.49		140.43	407.18	282.95	0.69
215763_at			AL080072	9.50	4.29	3.63		9.50	29.38	20.42	0.70
208882_s_at	51366	EDD1	U69567	945.38	867.08	1068.37		945.38	1484.56	1032.01	0.70
217939_s_at	54812	AFTPH	NM_017657	1520.47	1655.27	1558.81		1520.47	2550.11	1772.95	0.70
214308_s_at	3081	HGD	AI478172	50.39	66.35	71.66		50.39	224.25	156.05	0.70
214901_at	7554	ZNF8	AI671579	99.90	127.90	116.70		99.90	190.94	132.89	0.70
215290_at	645323	LOC65323	AI480014	8.32	4.20	11.61		8.32	15.01	10.45	0.70
221192_x_at	79157	ET	NM_024311	119.53	210.87	172.13		119.53	204.14	142.17	0.70
206497_at	55744	C7orf44	NM_018224	32.91	51.29	47.19		32.91	57.14	39.80	0.70
207201_s_at	6580	SLC22A1	NM_003057	1.23	7.13	3.56		1.23	19.78	13.79	0.70

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
205020_s_at	10124	ARL4A	NM_005738	410.69	351.50	947.75		410.69	768.54	536.18	0.70
201837_s_at	9913	SUPT7L	AF197954	710.81	903.90	958.65		710.81	1187.79	828.96	0.70
211449_at	2956	MSH6	D89646	10.46	13.90	6.52		10.46	27.64	19.30	0.70
202351_at	3685	ITGAV	AI093579	900.06	1130.88	1112.19		900.06	2638.30	1842.00	0.70
212964_at	23119	HIC2	AI912206	458.21	356.89	498.96		458.21	718.97	502.28	0.70
219028_at	28996	HIPK2	NM_022740	84.90	111.34	76.49		84.90	186.97	130.77	0.70
209246_at	10061	ABCF2	AF261091	39.27	106.79	95.59		39.27	156.67	109.58	0.70
220117_at	79750	ZNF659	NM_024697	5.62	3.51	5.54		5.62	30.25	21.16	0.70
204831_at	1024	CDK8	R59697	358.00	394.44	498.47		358.00	652.13	456.51	0.70
218650_at	54487	DGCR8	NM_022775	465.67	567.09	506.57		465.67	709.52	497.41	0.70
200921_s_at	694	BTG1	NM_001731	1503.67	1492.57	2660.36		1503.67	12888.20	9037.04	0.70
202423_at	7994	MYST3	NM_006766	1695.24	1817.39	2043.63		1695.24	3022.12	2119.35	0.70
209838_at	9318	COPS2	AA496247	177.77	178.21	177.15		177.77	277.06	194.36	0.70
216737_at			AK024525	1.92	14.72	13.93		1.92	10.46	7.34	0.70
219178_at	79691	QTRTD1	NM_024638	202.35	195.44	155.50		202.35	332.97	233.70	0.70
203693_s_at	1871	E2F3	NM_001949	382.28	471.34	584.57		382.28	989.90	694.99	0.70
214551_s_at	924	CD7	NM_006137	5.34	7.67	3.32		5.34	18.78	13.19	0.70
212802_s_at	26130	GAPVD1	AK023841	758.21	838.56	763.35		758.21	1151.03	808.51	0.70
220102_at	668	FOXL2	NM_023067	124.84	101.03	111.54		124.84	189.96	133.53	0.70
212170_at	10137	RBM12	BF447705	184.11	193.75	206.49		184.11	311.94	219.32	0.70
206096_at	7584	ZNF35	AI809774	134.20	164.65	138.85		134.20	240.65	169.40	0.70

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
221749_at	253943	YTHDF3	AU157915	1970.64	2080.51	2522.96		1970.64	3456.17	2434.35	0.70
221277_s_at	83480	PUS3	NM_031307	449.46	418.04	399.97		449.46	775.74	546.42	0.70
209639_s_at	6002	RGS12	AF030111	17.65	47.93	47.52		17.65	46.40	32.69	0.70
213168_at	6670	SP3	AU145005	1641.39	1383.59	2069.14		1641.39	2641.44	1861.45	0.70
211962_s_at	677	ZFP36L1	BG250310	93.53	182.47	272.65		93.53	384.50	271.07	0.70
216035_x_at	6934	TCF7L2	AV721430	77.97	95.55	113.77		77.97	133.66	94.25	0.71
202857_at	10330	TMEM4	NM_014255	4091.43	4007.43	3615.54		4091.43	7501.73	5291.66	0.71
204934_s_at	3249	HPN	NM_002151	28.10	35.60	32.97		28.10	56.85	40.10	0.71
212195_at	3572	IL6ST	AL049265	877.45	1383.26	1757.03		877.45	1832.20	1292.85	0.71
205799_s_at	6519	SLC3A1	NM_000341	28.63	30.21	32.41		28.63	49.28	34.78	0.71
222168_at	220	ALDH1A3	AF198444	10.34	9.23	8.40		10.34	20.97	14.81	0.71
202512_s_at	9474	ATG5	AK001899	223.75	207.22	164.81		223.75	339.40	239.64	0.71
217572_at			AA654586	4.01	3.97	2.78		4.01	10.34	7.30	0.71
203444_s_at	9219	MTA2	NM_004739	16.43	7.55	8.93		16.43	34.45	24.33	0.71
221356_x_at	22953	P2RX2	NM_016318	8.16	9.71	11.87		8.16	24.96	17.63	0.71
218242_s_at	51111	SUV420H1	AA056099	861.09	861.46	1109.93		861.09	1498.11	1058.86	0.71
221143_at	29935	RPA4	NM_013347	59.19	194.71	170.61		59.19	184.47	130.39	0.71
219735_s_at	29842	TFCP2L1	NM_014553	10.82	15.00	5.94		10.82	27.36	19.35	0.71
219782_s_at	51333	ZNF771	NM_016643	6.41	11.84	20.31		6.41	16.28	11.51	0.71
214235_at	1577	CYP3A5	X90579	22.16	26.09	8.78		22.16	34.79	24.64	0.71

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
219001_s_at	79269	WDR32	NM_024345	600.71	779.97	669.32		600.71	1071.57	759.37	0.71
202550_s_at	9217	VAPB	AF160212	552.79	593.15	692.99		552.79	1074.42	761.54	0.71
203078_at	8453	CUL2	U83410	26.90	34.69	26.84		26.90	57.44	40.75	0.71
209654_at	23379	KIAA0947	BC004902	210.18	237.85	261.27		210.18	424.64	301.58	0.71
204656_at	6461	SHB	AL138752	61.03	93.10	71.89		61.03	177.86	126.33	0.71
213682_at	10762	NUP50	AL036344	1702.89	2121.78	2154.63		1702.89	2858.81	2030.64	0.71
211936_at	3309	HSPA5	AF216292	8112.84	12515.14	10649.28		8112.84	16578.74	11784.32	0.71
219738_s_at	5101	PCDH9	NM_020403	3.58	3.80	7.62		3.58	10.28	7.30	0.71
205579_at	3269	HRH1	NM_000861	56.44	85.32	137.67		56.44	1043.96	742.28	0.71
216583_x_at			AC004079	108.06	145.46	131.13		108.06	180.75	128.54	0.71
208309_s_at	10892	MALT1	NM_006785	114.35	157.84	144.03		114.35	235.70	167.71	0.71
203549_s_at	4023	LPL	NM_000237	525.11	978.15	796.81		525.11	4603.58	3276.34	0.71
209323_at	5612	PRKRIR	AF081567	1265.89	1106.19	1227.42		1265.89	2034.55	1448.23	0.71
219361_s_at	64782	ISG20L1	NM_022767	151.18	137.02	81.90		151.18	613.16	436.66	0.71
36552_at	26005	DKFZP586P0123	AL080220	231.70	255.33	285.84		231.70	364.63	259.93	0.71
214113_s_at	9939	RBM8A	AI738479	1299.62	1551.86	1432.72		1299.62	2710.69	1933.28	0.71
201851_at	6455	SH3GL1	NM_003025	399.33	441.70	290.76		399.33	816.35	582.39	0.71
210018_x_at	10892	MALT1	AB026118	129.64	189.31	154.54		129.64	270.14	192.90	0.71
201910_at	10160	FARP1	BF213279	9.44	7.99	14.61		9.44	19.00	13.57	0.71
219522_at	24147	FJX1	NM_014344	36.44	37.15	34.57		36.44	250.00	178.70	0.71

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
91617_at	54487	DGCR8	AI028241	170.83	226.61	185.19		170.83	494.02	353.18	0.71
213262_at	26278	SACS	AI932370	312.38	280.21	255.51		312.38	518.33	370.62	0.72
211326_x_at	3077	HFE	AF150664	20.03	11.40	23.61		20.03	42.62	30.48	0.72
204229_at	57030	SLC17A7	H40895	33.62	46.71	54.86		33.62	81.09	57.98	0.72
221047_s_at	4139	MARK1	NM_018650	12.38	31.15	30.69		12.38	61.50	43.97	0.72
217494_s_at	11191	PTENP1	AF023139	8.49	4.41	5.65		8.49	15.21	10.88	0.72
201920_at	6574	SLC20A1	NM_005415	1024.95	1531.14	1552.34		1024.95	2201.60	1575.45	0.72
214047_s_at	8930	MBD4	AI913365	1055.41	968.06	1488.41		1055.41	1818.60	1301.52	0.72
201713_s_at	5903	RANBP2	D42063	1466.56	1607.08	1524.59		1466.56	2371.08	1698.11	0.72
210917_at	7525	YES1	AF119914	5.23	16.96	16.60		5.23	16.98	12.16	0.72
219286_s_at	64783	RBM15	NM_022768	1471.49	1661.22	1642.61		1471.49	2490.75	1784.15	0.72
210054_at	79441	C4orf15	BC003648	492.56	486.38	589.89		492.56	773.58	555.05	0.72
211775_x_at	84796	MGC13053	BC006134	8.06	4.13	4.33		8.06	14.79	10.61	0.72
222132_s_at	55750	MULK	AJ278150	353.70	420.12	338.88		353.70	574.29	412.25	0.72
203282_at	2632	GBE1	NM_000158	2653.48	2221.58	2792.95		2653.48	4128.11	2964.30	0.72
212792_at	23333	DPY19L1	AB020684	311.57	616.44	484.75		311.57	649.02	466.12	0.72
219976_at	51361	HOOK1	NM_015888	12.46	4.87	15.96		12.46	18.78	13.49	0.72
201143_s_at	1965	EIF2S1	BC002513	882.84	961.20	822.82		882.84	1622.30	1166.00	0.72
214815_at	51592	TRIM33	AU136587	69.95	123.66	162.19		69.95	138.11	99.33	0.72
211951_at	9221	NOLC1	AI355279	1100.14	881.10	909.25		1100.14	1895.54	1363.79	0.72
214039_s_at	55353	LAPT M4B	T15777	3554.81	3718.56	3599.88		3554.81	5666.72	4079.12	0.72

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
217001_x_at	3111	HLA-DOA	M29335	12.98	29.41	32.98		12.98	30.75	22.14	0.72
214925_s_at	6709	SPTAN1	AK026484	31.00	47.45	38.05		31.00	65.36	47.06	0.72
221963_x_at	730051	LOC730051	BE999967	303.85	286.02	286.26		303.85	497.31	358.30	0.72
218937_at	54925	ZNF434	NM_017810	330.65	302.59	352.84		330.65	515.16	371.54	0.72
216673_at	50858	TTY1	AF000990	18.16	10.80	20.74		18.16	34.83	25.12	0.72
206437_at	8698	EDG6	NM_003775	22.91	14.04	11.03		22.91	39.28	28.34	0.72
212377_s_at	4853	NOTCH2	AU158495	1356.47	1934.58	1641.78		1356.47	2441.62	1761.72	0.72
215893_x_at	2262	GPC5	AF339787	13.62	32.77	25.52		13.62	24.25	17.51	0.72
200797_s_at	4170	MCL1	AI275690	4187.99	4593.08	5116.10		4187.99	7034.20	5078.87	0.72
202613_at	1503	CTPS	NM_001905	4727.13	5077.70	3843.93		4727.13	7671.52	5542.36	0.72
217162_at	7258	TSPY1	M94893	5.65	6.68	6.95		5.65	22.86	16.52	0.72
213136_at	5771	PTPN2	AI828880	1015.49	1222.19	1430.00		1015.49	1976.07	1428.65	0.72
215344_at			AL137325	14.82	18.68	39.41		14.82	40.00	28.92	0.72
211725_s_at	637	BID	BC005884	1031.27	2006.66	1877.88		1031.27	4296.30	3107.50	0.72
212154_at	6383	SDC2	AI380298	761.09	569.17	722.51		761.09	1237.27	895.70	0.72
221732_at	124583	CANT1	AK026161	784.24	872.51	784.81		784.24	1386.89	1004.36	0.72
213009_s_at	4591	TRIM37	AK022701	393.96	426.07	508.32		393.96	711.22	515.24	0.72
203804_s_at	51747	CROP	NM_006107	1529.19	1398.67	1469.66		1529.19	2319.21	1680.83	0.72
214807_at			AI278204	41.44	59.51	43.94		41.44	64.50	46.78	0.73
206131_at	1208	CLPS	NM_001832	8.66	9.73	14.65		8.66	19.30	13.99	0.73
218732_at	51651	PTRH2	NM_016077	600.26	516.28	603.23		600.26	1051.28	762.69	0.73

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
206355_at	2774	GNAL	NM_002071	2.18	23.95	25.49		2.18	21.05	15.27	0.73
204405_x_at	27292	DIMT1L	NM_014473	1103.60	1057.30	1251.65		1103.60	1751.53	1272.07	0.73
216490_x_at	442175	LOC442175	AL133267	33.36	38.68	48.87		33.36	67.58	49.14	0.73
204837_at	66036	MTMR9	AL080178	804.57	1018.62	1031.17		804.57	1419.60	1032.26	0.73
218428_s_at	51455	REV1	NM_016316	612.12	614.11	781.15		612.12	944.68	687.90	0.73
214379_at	660	BMX	AI954458	10.38	34.44	33.99		10.38	30.97	22.56	0.73
213415_at	1193	CLIC2	AI768628	69.43	85.26	77.93		69.43	237.75	173.17	0.73
208212_s_at	238	ALK	NM_004304	8.04	6.48	16.11		8.04	17.29	12.60	0.73
215776_at	3645	INSRR	J05046	5.44	6.62	3.48		5.44	13.32	9.71	0.73
205352_at	5274	SERPINI1	NM_005025	239.82	290.12	285.15		239.82	514.65	375.34	0.73
217106_x_at	27292	DIMT1L	AF091078	1108.60	741.84	1180.24		1108.60	1709.37	1247.10	0.73
215114_at	26168	SENP3	AK000923	52.39	78.02	82.02		52.39	96.97	70.76	0.73
204601_at	9683	N4BP1	NM_014664	190.90	325.74	325.99		190.90	510.97	372.89	0.73
208901_s_at	7150	TOP1	J03250	2887.11	2813.70	2784.18		2887.11	5107.20	3728.25	0.73
210869_s_at	4162	MCAM	M29277	5.06	11.12	12.03		5.06	17.53	12.80	0.73
210557_x_at	1435	CSF1	M76453	8.39	38.30	32.20		8.39	25.45	18.59	0.73
50221_at	7942	TFEB	AI524138	406.72	626.55	588.76		406.72	1084.38	792.07	0.73
207513_s_at	7743	ZNF189	NM_003452	919.08	837.63	1302.04		919.08	1908.19	1394.27	0.73
219449_s_at	54968	TMEM70	BC002748	1845.91	1870.07	2171.13		1845.91	3162.08	2314.62	0.73
218578_at	79577	CDC73	NM_024529	464.99	597.79	711.52		464.99	1145.89	839.74	0.73
207680_x_at	5077	PAX3	NM_013942	3.57	4.64	3.77		3.57	11.00	8.06	0.73
211111_at			AB016902	20.65	16.42	4.45		20.65	45.93	33.68	0.73

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
203082_at	9790	BMS1L	NM_014753	305.56	413.45	320.62		305.56	467.58	342.88	0.73
203743_s_at	6996	TDG	NM_003211	1324.87	1331.25	1322.57		1324.87	2469.34	1810.83	0.73
31846_at	29984	RHOD	AW003733	156.72	372.47	357.99		156.72	350.43	257.00	0.73
214701_s_at	2335	FN1	AJ276395	20.32	25.69	34.88		20.32	38.80	28.58	0.74
208256_at	1943	EFNA2	NM_001405	10.68	5.10	16.23		10.68	26.39	19.44	0.74
215053_at	10847	SRCAP	AK023808	14.98	12.91	40.94		14.98	39.03	28.76	0.74
217987_at	54529	ASNSD1	NM_019048	1197.44	1010.71	930.38		1197.44	1821.81	1342.78	0.74
213030_s_at	5362	PLXNA2	AI688418	22.80	15.54	30.87		22.80	39.11	28.83	0.74
216213_at	4750	NEK1	AF155113	10.93	6.14	17.00		10.93	22.05	16.26	0.74
201991_s_at	3799	KIF5B	BF223224	1858.93	2197.39	2283.59		1858.93	2886.88	2130.15	0.74
208217_at	2570	GABRR2	NM_002043	21.07	28.02	26.58		21.07	34.27	25.30	0.74
212185_x_at	4502	MT2A	NM_005953	1296.38	1024.92	882.29		1296.38	4233.39	3131.46	0.74
212907_at	7779	SLC30A1	AI972416	1730.18	2175.51	4455.87		1730.18	3091.75	2287.08	0.74
201144_s_at	1965	EIF2S1	NM_004094	2093.74	2177.70	2519.45		2093.74	3878.47	2869.31	0.74
204651_at	4899	NRF1	AW003022	288.61	297.04	357.99		288.61	440.23	326.21	0.74
33579_i_at	8484	GALR3	Z97630	12.57	9.11	17.95		12.57	34.71	25.72	0.74
202981_x_at	6477	SIAH1	NM_003031	551.81	654.49	1013.27		551.81	1156.91	857.74	0.74
214155_s_at	113251	LARP4	AI743740	117.96	107.11	117.80		117.96	216.79	160.83	0.74
203590_at	1783	DYNC1L12	NM_006141	765.19	1027.22	832.83		765.19	1271.94	943.71	0.74
205178_s_at	5930	RBBP6	NM_006910	723.44	845.08	639.59		723.44	1229.40	912.59	0.74
201506_at	7045	TGFBI	NM_0003	5679.79	4780.41	5140.67		5679.79	8538.91	6345.51	0.74

EA 0732: 1 hr preincubation with test compounds, 4hr stimulation with LPS (1ug/ml) or TNFa (10ng/ml) in THP-1 monocytic cells											
(Affymetrix Human Gene array U133A 2.0)											
Probe Set ID	LocusLink	Gene Symbol	Seq Derived From	Control (DMSO)	TNFa (10ng/ml)	THIAA (10ug/ml) +TNFa	THIAA inhibition (Fraction of TNFa stimulation)	Control (DMSO)	LPS (1ug / ml)	THIAA (10ug) + LPS	THIAA inhibition (Fraction of LPS stimulation)
			58								
44146_at	26205	GMEB2	AA045183	535.44	484.37	540.33		535.44	873.18	648.95	0.74
204622_x_at	4929	NR4A2	NM_006186	14.85	62.09	57.73		14.85	114.14	84.90	0.74
221799_at	54480	CSGlcA-T	AB037823	232.43	369.80	285.95		232.43	519.09	386.20	0.74
222103_at	466	ATF1	AI434345	293.91	162.30	316.61		293.91	533.76	397.77	0.75
213370_s_at	51460	SFMBT1	BF057298	269.51	323.18	281.04		269.51	453.99	338.46	0.75
204630_s_at	9527	GOSR1	NM_004871	1480.16	1820.33	2140.78		1480.16	3284.39	2449.91	0.75
216263_s_at			AK022215	44.11	51.56	49.28		44.11	72.18	53.85	0.75
204977_at	1662	DDX10	NM_004398	676.61	609.50	708.35		676.61	1024.69	764.61	0.75
210953_at	9819	TSC2D2	AF201292	20.81	6.33	11.43		20.81	38.03	28.39	0.75
221549_at	83743	GRWD1	AF3337808	231.45	257.01	210.61		231.45	452.18	337.65	0.75
213750_at			AA928506	871.91	936.70	874.32		871.91	1862.02	1390.70	0.75
214712_at	445329	SULT1A4	AK023827	11.17	40.47	32.39		11.17	33.60	25.10	0.75
213596_at	837	CASP4	AL050391	77.77	133.92	129.03		77.77	174.35	130.31	0.75
202451_at	2965	GTF2H1	BC000365	958.24	1030.06	1421.25		958.24	1642.29	1230.38	0.75
201437_s_at	1977	EIF4E	NM_001968	556.50	418.04	503.01		556.50	876.69	656.82	0.75
203529_at	5537	PPP6C	NM_016294	2385.22	2315.48	2481.33		2385.22	3677.76	2756.60	0.75
212229_s_at	23014	FBXO21	AK001699	322.06	365.74	269.55		322.06	526.35	394.75	0.75

Example 3

Effect of Tetrahydro-Isoalpa Acid on Brachial Artery Flow Mediated Dilation

[0094] The purpose of this study was to evaluate the effects on brachial artery endothelial responsiveness (a measure of cardiovascular risk) of oral tetrahydro-isoalpa acid administration (100 mg).

[0095] Brachial artery endothelial responsiveness was evaluated in three healthy subjects by measuring Flow Mediated Vasodilation using a Sonosite MicroMaxx ultrasound machine according to the procedures as outlined in Corretti ,MC., et al., Guidelines for the Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery – A Report of the International Brachial Artery Reactive Task Force. J. Am. Coll. Cadiol. 2002; 39(2): 257-65. Briefly, ischemia was induced in the brachial artery using a blood pressure cuff inflated to 50 mm Hg above systolic pressure with baseline and post hyperemic flow rate measured by ultrasound. The tests were repeated between one and two hours following an oral dose of 1056 mg of tetrahydro-isoalpa acid.

[0096] *Results:* Subjects were noted to have a 40.2% increase in flow rate above that observed from baseline (calculated as the $100 \times (\text{ratio of hyperemic flow rate} - \text{baseline low rate} / \text{baseline flow rate})$) prior to tetrahydro-isoalpa acid administration. A 63.3% increase in flow rate was observed from baseline (calculated as the $100 \times (\text{ratio of hyperemic flow rate} - \text{baseline low rate} / \text{baseline flow rate})$) one to two hours after tetrahydro-isoalpa acid administration. This is an increase in flow rate relative to baseline of 57%. It was further noted that tetrahydro-isoalpa acid administration resulted in a 28.2% increase in peak post hyperemic flow rate as compared to the peak post hyperemic flow rate in the untreated individuals. The increase in flow rate may be attributed to an increase in vessel diameter insofar as blood pressure and heart rate remained relatively constant during the protocol.

CLAIMS


1. A method for improving a cardiovascular risk factor in a subject in need, the method comprising treating the subject with a therapeutically effective amount of a substituted 1,3-cyclopentadione compound wherein said amount modulates the expression of cardiovascular risk factor associated marker gene expression.
2. The method of Claim 1, wherein the substituted 1,3-cyclopentadione compound is selected from the group comprising (+)-(4*R*,5*S*)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (-)-(4*S*,5*S*)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (+)-(4*R*,5*S*)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-(3-methylpropanoyl)cyclopent-2-en-1-one, (-)-(4*S*,5*S*)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-(3-methylpropanoyl)cyclopent-2-en-1-one, (+)-(4*R*,5*S*)-3,4-dihydroxy-2-(2-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one and (+)-(4*R*,5*S*)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-pentanoylcyclopent-2-en-1-one.
3. The method of Claim 1, wherein the cardiovascular risk associated marker gene is selected from the group consisting of TNF α , MCP-1, VCAM-1, MMP-3, ICAM1 and SDF1.
4. The method of Claim 1, further comprising lifestyle modification or pharmaceutical treatment.
5. The method of Claim 1, wherein the lifestyle modification or pharmaceutical treatment is selected from the group consisting of blood pressure reduction, cholesterol level modulation, diabetes treatment, increased exercise, inflammation, obesity and weight reduction, prothrombotic factors treatment, reduction in serum homocysteine and lipoprotein (a), serum triglyceride reduction, smoking cessation, and stress reduction.
6. A method for promoting vascular elasticity in a subject in need, the method comprising treating the subject with a therapeutically effective amount of a substituted 1,3-cyclopentadione compound wherein said amount increases vascular elasticity or dilation.
7. The method of Claim 6, wherein the substituted 1,3-cyclopentadione compound is selected from the group comprising (+)-(4*R*,5*S*)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (-)-(4*S*,5*S*)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (+)-(4*R*,5*S*)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-(3-methylpropanoyl)cyclopent-2-en-1-one, (-)-(4*S*,5*S*)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-

methylpentanoyl)-2-(3-methylpropanoyl)cyclopent-2-en-1-one, (+)-(4*R*,5*S*)-3,4-dihydroxy-2-(2-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one and (+)-(4*R*,5*S*)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-pentanoylcyclopent-2-en-1-one.

8. A composition promoting cardiovascular health in a subject in need, said composition comprising a therapeutically effective amount of a substituted 1,3-cyclopentadione compound wherein said amount (a) modulates the expression of cardiovascular risk associated marker gene expression; or (b) increases vascular elasticity or dilation.
9. The composition of Claim 8, wherein the substituted 1,3-cyclopentadione compound is selected from the group comprising (+)-(4*R*,5*S*)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (-)-(4*S*,5*S*)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (+)-(4*R*,5*S*)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-(3-methylpropanoyl)cyclopent-2-en-1-one, (-)-(4*S*,5*S*)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-(3-methylpropanoyl)cyclopent-2-en-1-one, (+)-(4*R*,5*S*)-3,4-dihydroxy-2-(2-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one and (+)-(4*R*,5*S*)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-pentanoylcyclopent-2-en-1-one.
10. The composition of Claim 8, wherein the composition further comprises a pharmaceutically acceptable excipient.
11. The composition of Claim 10, wherein the pharmaceutically acceptable excipient is selected from the group consisting of coatings, isotonic and absorption delaying agents, binders, adhesives, lubricants, disintegrants, coloring agents, flavoring agents, sweetening agents, absorbants, detergents, and emulsifying agents.
12. The composition of Claim 8, wherein the composition further comprises one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, and carbohydrates.

Gini-Coefficient: META-060 shows high specificity for kinases regulating inflammation

META-060 inhibit activity of inflammatory kinases



Gini Coefficient (85 kinases, 10μM ATP)





Fig. 1

2/10



TNFα (10ng/ml)	-	+	+	+	+
META-060 (μg/ml)	-	-	10	5	1








Fig. 2

3/10

META-060 inhibits Endothelial-Monocyte Interactions



THP-1
 TNFα (10ng/ml) - + + +
 Parthenolide (10μM) - - + -
 META-060 (10μg/ml) - - - +




Fig. 3

META-060 inhibits THP-1 interactions to HAEC cells




Fig. 4

5/10

META-060 inhibits MCP-1 expression in THP-1 cells





Fig. 5

6/10


A. TNF α 

Fig. 6A

7/10




Fig. 6B

8/10

C. Zymography: LPS mediated MMP-9 activity





Fig. 6C

A. NF-κB EMSA analysis

NF-κB EMSA probe: 5'AGTTGAGGGGACTTTCCCAGGC



B. Proposed Signaling Mechanism




Fig. 7

10/10

META-060 inhibits TNF α activated genes in THP-1 cells





Fig. 8